{
  "documents": [
    "ESC/ESH GUIDELINES EuropeanHeartJournal(2018)39, 30213104 doi: 10. 1093/eurheartj/ehy339 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Authors/Task Force Members: Bryan Williams (ESC Chairperson) (UK), Giuseppe Mancia (ESH Chairperson) (Italy), Wilko Spiering (The Netherlands), Enrico Agabiti Rosei (Italy), Michel Azizi (France), Michel Burnier (Switzerland), Denis L. Clement (Belgium), Antonio Coca (Spain), Giovanni de Simone (Italy), Anna Dominiczak (UK), Thomas Kahan (Sweden), Felix Mahfoud (Germany), Josep Redon (Spain), Luis Ruilope (Spain), Alberto Zanchetti (Italy), Mary Kerins (Ireland), Sverre E. Kjeldsen (Norway), Reinhold Kreutz (Germany), Stephane Laurent (France), Gregory Y. H. Lip (UK), Richard McManus (UK), Krzysztof Narkiewicz (Poland), Frank Ruschitzka (Switzerland), Roland E. Schmieder (Germany), Evgeny Shlyakhto (Russia), Costas Tsioufis (Greece), Victor Aboyans (France), and Ileana Desormais (France) Correspondingauthors. BryanWilliams, InstituteofCardiovascularScience, UniversityCollegeLondon, MapleHouse, 1stFloor, SuiteA, 149TottenhamCourtRoad, London W1T7DN, UK, Tel: þ44(0)2031087907, E-mail: bryan. williamsucl. before meals. uk. GiuseppeMancia, UniversityofMilano-Bicocca, Milan, Italy; andHypertensionCenterIstituto UniversitarioPoliclinicodiMonza, Verano(MB), PiazzadeiDaini, 420126Milan, Italy, Tel: þ393474327142, E-mail: giuseppe. manciaunimib. it ProfessorZanchettidiedtowardstheendofthedevelopmentoftheseGuidelines, inMarch2018. HecontributedfullytothedevelopmentoftheseGuidelines, asamember oftheGuidelinesTaskForceandasasectionco-ordinator. Hewillbesadlymissedbycolleaguesandfriends. Thetwochairpersonscontributedequallytothedocument. ESCCommitteeforPracticeGuidelines(CPG), EuropeanSocietyofHypertension(ESH)Council, ESCNationalCardiacSocietieshavingparticipatedin thereviewprocess, ESHNationalHypertensionSocietieshavingparticipatedinthereviewprocess: listedintheAppendix. ESCentitieshavingparticipatedinthedevelopmentofthisdocument: Associations: EuropeanAssociationofCardiovascularImaging(EACVI), EuropeanAssociationofPreventiveCardiology(EAPC), EuropeanAssociationofPercutaneous CardiovascularInterventions(EAPCI), EuropeanHeartRhythmAssociation(EHRA), HeartFailureAssociation(HFA). Councils: CouncilforCardiologyPractice, CouncilonCardiovascularNursingandAlliedProfessions, CouncilonCardiovascularPrimaryCare, CouncilonHypertension, CouncilonStroke. WorkingGroups: CardiovascularPharmacotherapy, CoronaryPathophysiologyandMicrocirculation, e-Cardiology. Disclaimer. TheESC/ESHGuidelinesrepresenttheviewsoftheESCandESHandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledgeandtheevidence availableatthetimeoftheirdating. TheESCandESHarenotresponsibleintheeventofanycontradiction, discrepancy, and/orambiguitybetweentheESC/ESHGuidelinesandanyother officialrecommendationsorguidelinesissuedbytherelevantpublichealthauthorities, inparticularinrelationtogooduseofhealthcareortherapeuticstrategies. Healthprofessionalsare encouragedtotaketheESC/ESHGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgmentaswellasinthedeterminationandtheimplementationofpreventive, diagnostic, or therapeuticmedicalstrategies. However, theESC/ESHGuidelinesdonotoverrideinanywaywhatsoevertheindividualresponsibilityofhealthprofessionalstomakeappropriateandaccuratedecisionsinconsiderationofeachpatientshealthcondition, andinconsultationwiththatpatientandthepatientscaregiverwhereappropriateand/ornecessary. NordotheESC/ESH Guidelinesexempthealthprofessionalsfromtakingcarefulandfullconsiderationoftherelevantofficialupdatedrecommendationsorguidelinesissuedbythecompetentpublichealth authoritiesinordertomanageeachpatientscaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethicalandprofessionalobligations. Itisalsothehealthprofessionals responsibilitytoverifytheapplicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeofprescription. ThecontentoftheseEuropeanSocietyofCardiology(ESC)andEuropeanSocietyofHypertension(ESH)Guidelineshasbeenpublishedforpersonalandeducationaluseonly. Nocommercialuseisauthorized. NopartoftheESC/ESHGuidelinesmaybetranslatedorreproducedinanyformwithoutwrittenpermissionfromtheESCorESH. PermissioncanbeobtaineduponsubmissionofawrittenrequesttoOxfordUniversityPress, thepublisheroftheEuropeanHeartJournalandthepartyauthorizedtohandle suchpermissionsonbehalfoftheESC(journals. permissionsoup. com). Thisarticlehasbeenco-publishedintheEuropeanHeartJournal(doi: 10. 1093/eurheartj/ehy339)andJournalofHypertension(doi: 10. 1097/HJH. 10. 1097/HJH. 0000000000001940), andin ashortenedversioninBloodPressure. Allrightsreserved. VC EuropeanSocietyofCardiologyandEuropeanSocietyofHypertension2018. ThearticlesinEuropeanHeartJournaland JournalofHypertensionareidenticalexceptforminorstylisticandspellingdifferencesinkeepingwitheachjournalsstyle. Anycitationcanbeusedwhencitingthisarticle. Downloaded from by guest on 31 December 2025 3022 ESC/ESHGuidelines DocumentReviewers: GuyDeBacker(ESCReviewCo-ordinator)(Belgium), AnthonyM. Heagerty(ESH ReviewCo-ordinator)(UK), StefanAgewall(Norway), MurielleBochud(Switzerland), ClaudioBorghi (Italy), PierreBoutouyrie(France), JanaBrguljan(Slovenia), HectorBueno(Spain), EnricoG. Caiani(Italy), BoCarlberg(Sweden), NeilChapman(UK), RenataC(cid: 2)ıfkova(cid: 2)(CzechRepublic), JohnG. F. Cleland(UK), Jean-PhilippeCollet(France), IoanMirceaComan(Romania), PeterW. deLeeuw(TheNetherlands), VictoriaDelgado(TheNetherlands), PaulDendale(Belgium), Hans-ChristophDiener(Germany), MariaDorobantu(Romania), RobertFagard(Belgium), CsabaFarsang(Hungary), MarcFerrini(France), IanM. Graham(Ireland), GuidoGrassi(Italy), HermannHaller(Germany), F. D. RichardHobbs(UK), BojanJelakovic(Croatia), CatrionaJennings(UK), HugoA. Katus(Germany), AbrahamA. Kroon (TheNetherlands), ChristopheLeclercq(France), DraganLovic(Serbia), EmparLurbe(Spain), AthanasiosJ. Manolis(Greece), TheresaA. McDonagh(UK), FranzMesserli(Switzerland), MariaLorenza Muiesan(Italy), UweNixdorff(Germany), MichaelHechtOlsen(Denmark), GianfrancoParati(Italy), JoepPerk(Sweden), MassimoFrancescoPiepoli(Italy), JorgePolonia(Portugal), PiotrPonikowski (Poland), DimitriosJ. Richter(Greece), StefanoF. Rimoldi(Switzerland), MarcoRoffi(Switzerland), NaveedSattar(UK), PetarM. Seferovic(Serbia), IainA. Simpson(UK), MiguelSousa-Uva(Portugal), AliceV. Stanton(Ireland), PhilippevandeBorne(Belgium), PanosVardas(Greece), MassimoVolpe(Italy), SvenWassmann(Germany), StephanWindecker(Switzerland), JoseLuisZamorano(Spain) ThedisclosureformsofallexpertsinvolvedinthedevelopmentoftheseGuidelinesareavailableonthe ESCwebsitewww. escardio. org/guidelines ThecurrentbackgroundinformationanddetaileddiscussionofthedatacanbefoundinESCCardioMedSection44Systemichypertension Onlinepublish-ahead-of-print25August2018 Keywords Guidelines (cid: 129) Hypertension (cid: 129) Bloodpressure (cid: 129) Bloodpressuremeasurement (cid: 129) Bloodpressuretreatment thresholdsandtargets (cid: 129) Hypertension-mediatedorgandamage (cid: 129) Lifestyleinterventions (cid: 129) Drugtherapy (cid: 129) Combinationtherapy (cid: 129) Devicetherapy (cid: 129) Secondaryhypertension. Table of Contents. . 4. 6Advantagesanddisadvantagesofambulatorybloodpressure. . . monitoringandhomebloodpressuremonitoring 3037. . 1Preamble 3025. 4. 7White-coathypertensionandmaskedhypertension 3037. . 2Introduction 3025. 4. 7. 1White-coathypertension 3037. . 2. 1Whatisnewandwhathaschangedinthe2018European. 4. 7. 2Maskedhypertension 3038. . SocietyofCardiology/EuropeanSocietyofHypertension. 4. 8Screeningforthedetectionofhypertension 3038. . arterialhypertensionGuidelines? 3027. 4. 9Confirmingthediagnosisofhypertension 3038. . 3Definition, classification, andepidemiologicalaspects. 4. 10Clinicalindicationsforout-of-officeblood. . ofhypertension 3030. pressuremeasurements 3038. . 3. 1Definitionofhypertension 3030. 4. 11Bloodpressureduringexerciseandathighaltitude 3040. . 3. 2Classificationofbloodpressure 3030. 4. 12Centralaorticpressure 3040. . 3. 3Prevalenceofhypertension 3030. . 5Clinicalevaluationandassessmentofhypertension-mediated. 3. 4Bloodpressurerelationshipwithriskofcardiovascularand. . organdamageinpatientswithhypertension 3041. renalevents 3032. . 5. 1Clinicalevaluation 3041. 3. 5Hypertensionandtotalcardiovascularriskassessment 3032. . 5. 2Medicalhistory 3041. 3. 6Importanceofhypertension-mediatedorgandamagein. . 5. 3Physicalexaminationandclinicalinvestigations 3042. refiningcardiovascularriskassessmentinhypertensivepatients. . 3033. . 5. 4Assessmentofhypertension-mediatedorgandamage 3042. 3. 7Challengesincardiovascularriskassessment 3034. . 5. 4. 1Usinghypertension-mediatedorgandamagetohelp. 4Bloodpressuremeasurement 3035. . stratifyriskinhypertensivepatients 3042. 4. 1Conventionalofficebloodpressuremeasurement 3035. . 5. 5Characteristicsofhypertension-mediatedorgandamage 3044. 4. 2Unattendedofficebloodpressuremeasurement 3035. . 5. 5. 1Theheartinhypertension 3044. 4. 3Out-of-officebloodpressuremeasurement 3036. . 5. 5. 2Thebloodvesselsinhypertension 3044. 4. 4Homebloodpressuremonitoring 3036. . 5. 5. 3Thekidneyinhypertension 3045. . 4. 5Ambulatorybloodpressuremonitoring 3036. 5. 5. 4Hypertensiveretinopathy 3045 Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3023. . 5. 5. 5Thebraininhypertension 3045. 8. 4White-coathypertension 3076. . 5. 6Hypertension-mediatedorgandamageregressionand. 8. 5Maskedhypertension 3077. . cardiovascularriskreductionwithantihypertensivetreatment 3045. 8. 6Maskeduncontrolledhypertension 3077. . 5. 7Whentoreferapatientwithhypertensionfor. 8. 7Hypertensioninyoungeradults(age50years) 3077. . hospital-basedcare 3046. 8. 7. 1Isolatedsystolichypertensionintheyoung 3078. . 6Geneticsandhypertension 3047. 8. 8Hypertensioninolderpatients(age_65years) 3078. . 7Treatmentofhypertension 3048. 8. 9Women, pregnancy, oralcontraception, and. . 7. 1Beneficialeffectsofbloodpressure-loweringtherapy. hormone-replacementtherapy 3079. .",
    "6Geneticsandhypertension 3047. 8. 8Hypertensioninolderpatients(age_65years) 3078. . 7Treatmentofhypertension 3048. 8. 9Women, pregnancy, oralcontraception, and. . 7. 1Beneficialeffectsofbloodpressure-loweringtherapy. hormone-replacementtherapy 3079. . inhypertension 3048. . 8. 9. 1Hypertensionandpregnancy 3079. 7. 2. Whentoinitiateantihypertensivetreatment 3048. . 8. 9. 2Oralcontraceptivepillsandhypertension 3081. 7. 2. 1Recommendationsinpreviousguidelines 3048. . 8. 9. 3Hormone-replacementtherapyandhypertension 3081. 7. 2. 2Drugtreatmentforpatientswithgrade1. . 8. 10Hypertensionindifferentethnicgroups 3081. hypertensionatlowmoderatecardiovascularrisk 3048. . 8. 11Hypertensionindiabetesmellitus 3082. 7. 2. 3Initiationofbloodpressure-loweringdrug. . 8. 12Hypertensionandchronickidneydisease 3083. treatmentinolderpeoplewithgrade1hypertension 3049. . 8. 13Hypertensionandchronicobstructivepulmonarydisease 3084. 7. 2. 4Initiationofbloodpressure-loweringdrug. . 8. 14Hypertensionandheartdisease 3084. treatmentinpatientswithhighnormalbloodpressure 3049. . 8. 14. 1Coronaryarterydisease 3084. 7. 2. 5Shouldbloodpressure-loweringdrugtreatmentbe. . 8. 14. 2Leftventricularhypertrophyandheartfailure 3085. initiatedonthebasisofbloodpressurevaluesorthelevel. . 8. 15Cerebrovasculardiseaseandcognition 3086. oftotalcardiovascularrisk? 3050. . 8. 15. 1Acuteintracerebralhaemorrhage 3086. . 7. 2. 6Initiationofbloodpressure-loweringdrugtreatment. . 3050. 8. 15. 2Acuteischaemicstroke 3086. . 7. 3Bloodpressuretreatmenttargets 3052. 8. 15. 3Previousstrokeortransientischaemicattack 3086. . 7. 3. 1Newevidenceonsystolicbloodpressureand. 8. 15. 4Cognitivedysfunctionanddementia 3087. . diastolicbloodpressuretreatmenttargets 3052. 8. 16Hypertension, atrialfibrillation, andotherarrhythmias 3087. . 7. 3. 2Bloodpressuretargetsinspecificsubgroupsof. 8. 16. 1Oralanticoagulantsandhypertension 3088. . hypertensivepatients 3052. 8. 17Hypertensionandvasculardisease 3088. . 7. 4Treatmentofhypertension 3054. 8. 17. 1Carotidatherosclerosis 3088. . 7. 4. 1Lifestylechanges 3054. 8. 17. 2Arteriosclerosisandincreasedarterialstiffness 3088. . 7. 4. 2Dietarysodiumrestriction 3054. 8. 17. 3Lowerextremityarterialdisease 3089. . 7. 4. 3Moderationofalcoholconsumption 3055. 8. 18Hypertensioninvalvulardiseaseandaortopathy 3089. . 7. 4. 4Otherdietarychanges 3055. . 8. 18. 1Coarctationoftheaorta 3089. 7. 4. 5Weightreduction 3055. . 8. 18. 2Preventionofaorticdilationanddissectionin. 7. 4. 6Regularphysicalactivity 3056. . High-risksubjects 3089. 7. 4. 7Smokingcessation 3056. . 8. 18. 3Hypertensionbicuspidaorticvalve-related. 7. 5. Pharmacologicaltherapyforhypertension 3056. . aortopathy 3089. 7. 5. 1Drugsforthetreatmentofhypertension 3056. . 8. 19Hypertensionandsexualdysfunction 3089. 7. 5. 2Hypertensiondrugtreatmentstrategy 3059. . 8. 20Hypertensionandcancertherapy 3090. 7. 5. 3Thedrugtreatmentalgorithmforhypertension 3063. . 8. 21Perioperativemanagementofhypertension 3090. 7. 6Device-basedhypertensiontreatment 3067. . 9Managingconcomitantcardiovasculardiseaserisk 3091. 7. 6. 1Carotidbaroreceptorstimulation. . 9. 1Statinsandlipid-loweringdrugs 3091. (pacemakerandstent) 3067. . 9. 2Antiplatelettherapyandanticoagulanttherapy 3091. 7. 6. 2Renaldenervation 3067. . 9. 3. Glucose-loweringdrugsandbloodpressure 3092. . 7. 6. 3Creationofanarteriovenousfistula 3068. 10Patientfollow-up 3092. . 7. 6. 4Otherdevices 3068. 10. 1Follow-upofhypertensivepatients 3092. . 8Hypertensioninspecificcircumstances 3068. 10. 2Follow-upofsubjectswithhighnormalbloodpressure. . 8. 1Resistanthypertension 3068. andwhite-coathypertension 3092. . 8. 1. 1Definitionofresistanthypertension 3068. 10. 3Elevatedbloodpressureatcontrolvisits 3093. . 8. 1. 2Pseudo-resistanthypertension 3069. 10. 4Improvementinbloodpressurecontrolinhypertension: . . 8. 1. 3Diagnosticapproachtoresistanthypertension 3069. drugadherence 3093. . 8. 1. 4Treatmentofresistanthypertension 3070. 10. 5Continuedsearchforasymptomatichypertension-mediated. . 8. 2Secondaryhypertension 3071. organdamage 3094. . 8. 2. 1Drugsandothersubstancesthatmaycause. 10. 6Canantihypertensivemedicationsbereducedorstopped? . . 3094. . secondaryhypertension 3071. . 11Gapsintheevidence 3095. 8. 2. 2Geneticcausesofsecondaryhypertension 3071. . 12Keymessages 3096. 8. 3Hypertensionurgenciesandemergencies 3074. . 13WhattodoandwhatnottodomessagesfromtheGuidelines. . 3098. 8. 3. 1Acutemanagementofhypertensiveemergencies 3075. . 14Appendix 3100. 8. 3. 2Prognosisandfollow-up 3075. 15References 3100 Downloaded from by guest on 31 December 2025 3024 ESC/ESHGuidelines Abbreviations and acronyms. . . ESH EuropeanSocietyofHypertension. . . FEVER FelodipineEventReduction ABI Anklebrachialindex. . . HAS-BLED Hypertension, Abnormalrenal/liverfunction. ABPM Ambulatorybloodpressuremonitoring. . (1pointeach), Stroke, Bleedinghistoryor. ACCOMPLISH AvoidingCardiovascularEventsThrough. . predisposition, LabileINR, Elderly(65), . CombinationTherapyinPatientsLivingWith. . Drugs/alcoholconcomitantly(1pointeach). SystolicHypertension. . hemoglobin hemoglobin A1c HaemoglobinA1c. ACCORD ActiontoControlCardiovascularRiskin. . HBPM Homebloodpressuremonitoring. Diabetes. . HDL-C HDLcholesterol. ACE Angiotensin-convertingenzyme. . HELLP Haemolysis, elevatedliverenzymes, andlow. angiotensin-converting enzyme inhibitor Angiotensin-convertingenzymeinhibitor. . platelets. albumin-creatinine ratio Albumin: creatinineratio. . HFpEF Heartfailurewithpreservedejectionfraction. ADVANCE ActioninDiabetesandVascularDisease: . . HFrEF Heartfailurewithreducedejectionfraction. PreteraxandDiamicronMRControlled. . HMOD Hypertension-mediatedorgandamage. Evaluation. . . HOPE HeartOutcomesPreventionEvaluation. atrial fibrillation Atrialfibrillation. . HYVET HypertensionintheVeryElderlyTrial. ALLHAT AntihypertensiveandLipid-Lowering. . i. v. Intravenous. TreatmenttoPreventHeartAttackTrial. . IMT Intima-mediathickness. ALTITUDE AliskirenTrialinType2DiabetesUsing. . INVEST InternationalVerapamil-TrandolaprilStudy. CardiovascularandRenalDiseaseEndpoints. . ISH Isolatedsystolichypertension. angiotensin receptor blocker Angiotensinreceptorblocker. . JUPITER JustificationfortheUseofStatinsin. ASCOT Anglo-ScandinavianCardiacOutcomesTrial. . Prevention: anInterventionTrialEvaluating. AV Atrioventricular. . Rosuvastatin. body mass index Bodymassindex. . LDH Lactatedehydrogenase. blood pressure Bloodpressure. . LDL-C LDLcholesterol. bpm Beatsperminute. . LEAD Lowerextremityarterydisease. BSA Bodysurfacearea. . LIFE LosartanInterventionForEndpointreduction. coronary artery disease Coronaryarterydisease. . inhypertension. CAPPP CaptoprilPreventionProject. . LV Leftventricular. calcium channel blocker Calciumchannelblocker. . LVH Leftventricularhypertrophy. CHA2DS2-VASc Congestiveheartfailure, Hypertension, Age. . MAP Meanarterialpressure. _75years, Diabetesmellitus, Stroke, Vascular. . myocardial infarction Myocardialinfarction. disease, Age6574years, Sexcategory. . MR Magneticresonance. (female). . MRA Mineralocorticoidreceptorantagonist. chronic kidney disease Chronickidneydisease. . magnetic resonance imaging Magneticresonanceimaging. . CK-MB Creatininekinase-muscle/brain. MUCH Maskeduncontrolledhypertension. . CMR Cardiacmagneticresonance.",
    ". MRA Mineralocorticoidreceptorantagonist. chronic kidney disease Chronickidneydisease. . magnetic resonance imaging Magneticresonanceimaging. . CK-MB Creatininekinase-muscle/brain. MUCH Maskeduncontrolledhypertension. . CMR Cardiacmagneticresonance. . NORDIL NordicDiltiazem. COLM CombinationofOLMesartanandacalcium. . NS Non-significant. channelblockerordiureticinJapaneseelderly. . NT-proBNP N-terminalpro-Bnatriureticpeptide. hypertensivepatients. . o. d. Omnidie(everyday). CONVINCE ControlledOnsetVerapamilInvestigationof. . ONTARGET OngoingTelmisartanAloneandin. CardiovascularEndPoints. . combinationwithRamiprilGlobalEndpoint. COPD Chronicobstructivepulmonarydisease. . Trial. COPE CombinationTherapyofHypertensionto. . PAC Plasmaaldosteroneconcentration. PreventCardiovascularEvents. . peripheral arterial disease Peripheralarterydisease. computed tomography Computedtomography. . PATHS PreventionandTreatmentofHypertension. CV Cardiovascular. . Study. cardiovascular disease Cardiovasculardisease. . PRA Plasmareninactivity. DBP Diastolicbloodpressure. . PRC Plasmareninconcentration. DENERHTN RenalDenervationforHypertension. . PROGRESS Perindoprilprotectionagainstrecurrentstroke. DHP Dihydropyridine. . study. ECG Electrocardiogram. . PWV Pulsewavevelocity. estimated glomerular filtration rate Estimatedglomerularfiltrationrate. . renal artery stenosis Reninangiotensinsystem. ELSA EuropeanLacidipineStudyonAtherosclerosis. . RCT Randomizedcontrolledtrial. ENaC Epithelialsodiumchannel. . RWT Relativewallthickness. ESC EuropeanSocietyofCardiology. . SBP Systolicbloodpressure Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3025. . SCOPE StudyonCognitionandPrognosisinthe. . and updated. The Task Force received its entire financial support. Elderly. . fromtheESCandESHwithoutanyinvolvementfromthehealthcare. SCORE SystematicCOronaryRiskEvaluation. . industry. . SHEP SystolicHypertensionintheElderlyProgram. . TheESCCPGsupervisesandcoordinatesthepreparationofnew. SPC Single-pillcombination. . Guidelines. TheCommitteeisalsoresponsiblefortheendorsement. SPRINT SystolicBloodPressureInterventionTrial. . processoftheseGuidelines. TheESCGuidelinesundergoextensive. STOP-H SwedishTrialinOldPatientswith. . reviewbytheCPGandexternalexperts, andinthiscasebyESH-. Hypertension. . appointed experts. After appropriate revisions the Guidelines are. SUCH Sustaineduncontrolledhypertension. . approvedbyalltheexpertsinvolvedintheTaskForce. Thefinalized. Syst-China SystolicHypertensioninChina. . document is approved by theCPG and ESH for publication in the. Syst-Eur SystolicHypertensioninEurope. . EuropeanHeartJournalandintheJournalofHypertensionaswellas. TIA Transientischaemicattack. . BloodPressure. TheGuidelinesweredevelopedaftercarefulconsid-. TTE Transthoracicechocardiography. . eration of the scientific and medical knowledge and the evidence. VALUE ValsartanAntihypertensiveLong-termUse. . availableatthetimeoftheirdating. . Evaluation. . ThetaskofdevelopingESCandESHGuidelinesalsoincludesthe. VEGF Vascularendothelialgrowthfactor. . creation of educational tools and implementation programmes for. WUCH White-coatuncontrolledhypertension. . . the recommendations including condensed pocket guideline ver-. . sions, summary slides, booklets with essential messages, summary. . . cardsfornon-specialistsandanelectronicversionfordigitalapplica-. 1 Preamble. . tions (smartphones, etc. ). These versions are abridged and thus, if. . . needed, one should always refer to the full text version, which is. . Guidelinessummarizeandevaluateavailableevidencewiththeaimof. freelyavailableviathe ESCANDESHwebsitesandhostedonthe. . assistinghealthprofessionalsinselectingthebestmanagementstrat-. EHJANDJOURNALOFHYPERTENSIONwebsites. TheNational. . egiesforanindividualpatientwithagivencondition. Guidelinesand. SocietiesoftheESCareencouragedtoendorse, translateandimple-. . their recommendations should facilitate decision making of health. ment all ESC Guidelines. Implementation programmes are needed. . professionalsintheirdailypractice. However, thefinaldecisionscon-. because it has been shown that the outcome of disease may be. . cerninganindividualpatientmustbemadebytheresponsiblehealth. . favourably influenced by the thorough application of clinical. professional(s) in consultation with the patient and caregiver as. . recommendations. . appropriate. . . Surveysandregistriesareneededtoverifythatreal-lifedailyprac-. Agreatnumberofguidelineshavebeenissuedinrecentyearsby. . ticeisinkeepingwithwhatisrecommendedintheguidelines, thus. the European Society of Cardiology (ESC) and by the European. . completingtheloopbetweenclinicalresearch, writingofguidelines, . Society of Hypertension (ESH), as well as by other societies and. . disseminatingthemandimplementingthemintoclinicalpractice. . organisations. Becauseoftheimpactonclinicalpractice, qualitycrite-. . Health professionals are encouraged to take the ESC and ESH. riaforthedevelopmentofguidelineshavebeenestablishedinorder. . Guidelinesfullyintoaccountwhenexercisingtheirclinicaljudgment, . tomakealldecisionstransparenttotheuser. Therecommendations. . aswellasinthedeterminationandtheimplementationofpreventive, . for formulating and issuing ESC Guidelines can be found on the. . diagnosticortherapeuticmedicalstrategies. However, theESCand. ESCwebsite(. . ESHGuidelinesdonotoverrideinanywaywhatsoevertheindividual. Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). . . responsibilityofhealthprofessionalstomakeappropriateandaccu-. ESCGuidelinesrepresenttheofficialpositionoftheESConagiven. . ratedecisionsinconsiderationofeachpatientshealthconditionand. topicandareregularlyupdated. . . in consultation with that patient or the patients caregiver where. MembersofthisTaskForcewereselectedbytheESCandESHto. . appropriate and/or necessary. It is also the health professionals. represent professionals involved with the medical care of patients. . responsibilitytoverifytherulesandregulationsapplicabletodrugs. . withthispathology. Selectedexpertsinthefieldundertookacom-. anddevicesatthetimeofprescription. . . prehensive review of the published evidence for management of a. . . givenconditionaccordingtoESCCommitteeforPracticeGuidelines. . . (CPG)policyandapprovedbytheESH. Acriticalevaluationofdiag-. 2 Introduction. . nosticandtherapeuticprocedureswasperformed, includingassess-. . . mentoftheriskbenefitratio. Thelevelofevidenceandthestrength. Substantialprogresshasbeenmadeinunderstandingtheepidemiol-. . of the recommendation of particular management options were. ogy, pathophysiology, and risk associated with hypertension, and a. . weighed and graded according to predefined scales, as outlined in. . wealthofevidenceexiststodemonstratethatloweringbloodpres-. Tables1and2. . . sure(blood pressure)cansubstantiallyreduceprematuremorbidityandmortal-. Theexpertsofthewritingandreviewingpanelsprovideddeclara-. . ity. 110 A number of proven, highly effective, and well-tolerated. tionofinterestformsforallrelationshipsthatmightbeperceivedas. . lifestyleanddrugtreatmentstrategiescanachievethisreductionin. realorpotentialsourcesofconflictsofinterest. Theseformswere. . blood pressure. Despitethis, BPcontrolratesremainpoorworldwideandarefar. compiledintoonefileandcanbefoundontheESCwebsite(http: //. . from satisfactory across Europe. Consequently, hypertension. www. escardio. org/guidelines). Anychangesindeclarationsofinterest. . remains the major preventable cause of cardiovascular disease. thatariseduringthewritingperiodwerenotifiedtotheESCandESH. (cardiovascular disease)andall-causedeathgloballyandinourcontinent.",
    "Consequently, hypertension. www. escardio. org/guidelines). Anychangesindeclarationsofinterest. . remains the major preventable cause of cardiovascular disease. thatariseduringthewritingperiodwerenotifiedtotheESCandESH. (cardiovascular disease)andall-causedeathgloballyandinourcontinent. 1114 Downloaded from by guest on 31 December 2025 Table1 ESCClassesofrecommendations. . . are: (i) to base recommendations on properly conducted studies, Table2 ESCLevelsofevidence. . . identifiedfromanextensivereviewoftheliterature; (ii)togivethe. . . highest priority to data from randomized controlled trials (RCTs); . . . (iii)toalsoconsiderwell-conductedmeta-analysesofRCTsasstrong. . . evidence (this contrasts withnetwork meta-analyses, whichwe do. . . notconsidertohavethesamelevelofevidencebecausemanyofthe. . . comparisonsarenon-randomized); (iv)torecognizethatRCTscan-. . . notaddressmanyimportantquestionsrelatedtothediagnosis, risk. . . stratification, andtreatmentofhypertension, whichcanbeaddressed. . . by observational or registry-based studies of appropriate scientific. . . calibre; (v)togradethelevelofscientificevidenceandthestrengthof. . . recommendationsaccordingtoESCrecommendations(seesection. . . 1); (vi) torecognize that opinionsmaydiffer onkeyrecommenda-. . . tions, whichareresolvedbyvoting; and(vii)torecognizethatthere. . . arecircumstancesinwhichthereisinadequateornoevidence, but. . . that the question is important for clinical practice and cannot be. . These2018 ESC/ESHGuidelinesfor themanagement of arterial. . ignored. Inthesecircumstances, weresorttopragmaticexpertopin-. hypertensionaredesignedforadultswithhypertension, i. e. aged_18. . ionandendeavourtoexplainitsrationale. . years. ThepurposeofthereviewandupdateoftheseGuidelineswas. . EachmemberoftheTaskForcewasassignedspecificwritingtasks, . toevaluateandincorporatenewevidenceintotheGuidelinerecom-. . whichwerereviewedbysectionco-ordinatorsandthenbythetwo. mendations. ThespecificaimsoftheseGuidelinesweretoproduce. . chairs, oneappointedbytheESCandtheotherbytheESH. Thetext. pragmaticrecommendationstoimprovethedetectionandtreatment. . was developed over approximately 24 months, during which the. ofhypertension, andtoimprovethepoorratesofBPcontrolbypro-. . TaskForcemembersmetcollectivelyandcorrespondedintensively. motingsimpleandeffectivetreatmentstrategies. . . withoneanotherbetweenmeetings. Beforepublication, thedocu-. These joint 2018 Guidelines follow the same principles upon. . mentwasreviewedbyEuropeanreviewersselectedbytheESCand. whichaseriesofhypertensionGuidelineswerejointlyissuedbythe. . ESH, andbyrepresentativesofESCNationalCardiacSocietiesand. twosocietiesin2003, 2007, and2013. Thesefundamentalprinciples. . ESHNationalHypertensionSocieties. . 8102CSE 3026 ESC/ESHGuidelines Classes of Definition Suggested wording to use recommendations Class I Evidence and/orgeneralagreement Is recommended/is that a given treatmentorprocedure is indicated beneficial, useful, effective. Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure. Class IIa Weight of evidence/opinion is in favour Should be considered of usefulness/efficacy. Class IIb Usefulness/efficacy is less well May be considered established by evidence/opinion. Class III Evidence or general agreement that Is not recommended the given treatment or procedure is not useful/effective, and in some cases may be harmful. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3027 2. 1 What is new and what has changed in the 2018 ESC/ESH Arterial Hypertension Guidelines? Changesinrecommendations 2013 2018 Diagnosis Diagnosis OfficeBPisrecommendedforscreeninganddiagnosisof Itisrecommendedtobasethediagnosisofhypertensionon: hypertension. RepeatedofficeBPmeasurements; or Out-of-officeBPmeasurementwithABPMand/orHBPMiflogistically andeconomicallyfeasible. Treatmentthresholds Treatmentthresholds HighnormalBP(130139/8589mmHg): Unlessthenecessary HighnormalBP(130139/8589mmHg): Drugtreatmentmaybe evidenceisobtained, itisnotrecommendedtoinitiate consideredwhenCVriskisveryhighduetoestablishedCVD, especially antihypertensivedrugtherapyathighnormalBP. coronary artery disease. Treatmentthresholds Treatmentthresholds Treatmentoflow-riskgrade1hypertension: Treatmentoflow-riskgrade1hypertension: Initiationofantihypertensivedrugtreatmentshouldalsobe Inpatientswithgrade1hypertensionatlowmoderate-riskandwithout consideredingrade1hypertensivepatientsatlowmoderate-risk, evidenceofHMOD, blood pressure-loweringdrugtreatmentisrecommendedifthe whenBPiswithinthisrangeatseveralrepeatedvisitsorelevatedby patientremainshypertensiveafteraperiodoflifestyleintervention. ambulatoryBPcriteria, andremainswithinthisrangedespitea reasonableperiodoftimewithlifestylemeasures. Treatmentthresholds Treatmentthresholds Olderpatients Olderpatients Antihypertensivedrugtreatmentmaybeconsideredintheelderly blood pressure-loweringdrugtreatmentandlifestyleinterventionisrecommendedin (atleastwhenyoungerthan80years)whenSBPisinthe fitolderpatients(65yearsbutnot80years)whenSBPisinthe 140159mmHgrange, providedthatantihypertensivetreatmentis grade1range(140159mmHg), providedthattreatmentiswelltolerated. welltolerated. BPtreatmenttargets BPtreatmenttargets AnSBPgoalof140mmHgisrecommended. Itisrecommendedthatthefirstobjectiveoftreatmentshouldbeto lowerBPto140/90mmHginallpatientsand, providedthatthe treatmentiswelltolerated, treatedBPvaluesshouldbetargetedto 130/80mmHgorlowerinmostpatients. Inpatients65yearsitisrecommendedthatSBPshouldbelowered toaBPrangeof120129mmHginmostpatients. Continued Downloaded from by guest on 31 December 2025 3028 ESC/ESHGuidelines BPtreatmenttargetsinolder BPtreatmenttargetsinolderpatients(6580years) patients(6580years) AnSBPtargetofbetween140150mmHg Inolderpatients(_65years), itisrecommendedthatSBPshouldbe isrecommendedforolderpatients(6580years). targetedtoaBPrangeof130139mmHg. BPtreatmenttargetsinpatientsagedover80years BPtreatmenttargetsinpatientsagedover80years AnSBPtargetbetween140150mmHgshouldbeconsideredin AnSBPtargetrangeof130139mmHgisrecommendedforpeopleolder peopleolderthan80years, withaninitialSBP_160mmHg, provided than80years, iftolerated. thattheyareingoodphysicalandmentalcondition. DBPtargets DBPtargets ADBPtargetof90mmHgisalwaysrecommended, exceptin ADBPtargetof80mmHgshouldbeconsideredforallhypertensive patientswithdiabetes, inwhomvalues85mmHgare patients, independentofthelevelofriskandcomorbidities. recommended. Initiationofdrugtreatment Initiationofdrugtreatment Initiationofantihypertensivetherapywithatwo-drugcombination Itisrecommendedtoinitiateanantihypertensivetreatmentwitha maybeconsideredinpatientswithmarkedlyhighbaselineBPor two-drugcombination, preferablyinaSPC. Theexceptionsarefrailolder athighCVrisk. patientsandthoseatlowriskandwithgrade1hypertension(particularly ifSBPis150mmHg). Resistanthypertension Resistanthypertension Mineralocorticoidreceptorantagonists, amiloride, andthealpha-1 Recommendedtreatmentofresistanthypertensionistheadditionof blockerdoxazosinshouldbeconsideredifnocontraindication Low-dosespironolactonetoexistingtreatment, ortheadditionoffurther exists. diuretictherapyifintoleranttospironolactone, witheithereplerenone, amiloride, higher-dosethiazide/thiazide-likediureticoraloopdiuretic, ortheadditionofbisoprololordoxazosin. Device-basedtherapyforhypertension Device-basedtherapyforhypertension Incaseofineffectivenessofdrugtreatment, invasiveprocedures Useofdevice-basedtherapiesisnotrecommendedfortheroutine suchasrenaldenervationandbaroreceptorstimulationmaybe treatmentofhypertension, unlessinthecontextofclinicalstudiesand considered. RCTs, untilfurtherevidenceregardingtheirsafetyandefficacybecomes available. RecommendationGrading GradeI GradeIIa GradeIIb GradeIII ABPMambulatorybloodpressuremonitoring; blood pressurebloodpressure; coronary artery diseasecoronaryarterydisease; CVcardiovascular; cardiovascular diseasecardiovasculardisease; DBPdiastolic bloodpressure; HBPMhomebloodpressuremonitoring; HMODhypertension-mediatedorgandamage; RCTrandomizedcontrolledtrial; SBPsystolicbloodpressure; SPCsingle-pillcombination. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3029 Newsections/recommendations (cid: 2)Whentosuspectandhowtoscreenforthecausesofsecondaryhypertension (cid: 2)Managementofhypertensionemergencies (cid: 2)UpdatedrecommendationsonthemanagementofBPinacutestroke (cid: 2)Updatedrecommendationsonthemanagementofhypertensioninwomenandpregnancy (cid: 2)Hypertensionindifferentethnicgroups (cid: 2)TheeffectsofaltitudeonBP (cid: 2)Hypertensionandchronicobstructivepulmonarydisease (cid: 2)HypertensionandAFandotherarrhythmias (cid: 2)Oralanticoagulantuseinhypertension (cid: 2)Hypertensionandsexualdysfunction (cid: 2)Hypertensionandcancertherapies (cid: 2)Perioperativemanagementofhypertension (cid: 2)Glucose-loweringdrugsandBP (cid: 2)UpdatedrecommendationsonCVriskassessmentandmanagement: (i)usingtheSCOREsystemtoassessriskin patientswithoutCVD; (ii)theimportanceofHMODinmodifyingCVrisk; and(iii)theuseofstatinsandaspirinfor CVDprevention Newconcepts BPmeasurement Wideruseofout-of-officeBPmeasurementwithABPMand/orHBPM, especiallyHBPM, asanoptiontoconfirmthediagnosis ofhypertension, detectwhite-coatandmaskedhypertension, andmonitorBPcontrol. LessconservativetreatmentofBPinolderandveryoldpatients LowerBPthresholdsandtreatmenttargetsforolderpatients, withemphasisonconsiderationsofbiologicalratherthan chronologicalage(i. e. theimportanceoffrailty, independence, andthetolerabilityoftreatment). Recommendationthattreatmentshouldneverbedeniedorwithdrawnonthebasisofage, providedthattreatmentistolerated. ASPCtreatmentstrategytoimproveBPcontrol Preferreduseoftwo-drugcombinationtherapyfortheinitialtreatmentofmostpeoplewithhypertension. Asingle-pilltreatmentstrategyforhypertensionwiththepreferreduseofSPCtherapyformostpatients. SimplifieddrugtreatmentalgorithmswiththepreferreduseofanACEinhibitororARB, combinedwithaCCBand/ora thiazide/thiazide-likediuretic, asthecoretreatmentstrategyformostpatients, withbeta-blockersusedforspecificindications. NewtargetrangesforBPintreatedpatients TargetBPrangesfortreatedpatientstobetteridentifytherecommendedBPtargetandlowersafetyboundariesfortreatedBP, accordingtoapatientsageandspecificcomorbidities. Detectingpooradherencetodrugtherapy AstrongemphasisontheimportanceofevaluatingtreatmentadherenceasamajorcauseofpoorBPcontrol. Akeyrolefornursesandpharmacistsinthelonger-termmanagementofhypertension Theimportantroleofnursesandpharmacistsintheeducation, support, andfollow-upoftreatedhypertensivepatientsis emphasizedaspartoftheoverallstrategytoimproveBPcontrol. ABPMambulatorybloodpressuremonitoring; ACEangiotensin-convertingenzyme; atrial fibrillationatrialfibrillation; angiotensin receptor blockerangiotensinreceptorblocker; blood pressurebloodpressure; calcium channel blocker calciumchannelblocker; CVcardiovascular; cardiovascular diseasecardiovasculardisease; HBPMhomebloodpressuremonitoring; HMODhypertension-mediatedorgandamage; SCORESystematicCOronaryRiskEvaluation; SPCsingle-pillcombination.",
    "ABPMambulatorybloodpressuremonitoring; ACEangiotensin-convertingenzyme; atrial fibrillationatrialfibrillation; angiotensin receptor blockerangiotensinreceptorblocker; blood pressurebloodpressure; calcium channel blocker calciumchannelblocker; CVcardiovascular; cardiovascular diseasecardiovasculardisease; HBPMhomebloodpressuremonitoring; HMODhypertension-mediatedorgandamage; SCORESystematicCOronaryRiskEvaluation; SPCsingle-pillcombination. Downloaded from by guest on 31 December 2025 3030 ESC/ESHGuidelines. 3 Definition, classification, and. . age can be found in the 2016 ESH Guidelines for children and. . . adolescents. 18 epidemiological aspects of. . . . hypertension. . 3. 2 Classification of Blood Hypertension. . . 3. 1 Definition of hypertension ClassificationofBP The relationship between blood pressure and cardiovascular (CV) and renal eventsiscontinuous, makingthedistinctionbetweennormotension Recommendation Classa Levelb and hypertension, based on cut-off blood pressure values, somewhat arbitrary. 2, 4, 8However, inpractice, cut-offBPvaluesareusedforpragItisrecommendedthatBPbeclassifiedas matic reasons to simplify the diagnosis and decisions about optimal, normal, Highnormal, orgrades I C treatment. Epidemiological associations between blood pressure and CV risk 13hypertension, accordingtoofficeBP. extend from very Low levels of blood pressure i. e. systolic blood pressure (SBP) 115 mmHg. However, hypertension is defined as the level of blood pressure at blood pressurebloodpressure. which the benefits of treatment (either with lifestyle interventions aClassofrecommendation bLevelofevidence. or drugs) unequivocally outweigh the risks of treatment, as documentedbyclinicaltrials. Thisevidencehasbeenreviewed(seesection 7. 2 for detailed discussion of hypertension diagnostic 3. 3 Prevalence of hypertension thresholds)andprovidesthebasisfortherecommendationthatthe classificationofBPanddefinitionofhypertensionremainunchanged BasedonofficeBP, theglobalprevalenceofhypertensionwasestifrompreviousESH/ESCGuidelines(Table3). 15, 16, 17 Thecurrent matedtobe1. 13billionin2015, 5withaprevalenceofover150milbackground informationanddetailed discussionofthedataforthe lion in central and eastern Europe. The overall prevalence of following section of these Guidelines can be found in ESC hypertension in adults is around 30-45%, 12 with a global ageCardioMed. standardizedprevalenceof24and20%inmenandwomen, respecHypertensionisdefinedasofficeSBPvalues_140mmHgand/or tively, in 2015. 5 This High prevalence of hypertension is consistent diastolicBP(DBP)values_90mmHg. Thisisbasedonevidencefrom acrosstheworld, irrespectiveofincomestatus, i. e. inlower, middle, multipleRCTsthattreatmentofpatientswiththeseBPvaluesisbenandhigherincomecountries. 12Hypertensionbecomesprogressively eficial (see section 7). The same classification is used in younger, more common with advancing age, with a prevalence of 60% in middle-aged, andolderpeople, whereasBPcentilesareusedinchilpeopleaged60years. 12Aspopulationsage, adoptmoresedentary drenandteenagers, inwhomdatafrominterventionaltrialsarenot lifestyles, andincreasetheirbodyweight, theprevalenceofhypertenavailable. DetailsonBPclassificationinboysandgirls_16yearsof sionworldwidewillcontinuetorise. Itisestimatedthatthenumber Table3 Classificationofofficebloodpressureaanddefinitionsofhypertensiongradeb Category Systolic(mmHg) Diastolic(mmHg) Optimal 120 and 80 Normal 120129 and/or 8084 Highnormal 130139 and/or 8589 Grade1hypertension 140159 and/or 9099 Grade2hypertension 160179 and/or 100109 Grade3hypertension _180 and/or _110 Isolatedsystolichypertensionb _140 and 90 blood pressurebloodpressure; SBPsystolicbloodpressure. aBPcategoryisdefinedaccordingtoseatedclinicBPandbythehighestlevelofBP, whethersystolicordiastolic. bIsolatedsystolichypertensionisgraded1, 2, or3accordingtoSBPvaluesintherangesindicated. Thesameclassificationisusedforallagesfrom16years. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3031 Table4 Factorsinfluencingcardiovascularriskinpatientswithhypertension Demographiccharacteristicsandlaboratoryparameters Sexa(menwomen) Agea Smoking(currentorpasthistory)a TotalcholesterolaandHDL-C Uricacid Diabetesa Overweightorobesity FamilyhistoryofprematureCVD(menaged55yearsandwomenaged65years) Familyorparentalhistoryofearly-onsethypertension Early-onsetmenopause Sedentarylifestyle Psychosocialandsocioeconomicfactors Heartrate(restingvalues80beats/min) AsymptomaticHMOD Arterialstiffening: Pulsepressure(inolderpeople)_60mmHg CarotidfemoralPWV10m/s ECGLVH(SokolowLyonindex35mm, orRinaVL_11mm; Cornellvoltagedurationproduct2440mm. ms, orCornellvoltage28mmin menor20mminwomen) EchocardiographicLVHLVmassindex: men50g/m2. 7; women47g/m2. 7(heightinm2. 7); indexationforBSAmaybeusedinnormal-weight patients; LVmass/BSAg/m2115(men)and95(women) Microalbuminuria(30300mg/24h), orelevatedalbumincreatinineratio(30300mg/g; 3. 434mg/mmol)(preferentiallyonmorningspoturine)b ModerateCKDwitheGFR3059mL/min/1. 73m2(BSA)orsevereCKDeGFR30mL/min/1. 73m2b Ankle-brachialindex0. 9 Advancedretinopathy: haemorrhagesorexudates, papilloedema EstablishedCVorrenaldisease Cerebrovasculardisease: ischaemicstroke, cerebralhaemorrhage, TIA coronary artery disease: myocardialinfarction, angina, myocardialrevascularization Presenceofatheromatousplaqueonimaging Heartfailure, includingHFpEF Peripheralarterydisease Atrialfibrillation BSAbodysurfacearea; coronary artery diseasecoronaryarterydisease; chronic kidney diseasechronickidneydisease; CVcardiovascular; cardiovascular diseasecardiovasculardisease; ECGelectrocardiogram; estimated glomerular filtration rate estimatedglomerularfiltrationrate; HDL-CHDLcholesterol; HFpEFheartfailurewithpreservedejectionfraction; HMODhypertension-mediatedorgandamage; LV leftventricular; LVHleftventricularhypertrophy; PWVpulsewavevelocity; SCORESystematicCOronaryRiskEvaluation; TIAtransientischaemicattack. aCVriskfactorsincludedintheSCOREsystem. bProteinuriaandreducedeGFRareindependentriskfactors. SeeTable6forCVriskmodifiers. Downloaded from by guest on 31 December 2025 3032 ESC/ESHGuidelines Table5 Tenyearcardiovascularriskcategories(SystematicCOronaryRiskEvaluationsystem) Veryhighrisk Peoplewithanyofthefollowing: DocumentedCVD, eitherclinicalorunequivocalonimaging. ClinicalCVDincludesacutemyocardialinfarction, acutecoronarysyndrome, coronaryorotherarterialrevascularization, stroke, TIA, aorticaneurysm, andPAD UnequivocaldocumentedCVDonimagingincludessignificantplaque(i. e. _50%stenosis)onangiographyor ultrasound; itdoesnotincludeincreaseincarotidintima-mediathickness Diabetesmellituswithtargetorgandamage, e. g. proteinuriaorawithamajorriskfactorsuchasgrade3 hypertensionorhypercholesterolaemia SevereCKD(estimated glomerular filtration rate30mL/min/1. 73m2) Acalculated10yearSCOREof_10% Highrisk Peoplewithanyofthefollowing: Markedelevationofasingleriskfactor, particularlycholesterol8mmol/L(310mg/dL), e. g. familialhypercholesterolaemiaorgrade3hypertension(blood pressure_180/110mmHg) Mostotherpeoplewithdiabetesmellitus(exceptsomeyoungpeoplewithtype1diabetesmellitusandwithoutmajorriskfactors, whomaybeatmoderate-risk) HypertensiveLVH ModerateCKDeGFR30-59mL/min/1. 73m2) Acalculated10yearSCOREof5-10% Moderaterisk Peoplewith: Acalculated10yearSCOREof(cid: 4)1to5% Grade2hypertension Manymiddle-agedpeoplebelongtothiscategory Lowrisk Peoplewith: Acalculated10yearSCOREof1% blood pressurebloodpressure; chronic kidney diseasechronickidneydisease; cardiovascular diseasecardiovasculardisease; estimated glomerular filtration rateestimatedglomerularfiltrationrate; LVHleftventricularhypertrophy; TIA transientischaemicattack; peripheral arterial diseaseperipheralarterydisease; SCORESystematicCOronaryRiskEvaluation. . ofpeoplewithhypertensionwillincreaseby1520%by2025, reach-. . hypertension with an increased risk of developing atrial fibrillation. ingcloseto1. 5billion. 19. . (atrial fibrillation), 20andevidenceisemergingthatlinksearlyelevationsofBPto. . . increasedriskofcognitivedeclineanddementia. 21, 22. 3. 4 Blood Hypertension relationship with risk. . The continuous relationship between blood pressure and risk of events has. of cardiovascular and renal events. . been shown at all ages23 and in all ethnic groups, 24, 25 and extends. . . fromhighBPlevelstorelativelylowvalues. SBPappearstobeabetElevatedBPwastheleadingglobalcontributortoprematuredeathin. . . ter predictor of events than DBP after the age of 50 years.",
    ". . fromhighBPlevelstorelativelylowvalues. SBPappearstobeabetElevatedBPwastheleadingglobalcontributortoprematuredeathin. . . ter predictor of events than DBP after the age of 50 years. 23, 26, 27 2015, accountingforalmost10milliondeathsandover200million. . disability-adjustedlifeyears. 3Importantly, despiteadvancesindiagno-. . HighDBPisassociatedwithincreasedCVriskandismorecommonly. . elevated in younger (50 years) vs. older patients. DBP tends to sisandtreatmentoverthepast30years, thedisability-adjustedlife. . . decline from midlife as a consequence of arterial stiffening; conseyears attributable to hypertension have increased by 40% since. . 1990. 3SBP_140mmHgaccountsformostofthemortalityanddis-. . quently, SBPassumesevengreaterimportanceasariskfactorfrom. . midlife. 26Inmiddle-agedandolderpeople, increasedpulsepressure abilityburden((cid: 3)70%), andthelargestnumberofSBP-relateddeaths. . . (thedifferencebetweenSBPandDBPvalues)hasadditionaladverse per year are due to ischaemic Heart disease (4. 9 million), haemor-. . rhagicstroke(2. 0million), andischaemicstroke(1. 5million). 3. . . prognosticsignificance. 28, 29. BothofficeBPandout-of-officeBPhaveanindependentandcon-. . . 3. 5 Hypertension and total tinuous relationship with the incidence of several CV events hae-. . morrhagic stroke, ischaemic stroke, myocardial infarction, sudden. . . cardiovascular risk assessment. death, heartfailure, andperipheralarterydisease(peripheral arterial disease), aswellas. . Hypertensionrarelyoccursinisolation, andoftenclusterswithother. end-stage renal disease. 4 Accumulating evidence is closely linking. CV risk factors such as dyslipidaemia and glucose intolerance. 30, 31 Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3033 ThismetabolicriskfactorclusteringhasamultiplicativeeffectonCV Table6 Riskmodifiersincreasingcardiovascularrisk risk. 32Consequently, quantificationoftotalCVrisk(i. e. thelikelihood estimatedbytheSystemicCOronaryRiskEvaluation ofapersondevelopingaCVeventoveradefinedperiod)isanimpor- (SCORE)system35 tant part of the risk stratification process for patients with hypertension. Socialdeprivation, theoriginofmanycausesofCVD ManyCVriskassessmentsystemsareavailableandmostproject 10yearrisk. Since2003, theEuropeanGuidelinesonCVDprevenObesity(measuredbyBMI)andcentralobesity(measuredby tion have recommended use of the Systematic COronary Risk waistcircumference) Evaluation(SCORE)systembecauseitisbasedonlarge, representaPhysicalinactivity tiveEuropeancohortdatasets(availableat: Guidelines--Education/Practice-tools/cardiovascular disease-prevention-toolbox/SC Psychosocialstress, includingvitalexhaustion ORE-Risk-Charts). TheSCOREsystemestimatesthe10yearriskof FamilyhistoryofprematureCVD(occurringatage55yearsin afirstfatalatheroscleroticevent, inrelationtoage, sex, smokinghabmenand60yearsinwomen) its, totalcholesterollevel, andSBP. TheSCOREsystemalsoallows calibration for different CV risk levels across numerous European Autoimmuneandotherinflammatorydisorders countriesandhasbeenexternallyvalidated. 33Apreviouslimitation Majorpsychiatricdisorders oftheSCOREsystemwasthatitappliedonlytopatientsaged4065 years; however, the SCORE system has recently been adapted for Treatmentforinfectionwithhumanimmunodeficiencyvirus patientsovertheageof65years. 34DetailedinformationonCVrisk assessmentisavailable. 35 Atrialfibrillation FactorsinfluencingCVriskfactorsinpatientswithhypertension LVhypertrophy are shown in Table 4. Hypertensive patients with documented chronic kidney disease cardiovascular disease, including asymptomatic atheromatous disease on imaging, type1ortype2diabetes, veryhighlevelsofindividualriskfactors Obstructivesleepapnoeasyndrome (includinggrade3hypertension), orchronickidneydisease(chronic kidney disease; stages 3-5), are automatically considered to be at very High (i. e. body mass indexbodymassindex; chronic kidney diseasechronickidneydisease; cardiovascular diseasecardiovascular _10%CVDmortality)orhigh(i. e. 5-10%CVDmortality)10year disease; LVleftventricular. CVrisk(Table5). SuchpatientsdonotneedformalCVriskestimation to determine their need for treatment of their hypertension andotherCVriskfactors. Forallotherhypertensivepatients, estimation of 10 year CV risk using the SCORE system is recomTable7 CorrectionfactorsfortheSystemic mended. Estimation should be complemented by assessment of COronaryRiskEvaluation(SCORE)cardiovascularrisk hypertension-mediated organ damage (HMOD), which can also estimatesinfirst-generationimmigrantstoEurope35 increase CV risk to a higher level, even when asymptomatic (see Table4andsections3. 6and4). Regionoforigin Multiplicationfactor Thereisalsoemergingevidencethatanincreaseinserumuricacid tolevelslowerthanthosetypicallyassociatedwithgoutisindependSouthernAsia 1. 4 entlyassociatedwithincreasedCVriskinboththegeneralpopulaSub-SaharanAfrica 1. 3 tionandinhypertensivepatients. Measurementofserumuricacidis recommendedaspartofthescreeningofhypertensivepatients. 36 Caribbean 1. 3 The SCORE system only estimates the risk of fatal CV events. WesternAsia 1. 2 The risk of total CV events (fatal and non-fatal) is approximately three times higher than the rate of fatal CV events in men and NorthernAfrica 0. 9 fourtimeshigherinwomen. Thismultiplierisattenuatedtolessthan EasternAsia 0. 7 threetimesinolderpeopleinwhomafirsteventismorelikelytobe fatal. 37 SouthernAmerica 0. 7 ThereareimportantgeneralmodifiersofCVrisk(Table6)aswell asspecificCVriskmodifiersforpatientswithhypertension. CVrisk modifiersareparticularlyimportantattheCVriskboundaries, and. especiallyforpatientsatmoderate-riskinwhomariskmodifiermight. . 3. 6 Importance of hypertension-. convertmoderate-risktohighriskandinfluencetreatmentdecisions. . . mediated organ damage in refining with regard to CV risk factor management. Furthermore, CV risk. . . cardiovascular risk assessment in estimatesbytheSCOREsystemmaybemodifiedinfirst-generation. . immigrants to Europe and CV risk scores in such patients may be. . . hypertensive patients. adjustedbycorrectionfactors(Table7). Furtherdetailsoftheimpact. . AuniqueandimportantaspectofCVriskestimationinhypertensive. ofCVriskmodifiersareavailablefromtheESC2016CVDpreven-. . patientsistheneedtoconsidertheimpactofHMOD. Thiswasprevi-. tionGuidelines. 35. ously termed target organ damage, but HMOD more accurately Downloaded from by guest on 31 December 2025. describeshypertension-inducedstructuraland/orfunctionalchanges. . withamarkedlyabnormalriskfactorprofile. Inthelatter, relativerisk. inmajororgans(i. e. theheart, brain, retina, Kidney, andvasculature). . iselevatedevenifabsoluteriskislow. TheuseofCVriskagehas. . (Table4). Thereare three importantconsiderations: (i) notall fea-. been proposed as a useful way of communicating risk and making. . turesofHMODareincludedintheSCOREsystem(CKDandestab-. treatment decisions, especially for younger people at Low absolute. lished vascular disease are included) and several hypertensive. . risk but with High relative risk. 35 This works by illustrating how a. . HMODs (e. g. cardiac, vascular, and retinal) have well-established. youngerpatient(e. g. a40-year-old)withriskfactorsbutlowabsolute. . adverseprognosticsignificance(seesection5)andmay, especiallyif.",
    "HMODs (e. g. cardiac, vascular, and retinal) have well-established. youngerpatient(e. g. a40-year-old)withriskfactorsbutlowabsolute. . adverseprognosticsignificance(seesection5)andmay, especiallyif. riskhasaCVriskequivalenttoamucholderperson(60years)with. . HMODispronounced, leadtoahighCVriskevenintheabsenceof. optimalriskfactors; thus, theCVriskageoftheyoungerpatientis60. . classicalCVriskfactors; (ii)thepresenceofHMODiscommonand. years. The CV risk age can be automatically calculated using. oftengoesundetected; 38and(iii)thepresenceofmultipleHMODs. . HeartScore(www. heartscore. org). . . in the same patient is also common, and further increases CV. Asecondconsiderationisthatthepresenceofconcomitantdis-. risk. 3941 Consequently, the inclusion of HMOD assessment is. . easeisoftenrecordedinabinarywayinCVriskassessmentsystems. . importantinpatientswithhypertensionandhelpsidentifyhigh-risk. (e. g. Diabetes, yes/no). Thisdoesnotreflecttheimpactoftheseverity. . orveryhigh-riskhypertensivepatientswhomayotherwisebemis-. . ordurationofconcomitantdiseasesontotalCVrisk. Forexample, . classifiedashavingalowerlevelofriskbytheSCOREsystem. 42This. . long-standing Diabetes is clearly associated with High risk, whereas. is especially true for the presence of left ventricular hypertrophy. . theriskislesscertainforrecent-onsetdiabetes. 34. (LVH), CKDwithalbuminuriaorproteinuria, orarterialstiffening43. . A third conundrum specific to hypertensionis whatBPvalue to. (see section 5). The impact of progression of the stages of. . useinCVriskassessmentinapatientwhoisreceivingtreatmentfor. hypertension-associated disease (from uncomplicated through to. . hypertension. Iftreatmentwascommencedrecently, itseemsappro-. asymptomaticorestablisheddisease), accordingtodifferentgrades. . priate to use the pre-treatment blood pressure value. If treatment has been. of hypertension and the presence of CV risk factors, HMOD, or. . long-standing, using the current treated blood pressure value will invariably. comorbidities, isillustratedinFigure1formiddle-agedindividuals. . . underestimate risk because it does not reflect prior longer-term. . . exposure tohigher blood pressure levels, and antihypertensivetreatmentdoes. 3. 7 Challenges in cardiovascular risk. . notcompletelyreversetheriskevenwhenBPiswellcontrolled. If. assessment. . treatmenthasbeenlong-standing, thenthetreatedBPvalueshould. . CVriskisstronglyinfluencedbyage(i. e. olderpeopleareinvariably. . be used, with the caveat that the calculated CV risk will be lower. at highabsoluteCV risk). In contrast, theabsoluteriskofyounger. . thanthepatientsactualrisk. Afourthconundrumishowtoimpute. people, particularlyyoungerwomen, isinvariablylow, eveninthose. out-of-officeBPvaluesintoriskcalculatorsthathavebeencalibrated blood pressure (mmHg) grading Hypertension Other risk factors, disease High normal Grade 1 Grade 2 Grade 3 HMOD, or disease staging SBP 130139 SBP 140159 SBP 160179 SBP 180 DBP 8589 DBP 9099 DBP 100109 or DBP 110 No other risk Low risk Low risk Moderate risk High risk factors Stage 1 Moderate to (uncomplicated) 1 or 2 risk factors Low risk Moderate risk High risk High risk Low to Moderate to 3 risk factors High Risk High risk Moderate risk High risk HMOD, chronic kidney disease grade Stage 2 3, or Diabetes Moderate to High to (asymptomatic High risk High risk mellitus without High risk very High risk disease) organ damage Established cardiovascular disease, Stage 3 chronic kidney disease grade 4, or (established Very High risk Very High risk Very High risk Very High risk Diabetes mellitus disease) with organ damage 8102 HSE/CSE 3034 ESC/ESHGuidelines Figure1 Classificationofhypertensionstagesaccordingtobloodpressurelevels, presenceofcardiovascularriskfactors, hypertension-mediated organ damage, or comorbidities. CV risk is illustratedfor a middle-aged male. TheCVriskdoesnot necessarily correspond tothe actual risk atdifferentages. TheuseoftheSCOREsystemisrecommendedforformalestimationofCVriskfortreatmentdecisions. blood pressurebloodpressure; chronic kidney diseasechronickidneydisease; CVcardiovascular; DBPdiastolicbloodpressure; HMODhypertension-mediatedorgandamage; SBPsystolic bloodpressure; SCORESystematicCOronaryRiskEvaluation. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3035 accordingtoofficeBPreadings. Thesevariouslimitationsshouldbe Table8 Officebloodpressuremeasurement keptinmindwhenestimatingCVriskinclinicalpractice. Patientsshouldbeseatedcomfortablyinaquietenvironment HypertensionandCVriskassessment for5minbeforebeginningBPmeasurements. Recommendation Classa Levelb ThreeBPmeasurementsshouldberecorded, 12minapart, andadditionalmeasurementsonlyifthefirsttworeadingsdiffer CVriskassessmentwiththeSCOREsystem by10mmHg. BPisrecordedastheaverageofthelasttwoBP isrecommendedforhypertensivepatients readings. whoarenotalreadyathighorveryhighrisk Additionalmeasurementsmayhavetobeperformedinpatients duetoestablishedCVD, renaldisease, or I B withunstableBPvaluesduetoarrhythmias, suchasinpatents Diabetes, amarkedlyelevatedsingleriskfacwithAF, inwhommanualauscultatorymethodsshouldbeused tor(e. g. cholesterol), orhypertensive LVH. 33, 35 asmostautomateddeviceshavenotbeenvalidatedforBP measurementinpatientswithAF. a cardiovascular diseasecardiovasculardisease; LVH leftventricularhypertrophy; SCORE Useastandardbladdercuff(1213cmwideand35cmlong) SystematicCOronaryRiskEvaluation. formostpatients, buthavelargerandsmallercuffsavailablefor aClassofrecommendation. bLevelofevidence. larger(armcircumference32cm)andthinnerarms, respectively. Thecuffshouldbepositionedattheleveloftheheart, withthe 4 Blood Hypertension measurement backandarmsupportedtoavoidmusclecontractionandisometricexercise-dependantincreasesinBP. 4. 1 Conventional office Blood Hypertension measurement Whenusingauscultatorymethods, usephaseIandV(sudden reduction/disappearance)KorotkoffsoundstoidentifySBPand Auscultatory or oscillometric semiautomatic or automatic sphygDBP, respectively. momanometersarethepreferredmethodformeasuringBPinthe doctorsoffice. ThesedevicesshouldbevalidatedaccordingtostandMeasureBPinbotharmsatthefirstvisittodetectpossible ardizedconditionsandprotocols. 44BPshouldinitiallybemeasuredin between-armdifferences. Usethearmwiththehighervalueas bothupperarms, usinganappropriatecuffsizeforthearmcircumferthereference. ence. AconsistentandsignificantSBPdifferencebetweenarms(i. e. 15 mmHg) is associated with an increased CV risk, 45 most likely MeasureBP1minand3minafterstandingfromaseatedpositioninallpatientsatthefirstmeasurementtoexcludeortho- duetoatheromatousvasculardisease. Wherethereisadifferencein statichypotension. LyingandstandingBPmeasurementsshould BPbetweenarms, ideallyestablishedbysimultaneousmeasurement, alsobeconsideredinsubsequentvisitsinolderpeople, people thearmwiththehigherBPvaluesshouldbeusedforallsubsequent withdiabetes, andpeoplewithotherconditionsinwhichorthomeasurements. The current background information and statichypotensionmayfrequentlyoccur. detailed discussion of the data for the following section of these GuidelinescanbefoundinESCCardioMed. Recordheartrateandusepulsepalpationtoexclude Inolderpeople, peoplewithdiabetes, orpeoplewithothercauses arrhythmia. oforthostatichypotension, BPshouldalsobemeasured1minand3 minafterstanding. Orthostatichypotensionisdefinedasareductionin atrial fibrillationatrialfibrillation; blood pressurebloodpressure; DBPdiastolicbloodpressure; SBP SBPof_20mmHgorinDBPof_10mmHgwithin3minofstanding, systolicbloodpressure. andisassociatedwithanincreasedriskofmortalityandCVevents. 46 aMostautomaticdevicesarenotvalidatedforBPmeasurementinpatientswith AFandwillrecordthehighestindividualsystolicpressurewaveformratherthan HeartrateshouldalsoberecordedatthetimeofBPmeasurements anaverageofseveralcardiaccycles. ThiswillleadtooverestimationofBP. becauserestingheartrateisanindependentpredictorofCVmorbid orfatalevents, 47althoughheartrateisnotincludedinanyCVriskalgorithm. Table8summarizestherecommendedprocedureforroutine. office blood pressure measurement.",
    "andisassociatedwithanincreasedriskofmortalityandCVevents. 46 aMostautomaticdevicesarenotvalidatedforBPmeasurementinpatientswith AFandwillrecordthehighestindividualsystolicpressurewaveformratherthan HeartrateshouldalsoberecordedatthetimeofBPmeasurements anaverageofseveralcardiaccycles. ThiswillleadtooverestimationofBP. becauserestingheartrateisanindependentpredictorofCVmorbid orfatalevents, 47althoughheartrateisnotincludedinanyCVriskalgorithm. Table8summarizestherecommendedprocedureforroutine. office blood pressure measurement. It is emphasized that office blood pressure is often per-. . and unobserved, the white-coat effect (see section 4. 7. 1) can be. formed improperly, with inadequate attention to the standardized. . substantiallyreduced48oreliminated. 49Moreover, theBPvaluesare. conditions recommended for a valid measurement of office blood pressure. . . lowerthanthoseobtainedbyconventionalofficeBPmeasurement. ImpropermeasurementofofficeBPcanleadtoinaccurateclassifica-. . and are similar to, or even less than, those provided by daytime. tion, overestimationofapatientstrueBP, andunnecessarytreatment. . . ambulatorybloodpressuremonitoring(ABPM)orhomebloodpres-. . . sure monitoring (HBPM). 50 Use of unattended office blood pressure measure-. 4. 2 Unattended office Blood Hypertension. . ment in a recent clinical trial the Systolic Blood Hypertension. measurement. . InterventionTrial(SPRINT)51generatedcontroversyaboutitsquan-. . AutomatedmultipleBPreadingsinthedoctorsofficeimprovethe. . titative relationship to conventional office blood pressure measurement (which. reproducibilityofBPmeasurement, andifthepatientisseatedalone. hasbeen the basis for all previous epidemiological and clinical trial Downloaded from by guest on 31 December 2025 3036 ESC/ESHGuidelines. . data); its feasibility in routine clinical practice has also been ques-. availableprospectivestudieshavefurtherindicatedthatHBPMbetter. tioned. Presently, the relationship between blood pressure readings obtained. . predicts cardiovascular morbidity and mortality than office blood pressure. 59. . withconventionalofficeBPmeasurementandunattendedofficeBP. Thereisalsoevidencethatpatientself-monitoringmayhaveabenefi-. . measurement remains unclear, but available evidence suggests that. . cial effect on medication adherence and blood pressure control, 60, 61 especially. conventionalofficeSBPreadingsmaybeatleast515mmHghigher. . when combined with education and counselling. 62 Telemonitoring. than SBPlevelsobtained by unattended office blood pressure measurements. 52. . and smartphone applications may offer additional advantages, 63, 64. Thereisalsoverylimitedevidenceontheprognosticvalueofunat-. . suchasanaidtomemorytomakeBPmeasurements, andasacon-. tendedofficeBPmeasurements, i. e. whethertheyguaranteeatleast. . venientwaytostoreandreviewBPdatainadigitaldiaryandtransmit. the same ability to predict outcomes as conventional office blood pressure. . them. Wedonotrecommendtheuseofappsasacuff-independent. measurements. 53. . meansofmeasuringBP. . . . . . 4. 3 Out-of-office Blood Hypertension. . measurement. . . 4. 5 Ambulatory Blood Hypertension. . monitoring Out-of-officeBPmeasurementreferstotheuseofeitherHBPMor. . ABPM, thelatterusuallyover24h. ItprovidesalargernumberofBP. . . ABPM provides the average of blood pressure readings over a defined period, . measurements than conventional office blood pressure in conditions that are. . usually 24 h. The device is typically programmed to record blood pressure at. . 15-30minintervals, andaverageBPvaluesareusuallyprovidedfor morerepresentativeofdailylife. Recentpositionpapersandpractice. . guidelinesprovidecomprehensivedetailsforABPM54andHBPM, 55. . daytime, night-time, and24h. Adiaryofthepatientsactivitiesand. andarebrieflysummarizedbelow. 54, 56. . sleep time can also be recorded. A minimum of 70% usable blood pressure. . recordings are required for a valid ABPM measurement session. . . . ABPM valuesare, on average, lower thanofficeBPvalues, and the 4. 4 Home Blood Hypertension monitoring. . . diagnosticthresholdforhypertensionis_130/80mmHgover24h, . HomeBPistheaverageofallBPreadingsperformedwithasemiau-. . _135/85mmHgforthedaytimeaverage, and_120/70forthenight-. tomatic, validatedBPmonitor, foratleast3daysandpreferablyfor. . timeaverage(allequivalenttoofficeBP_140/90mmHg), seeTable9. . 67 consecutive days before each clinic visit, with readings in the. . ABPM is a better predictor of HMOD than office blood pressure. 65. morningandtheevening, takeninaquietroomafter5minofrest, . . . Furthermore, 24hambulatoryBPmeanhasbeenconsistentlyshown with the patient seated with their back and arm supported. Two. . . tohaveacloserrelationshipwithmorbidorfatalevents, 6668andisa measurementsshouldbe taken ateach measurement session, per-. . . moresensitiveriskpredictorthanofficeBPofCVoutcomessuchas formed12minapart. 57. . . coronarymorbidorfataleventsandstroke. 6872. ComparedwithofficeBP, HBPMvaluesareusuallylower, andthe. . BPnormallydecreasesduringsleep. Althoughthedegreeofnight-. diagnosticthresholdforhypertensionis_135/85mmHg(equivalent. . timeBPdippinghasanormaldistributioninapopulationsetting, an. toofficeBP_140/90mmHg)(Table9)whenconsideringtheaverage. . arbitrarycut-offhasbeenproposedtodefinepatientsasdippersif. of36daysofhomeBPvalues. ComparedwithofficeBP, HBPMpro-. . their nocturnal blood pressure falls by 10% of the daytime average blood pressure value; . vides more reproducible blood pressure data and is more closely related to. . however, thedippingstatusisoftenhighlyvariablefromdaytoday HMOD, particularly LVH. 58 Recent meta-analyses of the few. . . andthusispoorlyreproducible. 73Recognisedreasonsforanabsence. . . of nocturnal blood pressure dipping are sleep disturbance, obstructive sleep. . . apnoea, obesity, highsaltintakeinsalt-sensitivesubjects, orthostatic. . Table9 Definitionsofhypertensionaccordingto. . hypotension, autonomicdysfunction, chronic kidney disease, diabeticneuropathy, and office, ambulatory, andhomebloodpressurelevels. . old age. 54 Studies that accounted for daytime and night-time BPin. . . thesamestatisticalmodelfoundthatnight-timeBPisastrongerpre-. . . dictorofoutcomesthandaytimeBP. 54Thenight-to-dayratioisalsoa Category SBP DBP. . . significantpredictorofoutcome, andpatientswithareducednight- (mmHg) (mmHg). . . timedipinBP(i. e. 10%ofthedaytimeaverageBPoranight-to-day. OfficeBPa _140 and/or _90. . ratio 0.",
    ". . significantpredictorofoutcome, andpatientswithareducednight- (mmHg) (mmHg). . . timedipinBP(i. e. 10%ofthedaytimeaverageBPoranight-to-day. OfficeBPa _140 and/or _90. . ratio 0. 9) have an increased cardiovascular risk. 54 Moreover, in. . . thoseinwhomthereisnonight-timedipinBPorahighernight-time AmbulatoryBP. . . than daytime average blood pressure, there is a substantially increase in risk. 74. . Daytime(orawake)mean _135 and/or _85. Paradoxically, thereisalsosomeevidenceofincreasedriskinpatients. . . whohaveextremedippingoftheirnight-timeBP, 75althoughthelimNight-time(orasleep)mean _120 and/or _70. . . . itedprevalenceandreproducibilityofthisphenomenonmakesinter-. 24hmean _130 and/or _80. . pretationofdatadifficult. . . . A number of additional indices derived from ABPM recordings HomeBPmean _135 and/or _85. . . havesomeprognosticvalue, including24hBPvariability, 76morning. . . blood pressure surge, 77 and theambulatory arterialstiffness index. 78 However, B pr P es sur b e lo. od Hypertension; DBP diastolic Blood Hypertension; SBP systolic Blood. . . . theirincrementalpredictivevalueisnotyetclear. Thus, theseindices aReferstoconventionalofficeBPratherthanunattendedofficeBP. . . shouldberegardedasresearchtools, withnocurrentindicationfor. . routineclinicaluse. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3037. 4. 6 Advantages and disadvantages of. . elevatedwhenmeasuredbyHBPMorABPM. 81Thetermtruenor-. ambulatory Blood Hypertension monitoring. . motensionisusedwhenbothofficeandout-of-officeBPmeasure-. and home Blood Hypertension monitoring. . . ments are normal, and sustained hypertension is used when both. . are abnormal. In white-coat hypertension, the difference between AmajoradvantageofbothABPMandHBPMisthattheyenablethe. . . thehigherofficeandthelowerout-of-officeBPisreferredtoasthe diagnosisofwhite-coatandmaskedhypertension(seesection4. 7). . . . white-coat effect, and is believed to mainly reflect the pressor TherelativeadvantagesanddisadvantagesofHBPMandABPMare. . . responsetoanalertingreactionelicitedbyofficeBPmeasurements shown in Table 10. A particularly important advantage of HBPM is. . . by a doctorora nurse, 82althoughother factors are probably also thatitismuchcheaperandthusmoreavailablethanABPM. Another. . . involved. 83 isthatitprovidesmultiplemeasurementsoverseveraldaysoreven. . . Although the terms white-coat and masked hypertension were. longerperiods, whichisclinicallyrelevantbecauseday-to-dayBPvari-. . originallydefinedforpeoplewhowerenotbeingtreatedforhyperability may have an independent prognostic value. 79 Unlike ABPM, . . . tension, theyarenowalsousedtodescribediscrepanciesbetween. typicalHBPMdevicesdonotprovideBPmeasurementsduringrou-. . officeandout-of-officeBPinpatientstreatedforhypertension, with. tinedailyactivitiesandduringsleep, althoughrecenttechnicaladvan-. . the terms masked uncontrolled hypertension (MUCH) (office blood pressure. cesmayallowBPduringsleeptobemeasuredbyHBPM. Afurther. . controlled but home or ambulatory blood pressure elevated) and white-coat. consideration is the potential impact of impaired cognition on the. . uncontrolled hypertension (WUCH) (officeBP elevated but home. reliabilityofHBPMmeasurementsandrareinstancesofobsessional. . orambulatoryBPcontrolled), comparedwithsustaineduncontrolled. behaviour, circumstancesthatmayfavourtheuseofABPMifout-of-. . . hypertension(SUCH)84(bothofficeandhomeorambulatoryBPare officeBPreadingsarerequired. Ingeneral, bothmethodsshouldbe. . . uncontrolled). regardedascomplementaryratherthanabsolutealternatives. . . . Thewhite-coateffectisusedtodescribethedifferencebetween Despite the advances in out-of-office blood pressure measurement over the. . . an elevated office blood pressure (treated oruntreated) and a lower home or past50years, somefundamentalquestionsremain, themostimpor-. . . ambulatoryBPinbothuntreatedandtreatedpatients. tantofwhichiswhetherHBPM-orABPM-guidedtherapyresultsin. . . greater reductions in morbidity and mortality than conventional. . . 4. 7. 1White-coathypertension office blood pressure-guided treatment, which has been the diagnostic strategy. . . Althoughtheprevalencevariesbetweenstudies, white-coathyperforallclinicaloutcometrials. . . . . tensioncanaccountforupto30-40%ofpeople(and50%inthe. . . veryold)withanelevatedofficeBP. Itismorecommonwithincreas4. 7 White-coat hypertension and masked. . . ing age, in women, and in non-smokers. Its prevalence is lower in hypertension. . . patientswithHMOD, whenofficeBPisbasedonrepeatedmeasure-. White-coathypertensionreferstotheuntreatedconditioninwhich. . ments, orwhenadoctorisnotinvolvedintheBPmeasurement. A. BPiselevatedintheoffice, butisnormalwhenmeasuredbyABPM, . . significantwhite-coateffectcanbeseenatallgradesofhypertension. HBPM, or both. 80 Conversely, masked hypertension refers to. . (includingresistanthypertension), buttheprevalenceofwhite-coat. untreated patients in whom the blood pressure is normal in the office, but is. hypertensionisgreatestingrade1hypertension. Table10 Comparisonofambulatorybloodpressuremonitoringandhomebloodpressuremonitoring ABPM HBPM Advantages Advantages Canidentifywhite-coatandmaskedhypertension Canidentifywhite-coatandmaskedhypertension Strongerprognosticevidence Cheapandwidelyavailable Night-timereadings Measurementinahomesetting, whichmaybemorerelaxedthan Measurementinreal-lifesettings thedoctorsoffice AdditionalprognosticBPphenotypes PatientengagementinBPmeasurement Abundantinformationfromasinglemeasurementsession, including Easilyrepeatedandusedoverlongerperiodstoassessday-to-dayBP short-termBPvariability variability Disadvantages Disadvantages Expensiveandsometimeslimitedavailability OnlystaticBPisavailable Canbeuncomfortable Potentialformeasurementerror Nonocturnalreadingsa ABPMambulatorybloodpressuremonitoring; blood pressurebloodpressure; HBPMhomebloodpressuremonitoring. aTechniquesarebeingdevelopedtoenablenocturnalBPmeasurementwithhomeBPdevices. Downloaded from by guest on 31 December 2025 3038 ESC/ESHGuidelines. . HMODislessprevalentin white-coathypertensionthanin sus-. blood pressure should be remeasured at least every 3 years. Patients with. . tainedhypertension, andrecentstudiesshowthattheriskofcardio-. Highnormal blood pressure (130139/8589 mmHg) should have their blood pressure. . vasculareventsassociatedwithwhite-coathypertensionisalsolower. recorded annually because of the High rates of progression of. than that in sustained hypertension. 68, 85, 86 Conversely, compared. . Highnormal blood pressure to hypertension. This is true also for people in. . withtruenormotensives, patientswithwhite-coathypertensionhave. whommaskedhypertensionisdetected. . increasedadrenergicactivity, 87agreaterprevalenceofmetabolicrisk. . . . factors, more frequent asymptomatic cardiac and vascular damage, . . . 4. 9 Confirming the diagnosis of andagreaterlong-termriskofnew-onsetdiabetesandprogression. . tosustainedhypertensionandLVH.",
    "factors, more frequent asymptomatic cardiac and vascular damage, . . . 4. 9 Confirming the diagnosis of andagreaterlong-termriskofnew-onsetdiabetesandprogression. . tosustainedhypertensionandLVH. 82Inaddition, althoughtheout-. . . hypertension. of-officeBPvaluesare, bydefinition, normalinwhite-coathyperten-. . BPcanbehighlyvariable, thusthediagnosisofhypertensionshould. sion, theytendtobehigherthanthoseoftruenormotensivepeople, . . not be based on a single set of blood pressure readings at a single office visit, . which may explain the increased long-term risk of CV events. . unless the blood pressure is substantially increased (e. g. grade 3 hypertension). reportedinwhite-coathypertensionbyrecentstudiesafteradjust-. . andthereisclearevidenceofHMOD(e. g. hypertensiveretinopathy. ment for demographic and metabolic risk factors. 85, 86, 8890 White-. . withexudatesandhaemorrhages, orLVH, orvascularorrenaldam-. coathypertensionhasalsobeenshowntohaveagreaterCVriskin. . age). Forallothers(i. e. almostallpatients), repeatBPmeasurements. isolated systolic hypertension and older patients, 91 and does not. . atrepeatofficevisitshavebeenalong-standingstrategytoconfirma. appeartobeclinicallyinnocent. 68Thediagnosisshouldbeconfirmed. . persistentelevationinBP, aswellasfortheclassificationofthehyper-. by repeated office and out-of-office blood pressure measurements, and should. . tensionstatusinclinicalpracticeandRCTs. Thenumberofvisitsand. include an extensive assessment of risk factors and HMOD. Both. . thetimeintervalbetweenvisitsvariesaccordingtotheseverityofthe. ABPMandHBPMarerecommendedtoconfirmwhite-coathyper-. . hypertension, andisinverselyrelatedtotheseverityofhypertension. . . tension, becausetheCVriskappearstobelower(andclosetosus-. Thus, moresubstantialBPelevation(e. g. grade2ormore)requires. . tainednormotension)inthoseinwhombothABPMandHBPMare. fewervisitsandshortertimeintervalsbetweenvisits(i. e. afewdays. bothnormal; 82fortreatmentconsiderationsseesection8. 4. . . or weeks), dependingonthe severityofBP elevationand whether. . . thereisevidenceofCVDorHMOD. Conversely, inpatientswithBP. . . elevationinthegrade1range, theperiodofrepeatmeasurements 4. 7. 2Maskedhypertension. . . mayextendoverafewmonths, especiallywhenthepatientisatlow Maskedhypertensioncanbefoundinapproximately15%ofpatients. . . riskandthereisnoHMOD. DuringthisperiodofBPassessment, CV withanormalofficeBP. 17Theprevalenceisgreaterinyoungerpeo-. . . risk assessment and routine screening tests are usually performed ple, men, smokers, andthosewithhigherlevelsofphysicalactivity, . . alcohol consumption, anxiety, and job stress. 54 Obesity, Diabetes, . . . (seesection3). chronic kidney disease, familyhistoryofhypertension, andhighnormalofficeBPare. . . TheseGuidelinesalsosupporttheuseofout-of-officeBPmeasalso associated with an increased prevalence of masked hyperten-. . . urements (i. e. HBPM and/or ABPM) as an alternative strategy to sion. 17Maskedhypertensionisassociatedwithdyslipidaemiaanddys-. . . repeatedofficeBPmeasurementstoconfirmthediagnosisofhyperglycaemia, HMOD, 92 adrenergic activation, and increased risk of. . . tension, whenthesemeasurementsarelogisticallyandeconomically developing Diabetes and sustained hypertension. 81, 93 Meta-analyses. . . feasible (Figure 2). 99 This approach can provide important suppleandrecentstudies68haveshownthattheriskofCVeventsissubstan-. . . mentaryclinicalinformation, e. g. detectingwhite-coathypertension. . (seesection4. 7. 1), whichshouldbesuspected, especiallyinpeople tiallygreaterinmaskedhypertensioncomparedwithnormotension, . andclosetoorgreaterthanthatofsustainedhypertension. 68, 9396. . . withgrade1hypertensiononofficeBPmeasurementandinwhom. . thereisnoevidenceofHMODorCVD100(Table11). Aparticular MaskedhypertensionhasalsobeenfoundtoincreasetheriskofCV. . . challengeisthedetectionofmaskedhypertension(seesection4. 7. 2). andrenaleventsindiabetes, especiallywhentheBPelevationoccurs. duringthenight. 95, 97. . . Masked hypertension is more likely in people with a blood pressure in the. . Highnormalrangeinwhomout-of-officeBPshouldbeconsidered. . . to exclude masked hypertension (see Table 8). Out-of-office blood pressure 4. 8 Screening for the detection of. . . measurementsarealsoindicatedinspecificcircumstances(seesec-. hypertension. . tion4. 10andTable11). . . Hypertension is predominantly an asymptomatic condition that is. . . best detected by structured population screening programmes or. . . 4. 10 Clinical indications forout-of-office opportunistic measurement of blood pressure. When structured population. . screeningprogrammeshavebeenundertaken, analarmingnumberof. . Blood Hypertension measurements. . people(50%)wereunawaretheyhadhypertension. 12, 98Thishigh. Out-of-office blood pressure measurements are increasingly used, especially. . rateofundetectedhypertensionoccurredirrespectiveoftheincome. . HBPM but also ABPM, to confirm the diagnosis of hypertension. . statusofthecountriesstudiedacrosstheworld. . . Out-of-office blood pressure measurement provides important complementary. AlladultsshouldhavetheirBPrecordedintheirmedicalrecord. . information, asdiscussed above. The clinical indications for out-of-. andbeawareoftheirBP, andfurtherscreeningshouldbeundertaken. . officeBPmeasurementsareshowninTable11. HBPMisalsoincreas-. atregularintervalswiththefrequencydependentontheBPlevel. For. . inglyusedbypatientstomonitortheirBPcontrol, whichincreases. healthypeoplewithanoptimalofficeBP(120/80mmHg), BPshould. . their engagement and may improve their adherence to treatment. be remeasured at least every 5 years and more frequently when. . andBPcontrol. 61, 101, 102Itislikelythat, withincreasedavailabilityand. opportunitiesarise. InpatientswithanormalBP(120129/8084), . lowercostofthesedevices, thiswillbecomemorecommonplace. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3039 Figure2 Screeninganddiagnosisofhypertension. ABPMambulatorybloodpressuremonitoring; blood pressurebloodpressure; HBPMhomeblood pressuremonitoring. aAfterdetectingaspecificBPcategoryonscreening, eitherconfirmBPelevationwithrepeatedofficeBPmeasurementsonrepeatvisits orarrangeuseofout-of-officeBPtoconfirmthediagnosisofhypertension. Table11 Clinicalindicationsforhomebloodpressuremonitoringorambulatorybloodpressuremonitoring Conditionsinwhichwhite-coathypertensionismorecommon, e. g. : GradeIhypertensiononofficeBPmeasurement MarkedofficeBPelevationwithoutHMOD Conditionsinwhichmaskedhypertensionismorecommon, e. g. : HighnormalofficeBP NormalofficeBPinindividualswithHMODorathightotalCVrisk Posturalandpost-prandialhypotensioninuntreatedandtreatedpatients Evaluationofresistanthypertension EvaluationofBPcontrol, especiallyintreatedhigher-riskpatients ExaggeratedBPresponsetoexercise WhenthereisconsiderablevariabilityintheofficeBP Evaluatingsymptomsconsistentwithhypotensionduringtreatment SpecificindicationsforABPMratherthanHBPM: AssessmentofnocturnalBPvaluesanddippingstatus(e. g. suspicionofnocturnalhypertension, suchasinsleepapnoea, chronic kidney disease, Diabetes, endocrinehypertension, orautonomicdysfunction) ABPMambulatorybloodpressuremonitoring; blood pressurebloodpressure; chronic kidney diseasechronickidneydisease; CVcardiovascular; HBPMhomebloodpressuremonitoring; HMOD hypertension-mediatedorgandamage. Downloaded from by guest on 31 December 2025 3040 ESC/ESHGuidelines 4. 11 Blood Hypertension during exercise and BPmeasurement at High altitude ItisimportanttorecognisethatBPincreasesduringdynamicand Recommendations Classa Levelb staticexercise, andthattheincreaseismorepronouncedforSBP thanforDBP, 103althoughonlySBPcanbemeasuredreliablywith Screeningprogrammesforhypertensionare non-invasivemethods. Thereiscurrentlynoconsensusonnormal recommended. Alladults(18yearsor BPresponseduringexercise.",
    "Thereiscurrentlynoconsensusonnormal recommended. Alladults(18yearsor BPresponseduringexercise. TheincreaseinSBPduringexerciseis older)shouldhavetheirofficeBPmeasured I B related to pre-exercise resting blood pressure, age, arterial stiffness, and andrecordedintheirmedicalfile, andbe abdominalobesity, andissomewhatgreaterinwomenthaninmen awareoftheirBP. 12, 98 and in unfitindividuals. There is some evidence that anexcessive FurtherBPrecordingisindicated, atleast risein blood pressure during exercise predicts thedevelopmentofhypertenI C every5yearsifBPremainsoptimal. sion, independentlyfromBPatrest. 104Nevertheless, exercisetest- FurtherBPrecordingisindicated, atleast ing is not recommended as part of the routine evaluation of I C every3yearsifBPremainsnormal. hypertension because of various limitations, including a lack of IfBPremainshighnormal, furtherBP standardization of methodology and definitions. Importantly, recording, atleastannually, is I C exceptinthepresenceofveryhighBPvalues(grade3hypertenrecommended. sion), patients, orathletes, withtreatedoruntreatedhypertension Inolderpatients(50years), morefreshouldnotbediscouragedfromregularexercise, especiallyaerobic quentscreeningofofficeBPshouldbe exercise, whichisconsideredbeneficialaspartoflifestylechanges IIa C consideredforeachBPcategorybecause toreduceBP(seesection7. 4. 1). ofthesteeperriseinSBPwithageing. Evidence is available thatBP increaseswithhighaltitude exposure, especiallyabove3000mandpossiblyabove2000m. 105This ItisrecommendedthatofficeBPshouldbe is due to a number of factors including sympathetic activation. measuredinbotharmsatleastatthefirst Patients with grade 2 hypertension and increased CV risk should visitbecauseabetween-armSBPdifference I A check their blood pressure values before and during High altitude (2500 m) of15mmHgissuggestiveofatheromatous exposure. Patientswithgrade1hypertensionmayreachveryhigh diseaseandisassociatedwithanincreased altitude (4000 m) with adequate medical therapy; uncontrolled CVrisk. 45 severe hypertensive patients (grade 3) should avoid exposure to Ifabetween-armdifferenceinBPis veryhighaltitude. 105 recorded, thenitisrecommendedthatall I C subsequentBPreadingsusethearmwith 4. 12 Central aortic Hypertension thehigherBPreading. VarioustechniquesallowaorticBP(centralBP)tobederivedfrom peripheral blood pressure measurements using dedicated algorithms. 106, 107 Itisrecommendedthatthediagnosisof Somestudiesandmeta-analyseshaveshownthatinhypertensive hypertensionshouldbebasedon: patients, centralBPpredictsCVeventsandthatthereisadifferen- RepeatedofficeBPmeasurementson tialeffectofantihypertensivedrugsoncentralcomparedwithbramorethanonevisit, exceptwhenhyperchial blood pressure. 108 The incremental prognostic value of central vs. tensionissevere(e. g. grade3andespeconventionalclinicBPmeasurementremainsunclear. 109Anexcepciallyinhigh-riskpatients). Ateachvisit, tionmaybeisolatedsystolichypertensionintheyoung, inwhom threeBPmeasurementsshouldbe I C peripheralBPmaybedisproportionatelyelevatedrelativetoanorrecorded, 12minapart, andadditional malcentralBP. Thisoccursinasmallfractionofyoungerpeople, measurementsshouldbeperformedif mainly men with isolated systolic hypertension, and it remains thefirsttworeadingsdifferby10 unclearwhethersuchpatientsareatlowerriskthansuggestedby mmHg. ThepatientsBPistheaverageof theirbrachialofficeBP. 110, 111 thelasttwoBPreadings. Or Out-of-officeBPmeasurementwith ABPMand/orHBPM, providedthat I C thesemeasurementsarelogisticallyand economicallyfeasible. Continued Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3041 Out-of-officeBP(i. e. ABPMorHBPM)is Table12 Keyinformationtobecollectedinpersonal specificallyrecommendedforanumberof andfamilymedicalhistory clinicalindications, suchasidentifyingwhitecoatandmaskedhypertension, quantifying I A Riskfactors theeffectsoftreatment, andidentifyingposFamilyandpersonalhistoryofhypertension, cardiovascular disease, stroke, orrenal siblecausesofsideeffects17, 54, 62, 68, 72(e. g. disease symptomatichypotension). Familyandpersonalhistoryofassociatedriskfactors(e. g. familial Itisrecommendedthatallhypertensive hypercholesterolaemia) patientsundergopulsepalpationatrestto I C Smokinghistory determineheartrateandsearchfor Dietaryhistoryandsaltintake arrhythmiassuchasAF. 20, 47 Alcoholconsumption OtherBPmeasuresandindices(pulsepressure, BPvariability, exerciseBP, andcentral Lackofphysicalexercise/sedentarylifestyle blood pressure)maybeconsideredbutarenotoften Historyoferectiledysfunction usedforroutineclinicaluseatpresent. IIb C Sleephistory, snoring, sleepapnoea(informationalsofrompartner) Theymayprovideusefuladditionalinformationinsomecircumstancesandarevaluable Previoushypertensioninpregnancy/pre-eclampsia toolsforresearch. HistoryandsymptomsofHMOD, cardiovascular disease, stroke, andrenal disease ABPM ambulatory Blood Hypertension monitoring; atrial fibrillation atrial fibrillation; blood pressure Brainandeyes: headache, vertigo, syncope, impairedvision, TIA, bloodpressure; CVcardiovascular; HBPMhomebloodpressuremonitoring; sensoryormotordeficit, stroke, carotidrevascularization, cognitive SBPsystolicbloodpressure. impairment, dementia(intheelderly) aClassofrecommendation. bLevelofevidence. Heart: chestpain, shortnessofbreath, oedema, myocardialinfarction, coronaryrevascularization, syncope, historyofpalpitations, arrhythmias(especiallyAF), heartfailure 5 Clinical evaluation and Kidney: thirst, polyuria, nocturia, haematuria, urinarytractinfections assessment of hypertensionPeripheralarteries: coldextremities, intermittentclaudication, Painmediated organ damage in freewalkingdistance, painatrest, peripheralrevascularization patients with hypertension PatientorfamilyhistoryofCKD(e. g. polycystickidneydisease) Historyofpossiblesecondaryhypertension 5. 1 Clinical evaluation Youngonsetofgrade2or3hypertension(40years), orsudden Thepurposeoftheclinicalevaluationistoestablishthediagnosisand developmentofhypertensionorrapidlyworseningBPinolder grade of hypertension, screen for potential secondary causes of patients hypertension, identifyfactorspotentiallycontributingtothedevelopHistoryofrenal/urinarytractdisease ment ofhypertension (lifestyle, concomitant medications, orfamily Recreationaldrug/substanceabuse/concurrenttherapies: corticostehistory), identifyconcomitantCVriskfactors(includinglifestyleand roids, nasalvasoconstrictor, chemotherapy, yohimbine, liquorice familyhistory), identifyconcomitantdiseases, andestablishwhether thereisevidenceofHMODorexistingCV, cerebrovascular, orrenal Repetitiveepisodesofsweating, headache, anxiety, orpalpitations, suggestiveofPhaeochromocytoma disease. ThecurrentbackgroundinformationanddetaileddiscussionofthedataforthefollowingsectionoftheseGuidelinescanbe Historyofspontaneousordiuretic-provokedhypokalaemia, epifoundinESCCardioMed. sodesofmuscleweakness, andtetany(hyperaldosteronism) Symptomssuggestiveofthyroiddiseaseorhyperparathyroidism 5. 2 Medical history Historyoforcurrentpregnancyandoralcontraceptiveuse Athoroughmedicalhistory(Table12)shouldaddressinparticular: Historyofsleepapnoea Time of the first diagnosis of hypertension, including records of AntihypertensiveDrugTreatment anypreviousmedicalscreening, hospitalization, etc. RecordanycurrentandpastBPvalues Current/pastantihypertensivemedicationincludingeffectiveness Recordcurrentandpastantihypertensivemedications andintolerancetopreviousmedications Recordothermedications Adherencetotherapy Familyhistoryofhypertension, cardiovascular disease, stroke, orrenaldisease Lifestyleevaluation, includingexerciselevels, bodyweightchanges, atrial fibrillationatrialfibrillation; blood pressurebloodpressure; chronic kidney diseasechronickidneydisease; cardiovascular disease diet history, smoking history, alcohol use, recreational drug use, cardiovasculardisease; HMODhypertension-mediatedorgandamage; TIA sleephistory, andimpactofanytreatmentsonsexualfunction transientischaemicattack. HistoryofanyconcomitantCVriskfactors Downloaded from by guest on 31 December 2025 3042 ESC/ESHGuidelines. . Detailsandsymptomsofpastandpresentcomorbidities. 5. 4 Assessment of hypertension-. Specific history of potential secondary causes of hypertension. . . mediated organ damage (seesection8. 2). . Historyofpastpregnanciesandoralcontraceptiveuse. . . HMODreferstostructuralorfunctionalchangesinarteriesorend Historyofmenopauseandhormonereplacementtherapy. . organs (Heart, Blood vessels, brain, eyes, and Kidney) caused by an. Useofliquorice. . elevatedBP, andisamarkerofpre-clinicalorasymptomaticCVD. 112. Useofdrugsthatmayhaveapressoreffect. . . HMODiscommoninsevereorlong-standinghypertension, butcan. . . alsobefoundinlessseverehypertension. Withwideruseofimaging, . 5. 3 Physical examination and clinical. . HMOD is becoming increasingly apparent in asymptomatic. investigations. . . patients. 43CVriskincreaseswiththepresenceofHMOD, andmore. .",
    "3 Physical examination and clinical. . HMOD is becoming increasingly apparent in asymptomatic. investigations. . . patients. 43CVriskincreaseswiththepresenceofHMOD, andmore. . so when damage affects multiple organs. 16, 113, 114 Some types of Physical examination provides important indications of potential. . . HMOD can be reversed by antihypertensive treatment, especially causes of secondary hypertension, signs of comorbidities, and. . . whenusedearly, butwithlong-standinghypertension, HMODmay HMOD. OfficeBPandheartrateshouldbemeasuredassummarized. . . become irreversible despite improved blood pressure control. 115, 116 insection4. MeasurementsofofficeBPonmorethanoneoccasion. . . Nevertheless, blood pressure-loweringtreatmentisstillimportantasitmaydelay areusuallyrequiredtoconfirmthediagnosisofhypertensionunless. . . thefurtherprogressionofHMODandwillreducetheelevatedCV HBPMorABPMisusedtoconfirmthediagnosis(seesection4). . . . riskofthesepatients. 116Althoughpoortechnicalprovisionandcost Detailsoftherequirementsforacomprehensiveclinicalexamina-. . . may limit the search for HMOD in some countries, it is recomtionareoutlinedinTable13, andthisshouldbeadaptedaccordingto. . . mendedthatbasicscreeningforHMODisperformedinallhypertenthe severity of hypertension and clinical circumstances. Suggested. . . sivepatientsandmoredetailedassessmentisperformedwhenthe routineclinicalinvestigationsareoutlinedinTable14. . . . presenceofHMODmightinfluencetreatmentdecisions. Thevarious. . . . investigationstoestablishHMODareshowninTable15. . Table13 Keystepsinphysicalexamination. . . . . . 5. 4. 1Usinghypertension-mediatedorgandamagetohelp. Bodyhabitus. . stratifyriskinhypertensivepatients. . . As discussed in section 3, hypertensive patients with documented Weightandheightmeasuredonacalibratedscale, withcalcula-. . . cardiovascular disease, Diabetes, chronic kidney disease, grade3hypertension, ormarkedcholesterol tionofBMI. . . elevation(e. g. familialhypercholesterolaemia)arealreadyathighor. Waistcircumference. . veryhighCVrisk(_10%riskofafatalevent). Thus, thepresenceof. . HMOD is unlikely to influence treatment, asthese patients should SignsofHMOD Neurologicalexaminationandcognitivestatus Table14 RoutineworkupforevaluationofhypertenFundoscopicexaminationforhypertensiveretinopathy sivepatients Palpationandauscultationofheartandcarotidarteries Routinelaboratorytests Palpationofperipheralarteries Haemoglobinand/orhaematocrit ComparisonofBPinbotharms(atleastonce) FastingbloodglucoseandglycatedHbA 1c Secondaryhypertension Bloodlipids: totalcholesterol, LDLcholesterol, HDL Skininspection: cafe-au-laitpatchesofneurofibromatosis cholesterol (phaeochromocytoma) Bloodtriglycerides KidneypalpationforsignsofrenalenlargementinpolycystickidBloodpotassiumandsodium neydisease Blooduricacid Auscultationofheartandrenalarteriesformurmursorbruits indicativeofaorticcoarctation, orrenovascularhypertension BloodcreatinineandeGFR Comparisonofradialwithfemoralpulse: todetectradio-femoBloodliverfunctiontests raldelayinaorticcoarctation Urineanalysis: microscopicexamination; urinaryproteinbydipSignsofCushingsdiseaseoracromegaly sticktestor, ideally, albumin: creatinineratio Signsofthyroiddisease 12-leadECG body mass indexbodymassindex; blood pressurebloodpressure; HMODhypertension-mediated estimated glomerular filtration rateestimatedglomerularfiltrationrate; ECGelectrocardiogram; hemoglobin hemoglobin A1c organdamage. haemoglobinA1c. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3043 Table15 Assessmentofhypertension-mediatedorgandamage BasicscreeningtestsforHMOD Indicationandinterpretation 12-leadECG ScreenforLVHandotherpossiblecardiacabnormalities, andtodocumentheartrateandcardiac rhythm Urinealbumin: creatinineratio Todetectelevationsinalbuminexcretionindicativeofpossiblerenaldisease BloodcreatinineandeGFR Todetectpossiblerenaldisease Fundoscopy Todetecthypertensiveretinopathy, especiallyinpatientswithgrade2or3hypertension MoredetailedscreeningforHMOD Echocardiography Toevaluatecardiacstructureandfunction, whenthisinformationwillinfluencetreatment decisions Carotidultrasound Todeterminethepresenceofcarotidplaqueorstenosis, particularlyinpatientswithcerebrovasculardiseaseorvasculardiseaseelsewhere AbdominalultrasoundandDopplerstudies Toevaluaterenalsizeandstructure(e. g. scarring)andexcluderenaltractobstructionaspossibleunderlyingcausesofCKDandhypertension Evaluateabdominalaortaforevidenceofaneurysmaldilatationandvasculardisease Examineadrenalglandsforevidenceofadenomaorphaeochromocytoma(CTorMRIpreferredfordetailedexamination); seesection8. 2regardingscreeningforsecondary hypertension RenalarteryDopplerstudiestoscreenforthepresenceofrenovasculardisease, especiallyin thepresenceofasymmetricrenalsize PWV Anindexofaorticstiffnessandunderlyingarteriosclerosis ABI ScreenforevidenceofLEAD Cognitivefunctiontesting Toevaluatecognitioninpatientswithsymptomssuggestiveofcognitiveimpairment Brainimaging Toevaluatethepresenceofischaemicorhaemorrhagicbraininjury, especiallyinpatientswitha historyofcerebrovasculardiseaseorcognitivedecline ABIankle-brachialindex; chronic kidney diseasechronickidneydisease; computed tomographycomputedtomography; ECGelectrocardiogram; estimated glomerular filtration rateestimatedglomerularfiltrationrate; HMOD hypertension-mediatedorgandamage; LEADlowerextremityarterydisease; LVHleftventricularhypertrophy; magnetic resonance imagingmagneticresonanceimaging; PWVpulsewave velocity. . . alreadyreceivelifestyleinterventions, blood pressure-loweringmedications, sta-. . HMOD in younger patients with grade 1 hypertension provides. tins, and in some cases antiplatelet therapy, to reduce their risk35. . unequivocal evidence of hypertension-mediated damage and indi-. (seesection9). . . catesaclearneedforBP-loweringtreatmentinpatientswhomaybe. ThemainadvantageofdetectingHMODisthatitmayreclassifya. . reluctant to be treated. For the same reason, the presence of. patients SCORE risk assessment from Low to moderate or from. . HMOD in a patient with Highnormal blood pressure would also provide a. moderate to High risk. 117 The specific impact of HMOD114 with. . rationaletoconsiderBP-loweringtreatment. . regard to the reclassification of risk estimation according to the. . Another important consideration is whether the presence of a. SCORE system has not been clearly defined. The SCORE system. . specificmanifestationofHMOD(e. g. LVHorCKD)mightinfluence. alreadytakesaccountofthegradeofhypertensionasSBPisincluded. . the selectionofdrug treatment for hypertension. Thiswasconsid-. intheriskcalculation. Moreover, CKDandthepresenceofvascular. . eredimportantinthepreviousguidelines, 17butis nowconsidered. disease on imaging are already specified as High or very High risk. . lessimportant. InpatientsmorelikelytohaveHMOD(i. e. thosewith. . (Table5). ConditioningoftheriskscorebythepresenceofHMOD. highgrade1orgrade23hypertension), wenowrecommendinitial. . will be most important in middle-aged patients with hypertension, . treatmentwithacombinationoftwodrugs, usuallyanangiotensin-. . manyofwhomwillbeatmoderate-riskandathigherriskifHMODis. convertingenzyme(ACE)inhibitororangiotensinreceptorblocker. . detected. Moreover, arisk-conditioningeffectofHMODwillalsobe. (angiotensin receptor blocker) in combination with a calcium channel blocker (calcium channel blocker) or. . importantinyoungerhypertensivepatientswhoareinvariablyclassi-. thiazide-typediuretic, whichwouldbetheoptimaltreatmentforall. . fiedaslowriskaccordingtotheSCOREsystem. Inaddition, detecting. manifestationsofHMOD(seesection7). . Downloaded from by guest on 31 December 2025 3044 ESC/ESHGuidelines. 5. 5 Characteristics of hypertension-. . Three-dimensionalTTEisamorereliablemethodforquantitative. mediated organ damage. . analysis, 129specificallyforLVmass, 130volumes, andejectionfraction, . . . andhassuperiorreproducibilitytotwo-dimensionalTTEbutmuch 5. 5. 1Theheartinhypertension. . . lessprognosticvalidation. 131Moredetailedinformationontheuseof Chronicallyincreasedleftventricular(LV)workloadinhypertensive. . . echocardiography to assess the hypertensive Heart is available. 43 patientscanresultinLVH, impairedLVrelaxation, leftatrialenlarge-. . . Cardiacmagneticresonanceisthegoldstandardforcardiacanatomiment, an increased risk of arrhythmias, especially atrial fibrillation, and an. . . calandfunctionalquantification.",
    "43 patientscanresultinLVH, impairedLVrelaxation, leftatrialenlarge-. . . Cardiacmagneticresonanceisthegoldstandardforcardiacanatomiment, an increased risk of arrhythmias, especially atrial fibrillation, and an. . . calandfunctionalquantification. 132134 increased risk of Heart failure with preserved ejection fraction. . . AbnormalLVgeometryinhypertensivepatientsisfrequentlyasso- (HFpEF)andheartfailurewithreducedejectionfraction(HFrEF). . . . ciated with diastolic dysfunction, 127, 135 which can be further eval-. . . uated by a combination of transmitral flow and tissue Doppler 5. 5. 1. 1Electrocardiogram. . . studies. 136Leftatrialsizeisalsofrequentlyincreasedinhypertensive A 12-lead electrocardiogram (ECG) should be part of the routine. . . patientsandisassociatedwithadverseCVevents128, 137andincident assessmentinallhypertensivepatients. TheECGisnotaparticularly. . . atrial fibrillation, 138andisrelatedtodiastolicdysfunction. 139, 140DuringthediagsensitivemethodofdetectingLVHanditssensitivityvariesaccording. . . nostic workup for secondary hypertension, a suprasternal view tobodyweight. ECGLVHprovidesindependentprognosticinforma-. . . should also be performed for the identification of aortic tion, evenafteradjustingforotherCVriskfactorsandechocardio-. . graphic LV mass. 118 In addition to LVH, the presence of a strain. . . coarctation. 141. patternonanECGisassociatedwithincreasedrisk. 119Thepreva-. . . lence of ECG LVH increases with the severity of hypertension. 120. . 5. 5. 2Thebloodvesselsinhypertension. ThemostcommonlyusedcriteriatodefineECGLVHareshownin. . 5. 5. 2. 1Carotidartery. . Table16. . Carotid intima-media thickness (IMT) quantified by carotid ultra-. . The ECG cannot exclude LVH because it has poor sensitivity. . sound, and/or the presence of plaques, predicts CV risk. 42, 142 This. . When detailed information on cardiac structure and function will. . holdstruebothfortheIMTvalueatthecarotidbifurcations(reflect-. influence treatment decisions, echocardiography is recommended. . . ingprimarilyatherosclerosis)andfortheIMTvalueatthelevelofthe. WhenLVHispresentontheECG, itcanbeusedtodetectchanges. . common carotid artery (reflecting primarily hypertension-related inLVHduringfollow-upinuntreatedandtreatedpatients. 121, 122. . . hypertrophy). A carotid IMT 0. 9 mm is considered abnormal, 143. . . buttheupperlimitofnormalityvarieswithage. Thepresenceofa. 5. 5. 1. 2Transthoracicechocardiographyinhypertension. . plaquecanbeidentifiedbyanIMT_1. 5mm, orbyafocalincreasein. Echocardiographic LVH is a potent predictor of mortality in both. . thicknessof0. 5mmor50%ofthesurroundingcarotidIMTvalue. 144 hypertensivepatientsandthegeneralpopulation, 123, 124andregres-. . Stenotic carotid plaques have a strong predictive value for both sion of echocardiographic LVH due to treatment of hypertension predicts an improved prognosis. 125 Two-dimensional transthoracic Table17 Echocardiographicdefinitionsofleftventricechocardiography(TTE)alsoprovidesinformationaboutLVgeomeularhypertrophy, concentricgeometry, leftventricular try, leftatrialvolume, aorticrootdimensions, LVsystolicanddiastolic chambersize, andleftatrialdilatation function, pump performance, and output impedance. 123, 126, 127 WhetheradditionalparametersotherthanevidenceofincreasedLV Parameter Measure Abnormality mass and left atrial dilatation are useful to help stratify CV risk is uncertain. 123, 126, 128Thepartitionvaluesrecommendedforthedefinithreshold tionofLVHbyechocardiographyareshowninTable17. LVH LVmass/height2. 7(g/m2. 7) 50(men) 47(women) Table16 Themostcommonlyusedsimplecriteria andrecognisedcut-offpointsfordefinitionsofelectroLVHa LVmass/BSA(g/m2) 115(men) cardiogramleftventricularhypertrophy 95(women) ECGvoltagecriteria CriteriaforLVH LVconcentric RWT _0. 43 geometry S þR (SokolowLyoncriterion) 35mm V1 V5 LVchambersize LVend-diastolic 3. 4(men) RwaveinaVL _11mm diameter/height(cm/m) S þR (Cornellvoltage)a 28mm(men) 3. 3(women) V3 aVL Cornelldurationproductb Leftatrialsize Leftatrialvolume/height2 18. 5(men) 20mm(women) (elliptical) (mL/m2) 16. 5(women) 2440mm. ms BSAbodysurfacearea; LVleftventricular; LVHleftventricularhypertroECGelectrocardiogram; LVHleftventricularhypertrophy. aSumoflimbandprecordialleadvoltage. phy; RWTrelativewallthickness. bProductofCornellvoltagexQRSduration(mm. ms). aBSAnormalizationmaybeusedinnormalweightpatients. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3045. . strokeandmyocardialinfarction, independentoftraditionalCVrisk. to quantify urinary albumin excretion. A progressive reduction in. factors, 42, 142andconfersuperiorprognosticaccuracyforfuturemyo-. . estimated glomerular filtration rate and increased albuminuria indicate progressive loss of renal. cardialinfarctioncomparedwithIMT. 145Thepresenceofcarotidpla-. . function, and are both independent and additive predictors of. queswillautomaticallyreclassifypatientsfromintermediatetohigh. . increasedCVriskandprogressionofrenaldisease. 158. risk; 146, 147 however, routine carotid imaging is not recommended. . Serum Creatinine, estimated glomerular filtration rate, and albumin-creatinine ratio should be documented in all. . unlessclinicallyindicated(i. e. presenceofcarotidbruit, previousTIA. hypertensive patients, and if chronic kidney disease is diagnosed, repeated at least. orcerebrovasculardisease, oraspartoftheassessmentofpatients. . annually. 159Onenegativeurinarydipsticktestdoesnotruleoutalbu-. . withevidenceofvasculardisease). . minuria, incontrasttoanormalACR. 160. . . . . 5. 5. 2. 2Pulsewavevelocity. . 5. 5. 4Hypertensiveretinopathy. Large artery stiffening is the most important pathophysiological. . The prognostic significance of hypertensive retinopathy by fundo-. determinant of isolated systolic hypertension and age-dependent. . scopy has been well documented. 161 Detection of retinal haemor-. increase in pulse Hypertension. 148 Carotid-femoral pulse wave velocity. . rhages, microaneurysms, hard exudates, cotton wool spots, and. (PWV) is the gold standard for measuring large artery stiffness. 149. . papilloedema is highly reproducible, indicates severe hypertensive. Referencevalues for PWV are availableinhealthy populationsand. .",
    "149. . papilloedema is highly reproducible, indicates severe hypertensive. Referencevalues for PWV are availableinhealthy populationsand. . retinopathy, and is highly predictive of mortality. 161, 162 In contrast, . patientsatincreasedCVrisk. 150APWV10m/sisconsideredacon-. . evidenceofarteriolarnarrowing, eitherfocalorgeneral, andarterio-. servative estimate of significant alterations of aortic function in. . . venousnickingatearlystagesofhypertensiveretinopathyhaveless middle-aged hypertensive patients. 149 The additive value of PWV. . . predictive value, 163 and limited interobserver and intraobserver aboveandbeyondtraditionalriskfactors, includingSCOREandthe. . . reproducibility, even with experienced observers. 164 Fundoscopy Framingham risk score, has been suggested by several studies. 151. . . shouldbeperformedinpatientswithgrade2or3hypertensionor. However, routineuseofPWVmeasurementisnotpracticalandis. . hypertensivepatientswithdiabetes, inwhomsignificantretinopathy. notrecommendedforroutinepractice. . . ismorelikely. Fundoscopymaybeconsideredinotherhypertensive. . . patients. The increasing emergence of new techniques to visualize. 5. 5. 2. 3Anklebrachialindex. . thefundusthroughsmartphonetechnologiesshouldincreasethefea-. Ankle-brachialindex(ABI)maybemeasuredeitherwithautomated. . sibilityofmoreroutinefundoscopy. 165. devices, or with a continuous wave Doppler unit and a blood pressure sphyg-. . . momanometer. AlowABI(i. e. 0. 9)indicateslowerextremityartery. disease(LEAD), isusuallyindicativeofadvancedatherosclerosis, 152. . . 5. 5. 5Thebraininhypertension andhaspredictivevalueforCVevents, 153beingassociatedwithan. . . Hypertension increases the prevalence of brain damage, of which. . transient ischaemic attack (TIA) and stroke are the most dramatic almost two-fold greater 10 year CV mortality and major coronary. . . acuteclinicalmanifestations. Intheasymptomaticphase, braindameventrate, comparedwiththeoverallrateineachFraminghamcate-. . . agecanbedetectedbymagneticresonanceimaging(magnetic resonance imaging)aswhite gory. 153EvenasymptomaticLEAD, detectedbyalowABI, isassoci-. . . matterhyperintensities, silentmicroinfarcts, (mostofwhicharesmall ated in men with a High incidence of CV morbid and fatal events, . . . and deep, i. e. lacunar infarctions), microbleeds, and brain atroapproaching20%in10years. 153, 154RoutineuseofABIisnotrecom-. . . phy. 166, 167Whitematterhyperintensitiesandsilentinfarctsareassomended in hypertensive patients, but should be considered in. . . ciatedwithanincreasedriskofstrokeandcognitivedeclinedueto patients with symptoms or signs of LEAD, or in moderate-risk. . . degenerative and vascular dementia. 166169 Availability and cost do patientsinwhomapositivetestwouldreclassifythepatientashigh-. . . not permit the widespread use of brain magnetic resonance imaging for the evaluation of risk. . . . hypertensive patients, but white matter hyperintensity and silent. . . braininfarctsshouldbesoughtinallhypertensivepatientswithneu-. 5. 5. 3Thekidneyinhypertension. . rological disturbances, cognitive decline, and, particularly, memory. HypertensionisthesecondmostimportantcauseofCKDafterdia-. . loss. 168, 169 A family history of cerebral haemorrhage at middle age. betes. Hypertensionmayalsobethepresentingfeatureofasympto-. . andearly-onsetdementiashouldpromptMRI. Cognitiveimpairment. maticprimaryrenaldisease. Analterationofrenalfunctionismost. . inolderpatientsis, atleastinpart, hypertension-related, andcogni-. commonly detected by an increase in serum Creatinine. This is an. . tiveevaluationtestsshouldbeconsideredintheclinicalassessment. insensitivemarkerofrenalimpairmentbecauseamajorreductionin. . ofhypertensivepatientswithahistorysuggestiveofearlycognitive. renalfunctionisneededbeforeserumcreatininerises. Furthermore, . . impairment. TheMini-MentalStateExaminationhasbeenthemost. BPreductionbyantihypertensivetreatmentoftenleadstoanacute. . . widelyusedmethodinclinicaltrials, butisnowbeingsupersededby increaseinserumcreatininebyasmuchas2030%, especiallywith. . . moresophisticatedcognitiveteststhataremoresuitableforroutine renin-angiotensinsystem(renal artery stenosis)blockers, whichhasafunctionalbasis. . . clinicvisits. 170 anddoesnotusuallyreflectmanifestrenalinjury, butthelong-term. . . clinical significance is unclear. 155, 156 The diagnosis of hypertension-. . 5. 6 Hypertension-mediated organ. inducedrenaldamageisbasedonthefindingofreducedrenalfunc-. . . damage regression and cardiovascular tionand/orthedetectionofalbuminuria. CKDisclassifiedaccording. . . risk reduction with antihypertensive toestimatedglomerularfiltrationrate(estimated glomerular filtration rate), calculatedbythe2009. . chronic kidney disease-EpidemiologyCollaborationformula. 157. . . treatment. Thealbumin: creatinineratio(albumin-creatinine ratio)ismeasuredfromaspoturine. . Asdiscussedabove, HMODassessmentmayplayaroleinstratifying. sample(preferablyearlymorningurine), andisthepreferredmethod. the risk of patients with hypertension. In post hoc analyses, blood pressure Downloaded from by guest on 31 December 2025 3046 ESC/ESHGuidelines. . treatment-inducedregressionofsome(butnotall)manifestationsof. 5. 7 When to refer a patient with. . asymptomaticHMOD, asaconsequenceoftreatment, isassociated. . hypertension for hospital-based care. withareductioninCVrisk, therebyprovidingadditionalinformation. . . Hypertension is a very common condition and most patients with ontheeffectivenessoftreatmentinindividualpatients. 16, 104, 171This. . . hypertension, inmosthealthcaresystems, willbemanagedintheprihas been best illustrated for the treatment-induced regression of. . . mary care setting. However, there are circumstances in which a LVH measured by either ECG or echocardiography. 125, 172, 173 A. . . referralforroutinehospital-basedevaluationandtreatmentmaybe reducedincidenceofCVeventsandslowerprogressionofrenaldis-. . . required, keeping in mind that in some instances out-of-office or easehasbeenreportedwithatreatment-inducedreductioninuri-. . . office-basedcareofhypertensivepatientsdependsonthehealthcare nary Protein excretion in both diabetic and non-diabetic patients, . . . organizationofagivencountry: especiallyformicroalbuminuria, 174butresultsarediscordant. 175179. . . Thereisalsoevidencethattreatment-inducedchangesineGFRpre-. . Patients in whom secondary hypertension is suspected (see sec-. dictCVevents180andprogressiontoend-stagerenaldisease. 181, 182. . tion8. 2). Twometa-analyses183, 184failedtodocumentanypredictivevalueof. . Younger patients (40 years) with grade 2 or more severe.",
    "dictCVevents180andprogressiontoend-stagerenaldisease. 181, 182. . tion8. 2). Twometa-analyses183, 184failedtodocumentanypredictivevalueof. . Younger patients (40 years) with grade 2 or more severe. treatment-induced reductions in carotid IMT for CV events. . . hypertension in whom secondary hypertension should be. Evidenceonthepredictivepoweroftreatment-inducedchangeson. . excluded. other measures of HMOD (PWV and ABI) are either limited or. . Patientswithtreatment-resistanthypertension(seesection8. 1). . Patients in whom more detailed assessment of HMOD would absent. RegressionofHMODmightnotbepossibleevenwhenBPis. . . influencetreatmentdecisions controlled, particularlywhenHMODisadvanced, becausesomeof. . . Patients with sudden onset of hypertension when blood pressure has previthechangesbecomeirreversible. . . . ouslybeennormal Theinformationavailableonthesensitivityandtimingofchanges. . Other clinical circumstances in which the referring doctor feels. in HMOD during antihypertensive treatment is summarized in. . morespecialistevaluationisrequired. . Table18. If, when, andhowoftentheassessmentofHMODshould. . be performed has not been validated in follow-up studies. HMOD. . Therearealsorarercircumstancesinwhichapatientwithhyper-. canalsodevelopduringthecourseofantihypertensivetreatment, 185. . tensionshouldbereferredtohospitalforemergencycare, whichwill. andthismaybeaccompaniedbyincreasedrisk. 186188. . oftenrequireinpatientcare(seesection8. 3). . Table18 Sensitivitytodetecttreatment-inducedchanges, reproducibilityandoperatorindependence, timeto changes, andprognosticvalueofchangesprovidedbymarkersofhypertension-mediatedorgandamage CMRcardiacmagneticresonance; ECGelectrocardiogram; estimated glomerular filtration rateestimatedglomerularfiltrationrate; HMODhypertension-mediatedorgandamage; IMTintimamediathickness; LVHleftventricularhypertrophy; PWVpulsewavevelocity. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3047 ClinicalevaluationandHMODassessment Recommendations Classa Levelb Heart 12-leadECGisrecommendedforallhypertensivepatients. 120 I B Echocardiography: IsrecommendedinhypertensivepatientswhenthereareECGabnormalitiesorsignsorsymptomsofLV I B dysfunction. 42, 134 MaybeconsideredwhenthedetectionofLVHmayinfluencetreatmentdecisions. 42, 134 IIb B Bloodvessels Ultrasoundexaminationofthecarotidarteries: I B MaybeconsideredforthedetectionofasymptomaticatheroscleroticplaquesorcarotidstenosisinpatientswithdocuIIb B mentedvasculardiseaseelsewhere. 42 MeasurementofPWVmaybeconsideredformeasuringarterialstiffness. 109, 189 IIb B MeasurementofABImaybeconsideredforthedetectionofadvancedLEAD. 153, 190 IIb B Kidney MeasurementofserumcreatinineandeGFRisrecommendedinallhypertensivepatients. 180 I B Measurementofurinealbumin: creatinineratioisrecommendedinallhypertensivepatients. 43, 180 I B RenalultrasoundandDopplerexaminationshouldbeconsideredinpatientswithimpairedrenalfunction, albuminuria, orfor IIa C suspectedsecondaryhypertension. Fundoscopy Isrecommendedinpatientswithgrades2or3hypertensionandallhypertensivepatientswithdiabetes. I C Maybeconsideredinotherhypertensivepatients. IIb C Brain Inhypertensivepatientswithneurologicalsymptomsand/orcognitivedecline, brainMRIorCTshouldbeconsideredfor IIa B detectingbraininfarctions, microbleeds, andwhitematterlesions. 168, 169 ABIanklebrachialindex; computed tomographycomputedtomography; ECGelectrocardiogram; estimated glomerular filtration rateestimatedglomerularfiltrationrate; HMODhypertension-mediatedorgandamage; LEADlowerextremityarterialdisease; LVleftventricular; LVHleftventricularhypertrophy; magnetic resonance imagingmagneticresonanceimaging; PWVpulsewavevelocity; TIA transientischaemicattack. aClassofrecommendation. bLevelofevidence. . 6 Genetics and hypertension. . monogenic forms of hypertension have been described such as. . . glucocorticoid-remediable aldosteronism, Liddles syndrome, and. . A positive family history is a frequent feature in hypertensive. others, whereasinglegenemutationfullyexplainsthepathogenesis. patients, with the heritability estimated to vary between 35 and. . of hypertension and dictates the best treatment modality. 194196. 50%inmoststudies. 191, 192However, hypertensionisahighlyheter-. . Therearealsoinheritedformsofphaeochromocytomaandpara-. . ogeneousdisorderwithamultifactorialaetiology. Severalgenome-. . ganglioma, which are also rare causes of hypertension. 197200. wide association studies and their meta-analyses have identified. . Outsideofspecialistclinicsevaluatingpatientsfortheserarecauses. 120locithatareassociatedwithBPregulation, buttogetherthese. . of secondary hypertension, there is no role for genetic testing in only explain about 3. 5% of the trait variance. 193 Several rare, . . . hypertensioninroutineclinicalcare. Downloaded from by guest on 31 December 2025 3048 ESC/ESHGuidelines. . . theprogressionofCKDtowardsend-stagerenaldiseaseinbothdia-. Genetictestingandhypertension. . beticandnon-diabeticnephropathy. 2. . . . Therecommendationsthatfollowarebasedonoutcomeevidence Recommendations Classa Levelb. . . fromRCTs; however, itmustbeacknowledgedthatRCTsbasedon. Genetictestingshouldbeconsideredinspe-. . . clinicaloutcomeshavelimitations, themostimportantofwhichare cialistcentresforpatientssuspectedtohave. . . thatthedataarelargelylimitedtoolderandhigh-riskpatients, preferraremonogeniccausesofsecondaryhyper- IIa B. . . entiallyrecruitedtoincreasestatisticalpower, andoverarelatively tensionorforthosewith. . . shortdurationoffollow-up, rarelybeyond5years. Thismeansthat phaeochromocytoma. 198. . . recommendationsforlife-longtreatmentforyoungerandlowerrisk. . patients are necessarily based on considerable extrapolation. Big. Routinegenetictestingforhypertensive. . data, nowbeingcollectedbynationalhealthsystemregistries, health III C. patientsisnotrecommended. . . insurance companies, and prolonged observational follow-up of. . . RCTs, arebecominganimportantsourceoflong-terminformation. aClassofrecommendation. . . ontheeffectsofchronictreatment, 204whichaddstothatprovided. bLevelofevidence. . . byobservationalstudiesoverseveraldecades. 205207Suchevidence. . . suggeststhatthebenefitofcontinuedtreatmentismaintainedover. . . decades. 206. . . . 7 Treatment of hypertension. . 7. 2. When to initiate antihypertensive. . . treatment. 7. 1 Beneficial effects of Blood Hypertension-. . . 7. 2. 1Recommendationsinpreviousguidelines. lowering therapy in hypertension. . All guidelines agree that patients with grade 2 or 3 hypertension. . Therearetwowell-establishedstrategiestolowerBP: lifestyleinter-. should receive antihypertensive drug treatment alongside lifestyle. ventionsanddrugtreatment. Device-basedtherapyisalsoemerging, . . interventions. 208 Guidelines are also consistent in recommending. . butisnotyetprovenasaneffectivetreatmentoption. Lifestyleinter-. thatpatientswithgrade1hypertensionandhighCVriskorHMOD. . ventionscanundoubtedlylowerBPandinsomecasesCVrisk(see. shouldbetreatedwithBP-loweringdrugs. Therehasbeenlesscon-. . section7. 4. 1), butmostpatientswithhypertensionwillalsorequire. sistency about whether blood pressure-lowering drugs should be offered to. . drug treatment. The drug treatment of hypertension is founded on. patients with grade 1 hypertension and Lowmoderate CV risk or. . verysolidevidence, underpinnedbythelargestnumberofoutcome-. grade1hypertensioninolderpatients(60years), ortheneedfor. . based RCTs in clinical medicine. Meta-analyses of RCTs including.",
    ". verysolidevidence, underpinnedbythelargestnumberofoutcome-. grade1hypertensioninolderpatients(60years), ortheneedfor. . based RCTs in clinical medicine. Meta-analyses of RCTs including. blood pressure-lowering drug treatment in patients with Highnormal blood pressure lev-. several hundred thousand patients have shown that a 10 mmHg. . els. 17, 209, 210Thisuncertaintyrelatestothefactthatlow-riskpatients. . reductioninSBPora5mmHgreductioninDBPisassociatedwithsig-. with Highnormal blood pressure or grade 1 hypertension have rarely been. . nificantreductionsinallmajorCVeventsby(cid: 3)20%, all-causemortality. . included in RCTs, and that in older patients, RCTs have invariably. by10-15%, strokeby(cid: 3)35%, coronaryeventsby(cid: 3)20%, andheart. . recruitedpatientswithatleastgrade2hypertension. Newanalyses. failureby(cid: 3)40%. 2, 8Theserelativeriskreductionsareconsistent, irre-. . andRCTdata have become available in theseimportant areasand. spectiveofbaselineBPwithinthehypertensiverange, thelevelofCV. . arediscussedbelow. . risk, comorbidities(e. g. diabetesandCKD), age, sex, andethnicity. 2, 201. . . Thecurrentbackgroundinformationanddetaileddiscussionof. . 7. 2. 2Drugtreatmentforpatientswithgrade1. thedataforthefollowingsectionoftheseGuidelinescanbefound. . hypertensionatlowmoderatecardiovascularrisk. in ESC CardioMed Chapter 44. 7 Drug treatment of hypertension. . Recentmeta-analysesshowsignificanttreatment-inducedreductions. andChapter44. 8Device-basedtreatmentforhypertension. . . in CV events and mortality in patients with grade 1 hyperten-. Relative outcome reductions calculated by two recent meta-. . sion. 8, 201, 211However, thefirstoftheseanalysesincludedasubstan-. analysesaresimilartothoseprovidedbytheoriginalmeta-analysisof. . tial number of patients who had grade 1 hypertension despite. theeffectsofBPloweringonoutcomesin1994. 202Thus, thebenefits. . existingtreatment, andwerethereforelikelytohavehadinitialBPs. . ofantihypertensivetreatmenthavenotbeenattenuatedbythewide-. abovethegrade1range. Furthermore, manyofthepatientshaddia-. spread concomitant prescription of lipid-lowering and antiplatelet. . betes and were therefore at High CV risk. 211 The second meta-. . therapiesincontemporarymedicine. . analysis, limitedtoRCTsinpatientswithgrade1hypertensionand. . Another important objective of antihypertensive therapy is to. . Lowmoderate-risk(fiveRCTs, 8974patients), demonstratedasignif-. reducethedevelopmentofCKD; however, theslowrateofdecline. . icantreductioninallmajorCVeventsbyBP-loweringdrugtreatment. inrenalfunctioninmosthypertensivepatientsmakesthedemonstra-. . combined stroke and coronary artery disease (coronary artery disease) reduced by. tionofpotentialbenefitsofBPloweringdifficult. Consequently, the. . 34%, and all-cause mortality by 19% for an SBP reduction of (cid: 3)7. protective effect of blood pressure reduction on Kidney function can be less. . mmHg. 8AthirdanalysisdemonstratedabenefitofBPloweringin. obviousandhasbeenrestrictedtopatientswithdiabetesorCKD, in. . reducingdeathandCVDinpatientswithabaselineBP140/90mmHg whomthereisafasterrateofdiseaseprogression. 203Some, butnot. . . or higher, but not when baseline blood pressure was lower. 201 These findings. all, RCTshavealsoshownaprotectiveeffectiveofBPloweringon. have been supported by the results of a subgroup analysis of the Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3049. . Heart Outcomes Prevention Evaluation (HOPE)-3 trial, showing a. because physically and mentally frail and institutionalized patients. . significant27%reductioninmajorCVoutcomesinpatientsatinter-. . havebeenexcludedinmostRCTsofpatientswithhypertension. 214. mediateCVriskandbaselineSBPvaluesinthegrade1hypertensive. . Furtherdetailsofthetreatmentofhypertensioninolderpatientsand. rangei. e. 143. 5mmHg(mean154mmHg)whenSBPwaslowered. . veryoldpatientsisprovidedinsection8. 8. . bydrugtreatmentbyameanof6mmHg. 212. . . Basedonthesenewdata, thisTaskForcenowrecommendsthat. . 7. 2. 4Initiationofbloodpressure-loweringdrug. lifestyle advice should be accompanied by blood pressure-lowering drug treat-. . treatmentinpatientswithhighnormalbloodpressure. ment in patients with grade 1 hypertension at Lowmoderate CV. . Theprevious(2013)Guidelines17recommendednottoinitiateanti-. risk. . . hypertensive treatment in people with Highnormal blood pressure and. . . LowmoderateCVrisk. Thisrecommendationisfurthersupported. . 7. 2. 3Initiationofbloodpressure-loweringdrugtreat-. . bynewevidence: . mentinolderpeoplewithgrade1hypertension. . . (1) In all RCTs (including SPRINT)51 and meta-analyses2 that have Discussionaboutthetreatmentoftheelderlyorolderpeoplehas. . . reportedreducedmajoroutcomesbyloweringbaselineBPinthe. been complicated by the various definitions of older age used in. . Highnormalrange, thebaselineBPwascommonlymeasuredona. RCTs. Forexample, olderwasdefinedas60yearsintheearliesttri-. . backgroundofantihypertensivetreatment. Therefore, thesestudies als, then as 65, 70, and finally 7551 or 80 years213 in later trials. . . . . donotprovideevidencetosupporttreatmentinitiationinpatients Chronologicalageisoftenapoorsurrogateforbiologicalage, with. . . withouthypertension. 8 considerationoffrailtyandindependenceinfluencingthelikelytoler-. . . (2) TheHOPE-3trial, 212inwhichonly22%ofthepatientsatintermediabilityofBP-loweringmedications. Forthepurposesofthisguideline, . . . ate CV risk had background antihypertensive treatment, showed theoldaredefinedas_65yearsandtheveryoldas_80years. The. previousGuidelines17notedthatallavailableevidenceonCVevent. . . that blood pressure-lowering treatment did not reduce the risk ofmajor CV. . events in patients with baseline SBP values in the Highnormal reductionbyBPloweringinolderpatientswasobtainedinpatients. . . range. whosebaselineSBPwas_160mmHg, andthereisstrongevidence. . . (3) Ameta-analysisof13RCTsorRCTsubgroups(involving21128 that these patients should be offered blood pressure-lowering drug. . . individuals) in patients at Lowmoderate CV risk and untreated treatment. 210, 214. . . baselineBPinthehighnormalandnormalrange, showednoeffect Undoubtedly, thereareRCTsshowingoutcomebenefitswithBP-. . . ofBP-loweringtreatmentonanyCVoutcomes. 217 lowering treatment in older patients whose baseline blood pressure was in a. . . (4) Another recent analysis, including patients with Highnormal blood pressure, lowerSBPrange, butthesepatientswereoftenonbackgroundanti-. . . concludedthatprimarypreventiveBPloweringwasassociatedwith hypertensivetreatment, thustheycannotbedefinedashavingtrue. . . reducedriskfordeathandincidentCVDifbaselineSBPwas140 grade1hypertension. Thisisalsothecaseforthedatarecentlypub-. . . mmHgorhigher, butatlowerBPlevelsi.",
    ". . concludedthatprimarypreventiveBPloweringwasassociatedwith hypertensivetreatment, thustheycannotbedefinedashavingtrue. . . reducedriskfordeathandincidentCVDifbaselineSBPwas140 grade1hypertension. Thisisalsothecaseforthedatarecentlypub-. . . mmHgorhigher, butatlowerBPlevelsi. e. HighnormalBP(140/ lished from the SPRINT trial, which included a cohort of patients. . . 90mmHg), treatmentwasnotassociatedwithanybenefitinpriolderthan75years, inwhommoreintenseBPloweringreducedthe. . . maryprevention. 201 riskofmajorCVeventsandmortality. 51, 215However, inmostRCTs. . . (5) The situation may be different in very High-risk patients with a showingaprotectiveeffectofBP-loweringtreatmentinpatientswith. . . Highnormal blood pressure and established cardiovascular disease. In a meta-analysis of 10 an untreated baseline blood pressure in the grade 1 hypertension range, older. . . RCTsorRCTsubgroupsthatalsoincludedindividualsathigh or. patientswerewellrepresented. Thiswasfurthersupportedbythe. . very High CV risk, mostly with previous cardiovascular disease and untreated. recentHOPE-3trial, whichshowedbeneficialeffectsofBPlowering. . HighnormalandnormalBP(n26863), blood pressure-loweringdrugtreat-. onCVoutcomesinpatients, manywithgrade1hypertension(SBP. . . ment, achievinganSBPreductionof4mmHg, reducedtheriskof 143mmHgandmeanBP154mmHg), whosemeanagewas(cid: 3)66. years, andinwhomonly22%hadpriortreatmentofhypertension. 212. . . strokebutnotanyotherCVevents. 217Inanotheranalysisoftrials. . includingpeoplewithpreviousCADandameanbaselineSBPof The evidence supports the recommendation that older patients. . . 138mmHg, treatmentwasassociatedwithreducedriskformajor (65years, includingpatientsover80years)shouldbeofferedBP-. . . CVevents(relativerisk0. 90; 95%confidenceinterval0. 840. 97), loweringtreatmentiftheirSBPis_160mmHg. Thereisalsojustifica-. . . butwasnotassociatedwithanincreasedsurvival(relativerisk0. 98; tion to now recommend blood pressure-lowering treatment for old patients. . . 95%confidenceinterval0. 891. 07). 201Thus, thebenefitfortreating (aged65butnot80years)atalowerBP(i. e. grade1hypertension; . . . people with Highnormal blood pressure appears marginal and, if present, SBP140159mmHg). 201BP-loweringdrugsshouldnotbewith-. . . appearstoberestrictedtothoseatveryhighCVriskandestabdrawn on the basis of age alone. It is well established that blood pressure-. . . lishedCVD, especiallyCAD. loweringtreatmentwithdrawalleadstoamarkedincreaseinCVrisk. . . . Thiswasexemplifiedinolderpatientsbyarecentsubgroupanalysis. . We recommend that patients with Highnormal blood pressure and. oftheHypertensionintheVeryElderlyTrial(HYVET), 213reporting. . LowmoderateCVriskshouldbeofferedlifestyleadvice, becausethis. that in patients aged _80 years, CV risk reduction was greatest in. . reducestheirriskofprogressingtoestablishedhypertensionandmay. those who continued treatment rather than in those whose treat-. . furtherreducetheirCVrisk. ThesepatientsshouldnotbeofferedBP-. mentwasdiscontinued. 216Asstatedabove, alloftheaboverecom-. . lowering drug treatment. Nevertheless, based on the data from the. mendations relate to relatively fit and independent older patients, . HOPE-3trial, drugtreatmentmaybeconsideredinthesepatientsif Downloaded from by guest on 31 December 2025 3050 ESC/ESHGuidelines. . theirBP isclose tothehypertensiondiagnosticthresholdof140/90. effectivestrategytoreduceriskistopreventthedevelopmentofhigh. . mmHg, afteraprolongedattempttocontrolBPwithlifestylechanges. . CV-risksituationswithearlierintervention. TheassessmentofCVrisk. . blood pressure-lowering drugs may be considered for patients with. is at the core of the treatment strategy recommended by these. . Highnormal blood pressure and established cardiovascular disease, especially coronary artery disease. In these. GuidelinesbecauseofthefrequentcoexistenceofmultipleCVriskfac-. . patients, monotherapymaybesufficient. . tors in hypertensive patients, and to inform the use of concomitant. . . medications(e. g. statins, antiplatelettherapies, etc. , seesection9)to. . . reduceCVrisk. Weconcludethat, ingeneral, thedecisiontouseBP-. 7. 2. 5Shouldbloodpressure-loweringdrugtreatmentbe. . loweringtreatmentshouldnotbebasedsolelyonthelevelofCVrisk. initiatedonthebasisofbloodpressurevaluesorthelevel. . . because even in patients at the highest risk (with established cardiovascular disease), oftotalcardiovascularrisk? . Two recent meta-analyses of RCTs8, 218 have shown that when blood pressure-. . . whenbaselineBPisbelow140/90mmHg, thebenefitsofBP-lowering. . treatmentareatbestmarginalandmostevidentinpatientswithCAD loweringdataarestratifiedaccordingtoCVrisk, therelativeriskreduc-. . . attheupperendofthehighnormalBPrange. 201 tionsdonotdifferacrossthevariousriskstrata; notsurprisingly, the. . . absolute risk reduction is greater with increasing baseline CV risk. . . . These data have been taken as support for the hypothesis that blood pressure-. . . lowering treatmentshould be based onCV riskand targetthose at. 7. 2. 6Initiationofbloodpressure-loweringdrug. greatestCVrisk, irrespectiveoftheirBP. 218However, ithasrecently. . treatment. . beenmadethatwhereaspatientsathighorveryhighCVriskexhibit. Inpatientswithgrade2or3hypertension, itisrecommendedthat. . the greatest absolute reduction in CV outcomes with blood pressure-lowering. . blood pressure-lowering drug treatment should be initiated alongside lifestyle. treatment, theyalsohavethehighestresidualrisk, whichmeansfailure. . interventions. In patients with grade 1 hypertension at High riskor. of treatment to exert full protection. 8 It is the opinion of this Task. . withHMOD, drugtreatmentshouldalsobeinitiatedsimultaneously. ForcethatthesedatasupportearliertreatmentofpatientswithSBPor. . withlifestyleinterventions. Inlower-riskpatientswithgrade1hyper-. DBPvalues140/90mmHgwhentheirCVriskisstilllowmoderate, . . tension, blood pressure-lowering drug treatment should be initiated after 36. topreventthe accumulationof HMOD anda highincidence oflate. . months if blood pressure is not controlled by lifestyle interventions alone. treatmentfailure(residualrisk), whichwouldotherwiseoccuriftreat-. . (Figure3). RecommendedBPthresholdsfortheinitiationofantihy-. ment was delayed by a purely CV risk-based approach. The most. pertensivedrugtreatmentareshowninTable19. Figure3 Initiationofbloodpressure-loweringtreatment(lifestylechangesandmedication)atdifferentinitialofficebloodpressurelevels. blood pressure bloodpressure; coronary artery diseasecoronaryarterydisease; cardiovascular diseasecardiovasculardisease; HMODhypertension-mediatedorgandamage. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3051 InitiationofhypertensiontreatmentaccordingtoofficeBP Recommendations Classa Levelb PromptinitiationofBP-loweringdrugtreatmentisrecommendedinpatientswithgrade2or3hypertensionatanylevelofCV I A risk, simultaneouswiththeinitiationoflifestylechanges.",
    "Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3051 InitiationofhypertensiontreatmentaccordingtoofficeBP Recommendations Classa Levelb PromptinitiationofBP-loweringdrugtreatmentisrecommendedinpatientswithgrade2or3hypertensionatanylevelofCV I A risk, simultaneouswiththeinitiationoflifestylechanges. 2, 8 Inpatientswithgrade1hypertension: II B (cid: 2) LifestyleinterventionsarerecommendedtodetermineifthiswillnormalizeBP. 219 (cid: 2) Inpatientswithgrade1hypertensionatlowmoderate-riskandwithoutevidenceofHMOD, blood pressure-loweringdrugtreatmentis I A recommendedifthepatientremainshypertensiveafteraperiodoflifestyleintervention. 211, 212 (cid: 2) Inpatientswithgrade1hypertensionandathighriskorwithevidenceofHMOD, promptinitiationofdrugtreatmentisrecI A ommendedsimultaneouslywithlifestyleinterventions. 211, 212 Infitolderpatientswithhypertension(evenifaged80years), blood pressure-loweringdrugtreatmentandlifestyleinterventionarerecI A ommendedwhenSBPis_160mmHg. 210, 220, 221 blood pressure-loweringdrugtreatmentandlifestyleinterventionarerecommendedforfitolderpatients(65yearsbutnot80years) I A whenSBPisinthegrade1range(140159mmHg), providedthattreatmentiswelltolerated. 212 Antihypertensivetreatmentmayalsobeconsideredinfrailolderpatientsiftolerated. 215 IIb B WithdrawalofBP-loweringdrugtreatmentonthebasisofage, evenwhenpatientsattainanageof_80years, isnotrecomIII A mended, providedthattreatmentiswelltolerated. 213 InpatientswithhighnormalBP(130139/8589mmHg): I A (cid: 2) Lifestylechangesarerecommended. 17, 35 (cid: 2) DrugtreatmentmaybeconsideredwhentheirCVisveryhighduetoestablishedCVD, especiallyCAD. 217 IIb A blood pressurebloodpressure; coronary artery diseasecoronaryarterydisease; CVcardiovascular; cardiovascular diseasecardiovasculardisease; HMODhypertension-mediatedorgandamage; SBPsystolic bloodpressure. aClassofrecommendation. bLevelofevidence. cInpatientswithgrade1hypertensionandatlowmoderate-risk, drugtreatmentmaybeprecededbyaprolongedperiodoflifestyleinterventiontodetermineifthisapproach willnormalizeBP. ThedurationofthelifestyleinterventionalonewilldependonthelevelofBPwithinthegrade1range, i. e. thelikelihoodofachievingBPcontrolwithlifestyle interventionalone, andtheopportunitiesforsignificantlifestylechangeinindividualpatients. Table19 Summaryofofficebloodpressurethresholdsfortreatment Agegroup OfficeSBPtreatmentthreshold(mmHg) OfficeDBPtreatment threshold(mmHg) Hypertension 1Diabetes 1CKD 1CAD 1Stroke/TIA 18-65years _140 _140 _140 _140a _140a _90 65-79years _140 _140 _140 _140a _140a _90 _80years _160 _160 _160 _160 _160 _90 OfficeDBPtreatment _90 _90 _90 _90 _90 threshold(mmHg) blood pressurebloodpressure; coronary artery disease coronary artery disease; chronic kidney disease chronickidney disease; DBP diastolicblood Hypertension; SBP systolic Blood Hypertension; TIA transient ischaemicattack. aTreatmentmaybeconsideredintheseveryhigh-riskpatientswithhighnormalSBP(i. e. SBP130140mmHg). Downloaded from by guest on 31 December 2025 3052 ESC/ESHGuidelines. . 7. 3 Blood Hypertension treatment targets. baseline values between 130 and 139 mmHg, implying benefit at. . 7. 3. 1Newevidenceonsystolicbloodpressureand. . achievedSBPvaluesof130mmHg. Furthermore, abenefitofa10. diastolicbloodpressuretreatmenttargets. . mmHgreductioninSBPwasalsoreportedforpatientswithabase-. The 2013 ESH/ESC hypertension Guidelines17 recommended an. . line SBP of 130 mmHg, thereby achieving values 120 mmHg. . officeBPtreatmenttargetof140/90mmHg, regardlessofthenum-. . However, therewerefarfewerpatientsinthesesubgroups, andthis. berofcomorbiditiesandlevelofCVrisk. TheGuidelinesspecifically. . . lastsetofdatawillhavebeenheavilyinfluencedbytheunusuallylow statedthatevidencefromRCTs, meta-analyses, andposthocanalysis. . . BPvaluesintheSPRINTtrial, duetothemethodofBPmeasurement of large-scale RCTs all showed no obvious incremental benefit of. . . (see above). Importantly, this analysis showed consistent benefit lowering blood pressure to 130/80 mmHg. Since then, new information has. . . fromintensive BPloweringinpatientsatall levelsof risk, including emergedfromposthocanalysesoflargeoutcometrialsinpatientsat. . . thosewithandwithoutexistingCVD, stroke, Diabetes, andCKD. highCVrisk, 222224registriesinpatientswithcoronarydisease, and, . . . Finally, inthefirstmeta-analysis, 226theincrementalbenefitofBP moreimportantly, newRCTsandmeta-analysesofallavailableRCT. . . loweringoneventsprogressivelydecreasedasthetargetBPwaslow-. evidence. IntheposthocRCTanalysesandregistrydata, compared. . ered. Furthermore, an additional meta-analysis by the same group. withatargetSBPofbetween130mmHgand139mmHg, lowering. . found that permanent treatment discontinuation because of. SBPto130mmHgwas, ingeneral, associatedwithnofurtherbene-. . treatment-relatedadverseeffectswassignificantlyhigherinthosetarfitonmajorCVevents, exceptperhapsforfurtherreductionsinthe. . . geted to lower blood pressure values. 227 Therefore, advocatingmore intensive. . blood pressure-lowering targets for all has to be viewed in the context of an riskofstroke. A consistent finding wasthat reducing SBP to 120. . . increased risk of treatment discontinuation due to adverse events, mmHgincreasedtheincidenceofCVeventsanddeath. . . . which might offset, in part or completely, the limited incremental ArecentRCTrelevanttotheissueoftargetBPisSPRINT, which. . . reductioninCVrisk. compared two different SBP targets (140 or 120 mmHg) in. . . WhilstconsideringBPtargets, itisimportanttoacknowledgethat 9000patientsathighCVrisk, butexcludedpatientswithdiabetes. . . 50%ofpatientstreatedforhypertensioncurrentlyachieveatarget orpreviousstroke. MoreintensiveBP-loweringtreatment(achieved. . . officeSBPof140mmHg. 11, 12Thisisamajormissedopportunityfor SBP 121 vs. 136 mmHg) was associated with a 25% reduction in. . majorCVeventsanda27%reductioninall-causedeath(butnosig-. . CVDpreventioninmillionsofpeopleacrosstheworld. . nificantreductioninstrokeormyocardialinfarction). 51Thisoutcome. . This Task Force recommends that when blood pressure-lowering drugs are. unquestionablyprovidesstrongsupportforthebeneficialeffectsof. . used, thefirstobjectiveshouldbetolowerBPto140/90mmHgin. morevs. lessintensiveBP-loweringtreatmentstrategiesinhigherrisk. . allpatients. Providedthatthetreatmentiswelltolerated, treatedBP. patients. However, thisRCTdoesnotclarifytheoptimalBPtarget. . . valuesshouldbetargetedto130/80mmHgorlowerinmostpatients, because the method used for office blood pressure measurement in SPRINT. . . although in some groups the evidence is less compelling. In older (unattendedautomaticmeasurement)hadnotbeenusedinanypre-. . . patients (65 years), SBP should be targeted to between 130 and vious RCTs that provide the evidence base for the treatment of. . . 140mmHg, andDPBto80mmHg. TreatedSBPshouldnotbetarhypertension. 225 This is because unattended automated office blood pressure. . . getedto120mmHg. measurement results in lower blood pressure values, relative to conventional. . . Importantly, we specify a target range because the lower safety office blood pressure measurement, due to the absence of the white-coat. . . boundaryassumesgreaterimportancewhenBPistargetedtolower effect. 52, 54Thus, ithasbeensuggestedthattheBPvaluesreportedin. . . levels. Furthermore, ingeneral, whenSBPisloweredto120mmHg. SPRINTmaycorrespondtoconventionalofficeSBPsinthe130140. . inpatientsincludedinRCTs(i. e. olderandhigher-riskpatients, often.",
    ". . boundaryassumesgreaterimportancewhenBPistargetedtolower effect. 52, 54Thus, ithasbeensuggestedthattheBPvaluesreportedin. . . levels. Furthermore, ingeneral, whenSBPisloweredto120mmHg. SPRINTmaycorrespondtoconventionalofficeSBPsinthe130140. . inpatientsincludedinRCTs(i. e. olderandhigher-riskpatients, often. and 140150 mmHg ranges in the more vs. less intensive blood pressure-. . withcomorbiditiesandCVD), theriskofharmappearstoincrease loweringgroups, respectively. . . . andoutweighthebenefits. 222. . SomenewinformationonSBPandDBPtargetsfordrugtreatment. . . hasbeenprovidedbytworecent, largemeta-analysesofRCTsofBP. . . lowering. Inthefirstofthesemeta-analyses, achievedSBPwasstrati-. 7. 3. 2Bloodpressuretargetsinspecificsubgroupsof. . fiedaccordingtothreeSBPtargetranges(149140mmHg, 139130. hypertensivepatients. mmHg, and130mmHg). 226LoweringSBPto140mmHgreduced. . 7. 3. 2. 1. Diabetesmellitus. . therelativeriskofallmajorCVoutcomes(includingmortality); simi-. RCTsintype1diabetesmellitusdemonstratethatBP-loweringtreat-. . larbenefitswereseenwhenSBPwasloweredto130mmHg(aver-. menthasarenoprotectiveeffect, 228butbecausethesepatientstend. . age 126 mmHg). Importantly, the latter was also true when the. . tobeyounger, previousRCTshavehadinadequatepowertostudy. achieved SBP in the comparator group was 130-139 mmHg. . . CVoutcomesandtoestablishoptimalBPtargets. . StratificationofRCTsforachievedDBP, toeither89-80mmHgor. . Incontrast, therehavebeenmanyBP-loweringtreatmentRCTs, . 80 mmHg, also showed a reduction in all types ofCV outcomes. . either exclusively dedicated to patients with type 2 Diabetes or. comparedwithhigherDBPvalues. 226. . hypertensiontrialsthathaveincludedalargecohortofpatientswith. Thesecondmeta-analysis, whichalsoincludedtheSPRINTtrial, 2. . type2diabetes. 2MostoftheseRCTshaveshownthatBPlowering. noted that every 10 mmHg reduction in SBP reduced the rate of. . to140/85mmHgisbeneficialinpatientswithtype2diabetesand. majorCVeventsanddeathforbaselineSBPvalues160mmHgto. hypertension. However, the results have been less clear about Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3053. . whetheralowerBPtargetisassociatedwithfurtherbenefits. Theevi-. 7. 3. 2. 2. Olderpatients. . dencecanbesummarizedasfollows: . The definition of older is complex. As populations age, there is. . . increasinglywidevariationbetweenapatientschronologicalageand. i. A large RCT in patients with type 2 Diabetes has shown that an. . their functional status, ranging from fit, active, and independent, . achieved SBP of 135 mmHg, compared with (cid: 3)140 mmHg, was. . . throughtofrailanddependent. Theanticipatedbenefitsvs. potential associatedwithasignificantreductionincardiovascularandall-cause. . . harm of blood pressure treatment in older patients will be influenced by the mortality. 229. . . patientsabilitytotoleratetreatmentandtheirhealthandfunctional ii. EvidencefromanotherlargeRCTinpatientswithtype2diabetes. . . status. For the purposes of these Guidelines, older patients are showedthat, comparedwithpatientswithanon-treatmentSBPof. . . definedasthoseaged_65years. (cid: 3)135mmHg, reducingSBPto121mmHgdidnotreduceCVmor-. . . Inthe2013ESH/ESChypertensionGuidelines, thetargetSBPfor bidityandmortalityorall-causedeath, butsubstantiallyreducedthe. . . olderhypertensivepatientswassetat140150mmHgbecausethis riskofstroke. 230. . . was the range of systolic values achieved by major outcome trials iii. Althoughonerecentmeta-analysisconcludedthatmostofthebene-. . . demonstrating a beneficial effect of antihypertensive treatment in fitassociatedwithBPloweringwasobtainedathigherBPtargets(i. e. . . . thesepatients. AsimilarSBPtargetwassuggestedbytheHYVETtrial, 150 mmHg but not 140 mmHg), 231 other large meta-analyses. . . inwhichtreatingtoanSBPtargetof150mmHg(achievingamean haveconfirmedthatintype2diabetes, loweringSBPto140mmHg. . . SBPof144mmHg)intheveryold(80years)demonstratedsignifiisassociatedwithreductionsinallmajorCVevents. 1, 232234. . . cantreductionsinmortality, fatalstroke, andheartfailure, withthe iv. Twoofthemeta-analysesconcludedthattheoverallbenefitoflow-. . . caveatthattheveryoldpatientsinthisstudywereactiveandindeering blood pressure in patients with type 2 Diabetes (unlike patients without. . . pendent. 213MorerecentevidencesupportsalowerSBPtargetfor. type2diabetes)largelydisappearswhenSBPisloweredto130/80. . olderpatients(_65years): mmHg, 1, 235exceptforthecontinuingincrementalbenefitonstroke. . . . . v. SimilarevidenceforstrokebenefitfromlowerachievedSBPhasalso. (1) The SPRINT trial included a High proportion of patients over. . been reported from post hoc analysis of diabetic patients in the. theageof75years(n2636)anddemonstratedthatmoreinten-. . ONTARGET(OngoingTelmisartanAloneandincombinationwith. siveBP-loweringtreatment(meanachievedBP 124/62mmHg). . RamiprilGlobalEndpointTrial)study. Inaddition, reanalysisofthe. significantlyreducedtheriskofmajorCVevents, heartfailure, and. ActiontoControlCardiovascularRiskinDiabetes(ACCORD)230. . all-cause death (all by 30%) compared with standard treatment. trialintype2diabetes, afterremovingtheinteractionfromtheinten-. . (meanachievedBP135/67mmHg). 215Ithasbeennotedabove. . sive glucose-lowering arm andthereby limiting the analysistoBP-. that the blood pressure measurement technique used in SPRINT generated. . lowering effects, showed an overall reduction in CV events with. lower values than those provided by the conventional office. . intensiveSBPloweringto130mmHg. 236. . blood pressure measurement. 225, 242 Consequently, the SBP of 124 mmHg. vi. FurtherrecentanalysisoftheACCORDtrialhasshownthatreduc-. . achieved in the intensively treated older patients in the SPRINT. ingSBPto120mmHgwasassociatedwithincreasedriskofmajor. . trial most probably reflects a conventional office SBP range of. CVevents. 236. . 130139mmHg. . vii. WithregardtoDBP, earlierevidencesuggestedabenefitonmajor. . (2) Although HYVET and most other RCTs in older patients have. CV events when DBP was lowered to 85 mmHg. 237, 238 More. . recruitedrelativelyfitandindependentpatients, theSPRINTstudy. recently, intheActioninDiabetesandVascularDisease: Preterax. . alsosuggestedthattherearebenefitsofmoreintensivetreatment. and Diamicron MR Controlled Evaluation (ADVANCE) trial, 229. . beingextendedtoolderpatientswhoareatthefrailerendofthe. thebenefitsonCVoutcomeswasobservedatdiastolicpressuresof. . spectrumofpatientsmeetingtherecruitmentcriteria, withreduced. 75mmHg. Thisisconsistentwithevidencefromthemeta-analyses. . gaitspeed. 215. citedabove, thatitissafeandeffectivetolowerDBPto80mmHg. . inpatientswithtype2diabetes. . . . Based on the new data, the targets suggested by the previous. . Guidelinesnowappeartooconservativeformanyoldandveryold. Insummary, InpatientswithdiabetesreceivingBP-loweringdrugs, . .",
    ". . . Based on the new data, the targets suggested by the previous. . Guidelinesnowappeartooconservativeformanyoldandveryold. Insummary, InpatientswithdiabetesreceivingBP-loweringdrugs, . . patients, especially those who are active and independent. . itisrecommendedthatofficeBPshouldbetargetedtoanSBPof130. . Consequently, we recommend that in older patients treated for. mmHg, 229andloweriftolerated. Inolderpatients(aged_65years). . hypertension, blood pressure should be lowered to 140/80 mmHg, but not. theSBPtargetrangeshouldbe130140mmHg213iftolerated. SBP. . belowanSBPof130mmHg. Importantly, theimpactofBP-lowering. shouldnotbeloweredto120mmHgandDBPshouldbelowered. . onthewell-beingofthepatientshouldbecloselymonitored, because. to80mmHg. Attentionshouldalsobegiventotheconsistencyof. . theincreasedriskofadverseevents(e. g. injuriousfalls)withlowerBP. blood pressure control, because visit-to-visit blood pressure variability is associated with. . values could be more pronounced in older patients in the real-life. increasedCVandrenaldiseaserisk. Furthermore, CVprotectionhas. . setting than in the closely monitored conditions of RCTs. Further. . beenfoundtobegreaterwhenBPcontrolisaccompaniedbyfewer. detailsontheapproachtotreatmentofthefrailolderpatientaredis-. visit-to-visitBPvariations. 239241. . cussedinsection8. 8. Downloaded from by guest on 31 December 2025 3054 ESC/ESHGuidelines. . 7. 3. 2. 3Officevs. homeandambulatorybloodpressuretargets. 7. 4 Treatment of hypertension. . No outcome-based RCT has used ABPM or HBPM to guide the. . 7. 4. 1Lifestylechanges. treatment of hypertension. Thus, ABPM and HBPM blood pressure targets are. . Heathylifestylechoicescanpreventordelaytheonsetofhyperten-. basedonextrapolationfromobservationaldataratherthanonout-. . sionand canreduceCVrisk. 17, 35Effective lifestylechangesmaybe. cometrials. AlthoughwedonotprovideformalABPMorHBPMBP. . sufficienttodelayorpreventtheneedfordrugtherapyinpatients. targetsfortreatedpatients, itshouldbenotedthat: . . withgrade1hypertension. TheycanalsoaugmenttheeffectsofBP-. . . loweringtherapy, buttheyshouldneverdelaytheinitiationofdrug (1) In population studies, the difference between office and out-of-. . . therapyinpatientswithHMODoratahighlevelofCVrisk. Amajor office blood pressure levels decreases as office blood pressure decreases, to a point of. . . drawback of lifestyle modification is the poor persistence over around115-120/70mmHg, atwhichofficeand24hABPMmean. BPvaluesareusuallysimilar. 54. . . time. 245, 246 The recommended lifestyle measures that have been. (2) Thisconvergencehasalsobeenconfirmedintreatedpatients243in. . showntoreduceBParesaltrestriction, moderationofalcoholcon-. . sumption, highconsumptionofvegetablesandfruits, weightreducwhom the difference between office blood pressure and ambulatory blood pressure. . values diminishes and becomes negligible at an SBP of approxi-. . tion and maintaining an ideal body weight, and regular physical. mately120mmHg. . . . activity. 17 In addition, tobacco smoking has an acute prolonged (3) Intreatedpatients, atargetofficeSBPof130mmHgmighttherefore. . . pressor effect that may raise daytime ambulatory blood pressure, but smoking correspondtoaslightlylowermean24hSBP, i. e. approximately. . . cessationandotherlifestylemeasuresarealsoimportantbeyondBP 125mmHg. . . . (i. e. forCVDandcancerprevention). 35. (4) Althoughtherearenoavailabledata, thehomeSBPtarget, tobe. . . equivalenttoanofficeSBPtargetof130mmHg, mightalsobelower. . . 7. 4. 2Dietarysodiumrestriction than130mmHg. . . . Thereisevidenceofacausalrelationshipbetweensodiumintakeand. . . blood pressure, and excessive Sodium consumption (5 g Sodium per day, e. g. . OfficeBPtreatmenttargetsinhypertensivepatients. . onesmallteaspoonofsaltperday)hasbeenshowntohaveapressor. . . effectandbeassociatedwithanincreasedprevalenceofhyperten-. Recommendations Classa Levelb. . sionandtheriseinSBPwithage. 247Conversely, sodiumrestriction. . . hasbeenshowntohaveaBP-loweringeffectinmanytrials. Arecent Itisrecommendedthatthefirstobjectiveof. . treatmentshouldbetolowerBPto140/. . . meta-analysis of these trials showed that a reduction of (cid: 3)1. 75 g 90mmHginallpatientsand, providedthat. . . sodiumperday(4. 4gsalt/day)wasassociatedwithamean4. 2/2. 1 thetreatmentiswelltolerated, treatedBP I A. . . mmHgreductioninSBP/DBP, withamorepronouncedeffect(-5. 4/ valuesshouldbetargetedto130/80mmHg. . . -2. 8mmHg)inpeoplewithhypertension. 248Thebeneficialeffectofa orlowerinmostpatients. 2, 8. . . reducedsodiumintakeonBPtendstodiminishwithtime, inpartdue. . to poor dietary persistence. The blood pressure-lowering effect of Sodium. Inpatients65yearsreceivingBP-lowering. . restrictionisgreaterinblackpeople, inolderpatients, andinpatients. drugs, itisrecommendedthatSBPshould. . with Diabetes, metabolic syndrome, or chronic kidney disease. 249 In people with I A. beloweredtoaBPrangeof120129. . treated hypertension, effective Sodium restriction may reduce the. mmHginmostpatients. c2, 215, 229. . numberordoseofBP-loweringdrugsthatarenecessarytocontrol. . . blood pressure. 250, 251 Inolderpatients(aged_65years)receiving. . . The effect of reduced dietary Sodium on CV events remains blood pressure-loweringdrugs: . . . unclear. 252255Prospectivecohortstudieshavereportedanover- ItisrecommendedthatSBPshouldbe I A. . . allincreasedriskofmortalityandCVeventsonhighsodiumintake. targetedtoaBPrangeof130139. . . However, theyalsoreportedthatreducingsodiumintakebelowa mmHg. 2, 235, 244. . . certainlevel(about3gofsodiumperday)furtherreducedBP, but. Closemonitoringofadverseeffectsis. I C. . paradoxicallywasassociatedwithanincreasedriskofall-causeand recommended. . . CVmortalitiesinboththegeneralpopulationandinhypertensive. TheseBPtargetsarerecommendedfor. . people, suggesting a J-curve phenomenon. 256 The mechanism of. patientsatanylevelofCVriskandinpatients I A. . thisapparentincreasedriskatlowsodiumintakeisnotwellunder-. withandwithoutestablishedCVD. 2, 8. . stoodandmightbeconfoundedbyreversecausality. Thereisno. . ADBPtargetof80mmHgshouldbeconsid-. evidencefromepidemiologicalstudiesthatverylowsodiumintake. . eredforallhypertensivepatients, independent IIa B. . may cause harm. 257 Although a few trials and meta-analyses sug-. ofthelevelofriskandcomorbidities. 226, 235. . gestthatreducingsaltintakefromhightomoderateisaccompa-. . . niedbyalowerriskofCVevents, 254, 255, 258todate, noprospective. blood pressurebloodpressure; CVcardiovascular; cardiovascular diseasecardiovasculardisease; DBP. . RCT has provided definitive evidence about the optimal Sodium.",
    "blood pressurebloodpressure; CVcardiovascular; cardiovascular diseasecardiovasculardisease; DBP. . RCT has provided definitive evidence about the optimal Sodium. diastolicbloodpressure; SBPsystolicbloodpressure. . . intaketominimizeCVeventsandmortality. Increasedpotassium a b C Blood la v s e s l o o f f r e e v c id o e m n m ce e. ndation. . . . . intakeisassociatedwithBPreductionandmayhaveaprotective cLessevidenceisavailableforthistargetinlowmoderate-riskpatients. . . effect, therebymodifying the associationbetween Sodium intake, . . blood pressure, andCVD. 259 Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3055. . Globally, usualsodiumintakeisbetween3. 55. 5gperday(which. accompaniedbyotherlifestylechangessuchasphysicalexerciseand. corresponds to 9-12 g of salt per day), with marked differences. . weightloss. 35. . betweencountriesandevenbetweenregionswithincountries. We. Withregardtocoffeeconsumption, caffeinehasbeenshownto. recommendsodiumintaketobelimitedtoapproximately2. 0gper. . haveanacutepressoreffect. 267Nevertheless, coffeeconsumptionis. . day(equivalenttoapproximately5. 0gsaltperday)inthegeneral. associated with CV benefits, as highlighted by a recent systematic. . population and to try to achieve this goal in all hypertensive. reviewofprospectivecohortstudiesincludingmorethan1million. patients. Effectivesaltreductionisnoteasyandthereisoftenpoor. . participantsand36352CVevents. 267Moreover, greenorblacktea. . appreciationofwhichfoodscontainhighsaltlevels. Adviceshould. consumption may also have a small but significant blood pressure-lowering. begiventoavoidaddedsaltandhigh-saltfoods. Areductioninpop-. . effect. 268, 269. . ulation salt intake remains a public health priority but requires a. Regular consumption of Glucose-sweetened soft drinks has been. . combinedeffortbetweenthefoodindustry, governments, andthe. associated with overweight, metabolic syndrome, type 2 Diabetes, . . publicingeneral, as80%ofsaltconsumptioninvolveshiddensaltin. . and higher CV risk. The consumption of these drinks should be. processedfoods. . . discouraged. 35. . . Thus, adoptingahealthyandbalanceddietmayassistinBPreduc-. 7. 4. 3Moderationofalcoholconsumption. . . tionandalsoreduceCVrisk. . Thereisalong-establishedpositivelinearassociationbetweenalco-. . . holconsumption, blood pressure, theprevalenceofhypertension, andCVDrisk. . . . Bingedrinkingcanhaveastrongpressoreffect. 17ThePreventionand. . . 7. 4. 5Weightreduction TreatmentofHypertensionStudy(PATHS)investigatedtheeffects. . . Excessiveweightgainisassociatedwithhypertension, andreducing ofalcoholreductiononBP; theinterventiongrouphadamodest1. 2/. . . weight towards an ideal body weight decreases blood pressure. 270 In a meta0. 7mmHglowerBPthanthecontrolgroupattheendofthe6month. . . analysis, themeanSBPandDBPreductionsassociatedwithanaverperiod. 260AMendelianrandomizationmeta-analysisof56epidemio-. . . age weight loss of 5. 1 kg were 4. 4 and 3. 6 mmHg, respectively. 271 logicalstudiessuggestedthatreductionofalcoholconsumption, even. . . Bothoverweightandobesityareassociatedwithanincreasedriskof for lightmoderate drinkers, might be beneficial for CV health. 261. . . CVdeathandall-causemortality. Weightreductionisrecommended. Hypertensivemenwhodrinkalcoholshouldbeadvisedtolimittheir. . inoverweightandobesehypertensivepatientsforcontrolofmeta-. consumptionto14unitsperweekandwomento8unitsperweek. . bolicriskfactors, butweightstabilizationmaybeareasonablegoal. (1unitisequalto125mLofwineor250mLofbeer). Alcohol-free. . formany. TheProspectiveStudiesCollaboration272concludedthat days during the week and avoidance of binge drinking35 are also. . . mortalitywaslowestatabodymassindex(body mass index)ofapproximately. advised. . . 22. 5-25kg/m2, whereasamorerecentmeta-analysisconcludedthat. . . mortalitywaslowestinsubjectswithoverweight. 273, 274Althoughthe. . 7. 4. 4Otherdietarychanges. optimalBMIisunclear, maintenanceofahealthybodyweight(BMIof. Hypertensive patients should be advised to Eat a healthy balanced. . approximately 20-25 kg/m2 in people 60 years of age; higher in. . dietcontaining vegetables, legumes, freshfruits, Low-fatdairyprod-. olderpatients)andwaistcircumference(94cmformenand80. . ucts, wholegrains, Fish, and unsaturated fatty acids (especially olive. cmforwomen)isrecommendedfornon-hypertensiveindividualsto. oil), andtohavealowconsumptionofredmeatandsaturatedfatty. . preventhypertension, andforhypertensivepatientstoreduceBP. 35. . acids. 262264TheMediterraneandietincludesmanyofthesenutrients. Weightlosscanalsoimprovetheefficacyofantihypertensivemedica-. . and foods, with a moderate consumption of alcohol (mostly wine. . tionsandtheCVriskprofile. Weightlossshouldemployamultidisci-. with meals). A number of studies and meta-analyses262265 have. . plinary approach that includes dietary advice, regular exercise, and. shownthattheMediterraneandietisassociatedwithareductionin. . motivational counselling. 35, 275 Furthermore, short-term results are. CVeventsandall-causemortality. AnRCTinhigh-riskindividualson. . often not maintained over the long-term. Weight loss can also be. theMediterraneandietover5yearsshoweda29%CVriskreduction. . promoted by anti-obesity drugs and, to a greater degree, bariatric. compared with a Low-fat control diet, and a 39% reduction in. . surgery, which appears to decrease CV risk in severely obese. stroke. 265TheMediterraneandietalsosignificantlyreducedambula-. . patients. Further details are available in a recent document of the. tory blood pressure, Blood glucose, and lipid levels. 266 The diet should be. ESHandtheEuropeanAssociationfortheStudyofObesity. 276 Downloaded from by guest on 31 December 2025 3056 ESC/ESHGuidelines 7. 4. 6Regularphysicalactivity Lifestyleinterventionsforpatientswithhypertensionor PhysicalactivityinducesanacuteriseinBP, especiallySBP, followed High-normalBP byashort-liveddeclineinBPbelowbaseline. Epidemiologicalstudies suggest that regular aerobic physical activity may be beneficial for Recommendations Classa Levelb boththepreventionandtreatmentofhypertension, andtolowerCV risk and mortality. A meta-analysis of RCTs, which rely on selfSaltrestrictionto5gperdayis I A reported exercise and are by necessity unblinded, has shown that recommended. 248, 250, 255, 258 aerobicendurancetraining, dynamicresistancetraining, andisometric ItisrecommendedtorestrictalcoholcontrainingreducerestingSBPandDBPby3. 5/2. 5, 1. 8/3. 2, and10. 9/6.",
    "248, 250, 255, 258 aerobicendurancetraining, dynamicresistancetraining, andisometric ItisrecommendedtorestrictalcoholcontrainingreducerestingSBPandDBPby3. 5/2. 5, 1. 8/3. 2, and10. 9/6. 2 mmHg, respectively, in general populations. 277 Endurance training, sumptionto: I A Lessthan14unitsperweekformen. butnotothertypesoftraining, reducesBPmoreinhypertensivepar- Lessthan8unitsperweekforwomen. 35 ticipants(8. 3/5. 2mmHg). Regularphysicalactivityoflowerintensity anddurationlowersBPlessthanmoderate-orhigh-intensitytraining, Itisrecommendedtoavoidbingedrinking. III C butisassociatedwithatleasta15%decreaseinmortalityincohort studies. 278, 279 This evidence suggests that hypertensive patients Increasedconsumptionofvegetables, fresh fruits, Fish, nuts, andunsaturatedfattyacids should be advised to participate in at least 30 min of moderate- (oliveoil); lowconsumptionofredmeat; I A intensitydynamicaerobicexercise(walking, jogging, cycling, orswimandconsumptionoflow-fatdairyproducts ming)on57daysperweek. Performanceofresistanceexerciseson arerecommended. 262, 265 2-3 days per week can also be advised. For additional benefit in healthyadults, agradualincreaseinaerobicphysicalactivityto300 Body-weightcontrolisindicatedtoavoid mina week ofmoderate intensityor150mina weekofvigorousobesity(body mass index30kg/m2orwaistcircumferintensity aerobic physical activity, or an equivalent combination ence102cminmenand88cmin thereof, isrecommended. 35TheimpactofisometricexercisesonBP women), asisaimingathealthyBMI(about I A andCVriskislesswellestablished. 280 2025kg/m2)andwaistcircumferencevalues(94cminmenand80cminwomen) 7. 4. 7Smokingcessation toreduceBPandCVrisk. 262, 271, 273, 290 Smoking is a majorrisk factorfor cardiovascular disease and cancer. Although the Regularaerobicexercise(e. g. atleast30 rateofsmokingisdeclininginmostEuropeancountries, especially minofmoderatedynamicexerciseon57 I A inmen, itisstillcommoninmanyregionsandagegroups, andoverall the prevalence remains High at 2035% in Europe. 281 There is daysperweek)isrecommended. 262, 278, 279 also evidence suggesting ill-health effects of passive smoking. 282 Smokingcessation, supportivecare, and StudiesusingABPMhaveshownthatbothnormotensive subjects referraltosmokingcessationprogramsare I B anduntreatedhypertensivesmokerspresenthigherdailyBPvalues recommended. 286, 288, 291 than non-smokers. 283 No chronic effect of smoking has been reportedforofficeBP, 284whichisnotloweredbysmokingcessabody mass indexbodymassindex; blood pressurebloodpressure; CVcardiovascular. tion. SmokingissecondonlytoBPincontributingrisktotheglobal aClassofrecommendation. burden of disease, and smoking cessation is probably the single bLevelofevidencemostlybasedontheeffectonBPand/orCVriskprofile. mosteffectivelifestylemeasureforthepreventionofCVD, including stroke, myocardial infarction, and peripheral arterial disease. 285, 286 Therefore, the history of tobacco use should be established at each patient visit. . 7. 5. Pharmacological therapy for. andhypertensivesmokersshouldbecounselledregardingsmoking. . . hypertension cessation. . . Briefadvicefromaphysicianhasasmallbutsignificanteffectof. . 7. 5. 1Drugsforthetreatmentofhypertension. 1-3%overandabovetheunassisted12monthquitrate. 287Thiscan. . Mostpatientswillrequiredrugtherapyinadditiontolifestylemeas-. beimprovedbytheuseofpharmacologicalmeasures, withvareni-. . urestoachieveoptimalBPcontrol. InthepreviousGuidelines, five. clineandcombinationnicotinereplacementtherapybeingsuperior. . . majordrugclasseswererecommendedforthetreatmentofhyper-. tobupropionorsinglenicotinereplacementtherapy. 288Incompari-. . tension: ACE inhibitors, ARBs, beta-blockers, CCBs, and diuretics. sonwithplacebo, nicotinereplacementtherapyortreatmentwith. . (thiazidesandthiazide-likediureticssuchaschlortalidoneandindapa-. buproprion doubles the chance of quitting, whilst varenicline or. . mide), basedon: (i)provenabilitytoreduceBP; (ii)evidencefrom. combination nicotine replacement therapy triples the chance of. . placebo-controlledstudiesthattheyreduceCVevents; and(iii)evi-. quitting. Combining behavioural support with pharmacotherapy. . denceofbroadequivalenceonoverallCVmorbidityandmortality, . increasesthechanceofsuccessby70-100%comparedwithbrief. . withtheconclusionthatbenefitfromtheirusepredominantlyderives. advicealone. 289. fromBPlowering. Theseconclusionshavesincebeenconfirmedby Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3057. recent meta-analyses. 1, 2, 217, 292 These meta-analyses have reported. . 7. 5. 1. 1. Blockersoftherenin(cid: 5)angiotensinsystem(angiotensin-. . cause-specific differences on outcomes between some drugs (e. g. . convertingenzymeinhibitorsandangiotensinreceptorblockers). . lessstrokepreventionwithbeta-blockers, andlessheartfailurepre-. Both ACE inhibitors and ARBs are among the most widely used. . ventionwithCCBs); however, overall, majorCVoutcomesandmor-. classes of antihypertensive drugs. They have similar effective-. talityweresimilarwithtreatmentbasedoninitialtherapywithallfive. . ness295, 296aseachotherandothermajordrugclassesonmajorCV. majorclassesoftreatment. TheseGuidelinesthusrecommendthat. . eventsandmortalityoutcomes. 2, 292ARBsareassociatedwithsignifi-. . thesamefivemajorclassesofdrugsshouldformthebasisofantihy-. cantlylowertreatmentdiscontinuationratesforadverseeventsthan. pertensive therapy. There are compelling or possible contraindica-. . . thoseofallotherantihypertensivetherapies, 297andsimilarratesto. tionsforeachclassofdrug(Table20)andpreferentialuseofsome. . placebo. 294ACEinhibitorsandARBsshouldnotbecombinedforthe. drugsforsomeconditions, asdiscussedbelow. Thereisalsoevidence. . treatmentofhypertensionbecausethereisnoaddedbenefitonout-. thattherearedifferencesinthepersistenceanddiscontinuationrates. . comesandanexcessofrenaladverseevents. 298, 299Dualcombina-. ofthemajordrugclasses. 293, 294. . tionofRASblockersalsoledtotheprematurecessationofanother. Other classes of drugs have been less widely studied in event-. . trialduetoadverseevents, 291whenarenininhibitor, aliskiren, was. based RCTs or are known to be associated with a higher risk of. . combinedwitheitheranACEinhibitororanARBinpeoplewithdia-. adverseeffectse. g. alpha-blockers, centrallyactingagents, andmin-. . betes. Thisresulthaltedfurtherresearchintotheclinicalutilityofalis-. eralocorticoidreceptorantagonists(MRAs). Theseareusefuladdi-. . kirenforBPtreatment. . tionstothe antihypertensive armamentariuminpatientswhoseBP. . Both ACE inhibitors and ARBs reduce albuminuria more than. cannotbecontrolledbyprovencombinationsoftheaforementioned. . otherBP-loweringdrugsandareeffectiveatdelayingtheprogression. majordrugclasses. . . ofdiabeticandnon-diabeticCKD. 217Arecentmeta-analysisshows Table20 Compellingandpossiblecontraindicationstotheuseofspecificantihypertensivedrugs Drug Contraindications Compelling Possible Diuretics(thiazides/thiazide-like, e. g. chlortha- Gout Metabolicsyndrome lidoneandindapamide) Glucoseintolerance Pregnancy Hypercalcaemia Hypokalaemia Beta-blockers Asthma Metabolicsyndrome Anyhigh-gradesinoatrialoratrioventricularblock Glucoseintolerance Bradycardia(heartrate60beatspermin) Athletesandphysicallyactivepatients Calciumantagonists(dihydropyridines) Tachyarrhythmia Heartfailure(HFrEF, classIIIorIV) Pre-existingseverelegoedema Calciumantagonists(verapamil, diltiazem) Anyhigh-gradesinoatrialoratrioventricularblock Constipation SevereLVdysfunction(LVejectionfraction40%) Bradycardia(heartrate60beatspermin) ACEinhibitors Pregnancy Womenofchild-bearingpotential Previousangioneuroticoedema withoutreliablecontraception Hyperkalaemia(Potassium5. 5mmol/L) Bilateralrenalarterystenosis ARBs Pregnancy Womenofchild-bearingpotential Hyperkalaemia(Potassium5. 5mmol/L) withoutreliablecontraception Bilateralrenalarterystenosis ACEangiotensin-convertingenzyme; angiotensin receptor blockerangiotensinreceptorblocker; HFrEFheartfailurewithreducedejectionfraction; LVleftventricular. Downloaded from by guest on 31 December 2025 3058 ESC/ESHGuidelines. . thatRASblockersaretheonlyantihypertensiveagentsforwhichevi-. combination with a Potassium-sparing agent, has also been used in. denceisavailableofareducedriskofend-stagerenaldisease. 217. . blood pressure-loweringRCTs, withpositiveresults. 303Arecentmeta-analysisof. .",
    ". thatRASblockersaretheonlyantihypertensiveagentsforwhichevi-. combination with a Potassium-sparing agent, has also been used in. denceisavailableofareducedriskofend-stagerenaldisease. 217. . blood pressure-loweringRCTs, withpositiveresults. 303Arecentmeta-analysisof. . ACE inhibitors and ARBs also appear effective in preventing or. placebo-controlled studies based on thiazides, chlorthalidone, and. . regressingHMOD, suchasLVHandsmallarteryremodelling, foran. indapamide reported similar effects on CV outcomes of the three. equivalentreductioninBP. 292BothdrugsreduceincidentAF, which. . types of diuretics. 300 Therefore, in the absence of evidence from. . mayberelatedtoimprovedLVfunctionandmoreeffectiveLVstruc-. directcomparatortrialsandrecognizingthatmanyoftheapproved. turalregression. 292ACEinhibitorsandARBsarealsoindicatedpost-. . single-pill combinations (SPCs) are based on hydrochlorothiazide. . myocardialinfarctionandinpatientswithchronicHFrEF, whichare. (seebelow), werecommendthatthiazides, chlorthalidone, andinda-. . frequentcomplicationsofhypertension. . . pamidecanallbeconsideredsuitableantihypertensiveagents. Both. ACEinhibitorsareassociatedwithasmallincreasedriskofangio-. . thiazideandthiazide-likediureticscanreduceserumpotassiumand. neuroticoedema, especiallyinpeopleofblackAfricanoriginand, in. . have a side effectprofilethatisless favourablethanRASblockers, . suchpatients, whenRASblockersareused, anARBmaybepreferred. . . whichmayaccountfortheirassociationwithahigherrateoftreat-. . . ment discontinuation. 293, 300 They also exhibit dysmetabolic effects. 7. 5. 1. 2. Calciumchannelblockers. . that increase insulin resistance and the risk of new-onset Diabetes. . CCBsare widelyused for thetreatmentofhypertension and have. . Potassium may attenuate these effects, 304 and a recent study has. similar effectiveness as other major drug classes on blood pressure, major CV. . shown that the adverse effect of thiazides on glucose metabolism. events, andmortalityoutcomes. 2, 292CCBshaveagreatereffecton. . maybe reducedby the addition ofa Potassium-sparingdiuretic. 305. strokereductionthanexpectedfortheBPreductionachieved, but. . Boththiazidesandthiazide-likeagentsarelesseffectiveantihyperten-. mayalsobelesseffectiveatpreventingHFrEF. 2, 292However, inanti-. . siveagentsinpatientswithareducedGFR(estimated glomerular filtration rate45mL/min)and. hypertensivetreatmenttrials, emergentheartfailureistheeventcon-. . becomeineffectivewhentheeGFRis30mL/min. Insuchcircum-. . sidered. Though clinically a very relevant event, it is a difficult. stances, loop diuretics such as furosemide (or torasemide) should. . endpoint to quantify precisely, either because symptoms and signs. replacethiazidesandthiazide-likediureticstoachieveanantihyper-. . are relatively non-specific or because oedema due to CCBs may. tensiveeffect. . . resultinmisdiagnosis. Comparisonwithdiureticsmayalsobedifficult. . . because fluid loss maymask signs and symptoms ofincipient Heart. 7. 5. 1. 4. Beta-blockers. . failureratherthanpreventingit. CCBshavealsobeencomparedwith. RCTsandmeta-analysesdemonstratethatwhencomparedwithpla-. . other antihypertensive agents in HMOD-based trials, and are. cebo, beta-blockerssignificantlyreducetheriskofstroke, heartfail-. reportedtobemoreeffectivethanbeta-blockersinslowingthepro-. . ure, and major CV events in hypertensive patients. 300 When. . gression of carotid atherosclerosis, and in reducing LVH and. compared with other blood pressure-lowering drugs, beta-blockers are usually. . proteinuria. 17. equivalent in preventingmajorCV events, except for less effective. . CCBs are a heterogeneous class of agents. Most RCTs demon-. . preventionofstroke, whichhasbeenaconsistentfinding. 1, 2, 217Itis. strating thebenefitsofCCBs onoutcomeshaveused dihydropyri-. . possible that the difference originated from small differences in. dines (especially amlodipine). A smaller number of RCTs have. . achievedBP(includingcentralSBP108betweendifferentdrugtreat-. comparednon-dihydropyridines(verapamilanddiltiazem)withother. . ments), towhichcerebrovasculareventsmaybeespeciallysensitive. . drugs, and meta-analyses evaluating the two subclasses (vs. other. . RCTs based on HMOD have also indicated that beta-blockers are. drugs)havenotshownsubstantialdifferencesineffectiveness. 292. . somewhatlesseffectivethanRASblockersandCCBsinpreventing. . . or regressing LVH, carotid IMT, aortic stiffness, and small artery. 7. 5. 1. 3. Thiazide/thiazide-likediuretics(e. g. chlorthalidoneand. . remodelling. 17Inaddition, amortalitybenefitpost-myocardialinfarc-. indapamide). . tionisuncertaininpatientswithoutLVdysfunction. 306Beta-blockers, . Diureticshaveremainedthecornerstoneofantihypertensivetreat-. . aswellasdiuretics, andparticularlytheircombination, arealsoassoci-. mentsincetheirintroductioninthe1960s. Theireffectivenessinpre-. . atedwithincreasedriskofnew-onsetdiabetesinpredisposedsub-. ventingalltypesofCVmorbiditiesandmortalityhasbeenconfirmed. . jects(mostlythosewiththemetabolicsyndrome). Theyalsoexhibit. in RCTs and meta-analyses. 300 Diuretics also appear to be more. . asomewhatlessfavourablesideeffectprofilethanthatofRASblock-. effectivethanotherdrugclassesinpreventingheartfailure. 292There. . ers, withahigherrateoftreatmentdiscontinuationwhenassessedin. hasbeendebateaboutwhetherthiazide-likediureticssuchaschlor-. . real-lifeconditions. 293Beta-blockershavebeenshowntobeparticu-. . thalidoneandindapamideshouldbegivenpreferenceoverclassical. larly useful for the treatment of hypertension in specific situations. . thiazidediuretics(e. g. hydrochlorothiazideandbendrofluazide), but. suchassymptomaticangina, forheartratecontrol, post-myocardial. . theirsuperiorityonoutcomeshasneverbeentestedinhead-to-head. infarction, HFrEF, andasanalternativetoACEinhibitorsorARBsin. . RCTs. Chlorthalidoneandindapamidehavebeenusedinanumber. youngerhypertensivewomenplanningpregnancyorofchild-bearing. . ofRCTsshowingCVbenefits, andtheseagentsaremorepotentper. potential. . . milligram than hydrochlorothiazide in lowering blood pressure, with a longer. Finally, beta-blockersarenotahomogeneousclass. Inrecentyears, . . duration ofaction compared with hydrochlorothiazide and no evi-. the use of vasodilating beta-blockerssuch as labetalol, nebivolol, . . denceofagreaterincidenceofsideeffects. 301Lowerdosethiazide-. celiprolol, andcarvedilolhasincreased. Studiesonnebivololhave. . like diuretics (typical of modern antihypertensive treatment regi-. . shownthatithasmorefavourableeffectsoncentralBP, aorticstiff-. mens) also have more evidence from RCTs demonstrating reduc-. . ness, endothelialdysfunction, etc. Ithasnoadverseeffectontherisk. tionsinCVeventsandmortality, whencomparedwithlowerdose. . ofnew-onsetdiabetesandamorefavourablesideeffectprofilethan. thiazide diuretics. 302 That said, hydrochlorothiazide, alone or in. classicalbeta-blockers, 307, 308includinglessadverseeffectsonsexual Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3059. . function.",
    "classicalbeta-blockers, 307, 308includinglessadverseeffectsonsexual Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3059. . function. Bisoprolol, carvedilol, and nebivolol have been shown to. control can be achieved in most recruited patients, and that no. improveoutcomesinRCTsinheartfailure; 136however, thereareno. . more than 5-10% of these patients exhibit resistance to the. . RCTsreportingpatientoutcomeswiththesebeta-blockersinhyper-. selectedtreatmentregimen, suggeststhatineffectivedrugtherapyis. . tensivepatients. . notthesourceoftheproblem. . . . (2) Physicianortreatmentinertia. (i. e. failuretoadequatelyupti-. 7. 5. 1. 5. Otherantihypertensivedrugs. . trate treatment). Evidence suggests that inertia311 contributes to. . Centrallyactivedrugswerewidelyusedintheearliestdecadesofanti-. suboptimalBPcontrol, withmanypatientsremainingonmonother-. . hypertensive treatment when other treatments were not available, . apyand/orsuboptimaldoses, despiteinadequateBPcontrol. 12. . butarelessfrequentlyusednow, principallybecauseoftheirpoorer. . (3) Patientadherencetotreatment. Evidenceisaccumulatingthat. tolerabilityrelative to the newer major classes of drugs. The alpha-. . adherenceisamuchmoreimportantfactorthanpreviouslyrecog-. blocker doxazosin was effective in the Anglo-Scandinavian Cardiac. . nised. Studies using Urine or Blood assays for the presence or. OutcomesTrial(ASCOT)asthird-linetherapy(withnoincreasein. . absenceofmedicationhaveshownthatadherencetotreatmentis. theriskofheartfailure), 309andwasmoreeffectivethanplacebobut. . Low. Thisissupportedbystudiesinthegeneralpopulationinwhich. lesseffectivethanspironolactoneatloweringBPinresistanthyperten-. . adherencetotreatment, basedonprescriptionrefilling, was50%. sion in the Prevention And Treatment of Hypertension With. . ofthetreatmentinhalfofthepatients. 312Pooradherencehasalso. Algorithm-basedtherapY-2(PATHWAY-2)study. 310Alpha-blockers. . beshowntobeassociatedwithincreasedCVriskinvariousstud-. may also be required in specific indications (e. g. the treatment of. . ies313(seesection10). . symptomatic prostatic hypertrophy). Antihypertensive drugs, other. . (4) Insufficientuseofcombinationtreatment. BPisamultiregu-. thanthemajorclassesalreadydiscussedabove, arenolongerrecom-. . lated variable depending on many compensating pathways. . mendedfortheroutinetreatmentofhypertension, andareprimarily. . Consequently, combinations of drugs, working through different. . reservedforadd-ontherapyinrarecasesofdrug-resistanthyperten-. mechanisms, arerequiredtoreduceBPinmostpeoplewithhyper-. . sionwhereallothertreatmentoptionshavefailed. . tension. Thus, monotherapy is likely to be inadequate therapy in. . . most patients. Indeed, almost all patients in RCTs have required. . . combinationsofdrugstocontroltheirBP. 314 7. 5. 2Drugtreatmentstrategyforhypertension. . . (5) Complexityof current treatment strategies. There is also Guidelineshavegeneratedavarietyofdifferentstrategiestoinitiate. . . evidencethatadherencetotreatmentisadverselyaffectedbythe andescalateBP-loweringmedicationtoimproveBPcontrolrates. In. . . complexityoftheprescribedtreatmentregimen. Inarecentstudy, previous Guidelines, the emphasis was on initial use of different. . . adherencetotreatmentwasstronglyinfluencedbythenumberof monotherapies, increasing their dose, or substituting for another. . . pillsthatapatientwasprescribedforthetreatmentofhypertenmonotherapy. However, increasingthedoseofmonotherapyprodu-. . . sion. 315Non-adherencewasusually10%withasinglepill, risingto ceslittleadditionalBPloweringandmayincreasetheriskofadverse. . effects, whilst switchingfromone monotherapy to another is frus-. . . (cid: 3)20%withtwopills, (cid: 3)40%withthreepills, andveryhighratesof trating, time consuming, and often ineffective. For these reasons, . . . partial or complete non-adherence in patients receiving five or. . morepills. 315 more recent Guidelines have increasingly focused on the stepped-. . . careapproach, initiatingtreatmentwithdifferentmonotherapiesand. The above considerations suggest that the most effective. . then sequentially adding other drugs until blood pressure control is achieved. . evidence-basedtreatmentstrategytoimproveBPcontrolisonethat: . . Despite this, blood pressure control rates have remained poor worldwide. As. (i) encourages the use of combination treatment in most patients, . . shown by recent observations, irrespective of the world region, . especiallyinthecontextoflowerBPtargets; (ii)enablestheuseof. . whetherhigh-orlow-incomeeconomies, orthelevelofsophistica-. . SPCtherapyformostpatients, toimproveadherencetotreatment; . tionofhealthcareprovision, only(cid: 3)40% ofpatientswithhyperten-. . and (iii) follows a treatment algorithm that is simple, applies to all. sionaretreated; ofthese, only(cid: 3)35%arecontrolledtoaBPof140/. . patients, andispragmatic, withtheuseofSPCtherapyasinitialther90mmHg. 12ThisfailuretoachieveBPcontrolinmosthypertensive. . . apyformostpatients, exceptthosewithBPinthehighnormalrange. patients, despitenumerousiterationsofpreviousGuidelines, suggests. . andinfrailolderpatients(seebelow). . thatthesetreatmentstrategiesarenotworkingandthatadifferent. . . approachisneeded. ThisTaskForcebelievesthatoneofthemost. . . 7. 5. 2. 1. Drugcombinationsforhypertensiontreatment important issues to address in these Guidelines is how do we. . . AmongthelargenumberofRCTsofantihypertensivetherapy, onlya improveBPcontrolintreated patients? . Thishasbecome aneven. . . few have directly compared different two-drug combinations, with more pressing matter because, based on new evidence, current. . . systematicuseofthetwocombinationsinbotharms. Inothertrials, Guidelinesare recommendingmorestringentBP targets(on-treat-. . . treatmentwasinitiatedusingmonotherapyineitherarmandanother mentvaluesof_130/80mmHginthegeneralpopulationand_140/. . 90mmHginolderhypertensivepeople), whichwillmaketheachieve-. . . drug(and sometimesmore thanone drug)wasadded, usuallyina mentofBPcontrolevenmorechallenging. . . . non-randomizedfashion, accordingtoapre-specifiedtreatmentalgoSeveralreasonsneedtobeconsideredtoidentifywhythecurrent. . . rithm. Inafewtrials, thedesignprecludedtheuseofwhatmightbe treatmentstrategyhasfailedtoachievebetterBPcontrolrates: . . . considered optimal combinations because multiple monotherapies. . werebeingevaluatede. g. theAntihypertensiveandLipid-Lowering. (1) Efficacyofpharmacologicaltherapies. Arethebestavailable. . TreatmenttoPreventHeartAttackTrial(ALLHAT), wheretheadd-. treatments, inwhatevercombination, incapableofcontrollingBPin. . ontherapytoeitheradiuretic, calcium channel blocker, ACEinhibitor, oralpha-blocker. most patients? The evidence from RCTs demonstrating that blood pressure. wasabeta-blocker, clonidine, orreserpine. 316 Downloaded from by guest on 31 December 2025 3060 ESC/ESHGuidelines. . Withthiscaveat, Table21showsthatavarietyofdrugcombina-. diureticsfollowedbybeta-blockerswerenotassociatedwithasignifi-. tionshavebeenusedinatleastoneactivearmofplacebo-controlled. .",
    "wasabeta-blocker, clonidine, orreserpine. 316 Downloaded from by guest on 31 December 2025 3060 ESC/ESHGuidelines. . Withthiscaveat, Table21showsthatavarietyofdrugcombina-. diureticsfollowedbybeta-blockerswerenotassociatedwithasignifi-. tionshavebeenusedinatleastoneactivearmofplacebo-controlled. . cantly different risk of any CV outcome, 233, 234, 316, 319321 and the. . trialsandhavebeenassociatedwithsignificantbenefitonmajorCV. beta-blocker diuretic combination was significantly more effective. . events. Intrialscomparingdifferentregimens(Table22), allcombina-. . thanplacebointhreetrials. 322324Itshouldbementionedthatthe. tions havebeen used in a larger orsmaller proportion of patients, . . beta-blockerdiureticcombinationmayresultinmorecasesofnew-. withoutmajordifferencesinbenefits. Theonlyexceptionsaretwo. . onsetdiabetesinsusceptibleindividualscomparedwithothercombi-. trialsinwhichalargeproportionofthepatientsreceivedeitheran. . nations. 325 A rarely used combination of thiazide and Potassium-. angiotensin receptor blockerdiuretic combination317 or calcium channel blockerACE inhibitor combina-. . sparingdiuretic(amiloride)hasalsobeenshowntobeequivalentto. tion, 318withbothregimensbeingsuperiortoabeta-blockerdiuretic. . calcium channel blocker-basedtreatment, 310, 326andwasrecentlyreportedtobeassoci-. combinationinreducingCVoutcomes. However, insixothertrials. . ated with fewer metabolic adverse effects compared with thiazide. (with seven comparisons), beta-blockers followed by diuretics or. alone(lesshypokalaemiaandglucoseintolerance). 305 Table21 Majordrugcombinationsusedintrialsofantihypertensivetreatmentinasteppedapproachorasarandomizedcombination(combinationsvs. placeboormonotherapy) Trial Comparator Typeofpatients SBPdifference Outcomeschangeinrelativerisk(%) (mmHg) ACEinhibitoranddiureticcombination PROGRESS27 Placebo PreviousstrokeorTIA 9 28%strokes(P0. 001) ADVANCE229 Placebo Diabetes 5. 6 9%micro/macrovascularevents(P0. 04) HYVET220 Placebo Hypertensive; _80years 15 34%CVevents(P0. 001) ARBanddiureticcombination SCOPE330 Diureticþplacebo Hypertensive; _70years 3. 2 28%non-fatalstrokes(P0. 04) CCBanddiureticcombination FEVER331 Diureticþplacebo Hypertensive 4 27%CVevents(P0. 001) ACEinhibitorandCCBcombination Syst-Eur332 Placebo OlderwithISH 10 31%CVevents(P0. 001) Syst-China333 Placebo OlderwithISH 9 37%CVevents(P0. 004) Beta-blockeranddiureticcombination CoopeandWarrender322 Placebo Olderhypertensive 18 42%strokes(P0. 03) SHEP323 Placebo OlderwithISH 13 36%strokes(P0. 001) STOP-H324 Placebo Olderhypertensive 23 40%CVevents(P0. 003) STOP-H2334 ACEinhibitoror Hypertensive 0 NSdifferenceinCVevents conventional antihypertensive CombinationoftwoRASblockers/ACEinhibitor1ARBorRASblocker1renininhibitor) ONTARGET299 ACEinhibitororARB High-riskpatients Morerenalevents ALTITUDE291 ACEinhibitororARB High-riskdiabeticpatients Morerenalevents ACEangiotensin-convertingenzyme; ADVANCEActioninDiabetesandVascularDisease: PreteraxandDiamicronMRControlledEvaluation; ALTITUDEAliskiren TrialinType2DiabetesUsingCardiovascularandRenalDiseaseEndpoints; angiotensin receptor blockerangiotensinreceptorblocker; calcium channel blockercalciumchannelblocker; CVcardiovascular; FEVER FelodipineEventReduction; HYVETHypertensionintheVeryElderlyTrial; ISHisolatedsystolichypertension; NSnon-significant; ONTARGETOngoingTelmisartan AloneandincombinationwithRamiprilGlobalEndpointtrial; PROGRESSperindoprilprotectionagainstrecurrentstrokestudy; renal artery stenosisrenin-angiotensinsystem; SBPsystolicbloodpressure; SCOPEStudyonCognitionandPrognosisintheElderly; SHEPSystolicHypertensionintheElderlyProgram; STOP-HSwedishTrialinOldPatients withHypertension; Syst-ChinaSystolicHypertensioninChina; Syst-EurSystolicHypertensioninEurope; TIAtransientischaemicattack. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3061 Table22 Majordrugcombinationsusedintrialsofantihypertensivetreatmentinasteppedapproachorasarandomizedcombination(combinationsvs. othercombinations) Trial Comparator Typeofpatients SBPdifference Outcomeschangein (mmHg) relativerisk(%) ACEinhibitoranddiureticcombination CAPPP335 BBþdiuretic Hypertensive þ3 þ5%CVevents(NS) ACCOMPLISH327 ACEinhibitorþCCB Hypertensivewithriskfactors þ1 þ21%CVevents(P0. 001) ARBanddiureticcombination LIFE317 BBþdiuretic HypertensivewithLVH 1 26%stroke(P0. 001) CCBanddiureticcombination ELSA336 BBþdiuretic Hypertensive 0 NSdifferenceinCVevents CONVINCE233 BBþdiuretic Hypertensivewithriskfactors 0 NSdifferenceinCVevents VALUE337 ARBþdiuretic High-riskhypertensive 2. 2 3%CVevents(PNS) COPE338 CCBþBB Hypertensive þ0. 7 NSdifferenceinCVeventsorstroke ACEinhibitorandCCBcombination NORDIL339 BBþdiuretic Hypertensive þ3 NSdifferenceinCVevents INVEST340 BBþdiuretic HypertensivewithCAD 0 NSdifferenceinCVevents ASCOT318 BBþdiuretic Hypertensivewithriskfactors 3 16%CVevents(P0. 001) ACCOMPLISH327 ACEinhibitorþdiuretic Hypertensivewithriskfactors 1 21%CVevents(P0. 001) Beta-blockeranddiureticcombination CAPPP335 ACEinhibitorþdiuretic Hypertensive 3 5%CVevents(PNS) LIFE317 ARBþdiuretic HypertensivewithLVH þ1 þ26%stroke(P0. 001) ALLHAT316 ACEinhibitorþBB Hypertensivewithriskfactors 2 NSdifferenceinCVevents ALLHAT316 CCBþBB Hypertensivewithriskfactors 1 NSdifferenceinCVevents CONVINCE233 CCBþdiuretic Hypertensivewithriskfactors 0 NSdifferenceinCVevents NORDIL339 ACEinhibitorþCCB Hypertensive 3 NSdifferenceinCVevents INVEST340 ACEinhibitorþCCB HypertensivewithCAD 0 NSdifferenceinCVevents ASCOT318 ACEinhibitorþCCB Hypertensivewithriskfactors þ3 þ16%CVevents(P0. 001) Beta-blockerandCCBcombination COPE329 ARBþCCB Hypertensive þ0. 8 NSdifferenceinCVeventsorstroke ARBandCCBcombination COPE329 CCBþdiuretic Hypertensive 0. 7 NSdifferenceinCVeventsorstroke COPE329 CCBþBB Hypertensive 0. 8 NSdifferenceinCVeventsorstroke COLM328 ARBþdiuretic Olderhypertensive 0 NSdifferenceinCVevents ACCOMPLISH Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension; ACE angiotensin-converting enzyme; ALLHAT Antihypertensive and Lipid-LoweringTreatment to Prevent Heart Attack Trial; angiotensin receptor blocker angiotensin receptor blocker; ASCOT Anglo-Scandinavian Cardiac OutcomesTrial; beta blockerbeta-blocker; coronary artery diseasecoronaryarterydisease; CAPPPCaptoprilPreventionProject; calcium channel blockercalciumchannelblocker; COLMCombinationof OLMesartanandacalciumchannelblockerordiureticinJapaneseelderlyhypertensivepatients; CONVINCEControlledOnsetVerapamilInvestigationofCardiovascular EndPoints; COPECombinationTherapyofHypertensiontoPreventCardiovascularEvents; CVcardiovascular; ELSAEuropeanLacidipineStudyonAtherosclerosis; INVESTInternationalVerapamil-TrandolaprilStudy; LIFELosartanInterventionForEndpointreductioninhypertension; LVHleftventricularhypertrophy; NORDIL NordicDiltiazem; NSnon-significant; SBPsystolicbloodpressure; VALUEValsartanAntihypertensiveLong-termUseEvaluation. Downloaded from by guest on 31 December 2025 3062 ESC/ESHGuidelines. . Three outcome trials directly compared two different combina-. renal artery stenosis as well as inducing vasodilatation and/or diuresis, reduces the. . tions, eachinvolvingacombinationofaRASblocker(ACEinhibitor. heterogeneityoftheBPresponsetoinitialtreatmentandprovidesa. . or angiotensin receptor blocker) and a calcium channel blocker with other combinations. In the Avoiding. steeper dose response than is observed with escalating doses of. Cardiovascular Events Through Combination Therapy in Patients. . monotherapy. 342 Finally, two-drug combinations as initial therapy. . Living With Systolic Hypertension (ACCOMPLISH) trial, the ACE. have beenshown tobe safe and welltolerated, withno or only a. inhibitorCCBcombinationwassuperiortothesameACEinhibitor. . smallincreaseintheriskofhypotensiveepisodes, 341evenwhengiven. incombinationwithathiazidediureticatpreventingmajorCVout-. . to patients with grade 1 hypertension, 343 in which adverse events. . comes, despitenoapparentBPdifferencebetweenthetwoarms. 327. leadingtotreatmentdiscontinuationareinfrequent. 294. . ThisfindingwasnotconfirmedintheCombinationofOLMesartan. . AlthoughnoRCThascomparedmajorCVoutcomesbetweenini-. and a calcium channel blocker or diuretic in Japanese older hypertensive patients. .",
    "327. leadingtotreatmentdiscontinuationareinfrequent. 294. . ThisfindingwasnotconfirmedintheCombinationofOLMesartan. . AlthoughnoRCThascomparedmajorCVoutcomesbetweenini-. and a calcium channel blocker or diuretic in Japanese older hypertensive patients. . tial combination therapy and monotherapy, observational evidence. (COLM)328 and CombinationTherapy ofHypertensionto Prevent. . suggests that thetime taken to achieveBPcontrolis animportant. CardiovascularEvents(COPE)trials, 329whichreportednosignificant. . determinant of clinical outcomes, especially in higher risk patients, . differencesinCVeventswhenaRASblocker-CCBcombinationwas. . with a shorter time to control associated with lower risk. 344. compared with a renal artery stenosis blockerthiazide diuretic combination, but. . Furthermore, thereisevidencefromthemoregeneralhypertensive. bothofthesetrialshadinsufficientstatisticalpower. . . population that, compared with patients on initial monotherapy, . BasedontheresultsofoutcomeRCTsandrecentmeta-analyses, . . those who start treatment with a two-drug combination exhibit. andevidenceofBP-loweringeffectiveness, allfivemajordrugclasses. . morefrequentBPcontrolafter1year. 341, 345Thisisprobablybecause. can, in principle, be combined with one another, except for ACE. . initial combination treatment is associated with a better long-term. inhibitors and ARBs, whose concomitant use mayleadto noaddi-. . adherencetotheprescribedtreatmentregimen346andbecauseinitial. tionalbenefitbutincreasedadverseeffectsandisthusdiscouraged. . . two-drugadministrationpreventstherapeuticinertia(i. e. reluctance. . Werecommendthatthetreatmentofhypertensionshouldbepref-. orfailuretoupgradetreatmentfromonetomoredrugswhenBPis. erentiallybasedoncombinationsofanACEinhibitororARBwitha. . uncontrolled). 347 Studies from very large hypertension cohorts in. . CCBand/orathiazide/thiazide-likediuretic. Thesecombinationsare. usualcare haveshownthatinitialcombination treatmentresultsin. . nowwidelyavailableinasinglepillandinarangeofdoses, facilitating. reduced treatment discontinuation and a lower risk of CV events. . simplificationoftreatment, flexibleprescribing, anduptitrationfrom. than initial monotherapy followed by the traditional stepped-care. lower to higher doses. Combination therapy that includes anACE. . approach. 312, 346 The usual-care settings for these studies may be. . inhibitororARBwitheitheraCCBorthiazide/thiazide-likediuretic. especiallyrelevanttostudythe trueimpactoftreatmentstrategies. . are complementary because both CCBs or diuretics activate the. onadherenceandtherapeuticinertia, becausethiscanbedifficultto. . renal artery stenosis, whichwillbecounteractedbytheircombinationwithanACE. replicateinaconventionalRCTinwhichthemotivationoftheclinical. . inhibitororARB. Thesecombinationswillalsolimitpotentialadverse. staffandpatients, andthemonitoringoftreatment, areverydifferent. . effectsassociatedwithdiureticorCCBmonotherapy, reducingthe. . fromusualcare. Inthisregard, theoutcomeofthesereal-lifestudies. riskofhypokalaemiaduetodiureticsandreducingtheprevalenceof. . oftheimpactofinitialcombinationtherapyonadherence, BPcontrol, . peripheral oedema due to CCBs. These combinations also ensure. . andCVoutcomesmaybeespeciallyrelevant. 348. thattheRASisinhibitedaspartofthetreatmentstrategy, whichisan. . AconsiderationinthecurrentGuidelineswastopersistwiththe. importantconsiderationformanypatientgroups(e. g. Diabetes, LVH, . . current stepped-care approach to blood pressure treatment, which has been. proteinuria). . . interpreted as recommending monotherapy as initial therapy for. Othercombinations, suchasCCBþdiuretic, alsohaveevidence. . most patients, reflecting current practice. In fact, the previous. fromRCTssupportingtheiruse. 233, 329Theseare muchlesswidely. . Guidelinesdidacknowledgethepossibilityofinitialcombinationther-. availableasSPCsanddonotincludeblockadeoftheRAS, whichmay. . apyforpatientswithgrade2or3hypertension, orpatientsathighor. bedesirableinmanypatientgroups. . . veryhighrisk. Inotherwords, initialmonotherapywasonlyrecom-. Beta-blockersincombinationshouldbepreferentiallyusedwhen. . mended for grade 1 hypertension and Lowor moderate-risk. thereisaspecificclinicalindicationfortheiruse(e. g. inpatientswith. . patients. Thus, inreality, theshiftinemphasisinthisnewguidanceis. . symptomaticangina, forpatientsrequiringheartratecontrol, post-. subtle. However, normalizingtheconceptofinitiatingtherapywitha. . myocardial infarction, chronic HFrEF, and asanalternative toACE. two-drugcombinationformostpatientswithhypertensionislikely. . inhibitors or ARBs in younger hypertensive women planning preg-. tohaveamajoreffectonclinicalpracticeandthespeedandqualityof. . nancyorofchild-bearing potential). SPCsofbeta-blockerswithan. blood pressure control. We acknowledge that some Lowor moderate-risk. . ACEinhibitor, calcium channel blocker, ordiureticareavailable. . patientswithgrade1hypertensionmayachievetheirBPtargetwith. . . monotherapy, butthisisunlikelyinpatientswithaninitialSBP150. . 7. 5. 2. 2Rationaleforinitialtwo-drugcombinationtherapyformost. mmHgwhowouldrequireaBPreductionof_20mmHg. Moreover, . . patients. thepossibilityofstartingwithalow-dosecombinationoftwoantihy-. . As discussed above and with the emphasis in these Guidelines on. pertensive drugs, even in grade 1 hypertensive patients with. . achievingaBPtargetinmostpatientsof130/80mmHg, themajority. Lowmoderate-risk, is supported by the reduction of CV events. . ofpatientswillrequirecombinationtherapy. Initialcombinationther-. obtainedbycombinationtherapyintheuppertertile(grade1hyper-. . apy is invariably more effective at blood pressure lowering than monotherapy, . . tension)intheHOPE-3trial. 212InpatientswithhighnormalBPand. indeedevenlow-dosecombinationtherapyisusuallymoreeffective. . a High CV risk or in frail older patients, treatment initiation with. thanmaximaldosemonotherapy. 341Furthermore, thecombination. . monotherapymaybeappropriateintheformerbecauseonlyasmall. ofmedications targetingmultiplemechanisms, such asblockingthe. BPreductionmayberequiredtoachievetheBPtarget, andinthe Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3063. . latter because in older patients baroreflex sensitivity is frequently. patientswithhypertension. Nevertheless, theadvantageoftreatment. . impairedandtheriskofhypotensionisgreater. . simplificationandadherencesuggeststhatuseofthepolypillmaybe. . . considered in patients with hypertension as substitution therapy, . . 7. 5. 2. 3Uptitrationoftreatmenttothree-drugcombinationtherapy. when the need and effectiveness of each polypill component has. . Studiessuggestthattwo-drugcombinationtherapywillcontrolBPin. been previously established by their administration in separate. approximatelytwo-thirdsofpatients. 341ForpatientswhoseBPisnot. . tablets. 355. . controlledbytwo-drugcombinationtherapy, thelogicaloptionisto. . . increasetreatmenttothree-drugcombinationtherapy: usuallyaRAS. 7. 5. 2. 5Furtheruptitrationofantihypertensivetherapy. . blocker, aCCB, andadiuretic. Studiessuggestthatathree-drugcom-. . WhenBPremainsuncontrolledwiththree-drugcombinationtherapy, . binationshouldcontrolBPin80%ofpatients. 349, 350ThisrateofBP. . thepatientisclassifiedashavingresistanthypertension, assumingthat. controlismuchgreaterthanthecurrentrateofBPcontrolacross. . secondarycausesof hypertensionandpooradherencetotreatment. Europe in treated hypertensive patients. We do not recommend. . havebeenexcluded, andthattheelevationinBPhasbeenconfirmed. three-drugcombinationsasinitialtherapy. . . byrepeatedofficeBPmeasurement, ABPM, orHBPM(seesection8. 1).",
    "Europe in treated hypertensive patients. We do not recommend. . havebeenexcluded, andthattheelevationinBPhasbeenconfirmed. three-drugcombinationsasinitialtherapy. . . byrepeatedofficeBPmeasurement, ABPM, orHBPM(seesection8. 1). . . . Suchpatientsshouldbeconsideredforspecialistevaluation. Additional. 7. 5. 2. 4Rationaleforsingle-pillcombinationtherapyasusualtherapyfor. . treatment options include the addition of Low-dose spironolactone. hypertension. . (25-50 magnesium daily)310 or another additional diuretic therapy higher-. The2013ESH/ESCGuidelines17favouredtheuseofcombinationsof. . doseamiloride10-20mgdaily, 357higherdosethiazideorthiazide-like. twoantihypertensivedrugsinasinglepill, becausereducingthenum-. . diuretics, loop diuretics in patients with significant renal impairment. berofpillstobetakendailyimprovesadherenceandincreasesthe. . (estimated glomerular filtration rate45mL/min/m2), beta-blockers, alpha-blockers, centrallyacting. rate ofBPcontrol. 346, 351 This recommendation is endorsed bythe. . agents(e. g. clonidine), or, rarely, minoxidil(seesection8. 1). . . currentGuidelines. Itisfurthersupportedbydatafromrecentstud-. . . iesusingvariousmethodstoassessadherencetotreatment, including. . thequantificationofantihypertensivedrugsinurineandblood, 352, 353. . 7. 5. 3Thedrugtreatmentalgorithmforhypertension. and estimates such as pill counting or prescription refills, which, . . Reflectingontheevidenceabove, andrecognizingtheurgentneedto. although indirect, allow the measurement of adherence on a pro-. . addressthefactorscontributingtothepoorcontrolofBPintreated. longed basis, thereby accounting for its time-variable nature. 347, 354. . hypertensive patients (see section 7. 5. 1), this drug treatment algo-. Thesestudieshaveunequivocallyshownadirectinverserelationship. . rithmhasbeendevelopedtoprovideasimpleandpragmatictreat-. . betweenthe number ofpills and thelikelihood of adherence. This. mentrecommendationforthetreatmentofhypertension, basedon. . approachisnowfacilitatedbytheavailabilityofseveralSPCswitha. afewkeyrecommendations: . . rangeofdosages, whicheliminatestheoften-stateddisadvantageof. . . (1) TheinitiationoftreatmentinmostpatientswithanSPCcomprising SPCtherapy(i. e. theinabilitytoincreasethedoseofonedruginde-. . . twodrugs, toimprovethespeed, efficiency, andpredictabilityofBP pendently ofthe other). Itis also convenient that themost widely. . . control. available SPCs mirror the major drug class combinations recom-. . . (2) Preferredtwo-drugcombinationsareaRASblockerwithaCCBor mendedbytheseGuidelines. ThemajoradvantageofanSPCasthe. . . adiuretic. Abeta-blockerincombinationwithadiureticoranydrug usual therapeutic approach for hypertension is that patients can. . . fromtheothermajorclassesisanalternativewhenthereisaspeprogressfrom1, 2, or3drugtreatmentswhilstremainingonasimple. . . cificindicationforabeta-blocker, e. g. angina, post-myocardialinfarctreatmentregimenwithasinglepillthroughout, increasingthelikeli-. . . tion, heartfailure, orheartratecontrol. hood of adherence to therapy and achieving blood pressure control. Such an. . . (3) Usemonotherapyforlow-riskpatientswithstage1hypertension approach has the potential to double blood pressure control rates in treated. . . whoseSBPis150mmHg, veryhigh-riskpatientswithhighnormal patientsfromthepresentlowlevelof(cid: 3)40%. Although, atpresent, . . . blood pressure, orfrailolderpatients. theavailabilityoftwo-drugSPCsislargelylimitedtoaRASblocker. . . (4) Theuseofathree-drugSPCcomprisingaRASblocker, aCCB, and witheitheraCCBordiuretic, itwouldbedesirabletoseethedevel-. . . . adiureticifBPisnotcontrolledbyatwo-drugSPC. opmentofanexpandedrangeoflow-costSPCsindifferentdrugfor-. . . (5) Theadditionofspironolactoneforthetreatmentofresistanthypermulations, tailoredtodifferentclinicalrequirements. . . . tension, unlesscontraindicated(seesection8. 1. 4). PolypillshavealsoemergedasSPCs(i. e. afixed-dosecombination. . . (6) Theuseofotherclassesofantihypertensivedrugsintherarecirof one or more antihypertensive agents with a statin and Low-dose. . . cumstancesinwhichBPisnotcontrolledbytheabovetreatments. aspirin), withtherationalethathypertensivepatientsareoftenatsuffi-. . . (7) Information on availability and recommended doses of individual cientCVrisktobenefitfromstatintherapy. Studiesofbioequivalence. . . drugs, as well as SPCs and free combinations, can be found in suggestthatwhencombinedinthepolypill, differentagentsmaintain. all or most of their expected effect. 355 Furthermore, studies per-. . . nationalformularies. . . formedinthesettingofsecondaryprevention, particularlyinpatients. . Thistreatmentalgorithmfocusesonthefivemajorclassesofdrugs: . withapreviousmyocardialinfarction, haveshownthatuseofthepol-. . ACE inhibitors, ARBs, CCBs, thiazide or thiazide-like diuretics, and. ypillis accompanied by a better adherence to treatmentcompared. . beta-blockers. The algorithm recommends initial therapy for most. with separate medications. 356 The ESC Guidelines for the manage-. . patients with a two drug-combination, ideally as an SPC. Variations. mentofmyocardialinfarctionsuggestthattheuseofthepolypillmay. . fromthecoredrugtreatmentalgorithmforuncomplicatedhyperten-. beconsideredtoimprovelong-termadherencetoprescribedtherapy. . sionshowninFigure4arespecifiedinFigures5to8. Recommended. (classIIb, levelB). 353Nodataareavailableforprimarypreventionin. BPtargetrangesfortreatedhypertensionareshowninTable23. Downloaded from by guest on 31 December 2025 8102 HSE/CSE Consider monotherapy in Low risk 1 Pill Initial therapy angiotensin-converting enzyme inhibitor or angiotensin receptor blocker beta-blocker or calcium channel blocker grade 1 hypertension Dual combination (systolic blood pressure 150mmHg), or in or calcium channel blocker diuretic or beta-blocker very old ( 80 years) or frailer patients or beta-blocker diuretic Consider initiating therapy when systolic blood pressure is Step 2 1 Pill Triple combination of above 130 mmHg in these very Triple combination High risk patients with established cardiovascular disease Step 3 Resistant hypertension Triple combination Consider referral to a specialist centre 2 Pills spironolactone or Add spironolactone (2550 magnesium o. d. ) for further investigation or other diuretic, alpha-blocker or beta-blocker other drug Figure 5 Drugtreatmentstrategyforhypertensionandcoronaryartery disease. angiotensin-converting enzyme inhibitor angiotensin-convertingenzyme inhibitor; angiotensin receptor blockerangiotensinreceptorblocker; blood pressurebloodpressure; calcium channel blockercalciumchannelblocker; cardiovascular diseasecardiovasculardisease; o. d. omnidie(everyday).",
    "angiotensin-converting enzyme inhibitor angiotensin-convertingenzyme inhibitor; angiotensin receptor blockerangiotensinreceptorblocker; blood pressurebloodpressure; calcium channel blockercalciumchannelblocker; cardiovascular diseasecardiovasculardisease; o. d. omnidie(everyday). 8102 HSE/CSE 3064 ESC/ESHGuidelines Consider monotherapy in 1 Pill Initial therapy angiotensin-converting enzyme inhibitor or angiotensin receptor blocker calcium channel blocker or diuretic Low risk grade 1 hypertension Dual combination (systolic blood pressure 150mmHg), or in very old ( 80 years) or frailer patients Step 2 1 Pill angiotensin-converting enzyme inhibitor or angiotensin receptor blocker calcium channel blocker diuretic Triple combination Step 3 Resistant hypertension Triple combination Consider referral to a specialist centre 2 Pills spironolactone or Add spironolactone (2550 magnesium o. d. ) for further investigation other drug or other diuretic, alpha-blocker or beta-blocker Beta-blockers Consider beta-blockers at any treatment step, when there is a specific indication for their use, e. g. Heart failure, angina, post-myocardial infarction, atrial fibrillation, or younger women with, or planning, pregnancy Figure4 Coredrugtreatmentstrategyforuncomplicatedhypertension. Thecorealgorithmisalsoappropriateformostpatientswith HMOD, cerebrovasculardisease, Diabetes, orPAD. angiotensin-converting enzyme inhibitorangiotensin-convertingenzymeinhibitor; angiotensin receptor blockerangiotensinreceptorblocker; calcium channel blocker calciumchannelblocker; HMODhypertension-mediatedorgandamage; myocardial infarctionmyocardialinfarction; o. d. omnidie(everyday); peripheral arterial diseaseperipheral arterydisease. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3065 Figure 6 Drugtreatment strategyforhypertensionand chronic Kidney disease. angiotensin-converting enzyme inhibitor angiotensin-convertingenzymeinhibitor; angiotensin receptor blockerangiotensinreceptorblocker; blood pressurebloodpressure; calcium channel blockercalciumchannelblocker; chronic kidney diseasechronickidneydisease; estimated glomerular filtration rateestimated glomerularfiltrationrate; myocardial infarctionmyocardialinfarction; o. d. omnidie(everyday). aCKDisdefinedasaneGFR60mL/min/1. 72m2withorwithoutproteinuria. bUseloopdiureticswheneGFRis30mL/min/1. 72m2, becausethiazide/thiazide-likediureticsaremuchlesseffective/ineffectivewhen eGFRisreducedtothislevel. cCaution: riskofhyperkalaemiawithspironolactone, especiallywheneGFRis45mL/min/1. 72m2orbaselineKþ_4. 5mmol/L. Figure7 Drugtreatmentstrategyforhypertensionandhearfailurewithreducedejectionfraction. Donotusenon-dihydropyridine CCBs(e. g. verapamilordiltiazem). angiotensin-converting enzyme inhibitorangiotensin-convertingenzymeinhibitor; angiotensin receptor blockerangiotensinreceptorblocker; calcium channel blockercalciumchannel blocker; ESCEuropeanSocietyofCardiology; HFrEFheartfailurewithreducedejectionfraction; MRAmineralocorticoidreceptorantagonist. aConsideranangiotensinreceptor/neprilysininhibitorinsteadofACEiorARBperESCHeartFailureGuidelines. 136 bDiureticreferstothiazide/thiazide-likediuretic. Consideraloopdiureticasanalternativeinpatientswithoedema. cMRA(spironolactoneoreplerenone). Downloaded from by guest on 31 December 2025. The drug treatment strategy for patients with hypertension. . concomitantconditionsordiseasesarepresentthatrequirespe-. should be based on the algorithm shown (Figures 4 to 8), . . cificmodificationofthedrugs, asoutlinedintherecommendations. unless there are contraindications to these drugs (Table 20), or. . below. 8102 HSE/CSE 3066 ESC/ESHGuidelines angiotensin-converting enzyme inhibitor or angiotensin receptor blocker beta-blocker Initial therapy or non-DHP CCBa, Dual combination or beta-blocker calcium channel blocker angiotensin-converting enzyme inhibitor or angiotensin receptor blocker beta-blocker Step 2 DHP calcium channel blocker or diuretic Triple combination or beta-blocker DHP calcium channel blocker diuretic Add oral anticoagulation when indicated according to the CHA2DS2-VASc score, unless contraindicated. a Routine combination ofbeta-blockers with non-dihydropyridine CCBs (e. g. verapamil or diltiazem) is not recommended due toa potential marked reduction in Heart rate. Figure8 Drugtreatmentstrategyforhypertensionandatrialfibrillation. angiotensin-converting enzyme inhibitorangiotensin-convertingenzymeinhibitor; atrial fibrillationatrial fibrillation; angiotensin receptor blocker angiotensin receptor blocker; calcium channel blocker calcium channel blocker; CHADS-VASc CHADS-VASc Cardiac failure, 2 2 2 2 Hypertension, Age_75(Doubled), Diabetes, Stroke(Doubled)Vasculardisease, Age6574andSexcategory(Female); DHPdihydropyridine. aNon-DHPCCB(non-DHPCCB, e. g. verapamilordiltiazem). Table23 Officebloodpressuretreatmenttargetrange Agegroup OfficeSBPtreatmenttargetranges(mmHg) OfficeDBP treatment targetrange (mmHg) Hypertension 1Diabetes 1CKD 1CAD 1Strokea/TIA 18-65years Targetto130 Targetto130 Targetto140to Targetto130 Targetto130 7079 orloweriftolerated orloweriftolerated 130iftolerated orloweriftolerated orloweriftolerated Not120 Not120 Not120 Not120 65-79yearsb Targetto130-139 Targetto130-139 Targetto130-139 Targetto130-139 Targetto130-139 7079 iftolerated iftolerated iftolerated iftolerated iftolerated _80yearsb Targetto130-139 Targetto130-139 Targetto130-139 Targetto130-139 Targetto130-139 7079 iftolerated iftolerated iftolerated iftolerated iftolerated OfficeDBP 7079 7079 7079 7079 7079 treatment targetrange (mmHg) coronary artery diseasecoronaryarterydisease; chronic kidney diseasechronickidneydisease(includesdiabeticandnon-diabeticCKD); DBPdiastolicbloodpressure; SBPsystolicbloodpressure; TIA transientischaemicattack. aReferstopatientswithpreviousstrokeanddoesnotrefertobloodpressuretargetsimmediatelyafteracutestroke. bTreatmentdecisionsandbloodpressuretargetsmayneedtobemodifiedinolderpatientswhoarefrailandindependent. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3067 Drugtreatmentstrategyforhypertension Recommendations Classa Levelb Amongallantihypertensivedrugs, ACEinhibitors, ARBs, beta-blockers, CCBs, anddiuretics(thiazidesandthiazide-like drugssuchaschlorthalidoneandindapamide)havedemonstratedeffectivereductionofBPandCVeventsinRCTs, andthus I A areindicatedasthebasisofantihypertensivetreatmentstrategies. 2 Combinationtreatmentisrecommendedformosthypertensivepatientsasinitialtherapy. Preferredcombinationsshould compriseaRASblocker(eitheranACEinhibitororanARB)withaCCBordiuretic. Othercombinationsofthefivemajor I A classescanbeused. 233, 318, 327, 329, 341345 Itisrecommendedthatbeta-blockersarecombinedwithanyoftheothermajordrugclasseswhenthere I A arespecificclinicalsituations, e. g. angina, post-myocardialinfarction, heartfailure, orheartratecontrol. 300, 341 Itisrecommendedtoinitiateanantihypertensivetreatmentwithatwo-drugcombination, preferablyinanSPC. Exceptionsarefrailolderpatientsandthoseatlowriskandwithgrade1hypertension(particularlyifSBPis I B 150mmHg). 342, 346, 351 ItisrecommendedthatifBPisnotcontrolledcwithatwo-drugcombination, treatmentshouldbeincreasedtoa three-drugcombination, usuallyaRASblockerwithaCCBandathiazide/thiazide-likediuretic, preferably I A asanSPC. 349, 350 ItisrecommendedthatifBPisnotcontrolledcwithathree-drugcombination, treatmentshouldbeincreasedbytheaddition ofspironolactoneor, ifnottolerated, otherdiureticssuchasamilorideorhigherdosesofotherdiuretics, abeta-blocker, or I B analpha-blocker. 310 ThecombinationoftwoRASblockersisnotrecommended.",
    "349, 350 ItisrecommendedthatifBPisnotcontrolledcwithathree-drugcombination, treatmentshouldbeincreasedbytheaddition ofspironolactoneor, ifnottolerated, otherdiureticssuchasamilorideorhigherdosesofotherdiuretics, abeta-blocker, or I B analpha-blocker. 310 ThecombinationoftwoRASblockersisnotrecommended. 291, 298, 299 III A ACE angiotensin-converting enzyme; angiotensin receptor blocker angiotensin receptor blocker; blood pressure Blood Hypertension; calcium channel blocker calcium channel blocker; CV cardiovascular; renal artery stenosis renin-angiotensinsystem; RCTrandomizedcontrolledtrial; SBPsystolicbloodpressure; SPCsingle-pillcombination. aClassofrecommendation. bLevelofevidence. cAdherenceshouldbechecked. . . 7. 6 Device-based hypertension. complexsurgicalintervention. Thishasledtothedevelopmentofan. . treatment. . endovascular carotid baroreflex amplification device using a dedi-. . cated stent-like device designed to stretch the carotid bulb and Variousdevice-basedtherapieshaveemerged, principallytargetedat. . . increase baroreflex sensitivity. Preliminary data in humans have thetreatmentofresistanthypertension. Thesearediscussedbelow. . . . shownevidenceofBP-loweringefficacyofthisnewapproach, 360but. . . data from ongoing RCTs are needed to definitively understand its. . 7. 6. 1Carotidbaroreceptorstimulation(pacemakerand. longer-termefficacyandsafety. . . stent). . . Carotid baroreceptor stimulation or baroreflex amplification. . . therapyexternallyviaanimplantablepulsegeneratororinternally. 7. 6. 2Renaldenervation. . viaanimplantabledevicedesignedtoincreasethestrainonthecaro-. Therationaleforrenaldenervationlaywiththeimportanceofsym-. . three times daily bulbcanlower BPin patients withresistant hypertension. An. patheticnervoussysteminfluencesonrenalvascularresistance, renin. RCT with the first generation of an implantable pulse generator. . release, andsodiumreabsorption, 361theincreasedsympathetictone. . showedsustainedBP-loweringefficacy(andsympatheticnervoussys-. tothekidneyandotherorgansinhypertensivepatients, 361andthe. . teminhibition), butwithsomeconcernsaboutproceduralandlonger. . pressor effect of renal afferent fibres documented in experimental. termsafety. 358Asecond-generationunilateraldevicehasbeendevel-. . animals. 362 Catheter-based renal denervation using radiofrequency, . opedtoimprovesafetyandsustainedefficacy. Apropensityscore-. . ultrasound, or perivascular injection of neurotoxic agents such as. matched comparison of the firstand second-generation systems. . alcoholhasbeenintroducedasaminimallyinvasivetreatmentoption. revealedthatBPat12monthspost-implantationwassimilar, witha. . forpatientswithresistanthypertension. 363However, theclinicalevi-. bettersafetyprofileforthesecond-generationdevice. 359However, . . dence in support of renal denervation as an effective blood pressure-lowering. no RCT is currently available with this second-generation device. . . technique is conflicting. Several observational studies and national. Another consideration is that implantation is costly and requires a. and international registries364 support the blood pressure-lowering efficacy of Downloaded from by guest on 31 December 2025 3068 ESC/ESHGuidelines. . renal denervation originally reported in the Symplicity hypertension-1 and. 7. 6. 4Otherdevices. hypertension-2trials. 365Areductioninsympatheticactivityfollowingrenal. . Thecarotidbodyislocatedatthebifurcationofthecommoncarotid. . denervationhasalsobeenobserved. 366However, twoRCTswitha. . Itisinnervatedbynervefibresfromthevagusnervethroughthecer-. shamprocedurecontrol367, 368failedtodocumentthesuperiorityof. . vicalganglionandthecarotidsinusnerve. 379Stimulationofthecaro-. . renal denervation compared with the sham procedure in reducing. tidbodydrivessympathetictone, resultinginanincreaseinBPand. . blood pressure, butdidconfirmthesafetyoftheprocedure. AnotherRCT, the. . minuteventilation. Surgicalresectionofthecarotidbodyisassociated. RenalDenervationforHypertension(DENERHTN)trial, 369showed. . withreductionsinBP380andsympatheticoveractivityinpatientswith. thesuperiorityofrenaldenervationincombinationwithoptimized. . heartfailure. 381Devicesforendovascularcarotidbodymodification. pharmacotherapy compared with pharmacotherapy alone. The. . byultrasound-guidedablationhavebeendevelopedandarecurrently. PRAGUE-15 study370 documented similar effects between renal. . underinvestigation. . denervationandoptimizedpharmacotherapy(mainlybyaddingspi-. . In summary, device-based therapy for hypertension is a fast-. ronolactone)withrespecttoBP-loweringefficacy; however, thelat-. . moving field. Further sham-controlled studies are needed before. ter was associated with more side effects and highdiscontinuation. . device-basedtherapiescanberecommendedfortheroutinetreat-. rates. Beyond resistant hypertension, interim data in the first 80. . mentofhypertensionoutsideoftheframeworkofclinicaltrials. . patientstreatedwithrenaldenervationbutwithnobackgroundanti-. hypertensive therapy showed a modesteffectofrenal denervation Device-basedtherapiesforhypertension vs. shamcontrolon24hambulatoryBPafter3months. 366Thisstudy isongoing. Recommendation Classa Levelb Evaluating the efficacy of renal denervation has been challenging becausetheprocedureneedstobeappliedtoapopulationwitha Useofdevice-basedtherapiesisnotrecomhighprobabilityofBPresponse. Thisiscomplicatedby(i)thecommendedfortheroutinetreatmentofhyperten- plexpathophysiologyofhypertension, (ii)thelackofclinicallyapplicasion, unlessinthecontextofclinicalstudies III B blemeasuresofsympatheticactivity, (iii)theabsenceofpredictorsof andRCTs, untilfurtherevidenceregardingtheir thelong-termBPresponsefollowingrenaldenervation, and(iv)the safetyandefficacybecomesavailable. 367, 368 absence of reliable markers of procedural success to immediately establish whether denervation has been achieved. 371 There is eviRCTrandomizedcontrolledtrial. denceindicatingthatisolatedsystolichypertension, characterizedby aClassofrecommendation. bLevelofevidence. increased aortic stiffness, is associated with a limited response to renal denervation372, 373 and baroreceptor stimulation (see above). Except for rareproblems relatedto the catheterizationprocedure 8 Hypertension in specific (accesssitecomplications, vesseldissection, etc. ), nomajorcomplicacircumstances tionsordeteriorationofrenalfunctionhavebeenreported. Majoruncertaintiesremainastotheclinicalroleofrenaldenervationoutsideofclinicalstudies, whichshouldbeperformedincarefully 8. 1 Resistant hypertension selected patients at specialist hypertension centres and by experi8. 1. 1Definitionofresistanthypertension encedoperators. Hypertensionisdefined asresistantto treatmentwhenthe recommendedtreatmentstrategyfailstolowerofficeSBPandDBPvalues 7. 6. 3Creationofanarteriovenousfistula to140mmHgand/or90mmHg, respectively, andtheinadequate Thecentraliliacarteriovenousanastomosiscreatesafixed-calibre(4 control of blood pressure is confirmed by ABPM or HBPM in patients whose mm)conduitbetweentheexternaliliacarteryandveinusingastentadherencetotherapyhasbeenconfirmed. Therecommendedtreatlike nitinol device (ROX arteriovenous coupler). 374, 375 Device mentstrategyshouldincludeappropriatelifestylemeasuresandtreatdeploymentcanbeverifiedandisreversible, resultinginthediversion mentwithoptimalorbest-tolerateddosesofthreeormoredrugs, ofarterialblood(0. 81L/min)intothevenouscircuitwithimmediwhichshouldincludeadiuretic, typicallyanACEinhibitororanARB, ate, verifiablereductionsinBP. 374, 375TheBP-loweringeffectofarteandaCCB. Pseudo-resistanthypertension(seebelow)andsecondary riovenousanastomosiswasfirstobservedinastudyofpatientswith causesofhypertensionshouldalsohavebeenexcluded(seesection chronicobstructivepulmonarydisease(COPD), inwhomamoder8. 2). Thecurrentbackgroundinformationanddetaileddiscussion ateimprovementinthe6minwalkingtestwasshown. 376IntheROX ofthedataforthefollowingsectionoftheseGuidelinescanbefound CONTROL hypertension trial, patients with resistant hypertension were inESCCardioMedChapter44. 9Hypertensioninspecificconditions/ randomizedtoreceiveeitherstandardcareorinsertionofanarterioco-morbiditiesandChapter44. 10Hypertensioninspecialsituations. venouscouplerincombinationwithstandardcare.",
    "2). Thecurrentbackgroundinformationanddetaileddiscussion ateimprovementinthe6minwalkingtestwasshown. 376IntheROX ofthedataforthefollowingsectionoftheseGuidelinescanbefound CONTROL hypertension trial, patients with resistant hypertension were inESCCardioMedChapter44. 9Hypertensioninspecificconditions/ randomizedtoreceiveeitherstandardcareorinsertionofanarterioco-morbiditiesandChapter44. 10Hypertensioninspecialsituations. venouscouplerincombinationwithstandardcare. 377At6months, Prevalencestudiesofresistanthypertensionhavebeenlimitedby office and ambulatory BPweresignificantly reduced in the coupler variationinthedefinitionused, andreportedprevalenceratesrange group compared with the control group. Some important safety from530%inpatientswithtreatedhypertension. Afterapplyinga aspects need to be considered. Ipsilateral venous stenosis, which strictdefinition(seeabove)andhavingexcludedcausesofpseudoneeded venoplasty and/or stenting, occurred in 29% of patients. resistant hypertension (see section 8. 1. 2), the true prevalence of Therewerenoreportsofrightheartfailureorhigh-outputcardiac resistant hypertension is likely to be 10% of treated patients. failure after device implantation over the short-term, but longer Patients with resistant hypertension are at higher risk of HMOD, follow-upisclearlyneeded. 377, 378 chronic kidney disease, andprematureCVevents. 382 Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3069. . 8. 1. 2Pseudo-resistanthypertension. remedies, orrecreationaldruguse(cocaine, anabolicsteroids, etc. ). . Severalpossiblecausesofpseudo-resistanthypertensionshouldbe. (seeTable24). . . evaluatedandruledoutbeforeconcludingthatthepatienthasresist-. (3) Obstructive sleep apnoea (usually, but not invariably, associated. . anthypertension: . . withobesity). . . . (4) Undetectedsecondaryformsofhypertension(seesection8. 2). (1) Pooradherencetoprescribedmedicinesisafrequentcause. . . (5) AdvancedHMOD, particularlyCKDorlarge-arterystiffening. of pseudo-resistant hypertension, occurring in _50% of patients. . . assessedbytherapeuticdrugmonitoring, andisdirectlyrelatedto. . Resistanthypertensionisassociatedwitholderage(especially75. thenumberoftabletsprescribed315(seesection10). . . years), malesex, blackAfricanorigin, higherinitialBPatdiagnosisof. (2) White-coatphenomenon(inwhichofficeBPiselevatedbutBP. . hypertension, highest BPever reached duringthepatientslifetime, . is controlled at ABPM or HBPM) is not uncommon in these. . frequent outpatient visits, obesity, Diabetes, atherosclerotic disease. patients, hencetherecommendationtoconfirmofficehypertension. . and HMOD, chronic kidney disease, and a Framingham 10 yearcoronary riskscore. withABPMorHBPMbeforeconfirmingthediagnosisofresistant. . 20%. 383, 384. hypertension. . . . (3) PoorofficeBPmeasurementtechnique, includingtheuseof. . . cuffsthataretoosmallrelativetothearmcircumference, canresult. . inaspuriouselevationofBP. . . . 8. 1. 3Diagnosticapproachtoresistanthypertension (4) Marked brachial artery calcification, especially in older. . . Diagnosis of resistant hypertension requires detailed information. . about: patientswithheavilycalcifiedarteries. . . . (5) Clinicianinertia, resultingininadequatedosesorirrationalcom-. . (1) Thepatientshistory, includinglifestylecharacteristics, alcoholand. binationsofBP-loweringdrugtherapies. . . dietary Sodium intake, interfering drugs or substances, and sleep. Othercausesofresistanthypertension. . . history. . . (2) Thenatureanddosingoftheantihypertensivetreatment. . (1) Lifestylefactors, suchasobesityorlargegainsinweight, excessive. . (3) Aphysicalexamination, withaparticularfocusondeterminingthe. alcoholconsumption, andhighsodiumintake. . . presenceofHMODandsignsofsecondaryhypertension. . (2) Intake of vasopressor or Sodium-retaining substances, drugs pre-. . (4) Confirmationoftreatmentresistancebyout-of-officeBPmeasure-. scribed for conditions other than hypertension, some herbal. ments(i. e. ABPMorHBPM). Table24 Resistanthypertensioncharacteristics, secondarycauses, andcontributingfactors(adaptedfrom reference385) Characteristicsofpatientswith Causesofsecondaryresistant Drugsandsubstancesthatmay resistanthypertension hypertension causeraisedBP Demographics Morecommoncauses Prescribeddrugs Olderage(especially75years) Primaryhyperaldosteronism Oralcontraceptives Obesity Atheroscleroticrenovasculardisease Sympathomimeticagents(e. g. decon- Morecommoninblackpeople Sleepapnoea gestantsinproprietarycold Excessdietarysodiumintake chronic kidney disease remedies) HighbaselineBPandchronicityofuncon- Non-steroidalanti-inflammatorydrugs trolledhypertension Cyclosporin Erythropoietin Steroids(e. g. prednisoloneand hydrocortisone) Somecancertherapies Concomitantdisease Uncommoncauses Non-prescriptiondrugs HMOD: LVHand/orCKD Phaeochromocytoma Recreationaldrugs(e. g. cocaine, Diabetes Fibromusculardysplasia amphetamines, andanabolic Atheroscleroticvasculardisease Aorticcoarctation steroids) Aorticstiffeningandisolatedsystolic Cushingsdisease Excessiveliquoriceingestion hypertension Hyperparathyroidism Herbalremedies(e. g. ephedraandma huang) blood pressurebloodpressure; chronic kidney diseasechronickidneydisease; HMODhypertension-mediatedorgandamage; LVHleftventricularhypertrophy. Downloaded from by guest on 31 December 2025 3070 ESC/ESHGuidelines. . (5) Laboratory tests to detect electrolyte abnormalities (hypokalae-. release(4-8mg/day)asalternativestospironolactone. Neitherwas. . mia), associated risk factors (Diabetes), organ damage (advanced. . aseffectiveasspironolactone, buttheydidreduceBPsignificantlyvs. . renaldysfunction), andsecondaryhypertension. . . placebowhenaddedtobackgroundtreatmentinresistanthyperten-. (6) ConfirmationofadherencetoBP-loweringtherapy. . . sion. 310Thus, bisoprololanddoxazosinhaveanevidencebaseforthe. . . treatmentofresistanthypertensionwhenspironolactoneiscontrainPatients should be screened for a secondary cause of hyperten-. sion, especially primary aldosteronism386 or atherosclerotic renal. . . dicatedornottolerated. Directvasodilators, suchashydralazineor. . minoxidil, areinfrequentlyusedbecausetheymaycauseseverefluid arterystenosis, particularlyinolderpatientsorpatientswithCKD. . . . retentionandtachycardia. Pooradherencetotreatmentshouldbeconsidered, butitsidentifica-. . . NewBP-loweringdrugs(nitricoxidedonors, vasopressinantagotionmaybechallenginginroutineclinicalpractice. 387Somemethods. . . nists, aldosterone synthase inhibitors, neutralendopeptidase inhibiareeasytousebutoflimitedvalue(e. g. standardizedquestionnaires), . . . tors, andendothelinantagonists)areallunderinvestigation. 388 whereasothers, suchasdrugscreeningofurineorblood, showcon-. . . siderablepromisebutarenotyetwidelyavailable. 388Othermethods. include the measurement of blood pressure after directly observed treatment Resistanthypertension intake, 389whichhasbeenusedinclinicaltrials, 390butmaybemore difficulttoimplementinroutineclinicalpractice. Recommendations Classa Levelb Itisrecommendedthathypertensionbe 8. 1. 4Treatmentofresistanthypertension definedasresistanttotreatment(i. e. resistEffectivetreatmentcombineslifestylechanges(especiallythereducanthypertension)when: tionofsodiumintake), discontinuationofinterferingsubstances, and Optimaldoses(orbest-tolerateddoses)of thesequentialadditionofantihypertensivedrugstotheinitialtriple anappropriatetherapeuticstrategy, which therapy. Ultimately, replacingallcurrentdrugsbyasimplertreatment shouldincludeadiuretic(typicallyanACE regimenusingSPCtreatmentisrecommendedtoreducepillburden inhibitororanARBwithaCCBandathiaandimproveadherencetotreatment. Theoptimaldrugtreatmentof zide/thiazide-typediuretic), failstolower resistanthypertensionhasbeen poorlystudied. Themosteffective I C clinicSBPandDBPvaluesto140mmHg strategyseemstobeadditionaldiuretictreatmenttodecreasevoland/or90mmHg, respectively; and umeoverload, togetherwiththerestrictionofsaltintake, particularly TheinadequatecontrolofBPhasbeen inpatientswithCKD. BPcontrolmaybeimprovedbyincreasingthe confirmedbyABPMorHBPM; and dose of the existing diuretic or by switching to a more potent Afterexclusionofvariouscausesof thiazide-likediuretic(chlorthalidoneorindapamide). Aloopdiuretic pseudo-resistanthypertension(espeshouldreplacethiazides/thiazide-likediureticsiftheeGFRis30mL/ ciallypoormedicationadherence)and min. AlthoughresistanthypertensionmayshowaBPreductionifthe secondaryhypertension. existingdiureticdoseisfurtherincreased, mostpatientsrequirethe administrationofadditionaldrugs.",
    "Aloopdiuretic pseudo-resistanthypertension(espeshouldreplacethiazides/thiazide-likediureticsiftheeGFRis30mL/ ciallypoormedicationadherence)and min. AlthoughresistanthypertensionmayshowaBPreductionifthe secondaryhypertension. existingdiureticdoseisfurtherincreased, mostpatientsrequirethe administrationofadditionaldrugs. ThereisgrowingevidencetosugRecommendedtreatmentofresistant gestthatthefourth-linetreatmentshouldinvolveablockadeofthe hypertensionis: biologicaleffectsofaldosteronethroughtheuseofMRAs391(spiro- Reinforcementoflifestylemeasures, nolactoneupto50mg/day), asshowninthePATHWAY2study357 especiallysodiumrestriction. 395 andsupportedbyotherstudiesandtheirmeta-analysis. 392394Not Additionoflow-dosespironolactonecto allpatientswillbeabletotoleratespironolactoneduetoantiandroexistingtreatment; 310, 392, 394 genicsideeffectsresultinginbreasttendernessorgynaecomastia(in OrtheadditionoffurtherdiuretictherI B (cid: 3)6%), impotence in men, and menstrual irregularities in women. apyifintoleranttospironolactone, with Moreover, theefficacyandsafetyofspironolactoneforthetreatment eithereplerenone, camiloride, cahigherof resistant hypertension has not yet been established in patients dosethiazide/thiazide-likediuretic, ora withsignificantrenalimpairment. Assuch, theuseofspironolactone loopdiuretic; d357 for resistant hypertension should usually be restricted to patients Ortheadditionofbisoprololor withaneGFR_45mL/minandaplasmapotassiumconcentrationof doxazosin. 310 _ 4. 5 millimoles per liter. Moreover, electrolytes and estimated glomerular filtration rate should be monitoredsoonafterinitiationandatleastannuallythereafter. OntheoABPMambulatorybloodpressuremonitoring; ACEangiotensin-converting retical grounds, alternative additional diuretic therapy to enzyme; angiotensin receptor blockerangiotensinreceptorblocker; blood pressurebloodpressure; calcium channel blockercalcium channel blocker; DBP diastolic Blood Hypertension; HBPM home Blood spironolactone (when it is not tolerated due to androgen-like side pressuremonitoring. effects) could include the MRA eplerenone (50-100 magnesium/day). aClassofrecommendation. Amiloride(10-20mg/day)hasrecentlybeenshowntobeaseffecbLevelofevidence. cWhenspironolactoneisnottolerated, replacewithamilorideoreplerenone. tive as spironolactone 2550 magnesium daily) in reducing blood pressure in the TheuseofthesedrugsshouldberestrictedtopatientswithanestimatedglomerPATHWAY2study. 357Itisemphasizedthatthesamecautionsabout ularfiltrationrate_45mL/minandaplasmapotassiumconcentrationof_4. 5 theuseoftheseagentsshouldbeconsideredinpatientswithreduced millimoles per liter, becauseoftheriskofhyperkalaemia. dAloopdiureticshouldreplacethiazides/thiazide-likediureticsiftheestimated eGFRandbaselinepotassiumlevels4. 5mmol/L. ThePATHWAY-2 glomerularfiltrationrateis30mL/min. studyalsoevaluatedbisoprolol(5-10mg/day)ordoxazosinmodified Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3071. . 8. 2 Secondary hypertension. hypertension due to drugs and substances, and rarer monogenic. . . causes, aredescribedbelowandaresummarizedinTables28and29. Secondaryhypertensionishypertensionduetoanidentifiablecause, . . . whichmaybetreatablewithaninterventionspecifictothecause. A. . . highindex of suspicionand early detection ofsecondary causes of. . . 8. 2. 1Drugsandothersubstancesthatmaycause hypertensionareimportantbecauseinterventionsmaybecurative, . . . secondaryhypertension especially in younger patients e. g. corrective surgery for aortic. . . Medicationsandothersubstancesmaycauseasufficientincreasein coarctation, renal angioplasty in younger patients with renal artery. . . blood pressure to raise the suspicion of secondary hypertension397 (Table 28). fibromusculardysplasia, reversalofanendocrinecauseofhyperten-. . . Consequently, acarefuldrughistoryisimportantwhenconsideringa sion(e. g. byremovalofanadrenaladenoma), ordrugtreatmentofa. . . diagnosis of secondary hypertension. Moreover, other commonly monogenic disorder affecting a specific drug-sensitive ion channel. . . useddrugssuchasnon-steroidalanti-inflammatorydrugsorgluco- (e. g. selectiveuseofamilorideinLiddlessyndrome). Interventions. . . corticoidscanantagonizetheBP-loweringeffectofantihypertensive thattreatthe causeofsecondaryhypertensionlaterinlifeare less. . . medicationsinpatientstreatedforhypertension, andmaycontribute likelytobecurative(i. e. removetheneedforantihypertensivemedi-. . . toalossofBPcontrol. cation) because longstanding hypertension results in vascular and. . . otherorgandamagethatsustainstheelevatedBP, butinterventionis. . . stillimportantbecauseitwilloftenresultinmuchbetterBPcontrol. . 8. 2. 2Geneticcausesofsecondaryhypertension. withlessmedication. . . Geneticcausesofsecondaryhypertensionareusuallyduetosingle-. The prevalence of secondary hypertension is reported to be. . gene disorders (see section 6). 194, 195 They are rare but important. 515%396 of people with hypertension. Screening all hypertensive. . causesofsecondaryhypertensionbecauseidentifyingthecausecan. patientsforsecondaryhypertensionisnotfeasibleorcost-effective; . . pointtoaspecificdrugtreatment(Table29). 194, 195Commonfeatures. . however, therearesomegeneralpatientcharacteristicsthatsuggest. ofthesegeneticdisordersarethattheyusuallypresentwithhyper-. . those more likely to have secondary hypertension and in whom. tension in children, adolescents, or young adults, and most mono-. . screeningshouldbeconsideredafterconfirmingthatBPiselevated. genicdisordersinducehypertensionbyincreasingtherenaltubular. . withABPM(Table25). . reabsorptionofsodium. Thus, theyareusuallyassociatedwithasup-. . ItisbeyondthescopeoftheseGuidelinestodescribethedetailed. pressed plasma renin concentration (PRC) orplasma renin activity. . clinical management of specific causes of secondary hypertension. . (PRA), which is unusual in younger patients and especially those. . However, the commoner causes of secondary hypertension, clinical. . treatedwithantihypertensivemedications(e. g. RASblockers, CCBs, . history, andscreeningtestsaredescribedinTable26, andthetypical. . ordiuretics), thatwouldbeexpectedtoincreasePRCorPRA. Thus, . agedistributionofthesecausesofsecondaryhypertensionisshownin. . thefindingofasuppressedPRCorPRA, especiallywhilsttakingthese. Table27. Reviewofthesetablesdemonstratesthatmostscreeningcan. . drugs, should raise the suspicion of secondary hypertension due a. beundertakenwithbloodandurinetests, abdominalultrasound, and. . salt-retainingstate. Importantly, beta-blockersinparticular, butalso. echocardiography. Referraltoaspecialistcentreisrecommendedfor. . non-steroidalanti-inflammatory drugs, alpha-methyldopa, orcloni-. additionalinvestigationstoconfirmasuspecteddiagnosisofsecondary. . dine, suppressPRCandPRA. Thesedrugsshouldbediscontinued(if. hypertensionandforclinicalmanagement. Othercausesofsecondary. clinicallyfeasible)foratleast2weeksbeforemeasuringPRCorPRA. Table25 Patientcharacteristicsthatshouldraisethesuspicionofsecondaryhypertension Characteristic Youngerpatients(40years)withgrade2hypertensionoronsetofanygradeofhypertensioninchildhood Acuteworseninghypertensioninpatientswithpreviouslydocumentedchronicallystablenormotension Resistanthypertension(seesection8. 1) Severe(grade3)hypertensionorahypertensionemergency(seesection8. 3) PresenceofextensiveHMOD ClinicalorbiochemicalfeaturessuggestiveofendocrinecausesofhypertensionorCKD Clinicalfeaturessuggestiveofobstructivesleepapnoea Symptomssuggestiveofphaeochromocytomaorfamilyhistoryofphaeochromocytoma chronic kidney diseasechronickidneydisease; HMODhypertension-mediatedorgandamage.",
    "hypertensionandforclinicalmanagement. Othercausesofsecondary. clinicallyfeasible)foratleast2weeksbeforemeasuringPRCorPRA. Table25 Patientcharacteristicsthatshouldraisethesuspicionofsecondaryhypertension Characteristic Youngerpatients(40years)withgrade2hypertensionoronsetofanygradeofhypertensioninchildhood Acuteworseninghypertensioninpatientswithpreviouslydocumentedchronicallystablenormotension Resistanthypertension(seesection8. 1) Severe(grade3)hypertensionorahypertensionemergency(seesection8. 3) PresenceofextensiveHMOD ClinicalorbiochemicalfeaturessuggestiveofendocrinecausesofhypertensionorCKD Clinicalfeaturessuggestiveofobstructivesleepapnoea Symptomssuggestiveofphaeochromocytomaorfamilyhistoryofphaeochromocytoma chronic kidney diseasechronickidneydisease; HMODhypertension-mediatedorgandamage. Downloaded from by guest on 31 December 2025 3072 ESC/ESHGuidelines Table26 Commoncausesofsecondaryhypertension Cause Prevalencein Suggestivesymptomsandsigns ScreeningInvestigations hypertensive patients Obstructivesleepapnoea 510% Snoring; obesity(canbepresentinnonEpworthscoreandambulatory obese); morningheadache; daytime polygraphy somnolence Renalparenchymaldisease 210% Mostlyasymptomatic; Diabetes; haematuPlasmacreatinineandelectrolytes, ria, proteinuria, nocturia; anaemia, renal estimated glomerular filtration rate; urinedipstickforbloodandpromassinadultpolycysticCKD tein, urinaryalbumin: creatinineratio; renalultrasound Renovasculardisease Atheroscleroticrenovasculardisease 110% Older; widespreadatherosclerosis(espeDuplexrenalarteryDopplerorCT ciallyPAD); Diabetes; smoking; recurrent angiographyorMRangiography flashpulmonaryoedema; abdominalbruit Fibromusculardysplasia Younger; morecommoninwomen; abdominalbruit Endocrinecauses PrimaryAldosteronism 5-15% Mostlyasymptomatic; muscleweakness Plasmaaldosteroneandrenin, and (rare) aldosterone: reninratio; hypokalaemia (inaminority): notehypokalaemiacan depressaldosteronelevels Phaeochromocytoma 1% Episodicsymptoms(the5Ps): paroxysmal Plasmaor24hurinaryfractionated hypertension, poundingheadache, perspimetanephrines ration, palpitations, andpallor; labileBP; blood pressure surgesprecipitatedbydrugs(e. g. betablockers, metoclopramide, sympathomimetics, opioids, andtricyclic antidepressants) Cushingssyndrome 1% Moonface, centralobesity, skinatrophy, 24hurinary-freecortisol striaeandbruising; Diabetes; chronicsteroiduse Thyroiddisease(hyper-or 1-2% Signsandsymptomofhyper-or Thyroidfunctiontests hypothyroidism) hypothyroidism Hyperparathyroidism 1% Hypercalcaemia, hypophosphataemia Parathyroidhormone, Ca2þ Othercauses Coarctationoftheaorta 1% UsuallydetectedinchildrenoradolesEchocardiogram cence; differentBP(_20/10mmHg) betweenupperlowerextremitiesand/or betweenrightleftarmanddelayedradialfemoralfemoralpulsation; lowABIinterscapularejectionmurmur; ribnotchingon chestX-ray ABIankle-brachialindex; blood pressurebloodpressure; chronic kidney diseasechronickidneydisease; computed tomographycomputedtomography; estimated glomerular filtration rateestimatedglomerularfiltrationrate; MRmagneticresonance; peripheral arterial diseaseperipheralarterydisease. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3073 Table27 Incidenceandtypicalcausesofsecondaryhypertensionaccordingtoage Agegroup Percentwithunderlyingcause Typicalcauses Youngchildren(12years) 70-85 Renalparenchymaldisease Coarctationoftheaorta Monogenicdisorders Adolescents(1218years) 1015 Renalparenchymaldisease Coarctationoftheaorta Monogenicdisorders Youngadults(1940years) 510 Renalparenchymaldisease Fibromusculardysplasia(especiallyinwomen) Undiagnosedmonogenicdisorders Middle-agedadults(4165years) 515 Primaryaldosteronism Obstructivesleepapnoea Cushingssyndrome Phaeochromocytoma Renalparenchymaldisease Atheroscleroticrenovasculardisease Olderadults(65years) 510 Atheroscleroticrenovasculardisease Renalparenchymaldisease Thyroiddisease Table28 Medicationsandothersubstancesthatmayincreasebloodpresssure397 Medication/substance Oralcontraceptivepill Especiallyoestrogencontaining; causehypertensionin(cid: 3)5%ofwomen, usuallymildbutcanbesevere Dietpills Forexample, phenylpropanolamineandsibutramine Nasaldecongestants Forexample, phenylephrinehydrochlorideandnaphazolinehydrochloride Stimulantdrugs Amphetamine, cocaine, andecstasy; thesesubstancesusuallycauseacuteratherthanchronic hypertension Liquorice Chronicexcessiveliquoriceusemimicshyperaldosteronismbystimulatingthemineralocorticoidreceptorandinhibitingcortisolmetabolism Immunosuppressivemedications Forexample, cyclosporinA(tacrolimushaslesseffectonBPandrapamycinhasalmostnoeffectonBP) andsteroids(e. g. corticosteroidsandhydrocortisone) Antiangiogeniccancertherapies AntiangiogenicdrugssuchasVEGFinhibitors(e. g. bevacizumab), tyrosinekinaseinhibitors(e. g. sunitinib), andsorafenibhavebeenreportedtoincreaseBP Otherdrugsandsubstances Anabolicsteroids, erythropoietin, non-steroidalanti-inflammatorydrugs, andherbalremedies(e. g. ephethatmayraiseBP draandmahuang) blood pressurebloodpressure; VEGFvascularendothelialgrowthfactor. Downloaded from by guest on 31 December 2025 3074 ESC/ESHGuidelines Table29 Raregeneticcausesofsecondaryhypertension Condition Phenotype Mechanismandeffect Liddlesyndrome Hypokalaemia, metabolicalkalosis, lowPRAor IncreasedrenaltubularENaCactivity: PRC, lowPAC respondstotreatmentwithamiloride Apparentmineralocorticoid Hypokalaemia, metabolicalkalosis, lowPRAor Decreased11b-dehydrogenaseisoenzyme2 excess PRC, lowPAC Gordonsyndrome Hyperkalaemia, metabolicacidosis, lowPRAor OveractivityofsodiumchloridecoPRC, lowPAC transporter Gellersyndrome Pregnancy-exacerbatedhypertension, lowPRAor AgonisteffectofprogesteroneontheminPRC, lowPAC eralocorticoidreceptor Glucocorticoidremediable Hypokalaemia, metabolicalkalosis, lowPRCor ChimericCYP11b1toCYP11b2gene: hypertension PRA, andincreasedPAC responsetotreatmentwithglucocorticoids ENaCepithelialsodiumchannel; PACplasmaaldosteroneconcentration; PRAplasmareninactivity; PRCplasmareninconcentration. 8. 3 Hypertension urgencies and emergencies Table30 Diagnosticworkupforpatientswithasuspectedhypertensionemergency Hypertensionemergenciesaresituationsinwhichseverehypertension(grade 3)is associated with acuteHMOD, whichisoftenlifeCommontestsforallpotentialcauses threateningandrequiresimmediatebutcarefulinterventiontolower blood pressure, usuallywithintravenous(i. v. )therapy. 398Therateandmagnitude Fundoscopyisacriticalpartofthediagnosticworkup ofanincreaseinBPmaybeatleastasimportantastheabsolutelevel ofBPindeterminingthemagnitudeoforganinjury. 399Typicalpresen12-leadECG tationsofahypertensionemergencyare: Haemoglobin, plateletcount, fibrinogen Patients with malignant hypertension, characterized by Creatinine, estimated glomerular filtration rate, electrolytes, LDH, haptoglobin severe hypertension (usually grade 3) associated with funduscopic changes (flame haemorrhages and/or papilloedema), Urinealbumin: creatinineratio, urinemicroscopyforredcells, microangiopathy, anddisseminatedintravascularcoagulation, and leucocytes, casts can be associated with encephalopathy (in about 15% of cases), 400 acute Heart failure, and acute deterioration in renal Pregnancytestinwomenofchild-bearingage function. The hallmark of this condition is small artery fibrinoid Specifictestsbyindication necrosis in the Kidney, retina, and brain. The term malignant reflects the very poor prognosis for this condition if Troponin, CK-MB(insuspectedcardiacinvolvement, e. g. acute untreated. 401404 chestpainoracuteheartfailure)andNT-proBNP Patientswithseverehypertensionassociatedwithother clinical conditions who are likely to require an urgent reducChestX-ray(fluidoverload) tion of blood pressure, e. g. acute aortic dissection, acute myocardial ischaeEchocardiography(aorticdissection, heartfailure, orischaemia) mia, oracuteheartfailure. PatientswithsuddenseverehypertensionduetophaeoCTangiographyofthoraxand/orabdomeninsuspectedacute chromocytoma, associatedwithorgandamage. aorticdisease(e. g. aorticdissection) Pregnant women with severe hypertension or preeclampsia(seesection8. 9. 1). CTorMRIbrain(nervoussysteminvolvement) Renalultrasound(renalimpairmentorsuspectedrenalartery The most common emergency symptoms will depend of the stenosis) organsaffectedbutmayincludeheadache, visualdisturbances, chest Pain, dyspnoea, dizziness, andotherneurologicaldeficits. Inpatients Urinedrugscreen(suspectedmethamphetamineorcocaine with hypertensive encephalopathy, the presence of somnolence, use) lethargy, tonicclonicseizures, andcorticalblindnessmayprecedea loss of consciousness; however, focal neurological lesions are rare CK-MBcreatininekinase-muscle/brain; computed tomographycomputedtomography; ECG andshouldraisethesuspicionofstroke. electrocardiogram; estimated glomerular filtration rateestimatedglomerularfiltrationrate; LDHlactate Acute stroke, especially intracerebral haemorrhage, when dehydrogenase; magnetic resonance imagingmagneticresonanceimaging; NT-proBNPN-terminal pro-Bnatriureticpeptide. associated with severe hypertension has often been termed a Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3075. . hypertensionemergency, butamorecautiousapproachisnowrec-. whetherthereisaprecipitatingcausefortheacuteriseinBPthat. . ommendedforacuteBPloweringintheemergencysettingofacute. mightaffectthetreatmentplan(e. g. pregnancy); . . stroke(seesection8. 15). . . (2) The recommended timescale and magnitude of blood pressure lowering. Thetermhypertensionurgencyhasalsobeenusedtodescribe. . requiredforsafeBPreduction; . severehypertensioninpatientspresentingtotheemergencydepart-. . (3) ThetypeofBP-loweringtreatmentrequired. Withregardtodrug.",
    ". (2) The recommended timescale and magnitude of blood pressure lowering. Thetermhypertensionurgencyhasalsobeenusedtodescribe. . requiredforsafeBPreduction; . severehypertensioninpatientspresentingtotheemergencydepart-. . (3) ThetypeofBP-loweringtreatmentrequired. Withregardtodrug. ment in whom there is no clinical evidence of acute HMOD. 405. . treatment, inahypertensionemergency, i. v. treatmentwithadrug. Whilst these patients require blood pressure reduction, they do not usually. . with a short half-life is ideal to allow careful titration of the blood pressure. requireadmissiontohospital, andBPreductionisbestachievedwith. . response to treatment in a higher dependency clinical area with. oralmedicationaccordingtothedrugtreatmentalgorithmpresented. . facilitiesforcontinuoushaemodynamicmonitoring. . in Figure 4. However, these patients will require urgent outpatient. . reviewtoensurethattheirBPiscomingundercontrol. . . . Recommended drug treatments for specific hypertension emerAcuteandsevereincreasesinBPcansometimesbeprecipitated. . . gencies398, 406areshowninTable31andanexpandedrangeofpossiby ingestion of sympathomimetics such as meta-amphetamine or. . . ble drug choices398 is shown in Table 32. Rapid uncontrolled blood pressure cocaine. Thiscanresultinahypertensionemergencywhenthereis. . . loweringisnotrecommendedasthiscanleadtocomplications. 397. . Althoughi. v. drugadministrationisrecommendedformosthyperevidenceofacuteHMOD. . . . tension emergencies, oral therapy with ACE inhibitors, ARBs, or It is emphasized that many patients in an emergency. . . beta-blockersissometimesveryeffectiveinmalignanthypertension departmentwithacutepainordistressmayexperienceanacuteele-. . . becausethereninsystemisactivatedbyrenalischaemia. However, vationinBPthatwillberestoredtonormalwhenthepainanddis-. . . lowinitialdosesshouldbeusedbecausethesepatientscanbevery tressarerelieved, ratherthanrequiringanyspecificinterventionto. . . sensitivetotheseagentsandtreatmentshouldtakeplaceinhospital. lowerBP. . . . FurthercomprehensivedetailsontheclinicalmanagementofhyperForpatientswithasuspectedhypertensionemergency, adiagnos-. . . tensionemergenciesareavailable. 398 ticworkupisshowninTable30. . . . . . . . 8. 3. 2Prognosisandfollow-up. 8. 3. 1Acutemanagementofhypertensiveemergencies. . . Thesurvivalofpatientswithhypertensionemergencieshasimproved ApartfromacuteBPloweringinstroke, therearenoRCTsevaluating. . . dramaticallyoverpastdecades, 407butthesepatientsremainathigh differenttreatmentstrategiesforhypertensiveemergencies. Thekey. . . risk408, 409andshouldbescreenedforsecondaryhypertension(see considerationsindefiningthetreatmentstrategyare: . . . section8. 2). Afterdischargefromhospital, whenBPhasreached a. . safe and stable level on oral therapy, we recommend frequent, at. (1) Establishing the target organs that are affected, whether they. . leastmonthly, visitsinaspecializedsettinguntiltheoptimaltargetBP. require any specific interventions other than blood pressure lowering, and. isachievedandlong-termspecialistfollow-upthereafter. Table31 Hypertensiveemergenciesrequiringimmediatebloodpressureloweringwithintravenousdrugtherapy Clinicalpresentation TimelineandtargetforBP First-linetreatment Alternative reduction Malignanthypertensionwithor Severalhours Labetalol Nitroprusside withoutacuterenalfailure ReduceMAPby2025% Nicardipine Urapidil Hypertensiveencephalopathy ImmediatelyreduceMAPby Labetalol, nicardipine Nitroprusside 2025% Acutecoronaryevent ImmediatelyreduceSBPto140 Nitroglycerine, labetalol Urapidil mmHg Acutecardiogenicpulmonary ImmediatelyreduceSBPto140 Nitroprussideornitroglycerine Urapidil(withloopdiuretic) oedema mmHg (withloopdiuretic) Acuteaorticdissection ImmediatelyreduceSBPto120 Esmololandnitroprussideor LabetalolORmetoprolol mmHgANDheartrateto60 nitroglycerineornicardipine bpm EclampsiaandseverepreImmediatelyreduceSBPto160 Labetalolornicardipineand Considerdelivery eclampsia/HELLP mmHgANDDBPto105mmHg magnesiumsulfate blood pressurebloodpressure; bpmbeatspermin; DBPdiastolicbloodpressure; HELLPhaemolysis, elevatedliverenzymes, andlowplatelets; i. v. intravenous; MAPmean arterialpressure; SBPsystolicbloodpressure. Downloaded from by guest on 31 December 2025 3076 ESC/ESHGuidelines Table32 Drugtypes, doses, andcharacteristicsfortreatmentofhypertensionemergencies Drug Onsetofaction Duration Dose Contraindications Adverseeffects ofaction Esmolol 12min 1030min 0. 51mg/kgasi. v. bolus; Secondorthird-degreeAV Bradycardia 50300lg/kg/minasi. v. block, systolicheartfailure, infusion asthma, bradycardia Metoprolol 12min 58h 2. 55mgi. v. bolusover2 Secondorthird-degreeAV Bradycardia minutes-mayberepreated block, systolicheartfailure, every5minutestoamaximum asthma, bradycardia doseof15mg Labetalol 510min 36h 0. 250. 5mg/kgi. v. bolus; Secondorthird-degreeAV Bronchoconstriction, 24mg/mininfusionuntilgoalBP block; systolicheartfailure, foetalbradycardia isreached, thereafter520mg/h asthma, bradycardia Fenoldopam 515min 3060min 0. 1mg/kg/mini. v. infusion, Cautioninglaucoma increaseevery15minwith0. 05 -0. 1lg/kg/minincrementsuntil goalBPisreached Clevidipine 23min 515min 2mg/hi. v. infusion, increaseevery Headache, reflex 2minwith2mg/huntilgoalBP tachycardia Nicardipine 515min 3040min 515mg/hi. v. infusion, starting Liverfailure Headache, reflex dose5mg/h, increaseevery tachycardia 1530minwith2. 5mguntil goalBP, thereafterdecreaseto 3mg/h Nitroglycerine 15min 35min 5200lg/mini. v. infusion, Headache, reflex 5lg/minincreaseevery5min tachycardia Nitroprusside Immediate 12min 0. 310lg/kg/mini. v. infusion, Liver/kidneyfailure Cyanideintoxication increaseby0. 5lg/kg/minevery (relative) 5minuntilgoalBP Enalaprilat 515min 46h 0. 6251. 25mgi. v. bolus Historyofangioedema Urapidil 35min 46h 12. 525mgasbolusinjection; 540mg/hascontinuousinfusion Clonidine 30min 46h 150300mgi. v. bolusover Sedation, rebound 510min hypertension Phentolamine 12min 1030min 0. 51mg/kgi. v. bolusOR Tachyarrhythmias, 50300mg/kg/minasi. v. infusion chestpain AVatrioventricular; blood pressurebloodpressure; i. v. intravenous. . 8. 4 White-coat hypertension. . . aswellasanoverallincreasedriskofCVevents. 68, 410412Itisrecom-. Asdiscussedin section4, white-coathypertensionis defined asan. . mended that people with white-coat hypertension should have an. elevated office blood pressure despite a normal out-of-office blood pressure. White-coat. . accurate assessment oftheir CV risk profile, includinga search for. hypertensionmaybepresentinmanypeoplewithanincreasedoffice. . HMOD. Officeandout-of-officeBP(bothhomeandambulatoryBP). blood pressure, witha maximum in grade 1hypertension, and veryoldpeople. . should be measured frequently, e. g. no less than every 2 years. . (50%). Comparedwithnormotensivepeople, white-coathyperten-. . Treatmentshouldconsiderlifestylechangestoreducetheelevated. sionisassociatedwithanincreasedprevalenceofdysmetabolicrisk. . CVrisk. 85, 86, 89. factorsandasymptomaticorgandamage. Itisalsoassociatedwitha. . Whether or not patients with white-coat hypertension should. greaterriskofdevelopingtype2diabetesandsustainedhypertension, . .",
    "sionisassociatedwithanincreasedprevalenceofdysmetabolicrisk. . CVrisk. 85, 86, 89. factorsandasymptomaticorgandamage. Itisalsoassociatedwitha. . Whether or not patients with white-coat hypertension should. greaterriskofdevelopingtype2diabetesandsustainedhypertension, . . receive antihypertensive drugs is unresolved. In white-coat Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3077. . hypertension, antihypertensivedrugshavebeenshowntoeffectively. . (ABPMorHBPM). 84Registry-basedstudiesinSpainhavesuggested. and persistently lower office blood pressure, with no concomitant reduction. . that MUCH occurs in as many as 30% of treated hypertensive. (indeed, even a small increase) of ambulatory blood pressure values. 413, 414. . patients, 84andismorecommonwithcomorbiditiessuchasdiabetes. WhethertheseBPchangesleadtoCVprotectionhasnotbeeninves-. . andCKDandinthoseathighestrisk. Moreover, MUCHwasmore. tigated with adequately powered outcome studies and remains. . commonlyduetopoorlycontrollednocturnalratherthandaytime. unknown. However, itshouldbeconsideredthatpeoplewithwhite-. . pressuresonABPM. Presently, nodataareavailablefromoutcome. coathypertensionhaveinevitablybeenwellrepresentedintrialsdoc-. . trials for patients with MUCH; however, mindful of their High CV. umentingtheprotectiveeffectofantihypertensivedrugs, 415particu-. . risk, treatmentuptitrationshouldbeconsideredtoensurethatthat. larlythoseaddressingconditionsinwhichwhite-coathypertensionis. . bothofficeandout-of-officeBParecontrolled. 84. more common, such as grade 1 hypertension or hypertension in. . . olderpatients. InarecentsubanalysisoftheHYVETtrialofthevery Managementofwhitecoatandmaskedhypertension old with hypertension, white-coat hypertension was reported to account for 55% of the trial population. 416 Thus, antihypertensive drug treatment cannot definitively be excluded for patients with Managementofwhite-coathypertension white-coat hypertension and may be considered, in particular, in Recommendations Classa Levelb white-coathypertensivepeoplewithahigherCVriskprofile, suchas thosewithHMOD, anuncertainout-of-officeBPnormalitypattern Inwhite-coathypertensivepatients, itisrec- (i. e. ambulatorybutnothomeBPnormalityorviceversa), orapersisommendedtoimplementlifestylechanges tentofficeBPelevationatrepeatedvisits. 417420NoCVriskexcess aimedatreducingCVriskaswellasregular I C has been reported in patients in whom white-coat hypertension follow-upwithperiodicout-of-officeBP resultsfromtreatment-dependantnormalizationofout-of-officeBP monitoring. only. 418, 421Thus, whetherthisconditionbenefitsfromanuptitration Inpatientswithwhite-coathypertension: oftheexistingdrugtreatmentregimen(toalsoachieveofficeBPnor- Drugtreatmentmaybeconsideredin malization)remainstobedetermined. IIb C peoplewithevidenceofHMODorin 8. 5 Masked hypertension whomCVriskishighorveryhigh. Asreportedinsection4. 7. 2, maskedhypertensionisdefinedinpeople Routinedrugtreatmentisnotindicated. III C whoseBPisnormalintheofficebutelevatedonout-of-officeBPmeasManagementofmaskedhypertension urements. Such people usually have dysmetabolic risk factors and asymptomatic organ damage, which are substantially more frequent Recommendations thaninpeoplewhoaretrulynormotensive. 93, 410412, 422Thechallenge Inmaskedhypertension, lifestylechanges ishowtodiagnosemaskedhypertension, becausemosthypertension arerecommendedtoreduceCVrisk, with screeningprogrammesuseofficeBPmeasurement, whichisnormalin I C regularfollow-up, includingperiodicout-ofthese people. Masked hypertension is commoner in younger rather officeBPmonitoring. thanolderindividuals, andinthosewithanofficeBPintheborderline hypertensionrange(i. e. 130-139/80-89mmHg). Itisuncommonin Antihypertensivedrugtreatmentshouldbe people whose office blood pressure is 130/80 mmHg. Masked hypertension is consideredinmaskedhypertensiontonorassociatedwithprogressiontosustainedofficehypertension, increased malizetheout-of-officeBP, basedonthe IIa C frequencyofdevelopingtype2diabetes, andthepresenceofHMOD. prognosticimportanceofout-of-officeBP Thelong-termriskoffatalandnon-fatalCVeventsapproachesthatof elevation. patientswithsustainedhypertension. 68, 81, 93, 95, 423Patientswithmasked Antihypertensivedruguptitrationshouldbe hypertension should have an accurate initial assessment of their CV consideredintreatedpatientswhoseoutriskprofile. CVriskfactors(includingorgandamageandideallyboth home and ambulatory blood pressure) should then be periodically monitored. of-officeBPisnotcontrolled(i. e. masked IIa C uncontrolledhypertension), becauseofthe Factors contributing to the out-of-office blood pressure elevation (e. g. smoking) highCVriskofthesepatients. should be discouraged and lifestyle interventions implemented to improveout-of-officeBPlevels. Theimpactofantihypertensivedrug treatmentonCVoutcomesinpeoplewithmaskedhypertensionhas blood pressure Blood Hypertension; CV cardiovascular; HMOD hypertension-mediated organdamage. neverbeenstudied. Nevertheless, treatmentwithBP-loweringmedicaaClassofrecommendation. tionshouldbeconsideredbecausethesepatientsareathighCVrisk, bLevelofevidence. oftenhaveHMOD, andtheadverseprognosticimportanceofout-ofofficeBPelevationshasbeenwelldocumented. 68, 74 8. 7 Hypertension inyounger adults 8. 6 Masked uncontrolled hypertension (age 50 years) MUCH occurs in some treated patients in whom the office blood pressure Theprevalenceofhypertensionincreaseswithage. MosthypertenappearscontrolledtorecommendedBPtargets, butBPiselevated sionacrosstheagespanisduetosystolichypertension; however, eleandthusuncontrolledaccordingtoout-of-officeBPmeasurements vationsofDBPandisolateddiastolichypertension, whentheyoccur, Downloaded from by guest on 31 December 2025 3078 ESC/ESHGuidelines. aremorecommoninyoungerratherthanolderpatients. 211Thereis. . ForthepurposesoftheseGuidelines, olderisdefinedas_65years. . agreaterlikelihoodofdetectingsecondaryhypertensioninyounger. andtheveryoldas_80years. . . patients(50years), wheretheprevalenceofsecondaryhyperten-. Formanyyears, advancedagehasbeenabarriertothetreatment. . sionmaybeashighas10%andshouldbeconsidered, especiallyin. ofhypertensionbecauseofconcernsaboutpotentialpoortolerabil-. . thosewithmoreseverehypertension(seesection3). . ity, andevenharmfuleffectsofBP-loweringinterventionsinpeoplein. . All younger adults with grade 2 or more severe hypertension. whommechanismspreservingBPhomeostasisandvitalorganperfu-. . shouldbeofferedlifestyleadviceanddrugtreatment, aswellashigh-. sionmaybemorefrequentlyimpaired. Thisapproachisnotappro-. . risk younger adults with grade 1 hypertension (i. e. with HMOD, . priate, becauseevidencefromRCTshasshownthatinoldandvery. . cardiovascular disease, Diabetes, chronic kidney disease, orthoseathighCVDrisk, althoughCVriskis. . old patients, antihypertensive treatment substantially reduces CV. often underestimated in younger adults over shorter-term projec-. . morbidity and CV and all-cause mortality220, 431 (see section 7). . tions, suchas10years). 35. . Moreover, treatmenthasbeenfoundtobegenerallywelltolerated. . Thereiscontroversyaboutwhetheryoungeradultswithuncom-. . However, olderpatientsaremorelikelytohavecomorbiditiessuch. plicated grade 1 hypertension should be treated because of the. . as renal impairment, atherosclerotic vascular disease, and postural. obviousdifficultyinconductingconventionalclinicaloutcometrialsin. . hypotension, whichmaybeworsenedbyBP-loweringdrugs. Older. younger adults in whom the outcomes only occur after many. . patientsalsofrequentlytakeothermedications, whichmaynegatively. years. 424 There is little doubt that treating stage 1 hypertension in. . interactwiththoseusedtoachieveBPcontrol. Afurtherimportant. olderpatients, eventhoseatlowmoderate-risk, reducesCVmor-. . caveatisthatRCTshavenotincludedveryfrailpatients, dependent. bidityandmortality. 425Moreover, long-termepidemiologicalstudies. . patients, andpatientswithposturalhypotension. Itisthusuncertain. havedemonstratedaclearrelationshipbetweenBPandlonger-term. . whether, andtowhatextent, suchpatientswouldbenefitfromBP-. riskofCVeventsandmortalityinyoungadultswithaBP130/80. . loweringtreatmentinthecontextoftheircomorbiditiesandreduced. mmHg.",
    ". caveatisthatRCTshavenotincludedveryfrailpatients, dependent. bidityandmortality. 425Moreover, long-termepidemiologicalstudies. . patients, andpatientswithposturalhypotension. Itisthusuncertain. havedemonstratedaclearrelationshipbetweenBPandlonger-term. . whether, andtowhatextent, suchpatientswouldbenefitfromBP-. riskofCVeventsandmortalityinyoungadultswithaBP130/80. . loweringtreatmentinthecontextoftheircomorbiditiesandreduced. mmHg. 424, 426 Furthermore, earlier treatment23 can prevent more. . life expectancy. Thus, in older hypertensive patients, treatment. severehypertension427andthedevelopmentofHMOD, whichmay. . presentsmoredifficultiesthaninyoungerpeople, becausethedeci-. . notbecompletelyreversiblewithlatertreatment. Thus, despitethe. siontotreathypertensionmusttakeintoaccountthepatientsclinical. . absence ofRCT evidence demonstratingthebenefits ofantihyper-. condition, concomitant treatments, and frailty. That said, age alone. . tensive treatment in younger adults with uncomplicated grade 1. mustneverbeabarriertotreatmentbecausehighBPisanimportant. . hypertension, treatmentwithBP-loweringdrugsmaybeconsidered. riskfactoreven atthe most advanced ages. Furthermore, a recent. . prudent. Ifadecisionistakennottooffertreatmentortreatmentis. studyofacohortofolderpatientsfromthegeneralpopulation(thus. . declined, lifestyleadviceshouldbeprescribed, andlonger-termfol-. includingthosewithfrailty)hasshownthatbetteradherencetoanti-. . Low-upisessentialasBPwillinvariablyrise. Inyoungerpatientswith. hypertensive treatment was associated with a reduced risk of CV. . hypertensiontreatedwithBP-loweringmedication, officeBPshould. events and mortality, even when age was 85 years (mean 90. . bereducedto_130/80mmHgiftreatmentiswelltolerated. Other. . years). 432. interventions, e. g. statinsorantiplatelettherapy, shouldalsobecon-. . Itisrecommendedthatolderpatientsaretreatedaccordingtothe. sideredforhigher-riskpatients(seesection7. 2. 5). . . treatmentalgorithmoutlinedinsection7. Inveryoldpatients, itmay. . . beappropriatetoinitiatetreatmentwithmonotherapy. Inallolder. . . patients, whencombinationtherapyisused, itisrecommendedthat 8. 7. 1Isolatedsystolichypertensionintheyoung. . . thisisinitiatedatthelowestavailabledoses. Inallolderpatients, and Someyoung, healthypeople, andmeninparticular, maypresentwith. . . especiallyveryoldorfrailpatients, thepossibleoccurrenceofposisolated grade 1 systolic hypertension (i. e. brachial SBP _140-159. . . tural blood pressure should be closely monitored and symptoms of possible mmHgandanormalDBP90mmHg), andthismaybeassociated. . . hypotensive episodes checked by ABPM. Unless required for conwithanormalcentralaorticSBPduetoexcessiveperipheralsystolic. Hypertension amplification. 428 It is unclear whether isolated systolic. . . comitant diseases, loop diuretics and alpha-blockers should be. . avoidedbecauseoftheirassociationwithinjuriousfalls. 433, 434Renal hypertensioninthecontextofanormalaorticpressureisbenign. A. . . functionshouldbefrequentlyassessedtodetectpossibleincreasesin recent examination of prospective data from the Chicago Heart. . . serum Creatinine and reductions in estimated glomerular filtration rate as a result of blood pressure-related Association Detection Project found that young men with isolated. . . reductionsinrenalperfusion. Whentreated, BPshouldbelowered systolichypertensionhadaCVrisksimilartothatofindividualswith. . . to a systolic value of130139 mmHg and a diastolic value of80 HighnormalBPandthatisolatedsystolichypertensionintheyoung. . . mmHg if tolerated. Treated SBP values of 130 mmHg should be wascloselyassociatedwithsmoking. 429Onthebasisofcurrentevi-. . . avoided. Akeyemphasisintreatingolderpatients, andespeciallythe dence, theseyoungindividualsshouldreceiverecommendationson. . . veryold, istocarefullymonitorforanyadverseeffectsortolerability lifestyle modification (particularly cessation of smoking); whether. . . problems associated with blood pressure-lowering treatment, keeping in mind theyshouldreceive drugtreatmentisunclear, buttheydo require. . . thatadverseeffectscanbemorefrequentthanreportedinRCTs, in longer-term follow-up as many will develop sustained. . . which specific medical expertise and close patient supervision may hypertension. 430. . . minimizeadverseeffectsandtolerabilityproblems. . . . An important consideration is frail, dependent older patients, . 8. 8 Hypertension in older patients. . . including those with orthostatic hypotension. These have been (age (cid: 4)65 years). . . excludedfromRCTs. TheSPRINTtrialshowedthebenefitsofBP-. Theprevalenceofhypertensionincreaseswithage, withaprevalence. . loweringtreatmentbeingextendedtorecruitedpatientswhowere. of(cid: 3)60%overtheageof60yearsand(cid: 3)75%overtheageof75years. . atthefrailerendofthespectrum, includingthosewithreducedgait Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3079. speed. 215Thissuggeststhatthebenefitoftreatmentisnotlimitedto. . devicestendtounder-recordtheBPandareunreliableinseverepre-. fit and independent older patients; however, to what extent blood pressure-. . eclampsia. Onlyvalidateddevicesshouldbeusedinpregnancy. 439ABPM. lowering treatment benefits the very frail214 and institutionalized. . issuperiortoofficeBPmeasurementforthepredictionofpregnancy. patientsremainstobedetermined. . . outcome. 440 ABPM devices recommended for use in pregnancy are. . Insomepatients, thebestachievableBPmaybehigherthantherec-. more accurate than those used for office measurement or HBPM. . . ommendedtarget, butitshouldberecognisedthatanyamountofBP. ABPMhelpsavoidunnecessarytreatmentofwhite-coathypertension, . . loweringislikelytobeworthwhileandassociatedwithareducedrisk. and is useful in the management of High-risk pregnant women with. . ofmajorCVevents(especiallystrokeandheartfailure)andmortality. . hypertensionandthosewithdiabeticorhypertensivenephropathy. . . . . . 8. 9 Women, pregnancy, oral. . 8. 9. 1. 3Investigationofhypertensioninpregnancy. contraception, and hormone-. . Basic laboratory investigations recommended for monitoring preg-. replacement therapy. . nanthypertensivewomenincludeurineanalysis, bloodcount, haema-. . . tocrit, Liver enzymes, serum Creatinine, and serum uric acid 8. 9. 1Hypertensionandpregnancy. . . (increased in clinically evident pre-eclampsia). Hyperuricaemia in Hypertensive disorders in pregnancy affect 510% of pregnancies. . . hypertensive pregnancies identifies women at increased risk of worldwideandremainamajorcauseofmaternal, foetal, andneonatal. . . adversematernalandfoetaloutcomes. 441 morbidityandmortality. Maternalrisksincludeplacentalabruption, . . . All pregnant women should be assessed for proteinuria in early stroke, multipleorganfailure, anddisseminatedintravascularcoagula-. . . pregnancytodetectpre-existingrenaldiseaseand, inthesecondhalf tion.",
    ". . All pregnant women should be assessed for proteinuria in early stroke, multipleorganfailure, anddisseminatedintravascularcoagula-. . . pregnancytodetectpre-existingrenaldiseaseand, inthesecondhalf tion. The foetus is at High risk of intrauterine growth retardation. . . of pregnancy, to screen for pre-eclampsia. A dipstick test of _1þ (25% ofcasesofpre-eclampsia), prematurity(27% ofcasesofpre-. . . shouldpromptevaluationofACRinasinglespoturinesampleanda eclampsia), andintrauterinedeath(4%ofcasesofpre-eclampsia). 435. . . value30mg/mmolcanreliablyruleoutproteinuriainpregnancy. 442. . . In addition to basic laboratory tests, the following investigations 8. 9. 1. 1Definitionandclassificationofhypertensioninpregnancy. . . maybeconsidered: ThedefinitionofhypertensioninpregnancyisbasedonofficeBPval-. . . ues, SBP_140mmHgand/orDBP_90mmHg, 436, 437andisclassified. . Ultrasoundinvestigationofthekidneysandadrenals, andplasma. asmild(140159/90109mmHg)orsevere(_160/110mmHg), in. . or urinary fractionated metanephrine assays in pregnant women. contrasttotheconventionalhypertensiongrading. . . withahistorysuggestiveofphaeochromocytoma. . Hypertensioninpregnancyisnotasingleentitybutcomprises: . . Doppler ultrasound of uterine arteries (performed after 20. . weeks of gestation) to detect those at higher risk of gestational. Pre-existing hypertension: precedes pregnancy or develops. . hypertension, pre-eclampsia, and intrauterine growth. before20weeksofgestation, andusuallypersistsformorethan. . retardation. 443 6weekspost-partumandmaybeassociatedwithproteinuria. . . Asolublefms-liketyrosinekinase1: placentalgrowthfactorratio. . Gestationalhypertension: developsafter20weeksofgesta-. . of _ 38 can be used to exclude the development of pretionandusuallyresolveswithin6weekspost-partum. . . eclampsiainthenextweekwhensuspectedclinically. 444. . Pre-existing hypertension plus superimposed gesta-. . tionalhypertensionwithproteinuria. . . . 8. 9. 1. 4Preventionofhypertensionandpre-eclampsia. . Womenathighormoderate-riskofpre-eclampsiashouldbeadvised Pre-eclampsia: gestationalhypertensionwithsignificantprotei-. nuria (0. 3 g/24 h or _30 magnesium/mmol albumin-creatinine ratio). It occurs more fre-. . . totake100150mgofaspirindailyfromweeks1236. 445Highrisk. quently during the first pregnancy, in multiple pregnancy, in. . ofpre-eclampsiaincludesanyofthefollowing: . hydatidiform mole, in antiphospholipid syndrome, or with pre-. . . Hypertensivediseaseduringapreviouspregnancy existinghypertension, renaldisease, ordiabetes. Itisoftenassoci-. . chronic kidney disease. ated with foetal growth restriction due to placental insufficiency. . Autoimmune disease such as systemic lupus erythematosus or andisacommoncauseofprematurity. 438Theonlycureforpre-. . . antiphospholipidsyndrome eclampsia is delivery. As proteinuria may be a late manifestation. . . Type1ortype2diabetes ofpre-eclampsia, itshouldbesuspectedwhendenovohyperten-. . . Chronichypertension. sionisaccompanied byheadache, visualdisturbances, abdominal. . . Pain, or abnormal laboratory tests, specificallylow plateletsand/. Moderate-riskofpre-eclampsiaincludesoneormoreofthefol-. orabnormalliverfunction. . . lowingriskfactors: . . Antenatally unclassifiable hypertension: this term is used. . . Firstpregnancy when blood pressure is first recorded after 20 weeks of gestation and it is. . . Age_40years unclear if hypertension was pre-existing. Reassessment 6 weeks. post-partum will help distinguish pre-existing from gestational. . . Pregnancyintervalof10years. BMIof_35kg/m2atfirstvisit hypertension. . . . Familyhistoryofpre-eclampsia. . . Multiplepregnancy. 8. 9. 1. 2Bloodpressuremeasurementinpregnancy. . . BPinpregnancyshouldbemeasuredinthesittingposition(ortheleft. . . 8. 9. 1. 5Clinicalmanagementofhypertensioninpregnancy lateralrecumbentduringlabour)withanappropriatelysizedarmcuffat. . . heartlevelandusingKorotkoffVforDBP. Manualauscultationremains. . Mildhypertensionofpregnancy(BP140159/90109mmHg). The. thegoldstandardforBPmeasurementinpregnancy, becauseautomated. goal of drug treatment of hypertension in pregnancy is to reduce Downloaded from by guest on 31 December 2025 3080 ESC/ESHGuidelines. . maternalrisk; however, theagentsselectedmustbesafeforthefoetus. . lowplateletssyndrome), hospitalizationandBP-loweringtherapyis. . Thebenefitsofdrugtreatmentformotherandfoetusinhypertension. essential, anddeliveryneedstobeconsideredafterthematernalcon-. in pregnancy have not been extensively studied, with the best data. . dition has stabilized. 435 Intravenous magnesium sulfate is recom-. . from a single trial using alpha-methyldopa, performed 40 years. mendedforthepreventionofeclampsiaandtreatmentofseizures. . ago. 446448Afurtherstudysuggestedthattightervs. lesstightcontrol. . TheconsensusistolowerBPto160/105mmHgtopreventacute. . ofBPinpregnancyshowednodifferenceintheriskofadverseperinatal. hypertensivecomplicationsinthemother. Bothlabetalolandnicardi-. . outcomesandoverallseriousmaternalcomplications. However, sec-. pinehaveshowntobesafeandeffectiveforthetreatmentofsevere. ondaryanalysissuggested thattightercontrol ofBP mayreduce the. . pre-eclampsia if i. v. blood pressure-lowering therapy is necessary. 452 In both. riskofdevelopingmoreseverehypertensionandpre-eclampsia. 446. . cases, monitoringoffoetalheartrateisnecessary. Topreventfoetal. . Most women with pre-existing hypertension and normal renal. bradycardia, thecumulativedoseoflabetalolshouldnotexceed800. . function will not have severe hypertension and are a Low risk for. . magnesium/24h. Intravenoussodiumnitroprussideiscontraindicatedinpreg-. developing complications during pregnancy. Indeed, some of these. . nancybecauseofanincreasedriskoffoetalcyanidepoisoning. The. womenmaybeabletowithdrawtheirmedicationinthefirsthalfof. . drug of choice when pre-eclampsia is associated with pulmonary. pregnancybecauseofthephysiologicalfallinBP. Despitethepaucity. . oedemaisnitroglycerin(glyceryltrinitrate), givenasani. v. infusionof. ofevidence, EuropeanGuidelines17, 449, 450haverecommendedinitiat-. . 5lg/min, andgraduallyincreasedevery35mintoamaximumdose. ingdrugtreatment: . . of100lg/min. . . . Deliveryisindicated(i)urgentlyinpre-eclampsiawithvisualdistur- (1) InallwomenwithpersistentelevationofBP_150/95mmHg; . . . bances or haemostatic disorders, and (ii) at 37 weeks in asympto- (2) Inwomenwithgestationalhypertension(withorwithoutproteinu-. . . maticwomen. 453 ria), pre-existing hypertension with the superimposition of gesta-. . . tionalhypertension, orhypertensionwithsubclinicalHMOD, when. . . Bloodpressurepost-partum. Post-partumhypertensioniscommon BPis140/90mmHg. . . . inthefirstweek. Anydrugrecommendedcanbeusedaccordingto. . Women with pre-existing hypertension may continue their cur-.",
    ". . Bloodpressurepost-partum. Post-partumhypertensioniscommon BPis140/90mmHg. . . . inthefirstweek. Anydrugrecommendedcanbeusedaccordingto. . Women with pre-existing hypertension may continue their cur-. . thehypertensiontreatmentalgorithmshowninFigure4, withthecav-. rent antihypertensive medication, but ACE inhibitors, ARBs, and. . eats: (i)methyldopashouldbeavoidedbecauseoftheriskofpost-. directrenininhibitorsarecontraindicatedduetoadversefoetaland. . partum depression and (ii) consideration should be given to drug. neonataloutcomes. Methyldopa, labetalol, andCCBsarethedrugsof. . choiceinbreastfeedingwomen. . choice. Beta-blockersmayinducefoetalbradycardia; consequently, if. . . used, theirtypeanddoseshouldbecarefullyselected, withatenolol. . 8. 9. 1. 6Hypertensionandbreastfeeding. bestavoided. Diuretic therapy isgenerally avoidedbecauseplasma. . Allantihypertensivedrugstakenbythenursingmotherareexcreted. volumeisreducedinwomenwhodeveloppre-eclampsia. . . intobreastmilk. Mostarepresentatverylowconcentrationsexcept. There are no data to define the optimal blood pressure treatment target in. . forpropranololandnifedipine, withbreastmilkconcentrationssimi-. pregnantwomen. Nevertheless, forpragmaticreasons, iftreatmentis. . lartothoseinmaternalplasma. Referencetoprescribinginformation. initiateditisimportanttosuggestatreatmenttargettocalibratehow. . inbreastfeedingwomenisimportant. . . muchtreatmenttogive. ABPtargetof140/90issuggestedforpreg-. . nantwomenreceivingantihypertensivetherapy. . . 8. 9. 1. 7Riskofrecurrenceofhypertensivedisordersinasubsequent. . . pregnancy. Severe hypertension of pregnancy ((cid: 4)160/110 mmHg). There is. . Women experiencing hypertension in their first pregnancy are at. no agreed definition of severe hypertension, with values ranging. . increased risk in a subsequent pregnancy. The earlier the onset of. between160180mmHg/110mmHg. The2018ESC TaskForce. . hypertensioninthefirstpregnancy, thehighertheriskofrecurrence. on cardiovascular disease during pregnancy435 considers an SBP. . inasubsequentpregnancy. . . _170 mmHg or DBP _110 mmHg an emergency in a pregnant. . woman, whoshouldbeimmediatelyadmittedtohospitalfortreat-. . 8. 9. 1. 8Long-termcardiovascularconsequencesofgestational. . ment. The selection of the antihypertensive drug and its route of. . hypertension. administration depends on the expected time of delivery. . . Womenwhodevelopgestationalhypertensionorpre-eclampsiaare. Pharmacological treatment with i. v. labetalol, oral methyldopa, or. . atincreasedriskofhypertension, stroke, andischaemicheartdisease calcium channel blocker should be initiated. Intravenous hydralazine is no longer the. . . inlateradultlife. 454, 455Lifestylemodificationsareindicatedtoavoid. drugofchoiceasitisassociatedwithmoreperinataladverseeffects. . complicationsinsubsequentpregnanciesandtoreducematernalCV. than other drugs. 451 However, hydralazineis still used whenother. . riskinthefuture. Therefore, annualvisitstoaprimarycarephysician. treatmentregimensfailtoachieveadequateBPcontrol. Intravenous. . to check blood pressure and metabolic factors are recommended for these. urapidilcanalsobeconsidered. . . patients. . Inhypertensivecrises, i. e. inpatientswitheclampsiaorseverepre-. . FurtherdetailonthemanagementofhypertensionandotherCV eclampsia(withorwithouthaemolysis, elevatedliverenzymes, and. . . disordersinpregnancyisavailable. 435. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3081 Managementofhypertensioninpregnancy Recommendations Classa Levelb Inwomenwithgestationalhypertension, pre-existinghypertensionsuperimposedbygestationalhypertension, orwithhypertensionandsubclinicalorgandamageorsymptoms, initiationofdrugtreatmentisrecomI C mendedwhenSBPis_140mmHgorDBP_90mmHg. Inallothercases, initiationofdrugtreatmentisrecommendedwhenSBPis_150mmHgorDBPis_95 I C mmHg. Methyldopa, labetalol, andCCBsarerecommendedasthedrugsofchoiceforthetreatmentofhypertensionin B I pregnancy. 447, 448 (methyldopa) C I (labetalolorCCBs) ACEinhibitors, ARBs, ordirectrenininhibitorsarenotrecommendedduringpregnancy. III C SBP_170mmHgorDBP_110mmHginapregnantwomanisanemergency, andadmissiontohospitalis I C recommended. Inseverehypertension, drugtreatmentwithi. v. labetalol, oralmethyldopa, ornifedipineisrecommended. I C Therecommendedtreatmentforhypertensivecrisisisi. v. labetalolornicardipineandmagnesium. I C Inpre-eclampsiaassociatedwithpulmonaryoedema, nitroglyceringivenasani. v. infusionisrecommended. I C Inwomenwithgestationalhypertensionormildpre-eclampsia, deliveryisrecommendedat37weeks. 453 I B Itisrecommendedtoexpeditedeliveryinpre-eclampsiawithadverseconditions, suchasvisualdisturbances I C orhaemostaticdisorders. ACEangiotensin-convertingenzyme; angiotensin receptor blockerangiotensinreceptorblocker; calcium channel blockercalciumchannelblocker; DBPdiastolicbloodpressure; i. v. intravenous; SBPsystolic bloodpressure. aClassofrecommendation. bLevelofevidence. . . 8. 9. 2Oralcontraceptivepillsandhypertension. 8. 9. 3Hormone-replacementtherapyandhypertension. . Combined oestrogenprogesteroneoralcontraceptivepillscanbe. Cross-sectionalstudieshavelongestablishedthatmenopausedou-. . associatedwithasmallbutsignificantincreaseinBPandthedevelop-. blestheriskofdevelopinghypertension, evenafteradjustingforfac-. ment of hypertension in about 5% of users. 456, 457 blood pressure usually. . tors such as age and body mass index. 461 Although hormone-replacement. . decreasespromptlyfollowingcessationofthesepills; consequently, . therapycontainsoestrogens, thereisnoconvincingevidencethatsig-. . blood pressure should be monitored before and during oral contraceptive pill. nificantrisesinBPwilloccurinotherwisenormotensivemenopausal. . treatment. TheriseinBPappearstoberelatedtotheoestrogencon-. womenduetothistherapy, orthatBPwillincreasefurtherdueto. . tentandmaybelesslikelywiththeprogestogen-onlyoralcontracep-. hormone-replacement therapy in menopausal hypertensive. tivepill. Olderstudieshavedemonstratedarelationshipbetweenthe. . women. 462Hormone-replacementtherapyandselectiveoestrogen. . oral contraceptive pill and venous thrombosis and venous throm-. receptormodulatorsshouldnotbeusedforprimaryorsecondary. . boembolism, and, toalesserextent, myocardialinfarction(especially. . preventionofCVD. Insummary, currentevidencesuggeststhatthe. withconcomitantsmokinghistory)andstroke. 458Morerecentstud-. . use of hormone-replacement therapy is not associated with an. ies with newer-generation oral contraceptive pills have reported. . increase in blood pressure. Moreover, it is not contraindicated in women with. conflictingresults. Thus, theuseoforalcontraceptivesshouldcon-. . hypertension, and women with hypertension may be prescribed. sidertherisksandbenefitsfortheindividualpatient. ChangesinBP. . hormone-replacementtherapyaslongasBPlevelscanbecontrolled. should be carefully evaluated with follow-up readings. 459. . byantihypertensivemedication. . Concomitant CV risk factors (e. g. smoking history) should be. . . assessedandoralcontraceptivepilluseisnotrecommendedifBPis. . 8. 10 Hypertension in different ethnic. elevated. Insuchpatients, alternativeformsofcontraceptionshould. . groups. be offered. Discontinuation of combined oestrogenprogestin oral. . . In comparison with the non-black population, hypertension is more contraceptives in women with hypertensionmay improvetheir blood pressure. . .",
    ". In comparison with the non-black population, hypertension is more contraceptives in women with hypertensionmay improvetheir blood pressure. . . prevalentintheblackpopulationlivinginEurope, 463similarlytothat control. 460. . reportedfortheUSA. 464AsfortheEuropeanwhitepopulation, the Downloaded from by guest on 31 December 2025 3082 ESC/ESHGuidelines. black European population is heterogenous in nature, 463 although in. . 8. 11 Hypertension in Diabetes. almostallEuropeancountriesthelargestethnicgrouporiginatesfrom. . mellitus. the Sub-Saharan African region. 463 Hypertension epidemiology, diag-. . . High blood pressure is a common feature of type 1 and, particularly, type 2 nosis, andtreatmenthavebeenthoroughlystudiedinblack(i. e. Afro-. . . Diabetes. Moreover, maskedhypertensionandabluntednocturAmerican) ultrasound patients, 464 in contrast to the much scarcer database. . . nal fall in blood pressure are not infrequent in people with Diabetes. 472. availableforEuropeanblackpeople, andthusweextrapolatefromUS. . Recording 24 h ABPM in apparently normotensive people with. data. However, thisextrapolationrequiressomecautionasdifferences. . diabetesmaybeausefuldiagnosticprocedure, especiallyinthose. between the North American and the European black population. exist, especially with regard to socioeconomic status, CV risk, 465, 466. . . with HMOD. Substantial evidence supports the benefits of blood pressure and the response to antihypertensive drug treatment. 467 blood pressure-related. . . reductioninpeoplewithdiabetestoreducemajormacrovascular. . and microvascular complications of Diabetes, as well as reducing HMOD, aswellasCVandrenalcomplications, aremorecommonand. . . mortality. Proven benefits of blood pressure-lowering treatment in Diabetes severeinblackpatientscomparedwithage-matchedwhitepatientsat. anyBP level. 464Black hypertensive patientsexhibitasimilarpropor-. . . alsoincludea significantreductioninthe rate of end-stagerenal. . disease, 231, 235 retinopathy, 1 and albuminuria. 1 Diabetic neuropational reduction of CV and renal events in response to blood pressure-lowering. . . thy has never been included as an outcome in RCTs of blood pressuretreatmentaswhitepatients, withsomewhatdifferenttreatmentmodal-. . . loweringtreatment. ities. However, toachieveaneffectiveBPreductionandBPcontrol, . . . Whenconsideringtreatmentforhypertension, itisimportantto salt restriction is particularly important in black patients, in whom it. . . exclude significant postural hypotension, whichcan be marked in mayleadtogreaterBPfallsandmorefavourablyimpactontheeffec-. . . peoplewithdiabetesduetoautonomicneuropathy. 235Initiationof tivenessofBP-loweringdrugtreatment. 468Hypertensiveblackpatients. . . antihypertensivedrugtherapyisrecommendedwhentheofficeBP alsoshowareducedantihypertensiveresponsetoRAS-blockermono-. . . is 140/90 mmHg. Alongside lifestyle interventions, treatment therapy, whereastheyusuallyrespondmoreeffectivelytothiazideor. . . shouldusuallybeinitiatedwithatwo-drugcombinationofanACE thiazide-likediureticsandCCBs, 316, 469, 470whichinblackpatientsmay. . . inhibitororARBwithaCCBorthiazide/thiazide-likediuretic, and becombinedwitheachotherorwithaRASblocker, makingthelatter. . . treatment escalated according to the recommended treatment moreeffective. AngioedemaappearsmorecommonwithACEinhibi-. . . algorithm (see section 7). This approach ensures that the treattorsinblackpatients, whichmayfavourthepreferreduseofARBsin. . . mentstrategyincludes anACEinhibitororARB, which has been thispopulation. Despitesomeprogressinrecentyears, dataonhyper-. . . showntoreducealbuminuria andtheappearanceorprogression. tension prevalence, management, and control in European black. . of diabetic nephropathy more effectively than other drug. patients(andinotherimmigrantpopulationssuchasEuropeanindivid-. . classes. 235CombinationofanACEinhibitorwithanARBiscontraualsfromSouthAsia)arestillscarce, 463, 471whichmakesthisfieldan. . . indicatedbecauseitisaccompaniedbyanexcessofrenaladverse. importantareaforfutureresearch. ThereisnoevidencethattheBP. . . events. 298, 473, 474 response to treatment in other ethnic groups differs from that. . . Recent RCTs have shown that some antidiabetes agents (the reportedinthegeneralpopulationinEurope. . . . selectiveinhibitorsofsodiumglucosecotransporter2inthekidney). . . can reduce office and ambulatory blood pressure by several mmHg, 475, 476 and Hypertensioninethnicgroups. . . thatthisoccursevenwhenpeoplearetreatedwithantihypertensive. . . drugs. ThismayhelpimproveBPcontrol(seebelow), whichisespe-. Recommendations Classa Levelb. . cially difficult in Diabetes, 477 and may reduce the progression of. . . CKD478481(seealsosection8. 12). Itisrecommendedthatatwo-drugcombi-. . . There has been considerable debate about the target blood pressure nation, usuallyasanSPC, isusedasinitial I C. . . that should be achieved in people with Diabetes (see section 7). therapyformostblackpatients. c. . . We recommend that in people with Diabetes, the first objective. Inblackpatients, initialantihypertensive. . shouldbetolowerBPto140/80mmHg, aimingatanSBPof130. . treatmentshouldincludeadiureticora. mmHg. Provided that the treatment is well tolerated, treated I B. . calcium channel blocker, eitherincombinationorwithaRAS. SBP values of 130 mmHg should be considered because of the. blocker. d316, 469. . benefits on stroke prevention. Achieved SBP values of 120. . . mmHg should always be avoided. blood pressure targets for renoprotection Inotherethnicgroups, blood pressure-loweringtreat-. . . for patients with diabetic Kidney disease are discussed in. mentmaybebasedonthecoretreatment IIb C. . section8. 12. . algorithm(seeFigure4). . .",
    ". for patients with diabetic Kidney disease are discussed in. mentmaybebasedonthecoretreatment IIb C. . section8. 12. . algorithm(seeFigure4). . . ACEangiotensin-convertingenzyme; angiotensin receptor blockerangiotensinreceptorblocker; blood pressure bloodpressure; calcium channel blockercalciumchannelblocker; renal artery stenosisreninangiotensinsystem; SPCsingle-pillcombination. aClassofrecommendation. bLevelofevidence. cExceptinpatientswithlowgrade1hypertensionorfrailolderpatients, inwhom initialtreatmentwithasingledrugmaybemoreappropriate. dAngioedema is more common with ACE inhibitors and thus ARBs may be preferred. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3083. . . patientswithCKD, butonlyinthosewithalbuminuriaandwithout Treatmentstrategiesinpeoplewithdiabetes. . . anybeneficialeffectonCVevents. 203However, amorerecentand. . . larger meta-analysis has shown a significant reduction in all-cause. Recommendations Classa Levelb. . mortalityfollowingBPreductioninpatientswithCKD. 485. . . ReductionofalbuminuriahasalsobeenconsideredasatherapeuAntihypertensivedrugtreatmentisrecom-. . . tictarget. AnalysesofdatafromRCTshavereportedthatchangesin mendedforpeoplewithdiabeteswhen I A. . officeBPis_140/90mmHg. 1, 226, 235, 482. . . urinary albumin excretion are predictors of renal and CV. . events. 186, 486 However, there are also studies in which treatment. InpeoplewithdiabetesreceivingBP-lower-. . thatwaslesseffectiveatreducingalbuminuriawasmoreeffectiveat. ingdrugsitisrecommended: . . reducingCVevents175andviceversa. 176, 291Thus, whetherreducing. TotargetSBPto130mmHgand I A. . albuminuria per se is a proxy for cardiovascular disease prevention remains. 130mmHgiftolerated, butnot. . unresolved. . 120mmHg. 1, 231, 235. . Patients with chronic kidney disease should receive lifestyle advice, especially. Inolderpeople(aged_65yearsaged), to. . sodiumrestriction, anddrugtreatmentwhentheirofficeBPis140/. targettoanSBPrangeof130139 I A. . 90 mmHg. Achieving recommended blood pressure targets in chronic kidney disease usually. mmHg. 1, 205, 235. . requirescombinationtherapy, whichshouldbeinitiatedasacombi-. TotargettheDBPto80mmHg, but. . nationofaRASblockerwithaCCBordiureticinthesepatients. The not70mmHg. I C. . . combinationoftwoRASblockersisnotrecommended. 291Loopdiu-. . . retics should replace thiazide diuretics when the estimated glomerular filtration rate is Itisrecommendedtoinitiatetreatment. . . 30mL/min/1. 73m2. withacombinationofaRASblockerwitha. CCBorthiazide/thiazide-likediuretic. c I A. . . TheevidencewithrespecttoBPtargetsinpatientswithCKDis. . complex. In patients with non-diabetic chronic kidney disease, one meta-analysis 1, 175, 205. . . showedthattheslowestprogressiononCKDwasobtainedwitha. . SimultaneousadministrationoftwoRAS. treatedSBPintherangeof110-119mmHginpatientswithalbumi-. blockers, e. g. anACEinhibitorandARB, is III A. . nuria1g/day. 487Incontrast, inpatientswithaproteinuria1g/day, . notindicated. 291, 298, 299. . thelowestriskofdevelopingCKD(notCVrisk)wasobtainedwith. . . anSBPof140mmHg. 487Anothersystematicreviewfailedtodem-. . ACEangiotensin-convertingenzyme; angiotensin receptor blockerangiotensinreceptorblocker; blood pressure. . onstrate thataBPtargetof130/80mmHg improvedclinicalout-. bloodpressure; calcium channel blockercalciumchannelblocker; DBPdiastolicbloodpres-. . comes more than a target of 140/90 mmHg in non-diabetic s te u m re; ; S e B G P F R s yst e o st li i c m b a l t o e o d d g p lo r m es e su ru re la. rfiltrationrate; renal artery stenosisrenin-angiotensinsys-. . . . chronic kidney disease. 488Inalargeretrospectivecohortcontaining398419treated aClassofrecommendation. . . hypertensivepatients(30%withdiabetes), thenadirSBPandDBPfor bLevelofevidence. . . . thelowestriskofend-stagerenaldiseaseandmortalitywere137and s cW ide h r e u n si e n G g F a R lo o 3 p 0 d m international unit L re /m tic in w /1 h. 7 e 3 n m ad 2, international unit a r v e o t i i d c t is hi r a e z q id u e ir / e th d i. azide-likediureticsandcon-. . . . 71mmHg, respectively, withaclearincreaseinmortalityriskatSBP. . 120mmHg. 489. . . CurrentevidencesuggeststhatinpatientswithCKD, BPshouldbe. . . lowered to 140/90 mmHg and towards 130/80 mmHg. Lifestyle. . . advice, especially Sodium restriction, may be especially effective at 8. 12 Hypertension and chronic Kidney. . . aiding blood pressure lowering in patients with chronic kidney disease. Because blood pressure lowering. disease. . reducesrenalperfusionpressure, itisexpectedandnotunusualfor. Hypertensionisamajorriskfactorforthedevelopmentandprogres-. . eGFRtobereducedby10-20%inpatientstreatedforhypertension. . . sionofCKD, irrespectiveofthecauseofCKD. InpatientswithCKD, . Thus, carefulmonitoringofbloodelectrolytesandeGFRisessential, . . resistant hypertension, masked hypertension, and elevated night-. butcliniciansshouldnotbealarmedbytheanticipateddeclineinGFR. . timeBParecommon, andareassociatedwithalowereGFR, higher. whentreatmentisinitiated. Thisdeclineusuallyoccurswithinthefirst. levelsofalbuminuria, andHMOD. 483, 484. . few weeks of treatment and stabilizes thereafter. If the decline in. . The effects of lowering blood pressure in patients with chronic kidney disease have been the. GFRcontinuesorismoresevere, thetreatmentshouldbestopped, . . subject of many meta-analyses. A recent meta-analysis has shown. andthepatientinvestigatedtodeterminethepresenceofrenovascu-. . that blood pressure lowering significantly reduced end-stage renal disease in. lardisease. . . Downloaded from by guest on 31 December 2025 3084 ESC/ESHGuidelines.",
    "lardisease. . . Downloaded from by guest on 31 December 2025 3084 ESC/ESHGuidelines. . . effects. 492, 493 Beta-blockersmaynegativelyaffectthereducedbasal Therapeuticstrategiesfortreatmentofhypertensionin. . . lung function in patients with COPD, diminish the effectiveness of chronic kidney disease. . . emergency beta-agonist administration, reduce the benefit of long-. . . actingbeta-agonisttreatment, andmakethediscriminationofasthma. Recommendations Classa Levelb. . andCOPDmoredifficult. Thatsaid, whentolerated, theuseofcar-. . Inpatientswithdiabeticornon-diabetic. . diacbeta1-selectivebeta-blockersinpatientswithCOPDhasproven. chronic kidney disease, itisrecommendedthatanofficeBP. . to be safe in different settings, including hypertension. 494 It should of_140/90mmHgbetreatedwithlifestyle I A. . . alsobenotedthatdiureticsmaydecreasetheplasmalevelofpotas-. adviceandBP-loweringmedication. 9, 203, 485. . sium(inadditiontothehypokalaemiceffectsofglucocorticoidsand. . . beta2-adrenoceptor agonists), worsen carbon dioxide retention Inpatientswithdiabeticornon-diabetic. . . (including metabolic alkalosis-related hypoxia in hypoventilated chronic kidney disease: I A. . . patients), increasehaematocrit, and deteriorate mucussecretionin It is recommended to lower SBP to a. . . bronchi. Therefore, in general, diuretics are not recommended for rangeof130139mmHg. 9, 487, 489. . . widespreaduseinhypertensivepatientswithCOPD. 490, 495. Individualizedtreatmentshouldbecon-. . Inconclusion, managementofhypertensive patientswithCOPD. sideredaccordingtoitstolerabilityand IIa C. . shouldincludelifestylechanges, amongwhichcessationofsmokingis. impactonrenalfunctionandelectrolytes. . . essential. CCBs, ARBsorACEIs, ortheCCB/RASblockercombina-. . RASblockersaremoreeffectiveatreducing. . tion are recommended as the initial drugs of choice. If the blood pressure. albuminuriathanotherantihypertensive. . responseispoor, ordependingonothercomorbidities, thiazidesor. agents, andarerecommendedaspartofthe. . thiazide-like diuretics and beta1-selective beta-blockers can be I A. treatmentstrategyinhypertensivepatients. . considered. . inthepresenceofmicroalbuminuriaor. . proteinuria. 487, 489. . . 8. 14 Hypertension and Heart disease. . 8. 14. 1Coronaryarterydisease. AcombinationofaRASblockerwitha. . There are strong epidemiological relationships between coronary artery disease and. CCBoradiureticcisrecommendedasinitial I A. . . hypertension. The INTERHEART study showed that (cid: 3)50% of the therapy. 175. . . population-attributable risk of a myocardial infarction can be. AcombinationoftwoRASblockersisnot. . accounted for by lipids, with hypertension accounting for (cid: 3)25%. 10. recommended. 298 III A. . Anotherregistry-basedstudyofover1millionpatientsshowedthat. . . ischaemicheartdisease(anginaandmyocardialinfarction)accounted. . . formost(43%)oftheCVD-freeyearsoflifelostduetohypertension blood pressurebloodpressure; calcium channel blockercalciumchannelblocker; chronic kidney diseasechronickidneydis-. ease; estimated glomerular filtration rateestimatedglomerularfiltrationrate; renal artery stenosisrenin-angiotensinsys-. . fromtheageof30years. 7. tem; SBPsystolicbloodpressure. . . MorecompellingisthebeneficialeffectofBPtreatmentonreduca b C Blood la v s e s l o o f f r e e v c id o e m n m ce e. ndation. . . . . ingtheriskofmyocardialinfarction. Arecentmeta-analysisofRCTs cIncaseofeGFR30mL/min/1. 73m2, avoidthiazide/thiazide-likediureticsand. . ofantihypertensivetherapyshowedthatforevery10mmHgreduc-. considerusingaloopdiureticifrequired. . . tioninSBP, CADwasreducedby17%. 2Asimilarriskreductionhas. . . beenreportedbyotherswithmoreintensiveBPcontrol. 496Theben-. . . efitsofreducingcardiaceventsarealsoevidentinhigh-riskgroups, . . . suchasthosewithdiabetes. 231, 425. . . ThereremainssomeinconsistencyovertheoptimalBPtargetin. . . hypertensivepatientswithovertCAD, andespeciallywhetherthere 8. 13 Hypertension and chronic. . . isaJ-curverelationshipbetweenachievedBPandCVoutcomesin. obstructive pulmonary disease. . coronary artery disease. 497500Arecentanalysis501of22672patientswithstableCAD. . Hypertension is the most frequent comorbidity in patients with. who were treated for hypertension found that, after a median. . COPD, andcoincidenceofthetwodiseasesmayaffect2. 5%ofthe. follow-up of 5. 0 years, an SBP of _140 mmHg and a DBP of _80. adult population. 490 Patients with hypertension and COPD are at. . mmHg wereeach associated withincreased riskofCV events. An. particularlyhighCVrisk. 490, 491Bothconditionssharesimilarenviron-. . SBPof120mmHgwasalsoassociatedwithincreasedrisk, aswasa. mental risks and, in addition, hypoxia may exacerbate risk. 490, 491. . . DBPof70mmHg. Similarfindingswerealsoreportedfromanother. Treatment of COPD with anticholinergic agents and long-acting. . analysisofRCTdataevaluatingtherelationshipsbetweenachieved. beta-2 adrenoceptor agonists may adversely affect the CV system. . blood pressure and risks of CV outcomes. 222 Whether a J-curve phenomenon. (increase Heart rate and blood pressure). The presence of COPD also has an. . existsinpatientswithCADwhohavebeenrevascularizedremains. impactontheselectionofantihypertensivedrugs, whichshouldcon-. . uncertain. OtheranalysesdonotsupporttheexistenceofaJ-curve, . sider their effects on pulmonary function. Concern has been pre-. . eveninhypertensivepatientsatincreasedCVrisk. 239Forexample, in. dominantly directed to the use of beta-blockers, although there is. . patients with coronary artery disease and initially free from congestive Heart failure. evidence that in COPD these drugs maintain their CV-protective. enrolled in ONTARGET, a blood pressure reduction from baseline over the Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3085. . examinedBPrangehadlittleeffectontheriskofmyocardialinfarc-. . relaxation(so-calleddiastolicdysfunction)andisapotentpredictor. tion and predicted a lower risk of stroke.",
    "examinedBPrangehadlittleeffectontheriskofmyocardialinfarc-. . relaxation(so-calleddiastolicdysfunction)andisapotentpredictor. tion and predicted a lower risk of stroke. 502 Thus, a target blood pressure of. . ofheartfailure, evenwhenLVsystolicfunctionisnormalandthereis. approximately 130/80 mmHg in patients with coronary artery disease appears safe. . no preceding myocardial infarction (HFpEF). Hypertension-. andcanberecommended, butachievingaBP120/80mmHgisnot. . dependentfibrosisandstructuralalterationoflargeandsmallarteries. recommended. . . (microvasculardisease)alsocontribute. . InhypertensivepatientswithCAD, beta-blockersandRASblock-. . Treatinghypertensionhasamajorimpactonreducingtheriskof. ersmayimproveoutcomespost-myocardialinfarction. 503Inpatients. . incidentheartfailureandheartfailurehospitalization, especiallyinold. withsymptomaticangina, beta-blockersandcalciumantagonistsare. . andveryoldpatients. 51, 213, 316Thishasbeenobservedusingdiuretics, . thepreferredcomponentsofthedrugtreatmentstrategy. . . beta-blockers, ACEinhibitors, orARBs, withCCBsbeinglesseffec-. . . tiveincomparativetrials. 504. . . Reducing blood pressure can also lead to the regression of LVH, which has. Therapeuticstrategiesinhypertensivepatientswith. . . been shown to be accompanied by a reduction of CV events and coronary artery disease. . mortality. 125 The magnitude of LVH regression is associated with. . . baselineLVmass, durationoftherapy, theSBPreduction, 505, 506and. . Recommendations Classa Levelb. . thedrugsused, withARBs, ACEinhibitors, andCBBscausingmore. . effectiveLVHregressionthanbeta-blockers173ordiuretics. . InpatientswithCADreceivingBP-loweringdrugs, itis. . InpatientswithHFrEF, antihypertensivedrugtreatmentshould. recommended: . . start (if not already initiated) when blood pressure is 140/90 mmHg. It is. . . unclearhowlowBPshouldbeloweredinpatientswithheartfail- TotargetSBPto_130mmHgiftolerI A. . . ure. Outcomes for patients with Heart failure have repeatedly ated, butnot120mmHg. 2, 496. . . been shown to be poor if blood pressure values are Low, which suggests. Inolderpatients(aged_65years), totar-. . (althoughdatainterpretationismadedifficultbythepossibilityof. gettoanSBPrangeof130140 I A. . . reversedcausality)thatitmaybe wisetoavoidactivelylowering mmHg. 2, 496. . . BPto120/70mmHg. However, somepatientsmayachieveeven TotargetDBPto80mmHg, butnot I C. . . lowerBPlevelsthanthisbecauseofthedesirabilitytoremainon 70mmHg. . . . treatmentwithguideline-directedheartfailuremedications, which, . Inhypertensivepatientswithahistoryof. . if tolerated, should be continued because of their protective. myocardialinfarction, beta-blockersand I A. . . effect. 136 RASblockersarerecommendedaspartof. . Heartfailureguideline-directedmedicationsarerecommendedfor. treatment. 503. . thetreatmentofhypertensioninpatientswithHFrEF. 136ACEinhibi-. . . tors, ARBs, beta-blockers, andMRAs(e. g. spironolactoneandepleroInpatientswithsymptomaticangina, beta-. . . none)arealleffectiveinimprovingclinicaloutcomeinpatientswith b re lo c c o potassium m e m rs e a n n d d e / d o. r 50 C 3 CBsare I A. . . . establishedHFrEF, whereasfordiuretics, evidenceislimitedtosymp-. . tomaticimprovement. IffurtherBPloweringisrequired, adihydro-. . . pyridineCCBmaybeconsidered. Sacubutril/valsartanlowersBP, has blood pressurebloodpressure; coronary artery diseasecoronaryarterydisease; calcium channel blockercalciumchannel. . . alsobeenshowntoimproveoutcomesinpatientswithHFrEF, andis blocker; DBPdiastolicbloodpressure; renal artery stenosisreninangiotensinsystem; SBP. . systolicbloodpressure. . . indicatedforthetreatmentofHFrEFasanalternativetoACEinhibiaClassofrecommendation. . . torsorARBs. 507Non-dihydropiridineCCBs(diltiazemandverapabLevelofevidence. . . . mil), alpha-blockers, andcentrallyactingagents, suchasmoxonidine, . . . shouldnotbeused. . . . Antihypertensivetreatmentiscommonlyneededinpatientswith. . . HFpEF; the same blood pressure threshold and target for drug treatment indi-. . . catedforHFrEFshouldbeused. Theoptimaltreatmentstrategyfor. . 8. 14. 2Leftventricularhypertrophyandheartfailure. hypertensivepatientswithHFpEFisnotknown, butthestrategyout-. . Hypertensionistheleadingriskfactorforthedevelopmentofheart. . lined above for HFrEF patients might also be the one to adopt in failure, 7andmostpatientswithheartfailurewillhaveanantecedent. . . HFpEFpatients. HFpEFpatientscommonlyhavemultiplecomorbid-. historyofhypertension. ThismaybeaconsequenceofCAD, which. . ities that may adversely affect outcomes and complicate. results in HFrEF. Hypertension also causes LVH, which impairs LV. . management. Downloaded from by guest on 31 December 2025 3086 ESC/ESHGuidelines. . . AsubsequentRCT, inwhichSBPwasimmediatelyreduced(4. 5h) Therapeuticstrategiesinhypertensivepatientswith. . . fromameanof200mmHgtotwodifferenttargetintervals(140170 heartfailureorLVH. . . vs. 110139mmHg), showedthatmoreintensiveBPloweringhadno. . . benefitonthesameprimaryoutcomeandwasassociatedwithmore Recommendations Classa Levelb. . . renal adverse events. 512 Thus, we do not recommend treatment to. . Inhypertensivepatientswithheartfailure. . immediately lower blood pressure in patients with acute intracerebral haemor-. (withreducedorpreservedejectionfrac-. . rhage. One possible caveat to this recommendation is patients with IIa B. tion), blood pressure-loweringtreatmentshouldbecon-. . acuteintracerebralhaemorrhageandveryseverehypertension(SBP. sideredifBPis_140/90mmHg. c136. . _220mmHg), forwhomthere aremuchfewerdata. Ameta-analy-. . . sis513andsecondaryoutcomedatafromoneRCT511havesuggesteda InpatientswithHFrEF, itisrecommended. . . possible benefit on functional recovery at 3 months, and that acute thatBP-loweringtreatmentcomprisesan I A. . . loweringofSBPto180mmHginthesepatientsmightbebeneficial. ACEinhibitororARB, andabeta-blocker. . . Thus, careful lowering of blood pressure via i. v. infusion may be considered in anddiureticand/orMRAifrequired. 136. . . patientswithmarkedlyelevatedBP(SBP_220mmHg). . . D co ih n y tr d o r l o i p s y n r o id t in a e ch C ie C ve B d s. d maybeaddedifBP IIb C. . . . . 8. 15. 2Acuteischaemicstroke. .",
    ". . . 8. 15. 2Acuteischaemicstroke. . The beneficial effects of blood pressure reduction are even less clear in acute. InpatientswithHFpEF, BPtreatment. . ischaemic stroke. A key consideration is whether the patient will. thresholdandtargetvaluesshouldbethe IIa B. . receive thrombolysis, because observational studies have reported sameasforHFrEF. 136. . . an increased risk of intracerebral haemorrhage in patients with a. Becausenospecificdrughasprovenits. . . markedlyelevated BPwho received thrombolysis. 514, 515Inpatients superiority, allmajoragentscanbeused. I C. . . receivingi. v. thrombolysis, BPshouldbeloweredandmaintainedat. . 180/105mmHgfor atleastthe first24h afterthrombolysis. The. InallpatientswithLVH: . . benefitofacuteBPloweringinpatientswithacuteischaemicstroke. ItisrecommendedtotreatwithanRAS I A. . . whodonotreceivethrombolysisisuncertain. Ameta-analysissugblockerincombinationwithaCCBor. . gestedthatBPloweringearlyafteracuteischaemicstrokehadaneu-. diuretic. 504. . traleffectonthepreventionofdeathordependency. 516, 517Insuch. SBPshouldbeloweredtoarangeof. . patients with markedly elevated SBP or DBP (i. e. _220 or _120. 120130mmHg. 504, 506 IIa B. . mmHg, respectively), clinical judgement should define whether to. . . intervenewithdrugtherapy, inwhichcaseareasonablegoalmaybe. . ACEangiotensin-convertingenzyme; angiotensin receptor blockerangiotensinreceptorblocker; blood pressure. tolowerBPby15%, withclosemonitoring, duringthefirst24hafter. bloodpressure; calcium channel blockercalciumchannelblocker; HFrEFheartfailurewith. . strokeonset. 516, 518520PatientswithacuteischaemicstrokeandaBP. reducedejectionfraction; HFpEFheartfailurewithpreservedejectionfraction; . . lowerthanthisinthefirst72hafterstrokedonotseemtobenefit LVHleftventricularhypertrophy; MRAmineralocorticoidreceptorantago-. . nist; renal artery stenosisreninangiotensinsystem; SBPsystolicbloodpressure. . . from the introduction or reintroduction of blood pressure-lowering medicaa b C Blood la v s e s l o o f f r e e v c id o e m n m ce e. ndation. . . . . tion. 516, 521 For stable patients who remain hypertensive (_140/90 cAlowestsafetyBPvalueisnotgivenasmanypatientsreceivingintensivetreatment. . mmHg)3daysafteranacuteischaemicstroke, initiationorreintro-. forheartfailuremayachievemuchlowerBPlevelsthanrecommendedBPtargets. . . ductionofBP-loweringmedicationshouldbeconsidered. 522 dNon-dihydropyridinesarenotrecommendedinHFrEFbutmaybeusedinHFpEF. . . . . . . 8. 15. 3Previousstrokeortransientischaemicattack. . . RCTsofantihypertensivetreatment(placebocontrolled)inpatients. . . withapreviousstrokeorTIA, inastableclinicalcondition, andwith 8. 15 Cerebrovascular disease and. . . blood pressure140/90mmHg, haveshownthatBPloweringreducestheriskof cognition. . . recurrent stroke. 338, 523 No evidence is yet available that recurrent. Hypertensionisamajorriskfactorforhaemorrhagicandischaemic. . stroke is prevented by initiating therapy when blood pressure is in the. stroke, andariskfactorforrecurrentstroke. BPmanagementduring. . Highnormal range. We recommend resumption of blood pressure-lowering. the acute phase of haemorrhagic and ischaemic stroke remains an. . therapyseveraldaysafterstroke, orimmediatelyafterTIA, forprevi-. areaofuncertainty. BPisoftenelevatedatpresentationwithacute. . ouslytreatedoruntreatedpatientswithhypertension, forprevention. stroke, butoftendeclineswithoutintervention. 508. . ofbothrecurrentstrokeandotherCVevents. . . . TheappropriateBPtargetstopreventrecurrentstrokeareuncer-. . 8. 15. 1Acuteintracerebralhaemorrhage. . tain, butshouldbeconsideredinthecontextofaconsistentfindingin. Inacuteintracerebralhaemorrhage, anincreasedBPiscommonandis. . many meta-analyses that stroke is the one major CV event that is. associatedwithagreaterriskofhaematomaexpansion, increasedrisk. . reducedatlowerachievedBPlevels. Thisissupportedbytheresults. of death, and a worse prognosis for neurological recovery. 509, 510. . fromtherecentSecondaryPreventionofSmallSubcorticalStrokes3. Results from an RCT suggested that immediate blood pressure lowering (within. . study244, 524inpatientswitharecentlacunarstroke, whichsuggested. 6h)to140/90mmHgdidnotshowbenefitontheprimaryoutcome. . anSBPtargetof130mmHg, 525andotherstudies. 526. ofdisabilityordeathat3months, butmightreducehaematomaexpan-. . Prevention of stroke is a consistent benefit of antihypertensive. sion and improve functional recovery, and was generally safe. 511. therapyandhasbeenobservedinalllargeRCTsusingdifferentdrug Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3087. . regimens. However, individual RCTs comparing modern treatment. 8. 16 Hypertension, atrial fibrillation, and. regimens317, 527andmeta-analysessuggestthatbeta-blockersareless. . . other arrhythmias. effectiveatstrokepreventionthanotherclassesofantihypertensive. agents. 2, 528Althoughthebeta-blockerinthesestudieswasatenolol, . . . Hypertensionpredisposestocardiacarrhythmias, includingventricu-. . lararrhythmias, butmostcommonlyAF, 536538whichshouldbecontherearenodatawithmoremodernbeta-blockerswithregardsto. . . sidered a manifestation of hypertensive Heart disease. 539 Even stroke prevention in hypertension. Thus, optimal antihypertensive. . . HighnormalBPisassociatedwithincidentAF, 540, 541andhypertentreatment for stroke prevention should not include beta-blockers. . . sionisthemostprevalentconcomitantconditioninAFpatients. atrial fibrillation unlessthere is a compelling indication for their use, mindful ofthe. . . adds to theriskofstroke and Heart failure. AFnecessitates stroke factthatthemostcommonrecurrenteventafterstrokeisafurther. . . preventionwithoralanticoagulation, withmonitoringoftheassocistrokeratherthanmyocardialinfarction. 529. . . atedrisksandpreventionofbleeding. 542. . . MostpatientsshowahighventricularratewithAF542and, insuch. . 8. 15. 4Cognitivedysfunctionanddementia. patients, beta-blockers or non-dihydropyridine calcium antagonists. . Severalepidemiologicalandclinicalstudieshaveshownthathyper-. (e. g. diltiazemandverapamil)arerecommendedasantihypertensive. . tension in midlife predicts cognitive decline and dementia (both. agents. Non-dihydropyridine CCBs should be avoided in patients. Alzheimersdiseaseandvasculardementia)inolderpatients. 530533. . withreducedLVsystolicfunctionandmayprecipitateheartfailurein. . However, evidenceonthebeneficialeffectsofBPloweringoncogni-. some patients. Beta-blockers are often indicated in these patients, . tivedeclineisscantandconflicting. Ameta-analysis534of12studies. . andmayneedtobecombinedwithdigoxintogainratecontrol. 542. . investigating the impact of different antihypertensive drugs on. In RCTs of hypertensive patients with LVH and/or High CV. dementiaandcognitivefunctionconcludedthatBPloweringreduced. . . risk, 543, 544RASblockershavebeenshowntoreducefirstoccurrence. theincidenceandriskofcognitiveimpairmentanddementiaby9%. .",
    "In RCTs of hypertensive patients with LVH and/or High CV. dementiaandcognitivefunctionconcludedthatBPloweringreduced. . . risk, 543, 544RASblockershavebeenshowntoreducefirstoccurrence. theincidenceandriskofcognitiveimpairmentanddementiaby9%. . . ofAF, comparedwithbeta-blockersorCCBs, consistentwithsimilar. One study showed that achieving better blood pressure control over 4 years. . effects of renal artery stenosis blockers in patients with Heart failure. 545547 renal artery stenosis. reduced the progression of cerebral white matter lesions and the. . blockers do not prevent recurrence of paroxysmal or persistent. decreaseinglobalcognitiveperformance. 535. . atrial fibrillation. 548550 In patients with Heart failure, beta-blockers551 and. Trialsareurgentlyneededtobetterdefinethepotentialimpactof. . MRAs552mayalsopreventAF. ThepreventiveeffectofRASblockers. BPloweringonpreventingcognitivedeclineorindelayingdementia. . againstthe developmentofAFis indirectlysupported by ageneral. whencognitivedysfunctionisalreadypresent. . practice database in the UK, with approximately 5 million patient Therapeuticstrategiesinhypertensivepatientswithacutestrokeandcerebrovasculardisease Recommendations Classa Levelb Inpatientswithacuteintracerebralhaemorrhage: III A ImmediateBPloweringisnotrecommendedforpatientswithSBP220mmHg. 509513 InpatientswithSBP_220mmHg, carefulacuteBPloweringwithi. v. therapyto180mmHgshouldbeconsidered. 509513 IIa B Inacuteischaemicstroke, routineBPloweringwithantihypertensivetherapyisnotrecommended, 516, 517withtheexceptions: III A Inpatientswithacuteischaemicstrokewhoareeligiblefori. v. thrombolysis, BPshouldbecarefullyloweredandmaintained IIa B at180/105mmHgforatleastthefirst24hafterthrombolysis. 514, 515 InpatientswithmarkedlyelevatedBPwhodonotreceivefibrinolysis, drugtherapymaybeconsidered, basedonclinical IIb C judgement, toreduceBPby15%duringthefirst24hafterthestrokeonset. Inhypertensivepatientswithanacutecerebrovascularevent, antihypertensivetreatmentisrecommended: I A ImmediatelyforTIA. 526 Afterseveraldaysinischaemicstroke. 526 I A InallhypertensivepatientswithischaemicstrokeorTIA, anSBPtargetrangeof120130mmHgshouldbe IIa B considered. 244, 524, 526 TherecommendedantihypertensivedrugtreatmentstrategyforstrokepreventionisaRASblockerplusaCCBorathiazideI A likediuretic. 338 blood pressurebloodpressure; calcium channel blockercalciumchannelblocker; i. v. intravenous; renal artery stenosisreninangiotensinsystem; SBPsystolicbloodpressure; TIAtransientischaemicattack. aClassofrecommendation. bLevelofevidence. Downloaded from by guest on 31 December 2025 3088 ESC/ESHGuidelines. . records, which has reported that ACE inhibitors, ARBs, and beta-. 8. 17 Hypertension and vasculardisease. . blockers are associated with a lower risk of atrial fibrillation compared with. . 8. 17. 1Carotidatherosclerosis CCBs. 553Hence, RASblockersshouldbeconsideredaspartofthe. . . Asmallnumberofstudieshavereportedtheeffectsofthevarious. antihypertensive treatment strategy in hypertensive patients with a. . pharmacological classes of antihypertensive drugs on carotid IMT, . highriskofAF(e. g. LVH), topreventincidentAF. . . andveryfewoncarotidplaques. ReducingBPregressescarotidIMT. . . andmaydelaytheintimalatheroscleroticprocess. Thereappearto. . . be differential drug effects on IMT regression, with CCBs having 8. 16. 1Oralanticoagulantsandhypertension. . . greaterefficacythandiureticsandbeta-blockers, 146andACEinhibi-. Many patients requiring oral anticoagulants (e. g. with atrial fibrillation) will be. . . torsmorethandiuretics. 557However, therelevanceofthesefindings hypertensive. Hypertensionisnotacontraindicationtooralanticoa-. . . isunclearbecausemostpatientsreceivecombinationsoftreatment gulant use. However, although its role has been unappreciated in. most old and more recent RCTs on anticoagulant treatment, 537. . . andtheprogressionortreatment-inducedchangesincarotidIMTare. . poorlypredictiveoffutureCVevents. 184, 558Patientswithcarotidplahypertensiondoessubstantiallyincreasetheriskofintracerebralhae-. . . quesareathighriskofatheroembolicstrokeandCVevents, andBP morrhagewhenoralanticoagulantsareused, andeffortsshouldbe. . . loweringshouldbecomplementedbylifestyleadviceandtreatment directedtowardsachievingaBPgoalof130/80mmHginpatients. . . withstatinsandantiplatelettherapy. Acommonconundrumfacedby receivingoralanticoagulants. Detailed informationonhypertension. and oral anticoagulants has been published recently. 526, 536. . . clinicians is the hypertensive patient with a tight carotid stenosis, . . especiallywhenbilateral. Nostudyhasaddressedthisscenarioand Anticoagulantsshouldbeusedtoreducetheriskofstrokeinmost. . . thereforeadviceisnecessarilypragmatic, andwerecommendamore atrial fibrillation patients with hypertension, including those with atrial fibrillation in whom. . . cautiousapproachtoBPlowering, initiatingwithmonotherapyand hypertensionisthesingleadditionalstrokeriskfactor. 554, 555BPcon-. . . carefullymonitoringforadverseeffects. trolisimportanttominimizetherisksofAF-relatedstrokeandoral. . . anticoagulant-relatedbleeding. Untilmoredataareavailable, BPval-. . . uesinAFpatientstakingoralanticoagulantsshouldbeatleast140. . 8. 17. 2Arteriosclerosisandincreasedarterialstiffness. mmHgforSBPand90mmHgforDBP. Oralanticoagulantsshould. . LargearterystiffeningisamajorfactorcontributingtotheriseinSBP. beusedwithcautioninpatientswithpersistentuncontrolledhyper-. . andfall inDBPwithageing. Arterialstiffness isusuallymeasuredin. tension (SBP _180 mmHg and/or DBP _100 mmHg), and urgent. . studiesasPWV. Arterialstiffeningresultsfromarterioscleroticstruc-. effortstocontrolBPshouldbemade. . tural changes in large conduit arteries, leading to a loss of arterial TherapeuticstrategiesinhypertensivepatientswithAF Recommendation Classa Levelb InpatientswithAF, screeningforhypertensionisrecommended. 536 I C Abeta-blockerornon-dihydropyridineCCBshouldbeconsideredaspartofthetreatmentofhypertensionifratecontrolis IIa B needed. 536 StrokepreventionwithoralanticoagulationisrecommendedinpatientswithAFandhypertension, andaCHADS-VASc 2 2 I A scoreof_2inmenand_3inwomen. 536, 556 StrokepreventionwithoralanticoagulantsshouldbeconsideredinAFpatientswithhypertension, evenwhenhypertensionis IIa B thesingleadditionalriskfactor(CHADS-VAScscoreof1). 536, 556 2 2 OralanticoagulantsshouldbeusedwithcautioninpatientswithmarkedBPelevation(SBP_180mmHgand/orDBP _100mmHg); theaimshouldbetolowerSBPtoatleast140mmHg, andSBPloweringto130shouldbeconsidered. IIa B Ifthisisnotpossible, thenpatientsshouldmakeaninformeddecisionthattheyacceptthatthestrokeprotection providedbytheanticoagulantwillbeassociatedwithhigherbleedingrisk. 536 atrial fibrillationatrialfibrillation; blood pressurebloodpressure; calcium channel blockercalciumchannelblocker; CHA2DS2-VAScCongestiveheartfailure, Hypertension, Age_75years, Diabetesmellitus, Stroke, Vasculardisease, Age6574years, Sexcategory(female); DBPdiastolicbloodpressure; SBPsystolicbloodpressure aClassofrecommendation. bLevelofevidence. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3089. . elasticity, and the distending force resulting from the Hypertension. hypertension in patients with aortic coarctation should follow the. . exerted on the arterial wall. Thus, all antihypertensive drugs, by. treatmentalgorithmoutlinedinsection7, astherehavebeennofor-. reducingBP, reducearterialstiffness, asthereductioninBPunloads. . malRCTstodefineoptimaltreatmentstrategies. 567. . thestiffcomponentsofthearterialwall, leadingtoapassivedecrease. . inPWV. PharmacodynamicRCTs559andmeta-analyses560, 561suggest. . . 8. 18. 2Preventionofaorticdilationanddissectioninhigh-. thatACEinhibitorsandARBsmayreducePWVbeyondtheeffectof. . risksubjects. BPloweringonalong-termbasis. WhetherRASblockersaremore. . Chronichypertensioncanbeassociatedwithmodestaorticrootdila-. effective than other antihypertensive drugs in this regard has not. . tation. Whenmoreextensiveaorticrootdilatationispresentorthe. beendemonstrated. Moreover, whetheranylong-termreductionin. .",
    "WhetherRASblockersaremore. . Chronichypertensioncanbeassociatedwithmodestaorticrootdila-. effective than other antihypertensive drugs in this regard has not. . tation. Whenmoreextensiveaorticrootdilatationispresentorthe. beendemonstrated. Moreover, whetheranylong-termreductionin. . dilatation extends beyond the aortic root, an additional cause for. aorticstiffness562translatesintoareductioninCVeventsbeyondthe. . . aortopathy should be sought. All hypertensive patients with aortic impactofBPloweringalone563hasnotbeendemonstrated. . . . dilatation, whetherassociatedwithMarfansyndrome, bicuspidaortic. . . valve disease, or not, should have their blood pressure controlled _ 130/80. 8. 17. 3Lowerextremityarterialdisease. . mmHg. 568 In patients with Marfan syndrome, prophylactic use of. LEAD is often a manifestationofmore widespread atherosclerosis. . ACEinhibitors, ARBs, orbeta-blockersseemstobeabletoreduce. and especially atherosclerotic renal artery disease, 564 and these. . either the progression of the aortic dilation or the occurrence of. patientsareatveryhighCVrisk. 190BPcontrolisanimportantpartof. . complications. 568570However, thereisnoevidenceforthespecific. theCVrisk-reductionstrategyinthesepatients. Beta-blockershave. . efficacyofthesetreatmentsinaorticdiseaseofotheraetiologies. . . not been shown to worsen the symptoms of claudication in two. . . meta-analyses. 565, 566Thus, beta-blockersremainatreatmentoption. . 8. 18. 3Hypertensionbicuspidaorticvalve-related. inhypertensivepatientswithLEADwhenthereisaspecificindication. . aortopathy. fortheiruse. Whencriticallimbischaemiaispresent, BPreduction. . Bicuspidaorticvalvediseaseoccursin(cid: 3)1in100people, moreoften. shouldbe instituted slowly asit mayworsenischaemia. In patients. . men, and is associated with coexistent aortic coarctation, which. withLEAD, antihypertensivetreatmentshouldbecomplementedby. . should be excluded in patients with bicuspid aortic valve disease. . lifestyle changes and especially smoking cessation, as well as statin. . Bicuspidaorticvalvediseaseisassociatedwithanaortopathy, andthe. andantiplatelettherapy. 190. . riskofdevelopmentofaorticdilationishigherinpatientswithbicus-. . . pidaorticvalvediseasethaninthenormalpopulation571andisprob-. . Therapeuticstrategiesinhypertensivepatientswith. ably exacerbated by hypertension. Beyond aortic dilation and. LEAD. . aneurysmformation, bicuspidaorticvalvediseaseisalsoariskfactor. . . fordissectionandrupture. 572Thus, BPshouldbetightlycontrolledin. . Recommendations Classa Levelb. . patients with bicuspid aortic valve disease and targeted _ 130/80. . mmHgiftolerated. ThereispopularmisconceptionthatBP-lowering. blood pressure-loweringtreatmentisrecommendedto. reduceCVrisk. 2, 190, 503 I A. . . treatmenthasdeleteriouseffectsinpatientswithaorticstenosisand. . hypertension, wheninfactitiswelltoleratedeveninpatientswith. AcombinationofaRASblocker, calcium channel blocker, or. . severeaorticstenosis. Moreover, vasodilating drugs(includingRAS. diureticshouldbeconsideredasinitial IIa B. . blockers)alsoappeartobewelltolerated. Thus, treatmentofhyper-. therapy. 2. . tensionshouldbeconsideredinthesepatients. 573. . . Beta-blockersmayalsobeconsidered. 566 IIb C. . . 8. 19 Hypertension and sexual. . . dysfunction. blood pressure Blood Hypertension; calcium channel blocker calcium channel blocker; CV cardiovascular; . . LEADlowerextremityarterialdisease; renal artery stenosisreninangiotensinsystem. . . Sexual dysfunction may have an important negative effect on the aClassofrecommendation. . . qualityoflifeofbothmenandwomen. ComparedwiththenormobLevelofevidence. . . . tensivepopulation, theprevalenceofsexualdysfunctionisgreaterin. . . hypertensiveindividuals, inwhomitpresentsanimportantcauseof. . . Low adherence to or discontinuation of antihypertensive treat-. . . ment. 574Alargemeta-analysisofprospectivecohortstudieshaspro8. 18 Hypertension invalvulardisease and. . . vided strong evidence that in men, erectile dysfunction (i. e. . aortopathy. . inadequatepenileerection)isasignificantindependentriskfactorfor. . 8. 18. 1Coarctationoftheaorta. CVeventsandmortality, 575whichmeansthatitmaybeviewedasan. . Whenfeasible, treatmentofaorticcoarctationispredominantlysur-. . earlymarkerofvasculardamage. 576Sexualdysfunctionmaybetrig-. gical and usually done in childhood. Even after surgical correction, . . geredoraggravatedbytreatmentwiththiazideorthiazide-likediu-. thesepatientsmaydevelopsystolichypertensionatayoungageand. . retics, conventional beta-blockers, or centrally acting agents (e. g. . require long-term follow-up. Few patients with aortic coarctation. . clonidine), whileACEinhibitors, ARBs, CCBs, orvasodilating beta-. remain undetected until adult life, and by then often have severe. . blockers may have neutral or even beneficial effects. 574, 577. hypertension, HMOD(especially LVH and LVdysfunction), and an. . Phosphodiesterase-5inhibitorsareeffectiveagainsterectiledysfunc-. extensivecollateralcirculationbelowthecoarctation. Suchpatients. . tioninpatientswithhypertension. Theyshouldbegivenonlyinthe. shouldbe evaluated in a specialist centre. Themedical therapy for. absenceofnitrateadministration, butprescriptionalsoappearstobe Downloaded from by guest on 31 December 2025 3090 ESC/ESHGuidelines. . safeinpatientswithmultidrugBP-loweringtreatment, 578withsome. . leadingtopotentialtoxicity. 583Althoughanticancertherapytakes. caution if treatment includes alpha-blockers. 577 However, it seems. . anobviouspriority, itstemporarydiscontinuationmaybeconsid-. prudent for unstable patients with High CV risk or severe uncon-. . eredwhenBPvaluesareexceedinglyhighdespitemultidrugtreat-. trolled hypertensionto defer sexualactivity until their condition is. . ment, in the presence of severe hypertension-generated. stabilizedandtreatmentforerectiledysfunctioncanbeinitiated. 575. . symptoms, or when there is a CV event requiring an immediate. Overall, studiesontheeffectsofhypertensionandantihypertensive. . effectiveBPcontrol. 584. therapyonfemalesexualdysfunctionarelimited, andthesituationis. . . thuslessclearthaninmen, 577, 579althoughinarecentcross-sectional. . . analysisamongmiddle-agedandoldertreatedhypertensivewomen. . 8. 21 Perioperative management of. . intheSPRINTtrial, neitherBPvaluesnorantihypertensivemedica-. hypertension. tionwasassociatedwithsexualdysfunction. 579. . . Withtheincreasingnumberofpatientsundergoingsurgery, manage-. Itisrecommendedthatinformationonsexualdysfunctioniscol-. . ment of hypertension in the perioperative period (a term that. lected in all hypertensive patients at diagnosis and regularly at the. . includestheintraoperativephase)hasemergedasanimportantissue. follow-upvisits, withspecialattentiontoitspossiblerelationshipwith. . inclinicalpractice.",
    "lected in all hypertensive patients at diagnosis and regularly at the. . includestheintraoperativephase)hasemergedasanimportantissue. follow-upvisits, withspecialattentiontoitspossiblerelationshipwith. . inclinicalpractice. 585ESCGuidelineshavebeenissuedfortheassess-. reluctancetostartoradherencetodrugtreatment. Inmenreporting. . ment of CV variables, risk, and disease management of patients. sexual dysfunction, the antihypertensive agents more likely to be. . undergoingnon-cardiacsurgery. 586WhileaBPelevationispersenot. associatedwiththiseffect(e. g. beta-blockersandthiazidediuretics). . a strong risk factor for CV complications in non-cardiac surgery, . should be avoided or replaced, unless strictly necessary for the. . overallCVriskassessment, includingthesearchforHMOD, isimpor-. patientsclinicalcondition. . . tantintreatedanduntreatedhypertensivepatients, andmandatory. . . whenaBPelevationisnewlydetected. 537, 586Postponingnecessary. 8. 20 Hypertension and cancer therapy. . . surgeryisusuallynotwarrantedinpatientswithgrade1or2hyper-. HypertensionisthemostcommonCVcomorbidityreportedincan-. . tension, whereas in those with an SBP _180 mmHg and/or DBP. cerregistries, inwhichanelevatedBPisusuallyfoundinmorethan. . _110mmHg, deferringtheinterventionuntilBPisreducedorcon-. one-thirdofthepatients. 580Thiscanbeduetothehighprevalenceof. . trolledisadvisable, exceptforemergencysituations. Whatseemsto. hypertensionatanageinwhichcancerisalsocommon. However, it. . be also important is to avoid large perioperative blood pressure fluctua-. isalsoduetothepressoreffectoftwogroupsofwidelyusedanti-. . tions. 537, 586Thisapproachissupportedbythefindingsfromarecent. cancerdrugs, theinhibitorsofthevascularendothelialgrowthfactor. . RCTthathasshownthatinpatientsundergoingabdominalsurgery, . signallingpathway(bevacizumab, sorafenib, sunitinib, andpazopanib). . an individualized intraoperative treatment strategy, which kept blood pressure. andtheproteasomeinhibitors(carfilzomib). Whiletheformergroup. . values within a 10% difference from the preoperative office SBP, . ofdrugsinhibitstheproductionofnitricoxideinthearterialwall, the. . resultedinreducedriskofpostoperativeorgandysfunction. 587There. latter reduces the vasodilator response to acetylcholine, favouring. . isnoclearevidenceinfavouroragainstonevs. anotherantihyperten-. vasoconstrictionandvasospasm. 581. . sivetreatmentmodeinpatientsundergoingnon-cardiacsurgery, and. . In patients under treatment with the above-mentioned anti-. thusthegeneraldrugtreatmentalgorithmsapplytothesepatientsas. cancer drugs, a blood pressure increase has been reported in a variable but. . well. 588, 589 However, the perioperative use of betablockers has. . overallhighpercentofpatients(_30%). Theincreasefrequently. beentheobjectofcontroversyformanyyears, andtheconcernhas. . occursduringthefirstmonthsafterstartingtheanticancertherapy, . recentlybeenrevivedbymeta-analysesshowingsomeincreaseinthe. . the temporal association providing evidence for the anticancer. riskofhypotension, stroke, andmortalityinpatientsonperioperative. drugs pathophysiological role. It follows that office blood pressure should be. . beta-blockersvs. placebo. 586, 588, 589Continuationofbeta-blockersis. . measuredweeklyduringtheinitialpartofthefirstcycleoftherapy. nevertheless recommended in hypertensive patients on chronic. andatleastevery23weeksthereafter. 582Afterthefirstcycleis. . beta-blockertreatment586inwhomtheirabruptdiscontinuationmay. completedandBPvaluesappeartobestable, BPcanbemeasured. . leadtoBPorheartraterebounds. 537Thismayalsooccurwiththe. . atthetimeoftheroutineclinicalevaluationsorassessedbyHBPM. . abrupt discontinuation of central agents such as clonidine. More. . Patientsdevelopinghypertension(_140/90mmHg), orshowingan. . recently, thequestionhasbeenraisedwhetherRASblockersshould. increaseinDBP_20mmHgcomparedwith pretreatmentvalues, . . bediscontinuedbeforesurgerytoreducetheriskofintraoperative. shouldinitiateoroptimizeantihypertensivetherapy, forwhichRAS. . hypotension. 586, 590 Preoperative discontinuationofthesedrugshas. blockersandCCBsmaybeconsideredthepreferreddrugs, anda. . also been supported by a recent international prospective cohort. renal artery stenosis blocker-calcium channel blocker combination is a frequently needed strategy. . . study, inaheterogenousgroupofpatients, inwhichwithholdingACE. CCBsshouldonlybeofthedihydropiridinetype, becausediltiazem. . inhibitorsorARBs24hbeforenon-cardiacsurgerywasassociated. andverapamilblocktheCYP3A4isoenzyme, whichisinvolvedin. . withasignificantreductioninCVeventsandmortality30daysafter. themetabolicpathwayofsorafenib, increasingthedrugslevelsand. theintervention. 591 Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3091 Perioperativemanagementofhypertension Recommendations Classa Levelb Itisrecommendedthatnewlydiagnosedhypertensivepatientswhoarescheduledforelectivesurgeryshouldbepreoperatively I C screenedforHMODandCVrisk. ItisrecommendedtoavoidlargeperioperativeBPfluctuationsduringtheperioperativeperiod. 587 I C Non-cardiacsurgerymaynotbedeferredinpatientswithgrade1or2hypertension(SBP180mmHg; DBP110mmHg). IIb C Perioperativecontinuationofbeta-blockersisrecommendedinhypertensivepatientsonchronictreatmentwiththese I B drugs. 592, 593 Abruptdiscontinuationofbeta-blockersorcentrallyactingagents(e. g. clonidine)ispotentiallyharmfulandisnot III B recommended. 589, 594 TransientpreoperativediscontinuationofRASblockersshouldbeconsideredinpatientswithhypertensionundergoingnonIIa C cardiacsurgery. blood pressurebloodpressure; CVcardiovascular; DBPdiastolicbloodpressure; HMODhypertension-mediatedorgandamage; renal artery stenosisreninangiotensinsystem; SBPsystolic bloodpressure. aClassofrecommendation. bLevelofevidence. 9 Managing concomitant. . . 9. 2 Antiplatelet therapy and. . cardiovascular disease risk. . anticoagulant therapy. . . The most common complications of hypertension are related to. 9. 1 Statins and lipid-lowering drugs. . . thrombosis. 603 Hypertension predisposes to a prothrombotic. Patientswithhypertension, andmoresothosewithtype2diabetes. . state, 603 and alsopredisposes to LEAD, heartfailure, orAF, which. ormetabolicsyndrome, oftenhaveatherogenicdyslipidaemiacharac-. . arecommonconditionsassociatedwiththromboembolism, whether. terizedbyelevatedtriglyceridesandLDLcholesterol(LDL-C), and. . systemicorvenous. . lowHDLcholesterol(HDL-C). 595Thebenefitofaddingastatinto. . Antiplatelet and anticoagulant therapy use in patients with. antihypertensivetreatmentwaswellestablishedintheASCOT-Lipid. . hypertensionwasaddressed in aCochrane systematicreview, 604. Lowering Arm study596 and further studies, as summarized in pre-. . whichincludedfourrandomizedtrialswithacombinedtotalof44. viousEuropeanGuidelines. 16, 35Thebeneficialeffectofstatinadminis-. . 012 patients. The authors concluded that overall acetylsalicylic. trationtopatientswithoutpreviousCVeventstargetinganLDL-C. . acid (aspirin) did not reduce stroke or CV events compared. value of 3. 0 millimoles per liter (115 milligrams per deciliter) has been strengthened by the. . withplaceboinprimarypreventionpatientswithelevatedBPand. findingsfromtheJustificationfortheUseofStatinsinPrevention: an. . nopreviousCVD. 604Forsecondaryprevention, antiplateletther-. InterventionTrialEvaluatingRosuvastatin(JUPITER)597andHOPE-3. . apyinpatientswithelevatedBPwasreportedascausinganabso-. studies, 343, 598showingthatloweringLDL-Cinpatientswithbaseline. . lute reduction in vascular events of 4. 1% compared with. values3. 4mmol/L(130mg/dL)reducedtheincidenceofCVevents. . placebo. 604. bybetween44and24%. Thisjustifiestheuseofstatinsinhyperten-. . Benefit has not been demonstrated for anticoagulation therapy, . sivepatientswhohavemoderatehighCVrisk. 599. . aloneorincombinationwithaspirin, inpatientswithhypertensionin. AsdetailedintherecentESC/EASGuidelines, 599whenovertCVD. . theabsenceofotherindicationsrequiringanticoagulants, suchasAF. ispresentandtheCVriskisveryhigh, statinsshouldbeadministered. . or venous thromboembolism.",
    "sivepatientswhohavemoderatehighCVrisk. 599. . aloneorincombinationwithaspirin, inpatientswithhypertensionin. AsdetailedintherecentESC/EASGuidelines, 599whenovertCVD. . theabsenceofotherindicationsrequiringanticoagulants, suchasAF. ispresentandtheCVriskisveryhigh, statinsshouldbeadministered. . or venous thromboembolism. 604 In anticoagulated patients, uncon-. . toachieveLDL-Clevelsof1. 8mmol/L(70mg/dL)orareductionof. trolledhypertensionisoneoftheindependentriskfactorsforintra-. _50%ifthebaselineLDL-Cisbetween1. 8and3. 5mmol/L(70and. . cranial haemorrhage and major bleeding. 605 In such patients, . 135mg/dL). 600602InpatientsathighCVrisk, anLDL-Cgoalof2. 6. . attentiontomodifiablebleedingriskfactorsshouldbemadeduring. . millimoles per liter(100mg/dL)orareductionof_50%ifthebaselineLDL-Cis. allpatientcontacts. Bleedingriskassessmentwithclinicalriskscores. . between 2. 6 and 5. 2 millimoles per liter (100 and 200 milligrams per deciliter) is recom-. suchastheHAS-BLEDHypertension, Abnormalrenal/liverfunction. mended. 602Beneficialeffectsofstatintherapyhavealsobeenshown. . . (1pointeach), Stroke, Bleedinghistoryorpredisposition, LabileINR, . inpatientswithapreviousstrokewithLDL-Ctargets2. 6mmol/L. . Older (65), Drugs/alcohol concomitantly (1 point each) score, . (100 milligrams per deciliter). 525 Whether they also benefit from a target of 1. 8. . includesuncontrolledhypertension(definedasSBP160mmHg)as. millimoles per liter(70mg/dL)isopentofutureresearch. Thesummaryofthe. . oneoftheriskfactorsforbleeding; 606theseshouldbeusedtoflag. available evidence suggests that many patients with hypertension. . up patients at particularly High risk (e. g. HAS-BLED _3) for more. wouldbenefitfromstatintherapy. . regularreviewandfollow-up. 607 Downloaded from by guest on 31 December 2025 3092 ESC/ESHGuidelines. . Insummary, aspirinisnotrecommendedforprimarypreventionin. . received attention after the publication of the ultrasound Food and Drug. hypertensivepatientswithoutCVD. 35Forsecondaryprevention, the. . Administration recommendations for evaluating CV risk in new. benefitofantiplatelettherapyinpatientswithhypertensionmaybe. . therapiestotreattype2diabetes. Newgenerationsofantidiabetes. greaterthantheharm. 35, 604Ticlopidine, clopidogrel, andneweranti-. . drugs, i. e. dipeptidylpeptidase4inhibitorsandglucagon-likepeptide. plateletagentssuchasprasugrelandticagrelorhavenotbeensuffi-. . 1agonists, slightlyreduceBP, andalsobodyweightwithglucagon-like. cientlyevaluatedinpatientswithhighBP. . . peptide1agonists. Twoglucagon-likepeptide1agonists(liraglutide. . . andsemaglutide)reducedCVandtotalmortality, butnotheartfail-. . . ure, inpatientswithtype 2diabetes. 608, 609More data are required TreatmentofCVriskfactorsassociatedwith. . . withrespecttothecapacityofglucagon-likepeptide1agonistsand hypertension. . . dipeptidylpeptidase4inhibitorstopreventheartfailure. . . . Inhibitors of Sodium-glucose co-transporter-2 are the only Recommendations Classa Levelb. . . glucose-lowering drug class to reduce blood pressure beyond the projected. CVriskassessmentwiththeSCOREsystem. . . impact of weight reduction on blood pressure. Empaglifozine475 and canaglifloisrecommendedforhypertensivepatients. . . zin476havedemonstratedareductioninheartfailureandtotaland. whoarenotalreadyathighorveryhighrisk I B. . CVmortality, andaprotectiveeffectonrenalfunction. Severalmech-. duetoestablishedCVD, renaldisease, or. . anismsmayaccountfortheseeffects, andincreasedsodiumexcre-. Diabetes. 33. . tion and improvements in tubuloglomerular balance reducing. . hyperfiltrationaresuggestedmechanismsfortheobservedCVand. ForpatientsatveryhighCVrisk, statinsare. . renalprotection, respectively. . recommendedtoachieveLDL-Clevelsof. . . 1. 8mmol/L(70mg/dL), orareductionof I B. . . _50%ifthebaselineLDL-Cis1. 83. 5. . millimoles per liter(70135mg/dL). 596, 599, 602. . . 10 Patient follow-up. . . ForpatientsathighCVrisk, statinsarerec-. . 10. 1 Follow-up of hypertensive patients. ommendedtoachieveanLDL-Cgoalof. . . Aftertheinitiationofantihypertensivedrugtherapy, itisimportantto 2. 6mmol/L(100mg/dL), orareductionof I B. . . reviewthepatientatleastoncewithinthefirst2monthstoevaluate _50%ifthebaselineLDL-Cis2. 65. 2. . . the effects on blood pressure and assess possible side effects until blood pressure is under millimoles per liter(100200mg/dL). 599, 602. . . control. The frequency of review will depend on the severity of. . ForpatientsatlowmoderateCVrisk, sta-. hypertension, the urgency to achieve blood pressure control, and the patients. . tinsshouldbeconsideredtoachievean. comorbidities. SPCtherapyshouldreduceBPwithin1-2weeksand IIa C. . LDL-Cvalueof3. 0mmol/L(115mg/. maycontinuetoreduceBPoverthenext2months. OncetheBPtar-. . dL). 598. getisreached, avisitintervalofafewmonthsisreasonableandevi-. . . dence has been obtained that no difference exists in blood pressure control. Antiplatelettherapy, inparticularlow-dose. . between3and6monthintervals. 610Dependingonthelocalorganiaspirin, isrecommendedforsecondarypreI A. . . zationofhealthresources, manyofthelatervisitsmaybeperformed ventioninhypertensivepatients. 35, 604. . . by non-physician health workers such as nurses. 611 For stable. . Aspirinisnotrecommendedforprimary. . patients, HBPM and electronic communication with the physician. preventioninhypertensivepatientswithout III A. . mayalsoprovideanacceptablealternativetoreducethefrequency. cardiovascular disease. 35, 604. . ofvisits. 60, 612, 613Itisneverthelessadvisabletoassessriskfactorsand. . . asymptomaticorgandamageatleastevery2years. . . CVcardiovascular; cardiovascular diseasecardiovasculardisease; LDL-CLDLcholesterol; . . SCORESystematicCOronaryRiskEvaluation. . . aClassofrecommendation. . . 10. 2 Follow-up of subjects with. bLevelofevidence. . . Highnormal Blood Hypertension and white-. . . . coat hypertension. . . . PatientswithhighnormalBPorwhite-coathypertensionfrequently. . . haveadditionalriskfactors, includingHMOD, andhaveahigherrisk 9. 3. Glucose-lowering drugs and Blood. . . ofdevelopingsustainedhypertension427, 614618(seesection4). Thus, Hypertension. . . evenwhenuntreated, theyshouldbescheduledforregularfollow-up. Theimpactofnewglucose-loweringdrugsonBPandthereduction. . (atleastannualvisits)tomeasureofficeandout-of-officeBP, aswell. in CV and renal risk, beyond their effect of glucose control, have. astochecktheCVriskprofile. Atannualvisits, recommendationson Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3093. . lifestylechanges, whichrepresenttheappropriatetreatmentinmany. . on the most important issue: dosing history. Today, the most. ofthesepatients, shouldbereinforced. . . accuratemethodsthatcanberecommended, despitetheirlimita-. . . tions, arethedetectionofprescribeddrugsinbloodorurinesam-. 10. 3 Elevated Blood Hypertension at control. .",
    "ofthesepatients, shouldbereinforced. . . accuratemethodsthatcanberecommended, despitetheirlimita-. . . tions, arethedetectionofprescribeddrugsinbloodorurinesam-. 10. 3 Elevated Blood Hypertension at control. . ples. Directly observed treatment, followed by blood pressure measurement. visits. . oversubsequenthoursviaHBPMorABPM, canalsobeveryuseful. . . to determine if blood pressure really is poorly controlled despite witnessed ThefindingofanelevatedBPshouldalwaysleadphysicianstosearch. . . consumption of medication in patients with apparent resistant for the cause(s), particularly the most common ones such as poor. . . hypertension. Incontrast, questionnairesfrequentlyoverestimate adherence to the prescribed treatment regimen, persistence of a. . . drug adherence. The assessment of adherence should be white-coateffect, andoccasionalormoreregularconsumptionofsalt, . . . improved with the development of cheaper and more reliable drugs, or substances that raise blood pressure or oppose the antihypertensive. . . methods of detection that are easily applicable in daily effect of treatment (e. g. alcohol or non-steroidal anti-inflammatory. . . practice. 354, 626 drugs). Thismayrequiretactfulbutstringentquestioningofthepatient. . . Barrierstooptimal adherence maybe linked with physicianatti- (andhis/herrelatives)toidentifyinterferingfactors, aswellasrepeated. . . tudes, patientbeliefsandbehaviour, thecomplexityandtolerability measurements of blood pressure in the following weeks to ensure that blood pressure has. . . ofdrugtherapies, thehealthcaresystem, andseveralotherfactors. returned to controlled values. If ineffective treatment is regarded as. . . Therefore, theassessmentofadherenceshouldalwaysbeconducted thereasonforinadequateBPcontrol, thetreatmentregimenshould. . . in a no-blame approach, and should favour an open discussion to beuptitratedinatimelyfashion(seesection7); thisavoidsclinicaliner-. . . identifythespecificbarrierslimitingthepatientsabilitytofollowthe tia, amajorcontributortopoorBPcontrolworldwide. 311. . . therapeutic recommendations. Individualized solutions should be. . . found. Patientsshouldbeencouragedtotakeresponsibilityfortheir. 10. 4 Improvement in Blood Hypertension. . ownCVhealth. . control in hypertension: drug adherence. . . Patientadherencetotherapycanbeimprovedbyseveralinterven-. There is growing evidence that poor adherence to treatmentin. . tions. The most useful interventions are those linking drug intake. additiontophysicianinertia(i. e. lackoftherapeuticactionwhenthe. . with habits, 347 those giving adherence feedback to patients, self-. patientsBPisuncontrolled)isthemostimportantcauseofpoor. . monitoringofBP64usingpillboxesandotherspecialpackaging, and. blood pressure control. 293, 619621 Non-adherence to antihypertensive therapy. . motivational interviewing. Increasing the integration among health-. correlateswithhigherriskofCVevents. 312, 622. . care providers with the involvement of pharmacists and nurses. Earlydiscontinuationoftreatmentandsuboptimaldailyuseofthe. . increasesdrugadherence. Usingmultiplecomponentshasagreater. prescribedregimensarethemostcommonfacetsofpooradherence. . . effectonadherence, astheeffectsizeofeachinterventionisgenerally. After6months, morethanone-third, andafter1year, aboutone-half. . modest. Recentdatasuggestthatadherencetotreatmentmayalso. ofpatientsmaystoptheirinitialtreatment. 623Studiesbasedonthe. . beimprovedwiththeuseoftelemetryfortransmissionofrecorded. detection of antihypertensive medications in Blood or Urine have. . home values, maintaining contact between patients and physicians, . shownthatlowadherencetotheprescribedmedicationscanaffect. . andstudiesareongoing. 627. _50%ofpatientswithapparentlyresistanthypertension, 352, 624and. . Prescription of an appropriate therapeutic regimen is crucial. 389. . that poor adherence is strongly and inversely correlated with the. This might be achieved through: (i) possible drug-related adverse. . numberofpillsprescribed. Earlyrecognitionofalackofadherence. events, (ii) using long-acting drugs that require once daily dos-. might reduce the number of costly investigations and procedures. . age, 628, 629 (iii) avoiding complex dosing schedules, (iv) using SPCs. . (including interventional treatment), and avoid the prescription of. whenever possible, and (v) taking into consideration the effect of. unnecessarydrugs. 625. . treatmentonapatientsbudget. . . A major emphasis of these Guidelines has been to simplify the. Comparedwiththelargenumberoftrialsforindividualdrugsand. . treatmentstrategytotryandimproveadherencetotreatmentand. treatments, there are only a limited number of rigorous trials on. . BPcontrol, byprescribingasinglepilltomostpatientswithhyperten-. adherenceinterventions. Thus, thelevelofevidenceindicatingthata. . sion. Thisisaresponsetothefactthatdespitetheclear-cutbenefits. . sustained improvement in medication adherence can be achieved. ofBPtreatmentintrials, mosttreatedpatientsdonotachieverecom-. . withintheresourcesavailabletodayinclinicalpracticeislow. Thisis. mendedBPtargetsinreallife. ThelowerBPtargetsrecommendedin. . essentiallyduetotheshortdurationofmoststudies, theirheteroge-. theseGuidelineswillmeanthatBPcontrolrateswillbeevenworse. . neity, andtheirquestionabledesigns. Whetheravailableinterventions. unless action is taken to ensure that patients are more likely to. . ameliorate treatment outcomes remains to be demonstrated in. adheretologicalcombinationsoftreatment. . . adequatetrials. . Several methods are available to detect poor adherence, but. . Alistoftheinterventionsassociatedwithimprovedpatientadher-. most are indirect, poorly reliable, and provide little information. encetotreatmentisshowninTable33.",
    ". Alistoftheinterventionsassociatedwithimprovedpatientadher-. most are indirect, poorly reliable, and provide little information. encetotreatmentisshowninTable33. Downloaded from by guest on 31 December 2025 3094 ESC/ESHGuidelines Table33 Interventionsthatmayimprovedrugadherenceinhypertension Physicianlevel Provideinformationontherisksofhypertensionandthebenefitsoftreatment, aswellasagreeingatreatmentstrategytoachieveandmaintainBP controlusinglifestylemeasuresandasingle-pill-basedtreatmentstrategywhenpossible(informationmaterial, programmedlearning, andcomputer-aidedcounselling) Empowermentofthepatient Feedbackonbehaviouralandclinicalimprovements Assessmentandresolutionofindividualbarrierstoadherence Collaborationwithotherhealthcareproviders, especiallynursesandpharmacists Patientlevel Self-monitoringofBP(includingtelemonitoring) Groupsessions Instructioncombinedwithmotivationalstrategies Self-managementwithsimplepatient-guidedsystems Useofreminders Obtainfamily, social, ornursesupport Provisionofdrugsatworksite Drugtreatmentlevel SimplificationofthedrugregimenfavouringtheuseofSPCtherapy Reminderpackaging Healthsystemlevel Supportingthedevelopmentofmonitoringsystems(telephonefollow-up, homevisits, andtelemonitoringofhomeBP) Financiallysupportingthecollaborationbetweenhealthcareproviders(e. g. pharmacistsandnurses) ReimbursementofSPCpills Developmentofnationaldatabases, includingprescriptiondata, availableforphysiciansandpharmacists Accessibilitytodrugs blood pressurebloodpressure; SPCsingle-pillcombination. . 10. 5 Continued search for asymptomatic. 10. 6 Can antihypertensive medications. . . hypertension-mediated organ damage. be reduced or stopped? . . TheimportanceandneedtodetectHMODatinitialassessmentto. . InsomepatientsinwhomtreatmentisaccompaniedbyeffectiveBP. helpriskstratifythepatient, andtoreviewtheprogressionorregres-. . control for an extended period, it may be possible to reduce the. . sionofHMODduringfollow-up, havebeendescribedinsection4. . numberand/ordosageofdrugs. Thismayparticularlybethecaseif. . ThepresenceofHMODdemonstratesthatBPiselevatedandthat. BPcontrolisaccompaniedbyhealthylifestylechangessuchasweight. . thepatientwouldbenefitfromtreatment. Theregressionofasymp-. loss, exercise habit, and a Low-fat and Low-salt diet, which remove. . tomaticorgandamageoccurringduringtreatmentcanoftenindicate. environmentalpressorinfluences. Areductionofmedicationsshould. . animprovedprognosis(seesection5). . be made gradually, and the patient should be checked frequently Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3095 because reappearance of hypertension can occur quickly, within weeks, ormaytakemanymonths. PatientswithpriorHMODorprevious accelerated hypertension should not have their treatment withdrawn. 11 Gaps in the evidence Gapsintheevidenceandneedforfurtherstudies Whatistheoptimalpopulationscreeningprogrammefordetectinghypertension? WhatistheoptimalmethodtomeasureBPinpatientswithAF? WhatistheincrementalbenefitforCVriskpredictionoftheadditionofout-of-officeBP(HBPMandABPM)toofficeBPmeasurement? Whatistheincrementalbenefit, overtheSCOREsystem, ofmeasuresofHMODinreclassifyingtheCVriskofpatientswithhypertension? WhataretheappropriateBPthresholdsandtargetsfordrugtreatmentinyoungerhypertensivepatients? WhataretheoptimalBPtreatmenttargetsaccordingtoHBPMandABPM? Whataretheoutcomebenefitsassociatedwithantihypertensivetreatmentinpatientswithresistanthypertension? WhatarethebenefitsofBPtreatmentforpatientswithBPinthehighnormalrange? WhatbaselinelevelofCVriskpredictstreatmentbenefit? MoredataonthebenefitsofBPtreatmentintheveryelderlyandtheinfluenceoffrailty Outcome-basedcomparisonbetweenofficeBP-andout-of-officeBP-guidedtreatment Outcome-basedcomparisonbetweentreatmentsguidedbyBPcontrolandbyHMODreductions, especiallyinyoungerpatients MoreoutcomestudiesoftheoptimalSBPtreatmenttargetforpatientsatdifferentlevelsofbaselineCVriskandwithdifferentcomorbidities, includingdiabetesandCKD MoreoutcomestudiesoftheoptimalDBPtreatmenttarget Impactofsingle-pillvs. multidrugtreatmentstrategiesonadherencetotreatment, BPcontrol, andclinicaloutcomes Outcome-basedcomparisonbetweentreatmentstrategiesbasedoninitialmonotherapyvs. initialcombinationtherapy WhatistheoptimalsaltintaketoreduceCVandmortalityrisk? Whatarethelong-termoutcomebenefitsresultingfromtherecommendedlifestylechanges? Outcome-basedcomparisonbetweentreatmentsbasedonthiazidevs. thiazide-likediuretics Incrementalvalueofcentralvs. peripheralBPinriskestimationandriskreductionbytreatment Outcome-basedcomparisonofBPtreatmentwithclassicalvs. vasodilatorbeta-blockers OptimalBPtreatmenttargetsinspecificclinicalconditions(e. g. Diabetes, chronic kidney disease, andpost-stroke) Protectiveeffectofantihypertensivetreatmentinpatientswithcognitivedysfunctionordementia Roleofantihypertensivetreatmentinwhite-coathypertension Roleofantihypertensivetreatmentinmaskedhypertension Optimaltreatmentofhypertensionindifferentethnicgroups ABPMambulatorybloodpressuremonitoring; atrial fibrillationatrialfibrillation; blood pressurebloodpressure; chronic kidney diseasechronickidneydisease; CVcardiovascular; DBPdiastolicbloodpressure; HBPM homebloodpressuremonitoring; HMODhypertension-mediatedorgandamage; SBPsystolicbloodpressure; SCORESystematicCOronaryRiskEvaluation. Downloaded from by guest on 31 December 2025 3096 ESC/ESHGuidelines. 12 Key messages. . receivedrugtreatmentiftheirBPisnotcontrolledafteraperiod. . . oflifestyleinterventionalone. Forhigher-riskpatientswithgrade1. . (1) blood pressure, epidemiology, and risk. Globally, over 1 billion people. hypertension, includingthosewithHMOD, orpatientswithhigher. . havehypertension. Aspopulationsageandadoptmoresedentary. grades of hypertension (e. g. grade 2 hypertension, _160/100. . lifestyles, theworldwideprevalenceofhypertensionwillcontinue. mmHg), we recommend initiating drug treatment alongside life-. . torisetowards1. 5billionby2025. ElevatedBPistheleadingglobal. style interventions. These recommendations apply to all adults. . contributortoprematuredeath, accountingforalmost10million. aged80years. . . deathsin2015, 4. 9millionduetoischaemicheartdiseaseand3. 5. (8) Special considerations in frail and older patients. It is. . millionduetostroke. Hypertensionisalsoamajorriskfactorfor. . increasingly recognised that biological rather than chronological. heartfailure, atrial fibrillation, chronic kidney disease, peripheral arterial disease, andcognitivedecline. . . age, as well as consideration of frailty and independence, are. (2) Definition of hypertension. The classification of blood pressure and the. . important determinants of the tolerability of and likely benefit. definitionofhypertensionisunchangedfrompreviousEuropean. . fromBP-loweringmedications. Itisimportanttonotethatevenin. Guidelines, andisdefinedasanofficeSBP_140and/orDBP_90. . theveryold(i. e. 80years), blood pressure-loweringtherapyreducesmortal-. mmHg, whichisequivalenttoa24hABPMaverageof_130/80. . ity, stroke, andheart failure. Thus, these patientsshouldnot be. mmHg, oraHBPMaverage_135/85mmHg. . . denied treatment or have treatment withdrawn simply on the. (3) Screening and diagnosis of hypertension. Hypertension is. . basis of age. For people 80 years who have not yet received. usuallyasymptomatic(hencethetermsilentkiller). Becauseofits. . treatment for their blood pressure, treatment is recommended when their. highprevalence, screeningprogrammesshouldbeestablishedto. . office SBP is _160 mmHg, provided that the treatment is well. ensurethatBPismeasuredinalladultsatleastevery5years, and. . tolerated. . morefrequentlyinpeoplewithahighnormalBP. Whenhyper-. . (9) How Low should SBP be lowered? This has been a hotly. tensionissuspectedbecauseofanelevatedscreeningBP, thediag-. . debatedtopic. Akeydiscussionpointisthebalanceofpotential. nosis of hypertension should be confirmed either by repeated. . benefits vs. potential harm or adverse effects. This is especially. officeBPmeasurementsoveranumberofvisitsorbyout-of-office. . importantwheneverBPtargetsarelowered, asthereisagreater. BPmeasurementusing24hABPMorHBPM. . . potentialforharmtoexceedbenefit. Thus, intheseGuidelines, we. . (4) The importance of cardiovascular risk assessment and. recommend a target range. The evidence strongly suggests that. . detectionofHMOD. OtherCVriskfactorssuchasdyslipidae-. lowering office SBP to 140 mmHg is beneficial for all patient. . miaandmetabolicsyndromefrequentlyclusterwithhypertension. . groups, including independent older patients. There is also evi-. . Thus, unlessthepatientisalreadyathighorveryhighriskdueto. dencetosupporttargetingSBPto130mmHgformostpatients, if. . established cardiovascular disease, formal CV risk assessment is recommended. tolerated. EvenlowerSBPlevels(130mmHg)willbetolerated. . usingtheSCOREsystem. However, itisimportanttorecognise. andpotentiallybeneficialforsomepatients, especiallytofurther. . thatthepresenceofHMOD, especiallyLVH, chronic kidney disease, oradvanced. . reduce the risk of stroke.",
    "EvenlowerSBPlevels(130mmHg)willbetolerated. . usingtheSCOREsystem. However, itisimportanttorecognise. andpotentiallybeneficialforsomepatients, especiallytofurther. . thatthepresenceofHMOD, especiallyLVH, chronic kidney disease, oradvanced. . reduce the risk of stroke. SBP should not be targeted to 120. retinopathy, furtherincreasestheriskofCVmorbidityandmortal-. . mmHgbecausethebalanceofbenefitvs. harmbecomesconcern-. ity, andshouldbescreenedforaspartofriskassessmentinhyper-. . ingattheselevelsoftreatedSBP. . tensive patients because the SCORE system alone may. . (10) BPtargetsinoldandveryoldpatients. Asdiscussedabove, . underestimatetheirrisk. . . independence, frailty, andcomorbiditieswillallinfluencetreatment. (5) Think: could this patient have secondary hypertension? . . decisions, especiallyinolder(_65years)andveryold(80years). Formostpeoplewithhypertension, nounderlyingcausewillbe. . patients. The desiredSBPtargetrange forallpatientsaged65. detected. Secondary(andpotentiallyremediable)causesofhyper-. . yearsis130139mmHg. ThisislowerthaninpreviousGuidelines. tensionaremorelikelytobepresentinpeoplewithyoungonset. . andmaynotbeachievableinallolderpatients, butanyBPlowering. of hypertension (40 years), people with severe or treatment-. . towardsthistargetislikelytobebeneficialprovidedthatthetreat-. resistanthypertension, orpeoplewhosuddenlydevelopsignificant. . mentiswelltolerated. . hypertensioninmidlifeonabackgroundofpreviouslynormalBP. . . (11) BPtargetsinpatientswithdiabetesand/orCKD. TheBP. Suchpatientsshouldbereferredforspecialistevaluation. . . treatmenttargetsforpatientswithdiabetesorkidneydiseasehave. (6) Treatmentofhypertension: importanceoflifestyleinter-. . beenamovingtargetinpreviousGuidelinesbecauseofseemingly. ventions. Thetreatmentofhypertensioninvolveslifestyleinter-. . contradictory results from major outcome trials and meta-. ventionsanddrugtherapy. Manypatientswithhypertensionwill. . analyses. For Diabetes, targeting the SBP to 140 mmHg and. . require drug therapy, but lifestyle interventions are important. towards130mmHg, asrecommendedforallotherpatientgroups, . . becausetheycandelaytheneedfordrugtreatmentorcomple-. isbeneficialonmajoroutcomes. Moreover, targetingSBPto130. . menttheBP-loweringeffectofdrugtreatment. Moreover, lifestyle. mmHg, forthosewhowilltolerateit, mayfurtherreducetherisk. . interventions such as Sodium restriction, alcohol moderation, . ofstrokebutnotothermajoroutcomes. SBPshouldnotbe120. . healthyeating, regularexercise, weightcontrol, andsmokingcessa-. mmHg. ForpatientswithCKD, theevidencesuggeststhatthetar-. . tionallhavehealthbenefitsbeyondtheirimpactonBP. . getBPrangeshouldbe130139mmHg. . . (7) Whentoconsiderdrugtreatmentofhypertension. The. . (12) HowlowshouldDBPbelowered? TheoptimalDBPtarget. treatmentthresholdsforhypertensionarenowlessconservative. . hasbeenlesswelldefined, butaDBPtargetof80mmHgisrec-. thantheywereinpreviousGuidelines. Wenowrecommendthat. . ommended. Somepatientswithstiffarteriesandisolatedsystolic. patientswithlow-moderate-riskgrade1hypertension(officeBP. . hypertensionwillalreadyhaveDBPlevelsbelowthistarget. These. 140159/9099), eveniftheydonothaveHMOD, shouldnow. are High-risk patients and the Low DBP should not discourage Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3097. . treatmentoftheirelevatedSBPtotherecommendedtarget, pro-. . medication. WerecommendacombinationofanACEinhibitoror. videdthattreatmentiswelltolerated. . . ARBwithaCCBorthiazide/thiazide-likediureticasinitialtherapy. (13) TheneedtodobetteronBPcontrol. Akeymessageinthese. . formostpatients. Forthoserequiringthreedrugs, werecommend. GuidelinesistheneedtodobetteratimprovingBPcontrolrates. . . a combination of an ACE inhibitor or angiotensin receptor blocker with a calcium channel blocker and a. Despitetheoverwhelmingevidenceoftreatmentbenefit, onaver-. . thiazide/thiazide-likediuretic. Werecommendthatbeta-blockers. age, 50%ofpatientswithtreatedhypertensionachieveanSBP. . beusedwhenthereisaspecificindicationfortheiruse(e. g. angina, . targetof140mmHg. Physicianinertia(inadequateuptitrationof. . post-myocardialinfarction, HFrEF, orwhenheartratecontrolis. treatment, especiallyfrommonotherapy)andpoorpatientadher-. . required). . ence to treatment (especially when based on multiple pills) are. . (17) Hypertensioninwomenandinpregnancy. Inwomenwith. now recognised as the major factors contributing to poor blood pressure. . hypertension who are planning pregnancy, ACE inhibitors or. control. . . ARBsanddiureticsshouldbeavoided, andthepreferredmedica-. . (14) Start treatment in most patients with two drugs, not. tionstolowerBP, ifrequired, includealpha-methyldopa, labetalol, . . one. Monotherapyisusuallyinadequatetherapyformostpeople. orCCBs. ThesamedrugsaresuitableifBPloweringisrequiredin. . with hypertension; this will be especially true now that the blood pressure. pregnantwomen. ACEinhibitorsorARBsshouldnotbeusedin. . treatment targets for many patients are lower than in previous. pregnantwomen. . . Guidelines. TheseGuidelineshavesetouttonormalizethecon-. (18) Istherearolefordevice-basedtherapyforthetreatment. . ceptthatinitialtherapyforthemajorityofpatientswithhyperten-. ofhypertension? Anumberofdevice-basedinterventionshave. . sionshouldbewithacombinationoftwodrugs, notasingledrug. . beendevelopedandstudiedforthetreatmentofhypertension. To. . Theonlyexceptionwouldbeinalimitednumberofpatientswith. date, theresultsfromthesestudieshavenotprovidedsufficient. . alowerbaselineBPclosetotheirrecommendedtarget, whomight. evidencetorecommendtheirroutineuse. Consequently, theuse. . achievethattargetwithasingledrug, orinsomefraileroldorvery. of device-based therapies is not recommended for the routine. . oldpatientsinwhommoregentlereductionofBPmaybedesir-. treatmentofhypertension, unlessinthecontextofclinicalstudies. . able. Evidencesuggeststhatthisapproachwillimprovethespeed, . . andRCTs, untilfurtherevidenceregardingtheirsafetyandefficacy. efficiency, andconsistencyofinitial BPloweringandBP control, . . becomesavailable. . andiswelltoleratedbypatients. . . (19) Managing cardiovascular disease risk in hypertensive. (15) Asingle-pillstrategytotreathypertension. Pooradher-. . patientsbeyondBP: statins. Forhypertensivepatientsatmod-. encetolonger-termBP-loweringmedicationisnowrecognised. . erateCVDriskorhigher, orthosewithestablishedCVD, BPlow-. as a major factor contributing to poor blood pressure control rates. . . ering alone will not optimally reduce their risk. These patients. Researchhasshownadirectcorrelationbetweenthenumber. . wouldalsobenefitfromstatintherapy, whichfurtherreducesthe. of blood pressure-lowering pills and poor adherence to medications. . . risk of a myocardial infarction by approximately one-third and. Moreover, SPCtherapyhasbeenshowntoimproveadherence. . strokebyapproximatelyone-quarter, evenwhenBPiscontrolled. . totreatment. SPCtherapyisnowthepreferredstrategyforini-. . Similarbenefitshavebeenseeninhypertensivepatientsatthebor-. tial two-drug combination treatment of hypertension and for. . derbetweenlowandmoderate-risk. Thus, manymorehyperten-. . three-drugcombinationtherapywhenrequired. Thiswillcon-. sivepatientswouldbenefitfromstatintherapythanarecurrently. . troltheBPofmostpatientswithasinglepillandcouldtrans-. receivingthistreatment. . . formBPcontrolrates. . (20) Managing cardiovascular disease risk in hypertensive. . (16) Asimplifieddrugtreatmentalgorithm. Wehavesimplified. patientsbeyondBP: antiplatelettherapy. Antiplateletther-. . thetreatmentstrategysothatpatientswithuncomplicatedhyper-. apy, especially Low-dose aspirin, is recommended for secondary. . tension and many patients with a variety of comorbidities (e. g. . preventioninhypertensivepatients, butisnotrecommendedfor. . HMOD, Diabetes, peripheral arterial disease, orcerebrovasculardisease)receivesimilar. primaryprevention(i. e. inpatientswithoutCVD). .",
    "preventioninhypertensivepatients, butisnotrecommendedfor. . HMOD, Diabetes, peripheral arterial disease, orcerebrovasculardisease)receivesimilar. primaryprevention(i. e. inpatientswithoutCVD). . Downloaded from by guest on 31 December 2025 3098 ESC/ESHGuidelines 13 What to do and what not to do messages from the Guidelines Recommendations Classa Levelb ClassificationofBP ItisrecommendedthatBPbeclassifiedasoptimal, normal, orhighnormal, orgrades13hypertension, accordingtooffice I C blood pressure. Screeningforhypertension Screeningprogrammesforhypertensionarerecommended. Alladults(_18years)shouldhavetheirofficeBPmeasuredand I B recordedintheirmedicalfile, andbeawareoftheirBP. Diagnosisofhypertension Itisrecommendedtobasethediagnosisofhypertensionon: RepeatedofficeBPmeasurementsonmorethanonevisit, exceptwhenhypertensionissevere(e. g. grade3andespecially I C inhigh-riskpatients). Ateachvisit, threeBPmeasurementsshouldberecorded, 12minapart, andadditionalmeasurementsperformedifthefirsttworeadingsdifferby10mmHg. ThepatientsBPistheaverageofthelasttwoBPreadings. OR Out-of-officeBPmeasurementwithABPMand/orHBPM, providedthatthesemeasurementsarelogisticallyandeconomiI C callyfeasible. OfficeBPthresholdsfortheinitiationofdrugtreatmentforhypertension PromptinitiationofBP-loweringdrugtreatmentisrecommendedinpatientswithgrade2or3hypertensionatanylevelofCV I A risk, simultaneouslywiththeinitiationoflifestylechanges. Inpatientswithgrade1hypertension: I B LifestyleinterventionsarerecommendedtodetermineifthiswillnormalizeBP. Inpatientswithgrade1hypertensionatlow-moderate-riskandwithoutevidenceofHMOD, blood pressure-loweringdrugtreatmentis I A recommendedifthepatientremainshypertensiveafteraperiodoflifestyleintervention. c Inpatientswithgrade1hypertensionathighriskorwithevidenceofHMOD, promptinitiationofdrugtreatmentisrecomI A mendedsimultaneouslywithlifestyleinterventions. Infitolderpatientswithhypertension(evenifaged80years), blood pressure-loweringdrugtreatmentandlifestyleinterventionarerecI A ommendedwhenSBPis_160mmHg. blood pressure-loweringdrugtreatmentandlifestyleinterventionarerecommendedinfitolderpatients(65yearsbutnot80years) I A whenSBPisinthegrade1range(140159mmHg), providedthattreatmentiswelltolerated. InpatientswithhighnormalBP(130139/8589mmHg), lifestylechangesarerecommended. I A WithdrawalofBP-loweringdrugtreatmentonthebasisofage, evenwhenpatientsattainanageof_80years, isnotrecomIII A mended, providedthattreatmentiswelltolerated. OfficeBPtreatmenttargets ItisrecommendedthatthefirstobjectiveoftreatmentshouldbetolowerBPto140/90mmHginallpatients, andprovided I A thatthetreatmentiswelltolerated, treatedBPvaluesshouldbetargetedto130/80mmHgorlowerinmostpatients. Inpatients65yearsreceivingBP-loweringdrugs, itisrecommendedthatSBPshouldbeloweredtoaBPrangeof120129 I A mmHginmostpatients. d Inolderpatients(aged_65years)receivingBP-loweringdrugs, itisrecommendedthatSBPshouldbetargetedtoaBPrangeof I A 130139mmHg. Continued Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3099 Treatmentofhypertension: lifestyleinterventions Saltrestrictionto5gperdayisrecommended. I A Itisrecommendedtorestrictalcoholconsumptionto14unitsperweekformenand8unitsperweekforwomen. I A Increasedconsumptionofvegetables, freshfruits, Fish, nuts, unsaturatedfattyacids(oliveoil); lowconsumptionofredmeat; I A andconsumptionoflow-fatdairyproductsarerecommended. Bodyweightcontrolisindicatedtoavoidobesity(body mass index30kg/m2, orwaistcircumference102cminmenand88cmin women)andaimforhealthyBMI(about2025kg/m2)andwaistcircumferencevalues(94cminmenand80cminwomen) I A toreduceBPandCVrisk. Regularaerobicexercise(e. g. _30minofmoderatedynamicexerciseon57daysperweek)isrecommended. I A Smokingcessationandsupportivecareandreferraltosmokingcessationprogrammesarerecommended. I B Itisrecommendedtoavoidbingedrinking. III A Treatmentofhypertension: drugtreatment Combinationtreatmentisrecommendedformosthypertensivepatientsasinitialtherapy. PreferredcombinationsshouldcomI A priseaRASblocker(eitheranACEinhibitororanARB)withaCCBordiuretic. Othercombinationsofthefivemajorclasses canbeused. Itisrecommendedthatbeta-blockersarecombinedwithanyoftheothermajordrugclasseswhentherearespeI A cificclinicalsituations(e. g. angina, post-myocardialinfarction, heartfailure, orheartratecontrol). Itisrecommendedtoinitiateantihypertensivetreatmentwithatwo-drugcombination, preferablyinanSPC. Exceptionsare I B frailolderpatientsandthoseatlowriskandwithgrade1hypertension(particularlyifSBPis150mmHg). 342, 346, 351 ItisrecommendedthatifBPisnotcontrolledewithatwo-drugcombination, treatmentshouldbeincreasedtoathree-drug I A combination, usuallyaRASblockerwithaCCBandthiazide/thiazide-likediuretics, preferablyasanSPC. ItisrecommendedthatifBPisnotcontrolledewithathree-drugcombination, treatmentshouldbeincreasedbytheaddition ofspironolactoneor, ifnottolerated, otherdiureticssuchasamilorideorhigherdosesofotherdiuretics, abeta-blocker, oran I B alpha-blocker. ThecombinationoftwoRASblockersisnotrecommended. III A Treatmentofhypertension: device-basedtherapies Useofdevice-basedtherapiesisnotrecommendedfortheroutinetreatmentofhypertension, unlessinthecontextofclinical III B studiesandRCTs, untilfurtherevidenceregardingtheirsafetyandefficacybecomesavailable. ManagementofCVDriskinhypertensivepatients CVriskassessmentwiththeSCOREsystemisrecommendedforhypertensivepatientswhoarenotalreadyathighorvery I B highriskduetoestablishedCVD, renaldisease, ordiabetes. ForpatientsathighorveryhighCVrisk, statinsarerecommended. I B Antiplatelettherapy, inparticularlow-doseaspirin, isrecommendedforsecondarypreventioninhypertensivepatients. I A AspirinisnotrecommendedforprimarypreventioninhypertensivepatientswithoutCVD. III A Routinegenetictestingforhypertensivepatientsisnotrecommended. III C ABPMambulatorybloodpressuremonitoring; ACEangiotensin-convertingenzyme; angiotensin receptor blockerangiotensinreceptorblocker; body mass indexbodymassindex; blood pressurebloodpressure; calcium channel blockercalciumchannelblocker; CVcardiovascular; cardiovascular diseasecardiovasculardisease; HBPMhomebloodpressuremonitoring; HMODhypertension-mediatedorgandamage; renal artery stenosisreninangiotensinsystem; RCTrandomizedcontrolledtrial; SBPsystolicbloodpressure; SCORESystematicCOronaryRiskEvaluation; SPCsingle-pill combination. aClassofrecommendation. bLevelofevidence. cInpatientswithgrade1hypertensionandlow-moderate-risk, drugtreatmentmaybeprecededbyaprolongedperiodoflifestyleinterventiontodetermineifthiswillnormalize blood pressure. ThedurationofthelifestyleinterventionalonewilldependonthelevelofBPwithinthegrade1range(i. e. thelikelihoodofachievingBPcontrolwithlifestyleintervention alone)andtheopportunitiesforsignificantlifestylechangeinindividualpatients. dLessevidenceisavailableforthistargetinlow-moderate-riskpatients. eAdherencetomedicationshouldbechecked. Downloaded from by guest on 31 December 2025 3100 ESC/ESHGuidelines. 14 Appendix. . Society of Cardiology, Tonje Amb Aksnes; Poland: Polish Cardiac. . . Society, Piotr Jankowski; Portugal: Portuguese Society of. ESC Committee for Practice Guidelines (CPG): Stephan. . Cardiology, Jorge Polonia; Romania: Romanian Society of. Windecker (Chairperson) (Switzerland), Victor Aboyans (France), . . Cardiology, Dragos Vinereanu; Russian Federation: Russian. . Stefan Agewall (Norway), Emanuele Barbato (Italy), Hector Bueno. Society of Cardiology, ElenaI. Baranova; SanMarino: SanMarino. . (Spain), Antonio Coca (Spain), Jean-Philippe Collet (France), Ioan. SocietyofCardiology, MarinaFoscoli; Serbia: CardiologySocietyof. . MirceaComan(Romania), VeronicaDean(France), VictoriaDelgado. Serbia, AnaDjordjevicDikic; Slovakia: SlovakSocietyofCardiology, . . (The Netherlands), Donna Fitzsimons (UK), Oliver Gaemperli. SlavomiraFilipova; Slovenia: SlovenianSocietyofCardiology, Zlatko. . (Switzerland), GerhardHindricks(Germany), BernardIung(France), . . Fras; Spain: Spanish Society of Cardiology, Vicente Bertomeu-. Peter Juni (Canada), Hugo A. Katus (Germany), Juhani Knuuti. . Mart(cid: 2)ınez; Sweden: Swedish Society of Cardiology, Bo Carlberg; . (Finland), Patrizio Lancellotti (Belgium), Christophe Leclercq. . Switzerland: SwissSocietyofCardiology, ThiloBurkard; Tunisia: . (France), Theresa A. McDonagh (UK), Massimo Francesco Piepoli. . TunisianSocietyofCardiologyandCardio-VascularSurgery, Wissem. (Italy), Piotr Ponikowski (Poland), Dimitrios J. Richter (Greece), . . Sdiri; Turkey: Turkish Society of Cardiology, Sinan Aydogdu; . MarcoRoffi(Switzerland), EvgenyShlyakhto(Russia), IainA. Simpson. . Ukraine: Ukrainian Association of Cardiology, Yuriy Sirenko; . (UK), MiguelSousa-Uva(Portugal), JoseLuisZamorano(Spain). . . UnitedKingdom: BritishCardiovascularSociety, AdrianBrady. . ESH Council: Costas Tsioufis (President) (Greece), Empar. . ESH National Hypertension Societies actively involved in. Lurbe (Spain), Reinhold Kreutz (Germany), Murielle Bochud. . thereviewprocessofthe2018ESC/ESHGuidelinesforthemanage-. (Switzerland), EnricoAgabitiRosei(Italy), BojanJelakovic(Croatia), . . ment of arterial hypertension: Austria: Austrian Society of. MichelAzizi(France), AndrzejJanuszewics(Poland), ThomasKahan. . Hypertension, ThomasWeber; Belarus: BelarussianHypertension. (Sweden), JorgePolonia(Portugal), PhilippevandeBorne(Belgium), . . League, IrinaLazareva; Belgium: BelgianHypertensionCommittee, . BryanWilliams(UK), ClaudioBorghi(Italy), GiuseppeMancia(Italy), . . Tine De Backer; Bosnia and Herzegovina: Bosnia and. GianfrancoParati(Italy), DenisL. Clement(Belgium), AntonioCoca. . Herzegovina Society of Hypertension, Sekib Sokolovic; Croatia: . (Spain), AthanasiosManolis(Greece), DraganLovic(Serbia). . Croatian Society of Hypertension, Bojan Jelakovic; Czech.",
    ". Herzegovina Society of Hypertension, Sekib Sokolovic; Croatia: . (Spain), AthanasiosManolis(Greece), DraganLovic(Serbia). . Croatian Society of Hypertension, Bojan Jelakovic; Czech. ESC National Cardiac Societies actively involved in the. . Republic: CzechSocietyofHypertension, JiriWidimsky; Estonia: . reviewprocessofthe2018ESC/ESHGuidelinesforthemanagement. . EstonianSocietyofHypertension, MargusViigimaa; Finland: Finnish. of arterial hypertension: Algeria: Algerian Society of Cardiology, . . Hypertension Society, Ilkka Porsti; France: French Society of. . Salim Benkhedda; Armenia: Armenian Cardiologists Association, . Hypertension, Thierry Denolle; Germany: German Hypertension. . Parounak Zelveian; Austria: AustrianSociety of Cardiology, Peter. Society, Bernhard potassium. Kramer; Greece: Hellenic Society of. . Siostrzonek; Azerbaijan: AzerbaijanSocietyofCardiology, Ruslan. Hypertension, George S. Stergiou; Italy: Italian Society of. . Najafov; Belarus: Belorussian Scientific Society of Cardiologists, . Hypertension, Gianfranco Parati; Latvia: Latvian Society of. . Olga Pavlova; Belgium: Belgian Society of Cardiology, Michel De. . Hypertension and Atherosclerosis, potassium(cid: 4)arlis Tru(cid: 3)sinskis; Lithuania: . Pauw; Bosnia and Herzegovina: Association of Cardiologists of. . Lithuanian Hypertension Society, Marius Miglinas; Norway: . Bosnia and Herzegovina, Larisa Dizdarevic-Hudic; Bulgaria: . . Norwegian Society of Hypertension, Eva Gerdts; Poland: Polish. Bulgarian Society of Cardiology, Dimitar Raev; Cyprus: Cyprus. . Society of Hypertension, Andrzej Tykarski; Portugal: Portuguese. Society of Cardiology, Nikos Karpettas; Czech Republic: Czech. . SocietyofHypertension, ManueldeCarvalhoRodrigues; Romania: . Society of Cardiology, Ale(cid: 3)s Linhart; Denmark: Danish Society of. . Romanian Society of Hypertension, Maria Dorobantu; Russian. Cardiology, Michael Hecht Olsen; Egypt: Egyptian Society of. . Federation: Russian Society of Hypertension, Irina Chazova; . Cardiology, Amin Fouad Shaker; Estonia: Estonian Society of. . Serbia: Serbian Society of Hypertension, Dragan Lovic; Slovakia: . Cardiology, Margus Viigimaa; Finland: Finnish Cardiac Society, Kaj. . Slovak Society of Hypertension, Slavomira Filipova; Slovenia: . Metsarinne; The Former Yugoslav Republic of Macedonian: . . Slovenian Hypertension Society, Jana Brguljan; Spain: Spanish. Macedonian FYR Society of Cardiology, Marija Vavlukis; France: . . SocietyofHypertension, JulianSegura; Sweden: SwedishSocietyof. French Society of Cardiology, Jean-Michel Halimi; Georgia: . . Hypertension, Stroke and Vascular Medicine, Anders Gottsater; . GeorgianSocietyofCardiology, ZurabPagava; Germany: German. . Switzerland: Swiss Society ofHypertension, Antoinette Pechere-. Cardiac Society, Heribert Schunkert; Greece: Hellenic Society of. . Bertschi; Turkey: Turkish Society of Hypertension and. Cardiology, CostasThomopoulos; Hungary: HungarianSocietyof. . Atherosclerosis, SerapErdine; Ukraine: UkrainianAntihypertensive. Cardiology, DenesP(cid: 2)all; Iceland: IcelandicSocietyofCardiology, Karl. . Society, Yuriy Sirenko; United Kingdom: British and Irish. Andersen; Israel: Israel Heart Society, Michael Shechter; Italy: . . HypertensionSociety, AdrianBrady. . Italian Federation of Cardiology, Giuseppe Mercuro; Kosovo: . . . . KosovoSocietyofCardiology, GaniBajraktari; Kyrgyzstan: Kyrgyz. . 15 References. SocietyofCardiology, TatianaRomanova; Latvia: LatvianSocietyof. . 1. EmdinCA, RahimiK, NealB, CallenderT, PerkovicV, PatelA. Bloodpressure. Cardiology, potassium(cid: 4)arlis Tru(cid: 3)sinskis; Lebanon: Lebanese Society of. . lowering in type 2 Diabetes: a systematic review and meta-analysis. JAMA Cardiology, Georges A. Saade; Lithuania: Lithuanian Society of. . 2015; 313: 603615. . . 2. EttehadD, EmdinCA, KiranA, AndersonSG, CallenderT, EmbersonJ, Chalmers Cardiology, Gintare Sakalyte; Luxembourg: Luxembourg Society. . J, RodgersA, RahimiK. Bloodpressureloweringforpreventionofcardiovascular. of Cardiology, Stephanie Noppe; Malta: Maltese Cardiac Society, . . disease and death: a systematic review and meta-analysis. Lancet Daniela Cassar DeMarco; Moldova: Moldavian Society of. . 2016; 387: 957967. . . 3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Cardiology, Alexandru Caraus; The Netherlands: Netherlands. . . Estep potassium, Hassen Abate potassium, Akinyemiju TF, Ali R, Alvis-Guzman N, Azzopardi P, Society of Cardiology, Janneke Wittekoek; Norway: Norwegian. Banerjee A, Barnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3101. . Catala-LopezF, FeiginVL, FernandesJC, FischerF, GebruAA, GonaP, GuptaR, . Task Force for the Management of Arterial Hypertension of the European. Hankey GJ, Jonas JB, Judd SE, Khang YH, Khosravi A, Kim YJ, Kimokoti RW, .",
    "Hankey GJ, Jonas JB, Judd SE, Khang YH, Khosravi A, Kim YJ, Kimokoti RW, . Society of Hypertension (ESH) and of the European Society of Cardiology. KokuboY, KolteD, LopezA, LotufoPA, MalekzadehR, MelakuYA, MensahGA, . . (ESC). JHypertens2007; 25: 11051187. MisganawA, MokdadAH, MoranAE, NawazH, NealB, NgalesoniFN, Ohkubo. . 17. ManciaG, FagardR, NarkiewiczK, RedonJ, ZanchettiA, BohmM, ChristiaensT, . T, Pourmalek F, Rafay A, Rai RK, Rojas-Rueda D, Sampson UK, Santos IS, . CifkovaR, DeBackerG, DominiczakA, GalderisiM, GrobbeeDE, JaarsmaT, . SawhneyM, SchutteAE, SepanlouSG, ShifaGT, ShiueI, TedlaBA, ThriftAG, . . Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, . . SchmiederRE, SirnesPA, SleightP, ViigimaaM, WaeberB, ZannadF, RedonJ, . Venketasubramanian N, Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y, . DominiczakA, NarkiewiczK, NilssonPM, BurnierM, ViigimaaM, AmbrosioniE, . YonemotoN, ZakiME, MurrayCJ. Globalburdenofhypertensionandsystolic. Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, . Blood Hypertension of at least 110 to 115mmHg, 1990-2015. JAMA 2017; 317: . . ZamoranoJL, AchenbachS, BaumgartnerH, BaxJJ, BuenoH, DeanV, DeatonC, 165182. . . ErolC, FagardR, FerrariR, HasdaiD, HoesAW, KirchhofP, KnuutiJ, KolhP, . 4. LewingtonS, ClarkeR, QizilbashN, PetoR, CollinsR. Age-specificrelevanceof. Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes. usualbloodpressuretovascularmortality: ameta-analysisofindividualdatafor. PA, TamargoJL, TenderaM, TorbickiA, WijnsW, WindeckerS, ClementDL, . onemillionadultsin61prospectivestudies. Lancet2002; 360: 19031913. . . Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, . 5. NCD Risk Factor Collaboration. Worldwide trends in Blood Hypertension from. BauersachsJ, HitijJB, CaulfieldM, DeBuyzereM, DeGeestS, DerumeauxGA, . 1975to2015: apooledanalysisof1479population-basedmeasurementstudies. ErdineS, FarsangC, Funck-BrentanoC, GercV, GermanoG, GielenS, HallerH, . with19. 1millionparticipants. Lancet2017; 389: 3755. . . Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, 6. ODonnellMJ, ChinSL, RangarajanS, XavierD, LiuL, ZhangH, Rao-MelaciniP, . . OstergrenJ, ParatiG, PerkJ, PoloniaJ, PopescuBA, ReinerZ, RydenL, Sirenko. Zhang X, Pais P, Agapay S, Lopez-Jaramillo P, Damasceno A, Langhorne P, . Y, StantonA, Struijker-BoudierH, TsioufisC, vandeBorneP, VlachopoulosC, . McQueen MJ, Rosengren A, Dehghan M, Hankey GJ, Dans AL, Elsayed A, . VolpeM, WoodDA. 2013ESH/ESCguidelinesforthemanagementofarterial. AvezumA, MondoC, DienerHC, RyglewiczD, CzlonkowskaA, PogosovaN, . . hypertension: theTaskForcefortheManagementofArterialHypertensionof WeimarC, IqbalR, DiazR, YusoffK, YusufaliA, OguzA, WangX, Penaherrera. . the European Society of Hypertension (ESH) and of the European Society of. E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, . Cardiology(ESC). EurHeartJ2013; 34: 21592219. . OveisgharanS, AlHussainF, MagaziD, NilanontY, FergusonJ, PareG, YusufS, . . 18. LurbeE, Agabiti-RoseiE, CruickshankJK, DominiczakA, ErdineS, HirthA, Invitti INTERSTROKE Investigators. Global and regional effectsof potentially modifi-. . C, LitwinM, ManciaG, PallD, RascherW, RedonJ, SchaeferF, SeemanT, Sinha. ableriskfactorsassociatedwithacutestrokein32countries(INTERSTROKE): a. M, Stabouli S, Webb NJ, Wuhl E, Zanchetti A. 2016 European Society of. case-controlstudy. Lancet2016; 388: 761775. . Hypertensionguidelinesforthemanagementofhighbloodpressureinchildren. 7. RapsomanikiE, TimmisA, GeorgeJ, Pujades-RodriguezM, ShahAD, DenaxasS, . . andadolescents. JHypertens2016; 34: 18871920. White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, . . 19. Kearney PM, Whelton M, Reynolds potassium, Muntner P, Whelton PK, He J. . HemingwayH. Bloodpressureandincidenceoftwelvecardiovasculardiseases: . Global burden of hypertension: analysis of worldwide data. Lancet. lifetimerisks, healthylife-yearslost, andage-specificassociationsin1. 25million. 2005; 365: 217223. . people. Lancet2014; 383: 18991911. . . 20. LipGYH, CocaA, KahanT, BorianiG, ManolisAS, OlsenMH, OtoA, Potpara. 8. ThomopoulosC, ParatiG, ZanchettiA. Effectsofbloodpressureloweringon. TS, Steffel J, Marin F, de Oliveira Figueiredo MJ, de Simone G, Tzou WS, En. outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-. ChiangC, WilliamsB. Hypertensionandcardiacarrhythmias: executivesummary. regressionanalysesofrandomizedtrials. JHypertens2014; 32: 22852295. . . ofaconsensusdocumentfromtheEuropeanHeartRhythmAssociation(EHRA) 9. TsaiWC, WuHY, PengYS, YangJY, ChenHY, ChiuYL, HsuSP, KoMJ, PaiMF, . . and ESC Council on Hypertension, endorsed by the Heart Rhythm Society. TuYK, HungKY, ChienKL. Associationofintensivebloodpressurecontroland. (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad.",
    "TuYK, HungKY, ChienKL. Associationofintensivebloodpressurecontroland. (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad. kidneydiseaseprogressioninnondiabeticpatientswithchronickidneydisease: a. Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Eur. systematicreviewandmeta-analysis. JAMAInternMed2017; 177: 792799. . . HeartJCardiovascPharmacother2017; 3: 235250. 10. YusufS, HawkenS, OunpuuS, DansT, AvezumA, LanasF, McQueenM, Budaj. . 21. GottesmanRF, AlbertMS, AlonsoA, CokerLH, CoreshJ, DavisSM, DealJA, . A, PaisP, VarigosJ, LishengL, INTERHEARTStudyInvestigators. Effectofpoten-. McKhannGM, MosleyTH, SharrettAR, SchneiderALC, WindhamBG, Wruck. tiallymodifiableriskfactorsassociatedwithmyocardialinfarctionin52countries. . LM, KnopmanDS. Associationsbetweenmidlifevascularriskfactorsand25-year (theINTERHEARTstudy): case-controlstudy. Lancet2004; 364: 937952. . . incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. . 11. Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, . JAMANeurol2017; 74: 12461254. . Masso-Gonzalez EL, Jimenez FJ, Perk J, Steg PG, De Backer G, Rodriguez-. 22. RovioSP, PahkalaK, NevalainenJ, JuonalaM, SaloP, KahonenM, Hutri-Kahonen. ArtalejoF. Achievementoftreatmentgoalsforprimarypreventionofcardiovas-. . N, Lehtimaki T, Jokinen E, Laitinen T, Taittonen L, Tossavainen P, Viikari JSA, culardiseaseinclinicalpracticeacrossEurope: theEURIKAstudy. EurHeartJ. . RinneJO, RaitakariOT. Cardiovascularriskfactorsfromchildhoodandmidlife. 2011; 32: 21432152. . cognitive performance: the Young Finns study. J Am Coll Cardiol. 12. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, . 2017; 69: 22792289. . Chifamba J, Dagenais G, Diaz R, Kazmi potassium, Lanas F, Wei L, Lopez-Jaramillo P, . . 23. VishramJK, BorglykkeA, AndreasenAH, JeppesenJ, IbsenH, JorgensenT, Broda FanghongL, IsmailNH, PuoaneT, RosengrenA, SzubaA, TemizhanA, Wielgosz. . G, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, . A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S, PURE Study. KuulasmaaK, SansS, OlsenMH, MORGAMProject. Impactofageontheimpor-. Investigators. Prevalence, awareness, treatment, andcontrolofhypertensionin. . tanceofsystolicanddiastolicbloodpressuresforstrokerisk: theMOnica, Risk, ruralandurbancommunitiesinhigh-, middle-, andlow-incomecountries. JAMA. . Genetics, Archiving, and Monograph (MORGAM) project. Hypertension. 2013; 310: 959968. . 2012; 60: 11171123. . 13. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in. 24. BrownDW, GilesWH, GreenlundKJ. Bloodpressureparametersandriskof. England: a serial cross-sectional study from 1994 to 2011. Lancet. . fatalstroke, NHANESIImortalitystudy. AmJHypertens2007; 20: 338341. 2014; 383: 19121919. . . 25. LawesCM, RodgersA, BennettDA, ParagV, SuhI, UeshimaH, MacMahonS, . 14. Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A, Mancia G, . AsiaPacificCohortStudiesCollaboration. Bloodpressureandcardiovasculardis-. MorgantiA, PontremoliR, TrimarcoB, ZanchettiA, VolpeM. Bloodpressure. . easeintheAsiaPacificregion. JHypertens2003; 21: 707716. controlinItaly: analysisofclinicaldatafrom2005-2011surveysonhypertension. . . 26. FranklinSS, KhanSA, WongND, LarsonMG, LevyD. Ispulsepressureusefulin. JHypertens2012; 30: 10651074. . predicting risk for coronary Heart disease? The Framingham Heart study. . 15. European Society of Hypertension-European Society of Cardiology Guidelines. Circulation1999; 100: 354360. . Committee. 2003 European Society of Hypertension-European Society of. . 27. Williams B, Lindholm LH, SeverP. Systolicpressureis allthat matters. Lancet Cardiologyguidelinesforthemanagementofarterialhypertension. JHypertens. . 2008; 371: 22192221. . 2003; 21: 10111053. . 28. DomanskiM, MitchellG, PfefferM, NeatonJD, NormanJ, SvendsenK, GrimmR, . 16. ManciaG, DeBackerG, DominiczakA, CifkovaR, FagardR, GermanoG, Grassi. CohenJ, StamlerJ, MRFITResearchGroup. Pulsepressureandcardiovascular. G, HeagertyAM, KjeldsenSE, LaurentS, NarkiewiczK, RuilopeL, RynkiewiczA, . . disease-related mortality: follow-up study of the Multiple Risk Factor SchmiederRE, BoudierHA, ZanchettiA, VahanianA, CammJ, DeCaterinaR, . . InterventionTrial(MRFIT). JAMA2002; 287: 26772683. . Dean V, Dickstein potassium, FilippatosG, Funck-Brentano C, Hellemans I, Kristensen. 29. FranklinSS, LopezVA, WongND, MitchellGF, LarsonMG, VasanRS, LevyD. . SD, McGregorK, SechtemU, SilberS, TenderaM, WidimskyP, ZamoranoJL, . . Singleversuscombinedbloodpressurecomponentsandriskforcardiovascular ErdineS, KiowskiW, Agabiti-RoseiE, AmbrosioniE, LindholmLH, ViigimaaM, . . disease: theFraminghamHeartStudy. Circulation2009; 119: 243250. . AdamopoulosS, Agabiti-RoseiE, AmbrosioniE, BertomeuV, ClementD, Erdine. 30. BhattDL, StegPG, OhmanEM, HirschAT, IkedaY, MasJL, GotoS, LiauCS, . S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, OBrien E, . Richard AJ, Rother J, Wilson PW, REACH Registry Investigators. International. Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, . . prevalence, recognition, and treatment of cardiovascular risk factors in outpaWilliams B. 2007 Guidelines forthemanagementof arterialhypertension: the. tientswithatherothrombosis. JAMA2006; 295: 180189.",
    "prevalence, recognition, and treatment of cardiovascular risk factors in outpaWilliams B. 2007 Guidelines forthemanagementof arterialhypertension: the. tientswithatherothrombosis. JAMA2006; 295: 180189. Downloaded from by guest on 31 December 2025 3102 ESC/ESHGuidelines. . 31. ManciaG, FacchettiR, BombelliM, PoloFrizH, GrassiG, GiannattasioC, Sega. 49. ParatiG, PomidossiG, CasadeiR, ManciaG. Lackofalertingreactionstointer-. R. Relationshipofoffice, home, andambulatorybloodpressuretobloodglucose. mittent cuff inflations during noninvasive Blood Hypertension monitoring. . andlipidvariablesinthePAMELApopulation. Hypertension2005; 45: 10721077. . . Hypertension1985; 7: 597601. 32. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van. . 50. Myers magnesium, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. . HornL, TracyRP, Lloyd-JonesDM. Lifetimerisksofcardiovasculardisease. N. Measurementofbloodpressureintheoffice: recognizingtheproblemandpro-. EnglJMed2012; 366: 321329. . . posingthesolution. Hypertension2010; 55: 195200. 33. Aktas MK, Ozduran V, Pothier CE, Lang R, Lauer MS. Global risk scores and. . 51. SPRINTResearchGroup, WrightJTJr, WilliamsonJD, WheltonPK, SnyderJK, . exercisetestingforpredictingall-causemortalityinapreventivemedicinepro-. SinkKM, RoccoMV, ReboussinDM, RahmanM, OparilS, LewisCE, KimmelPL, . gram. JAMA2004; 292: 14621468. . Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, . 34. CooneyMT, DudinaAL, GrahamIM. Valueandlimitationsofexistingscoresfor. . AmbrosiusWT. Arandomizedtrialofintensiveversusstandardblood-Hypertension the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol. . control. NEnglJMed2015; 373: 21032116. . 2009; 54: 12091227. . 52. Filipovsky J, Seidlerova J, Kratochvil Z, Karnosova P, Hronova M, Mayer O Jr. . 35. PiepoliMF, HoesAW, AgewallS, AlbusC, BrotonsC, CatapanoAL, Cooney. Automatedcomparedtomanualofficebloodpressureandtohomebloodpres-. MT, CorraU, CosynsB, DeatonC, GrahamI, HallMS, HobbsFDR, LochenML, . . sureinhypertensivepatients. BloodPress2016; 25: 228234. . Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, . 53. MyersMG, KaczorowskiJ, DolovichL, TuK, PatersonJM. Cardiovascularriskin. SmuldersY, TiberiM, vanderWorpHB, vanDisI, VerschurenWMM, BinnoS, . hypertension in relation to achieved Blood Hypertension using automated office. ESC Scientific DocumentGroup. 2016 European Guidelines on cardiovascular. . bloodpressuremeasurement. Hypertension2016; 68: 866872. disease prevention in clinical practice: The Sixth Joint Task Force of the. . 54. Parati G, Stergiou G, OBrien E, Asmar R, Beilin L, Bilo G, Clement D, de la. EuropeanSocietyofCardiologyandOtherSocietiesonCardiovascularDisease. SierraA, deLeeuwP, DolanE, FagardR, GravesJ, HeadGA, ImaiY, KarioK, . PreventioninClinicalPractice(constitutedbyrepresentativesof10societiesand. LurbeE, MallionJM, ManciaG, MengdenT, MyersM, OgedegbeG, OhkuboT, . by invited experts)Developed with the special contribution of the European. . Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, AssociationforCardiovascularPreventionRehabilitation(EACPR). EurHeartJ. . vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y, . 2016; 37: 23152381. . European Society of Hypertension Working Group on Blood Hypertension. 36. BorghiC, RoseiEA, BardinT, DawsonJ, DominiczakA, KielsteinJT, ManolisAJ, . . Monitoring and Cardiovascular Variability. European Society of Hypertension Perez-RuizF, ManciaG. Serumuricacidandtheriskofcardiovascularandrenal. . practice guidelines for ambulatory Blood Hypertension monitoring. J Hypertens. disease. JHypertens2015; 33: 17291741; discussion1741. . 2014; 32: 13591366. . 37. vanDisI, GeleijnseJM, BoerJM, KromhoutD, BoshuizenH, GrobbeeDE, van. 55. Stergiou GS, Parati G, VlachopoulosC, AchimastosA, Andreadis E, Asmar R, . derSchouwYT, VerschurenWM. Effectofincludingnonfataleventsincardio-. . AvolioA, BenetosA, BiloG, BoubouchairopoulouN, BoutouyrieP, Castiglioni vascularriskestimation, illustratedwithdatafromTheNetherlands. EurJPrev. . P, delaSierraA, DolanE, HeadG, ImaiY, KarioK, KolliasA, KotsisV, ManiosE, . Cardiol2014; 21: 377383. . McManusR, MengdenT, MihailidouA, MyersM, NiiranenT, OchoaJE, Ohkubo. 38. CuspidiC, AmbrosioniE, ManciaG, PessinaAC, TrimarcoB, ZanchettiA. Role. T, Omboni S, Padfield P, Palatini P, Papaioannou T, Protogerou A, Redon J, . of echocardiography and carotid ultrasonography in stratifying risk in patients. . VerdecchiaP, WangJ, ZanchettiA, ManciaG, OBrienE. Methodologyandtech-. with essential hypertension: the Assessment of Prognostic Risk Observational. nologyforperipheralandcentralbloodpressureandbloodpressurevariability. Survey. JHypertens2002; 20: 13071314. . measurement: currentstatusandfuturedirections-Positionstatementofthe. 39. RomanMJ, PickeringTG, SchwartzJE, PiniR, DevereuxRB. Associationofcaro-. . EuropeanSocietyofHypertensionWorkingGrouponbloodpressuremonitorthree times daily atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol. . ingandcardiovascularvariability. JHypertens2016; 34: 16651677. . 1995; 25: 8390. . 56. OBrien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, Clement D, de la. 40. CuspidiC, ValerioC, SalaC, EspositoA, MasaidiM, NegriF, ZanchettiA, Mancia.",
    "40. CuspidiC, ValerioC, SalaC, EspositoA, MasaidiM, NegriF, ZanchettiA, Mancia. SierraA, deLeeuwP, DolanE, FagardR, GravesJ, HeadGA, ImaiY, KarioK, . G. Prevalenceandcorrelatesofmultipleorgandamageinanever-treatedhyper-. . LurbeE, MallionJM, ManciaG, MengdenT, MyersM, OgedegbeG, OhkuboT, tensive population: role of ambulatory Blood Hypertension. Blood Press Monit. . Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, . 2008; 13: 713. . vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y, . 41. PontremoliR, RaveraM, BezanteGP, ViazziF, NicolellaC, BerrutiV, LeonciniG, . . European Society of Hypertension Working Group on Blood Hypertension M. DelSetteM, BrunelliC, TomolilloC, DeferrariG. Leftventriculargeometryand. . EuropeanSocietyofHypertensionpositionpaperonambulatorybloodpressure. function in patients with essential hypertension and microalbuminuria. J. monitoring. JHypertens2013; 31: 17311768. . Hypertens1999; 17: 9931000. . 57. ParatiG, StergiouGS, AsmarR, BiloG, deLeeuwP, ImaiY, KarioK, LurbeE, . 42. Sehestedt T, Jeppesen J, HansenTW, Wachtell potassium, IbsenH, Torp-Pedersen C, . . ManolisA, MengdenT, OBrienE, OhkuboT, PadfieldP, PalatiniP, PickeringT, HildebrandtP, OlsenMH. Riskpredictionisimprovedbyaddingmarkersofsub-. . RedonJ, ReveraM, RuilopeLM, ShennanA, StaessenJA, TislerA, WaeberB, . clinicalorgandamagetoSCORE. EurHeartJ2010; 31: 883891. . ZanchettiA, ManciaG. EuropeanSocietyofHypertensionguidelinesforblood. 43. Perrone-FilardiP, CocaA, GalderisiM, PaolilloS, AlpenduradaF, deSimoneG, . Hypertension monitoring at home: a summary report of the Second International. DonalE, KahanT, ManciaG, RedonJ, SchmiederR, WilliamsB, Agabiti-RoseiE. . . Consensus Conference on Home Blood Hypertension Monitoring. J Hypertens Noninvasivecardiovascularimagingforevaluatingsubclinicaltargetorgandamage. . 2008; 26: 15051526. . inhypertensivepatients: aconsensusarticlefromtheEuropeanAssociationof. 58. BliziotisIA, DestounisA, StergiouGS. Homeversusambulatoryandofficeblood. Cardiovascular Imaging, the European Society of Cardiology Council on. . pressureinpredictingtargetorgandamageinhypertension: asystematicreview Hypertension and the European Society of Hypertension. J Hypertens. . andmeta-analysis. JHypertens2012; 30: 12891299. . 2017; 35: 17271741. . 59. WardAM, TakahashiO, StevensR, HeneghanC. Homemeasurementofblood. 44. StergiouGS, AlpertB, MiekeS, AsmarR, AtkinsN, EckertS, FrickG, Friedman. pressureandcardiovasculardisease: systematicreviewandmeta-analysisofpro-. B, GrasslT, IchikawaT, IoannidisJP, LacyP, McManusR, MurrayA, MyersM, . . spectivestudies. JHypertens2012; 30: 449456. PalatiniP, ParatiG, QuinnD, SarkisJ, ShennanA, UsudaT, WangJ, WuCO, . . 60. McManus RJ, Mant J, Bray EP, Holder R, Jones myocardial infarction, Greenfield S, Kaambwa B, . OBrienE. Auniversalstandardforthevalidationofbloodpressuremeasuring. Banting M, Bryan S, Little P, Williams B, Hobbs FD. Telemonitoring and self-. devices: AssociationfortheAdvancementofMedicalInstrumentation/European. . management in the control of hypertension (TASMINH2): a randomised conSociety of Hypertension/International Organization for Standardization (AAMI/. . trolledtrial. Lancet2010; 376: 163172. . ESH/ISO)CollaborationStatement. JHypertens2018; 36: 472478. . 61. McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, Jones myocardial infarction, . 45. Clark CE, Taylor RS, Shore before meals, Ukoumunne OC, Campbell JL. Association. JowettS, LittleP, PenalozaC, SchwartzC, ShacklefordH, ShoveltonC, Varghese. of a difference in systolic Blood Hypertension between arms with vascular. . J, WilliamsB, HobbsFD, GoodingT, MorreyI, FisherC, BuckleyD. Effectof disease and mortality: a systematic review and meta-analysis. Lancet. . self-monitoringandmedicationself-titrationonsystolicbloodpressureinhyper-. 2012; 379: 905914. . tensivepatientsathighriskofcardiovasculardisease: theTASMIN-SRrandom-. 46. FagardRH, DeCortP. Orthostatichypotensionisamorerobustpredictorof. izedclinicaltrial. JAMA2014; 312: 799808. . cardiovascular events than nighttime reverse dipping in elderly. Hypertension. . 62. Tucker KL, Sheppard JP, Stevens R, Bosworth hemoglobin, Bove A, Bray EP, Earle potassium, 2010; 56: 5661. . . George J, Godwin M, Green beta blocker, Hebert P, Hobbs FDR, Kantola I, Kerry SM, . 47. JuliusS, PalatiniP, KjeldsenSE, ZanchettiA, WeberMA, McInnesGT, Brunner. LeivaA, MagidDJ, MantJ, MargolisKL, McKinstryB, McLaughlinMA, OmboniS, . heart rate, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, . . OgedegbeO, ParatiG, QamarN, TabaeiBP, VarisJ, VerberkWJ, WakefieldBJ, Jamerson potassium, Koylan N. Usefulness of Heart rate to predict cardiac events in. . McManus RJ. Self-monitoring of Blood Hypertension in hypertension: a systematic. treated patients with High-risk systemic hypertension. Am J Cardiol. reviewandindividualpatientdatameta-analysis. PLoSMed2017; 14: e1002389. . 2012; 109: 685692. . 63. OmboniS, GazzolaT, CarabelliG, ParatiG. Clinicalusefulnessandcosteffec-. 48. MyersMG. Ashorthistoryof automated office bloodpressure15yearsto. . tiveness of home Blood Hypertension telemonitoring: meta-analysis of randomized SPRINT. JClinHypertens(Greenwich)2016; 18: 721724. . controlledstudies. JHypertens2013; 31: 455467; discussion467458.",
    ". tiveness of home Blood Hypertension telemonitoring: meta-analysis of randomized SPRINT. JClinHypertens(Greenwich)2016; 18: 721724. . controlledstudies. JHypertens2013; 31: 455467; discussion467458. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3103. . 64. ParatiG, OmboniS. Roleofhomebloodpressuretelemonitoringinhyperten-. 84. BanegasJR, Ruilope LM, delaSierra A, delaCruz JJ, GorostidiM, SeguraJ, . sionmanagement: anupdate. BloodPressMonit2010; 15: 285295. . Martell N, Garcia-Puig J, Deanfield J, Williams B. High prevalence of masked. 65. GaborieauV, DelarcheN, GosseP. Ambulatorybloodpressuremonitoringver-. . uncontrolled hypertension in people with treated hypertension. Eur Heart J susself-measurementofbloodpressureathome: correlationwithtargetorgan. . 2014; 35: 33043312. . damage. JHypertens2008; 26: 19191927. . 85. HuangY, HuangW, MaiW, CaiX, AnD, LiuZ, HuangH, ZengJ, HuY, XuD. . 66. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, . . White-coathypertensionisariskfactorforcardiovasculardiseasesandtotal Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, . . mortality. JHypertens2017; 35: 677688. . OBrien E, Office versus Ambulatory Hypertension Study Investigators. Prognostic. 86. BriasoulisA, AndroulakisE, PallaM, PapageorgiouN, TousoulisD. White-coat. valueofambulatoryblood-pressurerecordingsinpatientswithtreatedhyper-. hypertension and cardiovascular events: a meta-analysis. J Hypertens 2016; 34: . tension. NEnglJMed2003; 348: 24072415. . . 593599. 67. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. . . 87. GrassiG, SeravalleG, TrevanoFQ, DelloroR, BollaG, CuspidiC, ArenareF, . Prognosticvalueofambulatoryandhomebloodpressurescomparedwithoffice. Mancia G. Neurogenic abnormalities in masked hypertension. Hypertension. bloodpressureinthegeneralpopulation: follow-upresultsfromthePressioni. 2007; 50: 537542. . Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. . 88. Mancia G. Clinical significance of white-coat hypertension. J Hypertens. 2005; 111: 17771783. . 2016; 34: 623626. . 68. BanegasJR, RuilopeLM, delaSierraA, VinyolesE, GorostidiM, delaCruzJJ, . 89. ManciaG. White-coathypertension: growingevidenceinfavourofitsadverse. Ruiz-Hurtado G, Segura J, Rodriguez-Artalejo F, Williams B. Relationship. . prognosticsignificance. JHypertens2017; 35: 710712. betweenclinicandambulatoryblood-pressuremeasurementsandmortality. N. . 90. ManciaG, GrassiG. Theheterogeneousnatureofwhite-coathypertension. J. EnglJMed2018; 378: 15091520. . AmCollCardiol2016; 68: 20442046. . 69. Investigators ABC-H, Roush GC, Fagard RH, Salles GF, Pierdomenico SD, . 91. AsayamaK, LiY, FranklinSS, ThijsL, OBrienE, StaessenJA. Cardiovascularrisk. ReboldiG, VerdecchiaP, EguchiK, KarioK, HoshideS, PoloniaJ, delaSierraA, . . associated with white-coat hypertension: con side of the argument. HermidaRC, DolanE, ZamalloaH. Prognosticimpactfromclinic, daytime, and. . Hypertension2017; 70: 676682. . night-timesystolicbloodpressureinninecohortsof13, 844patientswithhyper-. 92. Lurbe E, Torro I, Alvarez V, Nawrot T, Paya R, Redon J, Staessen JA. . tension. JHypertens2014; 32: 23322340; discussion2340. . . Prevalence, persistence, and clinical significance of masked hypertension in 70. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De. . youth. Hypertension2005; 45: 493498. . BacquerDA. Daytimeandnighttimebloodpressureaspredictorsofdeathand. 93. ManciaG, FacchettiR, BombelliM, GrassiG, SegaR. Long-termriskofmortal-. cause-specific cardiovascular events in hypertension. Hypertension 2008; 51: . ityassociatedwithselectiveandcombinedelevationinoffice, home, andambu-. 5561. . . latorybloodpressure. Hypertension2006; 47: 846853. 71. ParatiG, OchoaJE, BiloG, AgarwalR, CovicA, DekkerFW, FliserD, HeineGH, . . 94. BobrieG, ChatellierG, GenesN, ClersonP, VaurL, VaisseB, MenardJ, Mallion. JagerKJ, GarganiL, KanbayM, MallamaciF, MassyZ, OrtizA, PicanoE, Rossignol. JM. Cardiovascularprognosisofmaskedhypertensiondetectedbybloodpres-. P, SarafidisP, SicariR, VanholderR, WiecekA, LondonG, ZoccaliC, European. sure self-measurement in elderly treated hypertensive patients. JAMA. Renal and Cardiovascular Medicine Working Group of the European Renal. . 2004; 291: 13421349. . Association-European Dialysis and Transplant Association. Hypertension in. 95. FagardRH, CornelissenVA. Incidenceofcardiovasculareventsinwhite-coat, . chronic Kidney disease part 2: role of ambulatory and home Blood Hypertension. maskedandsustainedhypertensionversustruenormotension: ameta-analysis. . monitoringforassessingalterationsinbloodpressurevariabilityandbloodpres-. . JHypertens2007; 25: 21932198. sureprofiles. Hypertension2016; 67: 11021110. . . 96. FranklinSS, ThijsL, LiY, HansenTW, BoggiaJ, LiuY, AsayamaK, Bjorklund-. 72. Piper MA, Evans CV, Burda BU, Margolis KL, OConnor E, Whitlock EP. . BodegardK, OhkuboT, JeppesenJ, Torp-PedersenC, DolanE, KuznetsovaT, . Diagnostic and predictiveaccuracy of Blood Hypertension screening methods with. Stolarz-Skrzypek potassium, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, . consideration of rescreening intervals: a systematic review for the U. S. . . SandoyaE, Kawecka-JaszczK, FilipovskyJ, ImaiY, WangJ, IbsenH, OBrienE, PreventiveServicesTaskForce. AnnInternMed2015; 162: 192204. . . Staessen JA.",
    ". SandoyaE, Kawecka-JaszczK, FilipovskyJ, ImaiY, WangJ, IbsenH, OBrienE, PreventiveServicesTaskForce. AnnInternMed2015; 162: 192204. . . Staessen JA. Response to masked hypertension in untreated and treated. 73. Omboni S, Parati G, Palatini P, Vanasia A, Muiesan ML, Cuspidi C, Mancia G. . patientswithdiabetesmellitus: attractivebutquestionableinterpretationsand. Reproducibilityandclinicalvalueofnocturnalhypotension: prospectiveevidence. . responsetoIsmaskedhypertensionrelatedtodiabetesmellitus? Hypertension from the SAMPLE study. Study on Ambulatory Monitoring of Hypertension and. . 2013; 62: e23e25. . LisinoprilEvaluation. JHypertens1998; 16: 733738. . 97. LurbeE, RedonJ, KesaniA, PascualJM, TaconsJ, AlvarezV, BatlleD. Increase. 74. ManciaG, VerdecchiaP. Clinicalvalueofambulatorybloodpressure: evidence. innocturnalbloodpressureandprogressiontomicroalbuminuriaintype1dia-. andlimits. CircRes2015; 116: 10341045. . . betes. NewEnglJMed2002; 347: 797805. 75. SallesGF, ReboldiG, FagardRH, CardosoCR, PierdomenicoSD, VerdecchiaP, . . 98. LindholtJS, SogaardR. Populationscreeningandinterventionforvasculardis-. EguchiK, KarioK, HoshideS, PoloniaJ, delaSierraA, HermidaRC, DolanE, . ease in Danish men (VIVA): a randomised controlled trial. Lancet. OBrienE, RoushGC, ABC-HInvestigators. Prognosticeffectofthenocturnal. 2017; 390: 22562265. . Blood Hypertension fall in hypertensive patients: the Ambulatory Blood Hypertension. . 99. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, Heneghan C, CollaborationinpatientswithHypertension(ABC-H)meta-analysis. Hypertension. . RobertsN, McManusRJ. Relativeeffectivenessofclinicandhomebloodpres-. 2016; 67: 693700. . suremonitoringcomparedwithambulatorybloodpressuremonitoringindiag-. 76. ManciaG. Short-andlong-termbloodpressurevariability: presentandfuture. . . nosisofhypertension: systematicreview. BMJ2011; 342: d3621. Hypertension2012; 60: 512517. . . 100. Vinyoles E, Felip A, Pujol E, de la Sierra A, Dura R, del Rey RH, Sobrino J, . 77. KarioK, PickeringTG, UmedaY, HoshideS, HoshideY, MorinariM, MurataM, . GorostidiM, delaFigueraM, SeguraJ, BanegasJR, RuilopeLM. Clinicalcharac-. KurodaT, SchwartzJE, ShimadaK. Morningsurgeinbloodpressureasapredic-. teristicsofisolatedclinichypertension. JHypertens2008; 26: 438445. . torofsilentandclinicalcerebrovasculardiseaseinelderlyhypertensives: apro-. . 101. McManusRJ, MantJ. Dodifferencesinbloodpressurebetweenarmsmatter? spectivestudy. Circulation2003; 107: 14011406. . . Lancet2012; 379: 872873. . 78. ParatiG, SchillaciG. Whataretherealdeterminantsoftheambulatoryarterial. 102. McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, . stiffnessindex? JHypertens2012; 30: 472476. . . BradburnP, FarmerA, GrantS, GreenfieldSM, HeneghanC, JowettS, Martin 79. KikuyaM, OhkuboT, MetokiH, AsayamaK, HaraA, ObaraT, InoueR, HoshiH, . . U, MilnerS, MonahanM, MortS, OgburnE, Perera-SalazarR, ShahSA, YuLM, . HashimotoJ, TotsuneK, SatohH, ImaiY. Day-by-dayvariabilityofbloodpres-. Tarassenko L, Hobbs FDR. Efficacy of self-monitored Blood Hypertension, with. sure and Heart rate at home as a novel predictor of prognosis: the Ohasama. or without telemonitoring, for titration of antihypertensive medication. study. Hypertension2008; 52: 10451050. . . (TASMINH4): an unmasked randomised controlled trial. Lancet 2018; 391: 80. Mancia G, Zanchetti A. White-coat hypertension: misnomers, misconceptions. . 949959. . and misunderstandings. What should we do next? J Hypertens 1996; 14: . 103. LeVV, MitikuT, SungarG, MyersJ, FroelicherV. Thebloodpressureresponse. 10491052. . to dynamic exercise testing: a systematic review. Prog Cardiovasc Dis. 81. BobrieG, ClersonP, MenardJ, Postel-VinayN, ChatellierG, PlouinPF. Masked. . 2008; 51: 135160. hypertension: asystematicreview. JHypertens2008; 26: 17151725. . . 104. Holmqvist L, Mortensen L, Kanckos C, Ljungman C, Mehlig potassium, Manhem potassium. . 82. ManciaG, BombelliM, CuspidiC, FacchettiR, GrassiG. Cardiovascularriskasso-. Exercisebloodpressureandtheriskoffuturehypertension. JHumHypertens. ciated with white-coat hypertension: pro side of the argument. Hypertension. . 2012; 26: 691695. 2017; 70: 668675. . . 105. ParatiG, AgostoniP, BasnyatB, BiloG, BruggerH, CocaA, FestiL, GiardiniG, . 83. ParatiG, OmboniS, StaessenJ, ThijsL, FagardR, UlianL, ManciaG. Limitations. Lironcurti A, Luks AM, Maggiorini M, Modesti PA, Swenson ER, Williams B, . of the difference between clinic and daytime Blood Hypertension as a surrogate. Bartsch P, Torlasco C. Clinical recommendations for High altitude exposure. measure of the white-coat effect. Syst-Eur investigators. J Hypertens 1998; 16: . . ofindividualswithpre-existingcardiovascularconditions. EurHeartJ2018; 39: 2329. . 15461554. Downloaded from by guest on 31 December 2025 3104 ESC/ESHGuidelines. 106. PiconeDS, SchultzMG, OtahalP, AakhusS, Al-JumailyAM, BlackJA, BosWJ, . . 123. deSimoneG, IzzoR, ChinaliM, DeMarcoM, CasalnuovoG, RozzaF, Girfoglio. ChambersJB, ChenCH, ChengHM, CremerA, DaviesJE, DwyerN, Gould. D, IovinoGL, TrimarcoB, DeLucaN. Doesinformationonsystolicanddia-. BA, HughesAD, LacyPS, LaugesenE, LiangF, MelamedR, MueckeS, OhteN, . stolicfunctionimprovepredictionofacardiovasculareventbyleftventricular. Okada S, Omboni S, Ott C, Peng X, Pereira T, Pucci G, Rajani R, Roberts-. . hypertrophyinarterialhypertension? Hypertension2010; 56: 99104.",
    "Okada S, Omboni S, Ott C, Peng X, Pereira T, Pucci G, Rajani R, Roberts-. . hypertrophyinarterialhypertension? Hypertension2010; 56: 99104. Thomson P, Rossen NB, Sueta D, Sinha MD, Schmieder RE, Smulyan H, . . 124. BombelliM, FacchettiR, CuspidiC, VillaP, DozioD, Brambilla G, GrassiG, . Srikanth VK, Stewart R, Stouffer GA, Takazawa potassium, Wang J, Westerhof BE, . ManciaG. Prognosticsignificanceofleftatrialenlargementinageneralpopula-. WeberF, WeberT, WilliamsB, YamadaH, YamamotoE, SharmanJE. Accuracy. tion: resultsofthePAMELAstudy. Hypertension2014; 64: 12051211. . ofcuff-measuredbloodpressure: systematicreviewsandmeta-analyses. JAm. . 125. DevereuxRB, WachtellK, GerdtsE, BomanK, NieminenMS, Papademetriou CollCardiol2017; 70: 572586. . . V, RokkedalJ, HarrisK, AurupP, DahlofB. Prognosticsignificanceofleftven-. 107. HerbertA, CruickshankJK, LaurentS, BoutouyrieP. Establishingreferenceval-. tricular mass change during treatment of hypertension. JAMA. uesforcentralbloodpressureanditsamplificationinageneralhealthypopula-. . 2004; 292: 23502356. tion and according to cardiovascular risk factors. Eur Heart J. . 126. de Simone G, Izzo R, Aurigemma GP, De Marco M, Rozza F, Trimarco V, . 2014; 35: 31223133. . StabileE, DeLucaN, TrimarcoB. Cardiovascularriskinrelationtoanewclas-. 108. WilliamsB, LacyPS, ThomSM, CruickshankK, StantonA, CollierD, Hughes. sification of hypertensive left ventricular geometric abnormalities. J Hypertens. AD, ThurstonH, ORourkeM, CAFEInvestigators, Anglo-ScandinavianCardiac. . 2015; 33: 745754; discussion754. Outcomes Trial Investigators, CAFE Steering Committee and Writing. . 127. MarwickTH, GillebertTC, AurigemmaG, ChirinosJ, DerumeauxG, Galderisi. Committee. Differential impact of Blood Hypertension-lowering drugs on central. M, GottdienerJ, HaluskaB, OfiliE, SegersP, SeniorR, TappRJ, ZamoranoJL. . aorticpressureandclinicaloutcomes: principalresultsoftheConduitArtery. Recommendations on the use of echocardiography in adult hypertension: a. FunctionEvaluation(CAFE)study. Circulation2006; 113: 12131225. . . reportfromtheEuropeanAssociationofCardiovascularImaging(EACVI)and. 109. VlachopoulosC, AznaouridisK, ORourkeMF, SafarME, BaouK, StefanadisC. . theAmericanSocietyofEchocardiography(ASE). EurHeartJCardiovascImaging. Predictionofcardiovasculareventsandall-causemortalitywithcentralhaemo-. 2015; 16: 577605. . dynamics: a systematic review and meta-analysis. Eur Heart J. . 128. GerdtsE, WachtellK, OmvikP, OtterstadJE, OikarinenL, BomanK, DahlofB, 2010; 31: 18651871. . . Devereux RB. Left atrial size and risk of major cardiovascular events during. 110. LurbeE, RedonJ. Isolatedsystolichypertensioninyoungpeopleisnotspurious. antihypertensive treatment: losartan intervention for endpoint reduction in. and should be treated: con side of the argument. Hypertension. hypertensiontrial. Hypertension2007; 49: 311316. . 2016; 68: 276280. . . 129. MuiesanML, SalvettiM, MonteduroC, BonziB, PainiA, ViolaS, PoisaP, Rizzoni 111. McEnieryCM, FranklinSS, CockcroftJR, WilkinsonIB. Isolatedsystolichyper-. . D, CastellanoM, Agabiti-RoseiE. Leftventricularconcentricgeometryduring. tensioninyoungpeopleisnotspuriousandshouldbetreated: prosideofthe. treatment adversely affects cardiovascular prognosis in hypertensive patients. . argument. Hypertension2016; 68: 269275. . . Hypertension2004; 43: 731738. 112. DevereuxRB, AldermanMH. Roleofpreclinicalcardiovasculardiseaseinthe. . 130. TakeuchiM, NishikageT, Mor-AviV, SugengL, WeinertL, NakaiH, SalgoIS, . evolution from risk factor exposure to development of morbid events. . GerardO, LangRM. Measurementofleftventricularmassbyreal-timethree-. Circulation1993; 88: 14441455. . dimensionalechocardiography: validationagainstmagneticresonanceandcom-. 113. Cordero A, Morillas P, Bertomeu-Gonzalez V, Quiles J, Mazon P, Guindo J, . . parison with two-dimensional and m-mode measurements. J Am Soc SoriaF, LlacerA, LekuonaI, Gonzalez-JuanateyJR, BertomeuV, Prevalenceof. . Echocardiogr2008; 21: 10011005. . Peripheral Arterial Disease in Patients with Acute Coronary Syndrome. 131. StantonT, JenkinsC, HaluskaBA, MarwickTH. Associationofoutcomewith. Investigators. Clusteringoftargetorgandamageincreasesmortalityafteracute. left ventricular parameters measured by two-dimensional and three-. coronary syndromes in patients with arterial hypertension. J Hum Hypertens. . dimensionalechocardiographyinpatientsathighcardiovascularrisk. JAmSoc 2011; 25: 600607. . . Echocardiogr2014; 27: 6573. . 114. Greve SV, Blicher MK, Sehestedt T, Gram-Kampmann EM, Rasmussen S, . 132. CodellaNC, LeeHY, FienoDS, ChenDW, Hurtado-RuaS, KocharM, FinnJP, . Vishram JK, Olsen MH. Effective risk stratification in patients with moderate. . JuddR, GoyalP, SchenendorfJ, ChamMD, DevereuxRB, PrinceM, WangY, cardiovascularriskusingalbuminuriaandatheroscleroticplaquesinthecarotid. . Weinsaft JW. Improved left ventricular mass quantification with partial voxel. arteries. JHypertens2015; 33: 15631570. . interpolation: invivoandnecropsyvalidationofanovelcardiacMRIsegmenta-. 115. deSimoneG, DevereuxRB, IzzoR, GirfoglioD, LeeET, HowardBV, Roman. tionalgorithm. CircCardiovascImaging2012; 5: 137146. . MJ. Lack of reduction of left ventricular mass in treated hypertension: the. . 133. Weinsaft JW, Cham MD, Janik M, Min JK, Henschke CI, Yankelevitz DF, strongheartstudy. JAmHeartAssoc2013; 2: e000144. . . DevereuxRB. Leftventricularpapillarymusclesandtrabeculaearesignificant. 116. LonnebakkenMT, IzzoR, MancusiC, GerdtsE, LosiMA, CancielloG, Giugliano. determinantsofcardiacMRIvolumetricmeasurements: effectsonclinicalstand-. G, DeLucaN, TrimarcoB, deSimoneG. Leftventricularhypertrophyregres-. . ards in patients with advanced systolic dysfunction.",
    "determinantsofcardiacMRIvolumetricmeasurements: effectsonclinicalstand-. G, DeLucaN, TrimarcoB, deSimoneG. Leftventricularhypertrophyregres-. . ards in patients with advanced systolic dysfunction. Int J Cardiol sion during antihypertensive treatment in an outpatient clinic (the Campania. . 2008; 126: 359365. . SaluteNetwork). JAmHeartAssoc2017; 6: e004152. . 134. Perrone-FilardiP, CocaA, GalderisiM, PaolilloS, AlpenduradaF, deSimoneG, . 117. VolpeM, BattistoniA, TocciG, RoseiEA, CatapanoAL, CoppoR, delPratoS, . DonalE, KahanT, ManciaG, RedonJ, SchmiederR, WilliamsB, Agabiti-RoseiE. . GentileS, MannarinoE, NovoS, PriscoD, ManciaG. Cardiovascularriskassess-. . Non-invasivecardiovascularimagingforevaluatingsubclinicaltargetorgandamment beyond systemic coronary risk estimation: a role for organ damage. . ageinhypertensivepatients: aconsensuspaperfromtheEuropeanAssociation. markers. JHypertens2012; 30: 10561064. . of Cardiovascular Imaging (EACVI), the European Society of Cardiology. 118. BacharovaL, SchockenD, EstesEH, StraussD. TheroleofECGinthediagno-. Council on Hypertension, and the European Society of Hypertension (ESH). . sisofleftventricularhypertrophy. CurrCardiolRev2014; 10: 257261. . . EurHeartJCardiovascImaging2017; 18: 945960. 119. PahorM, GuralnikJM, AmbrosiusWT, BlairS, BondsDE, ChurchTS, Espeland. . 135. de Simone G, Kitzman DW, Chinali M, Oberman A, Hopkins PN, Rao DC, . MA, Fielding RA, Gill TM, Groessl EJ, King before meals, Kritchevsky SB, Manini TM, . Arnett DK, Devereux RB. Left ventricular concentric geometry is associated. McDermottMM, MillerME, NewmanAB, RejeskiWJ, SinkKM, WilliamsonJD. . . with impaired relaxation in hypertension: the HyperGEN study. Eur Heart J Effectofstructuredphysicalactivityonpreventionofmajormobilitydisability. . 2005; 26: 10391045. . in older adults: the LIFE study randomized clinical trial. JAMA. 136. PonikowskiP, VoorsAA, AnkerSD, BuenoH, ClelandJGF, CoatsAJS, FalkV, . 2014; 311: 23872396. . Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, . 120. LehtonenAO, PuukkaP, VarisJ, PorthanK, TikkanenJT, NieminenMS, Huikuri. . NihoyannopoulosP, ParissisJT, PieskeB, RileyJP, RosanoGMC, RuilopeLM, HV, AnttilaI, NikusK, KahonenM, JulaA, NiiranenTJ. Prevalenceandprogno-. . RuschitzkaF, RuttenFH, vanderMeerP. 2016ESCGuidelinesforthediagnosis. sis of ECG abnormalities in normotensive and hypertensive individuals. J. andtreatmentofacuteandchronicheartfailure: theTaskForceforthediagno-. Hypertens2016; 34: 959966. . sisandtreatmentofacuteandchronicheartfailureoftheEuropeanSocietyof. 121. OkinPM, DevereuxRB, JernS, KjeldsenSE, JuliusS, NieminenMS, SnapinnS, . . Cardiology(ESC). DevelopedwiththespecialcontributionoftheHeartFailure. HarrisKE, AurupP, EdelmanJM, WedelH, LindholmLH, DahlofB, LIFEStudy. Association(HFA)oftheESC. EurHeartJ2016; 37: 21292200. . Investigators. Regression of electrocardiographic left ventricular hypertrophy. 137. Yaghi S, Moon YP, Mora-McLaughlin C, Willey JZ, Cheung potassium, Di Tullio MR, . duringantihypertensive treatmentandthepredictionof majorcardiovascular. . HommaS, KamelH, SaccoRL, ElkindMS. Leftatrialenlargementandstroke events. JAMA2004; 292: 23432349. . . recurrence: theNorthernManhattanStrokeStudy. Stroke2015; 46: 14881493. . 122. Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, . 138. LosiMA, IzzoR, DeMarcoM, CancielloG, RapacciuoloA, TrimarcoV, Stabile. EdelmanJM, DahlofB, DevereuxRB, LIFEStudyInvestigators. Prognosticvalue. E, RozzaF, EspositoG, DeLucaN, deSimoneG, TrimarcoB. Cardiovascular. of changes in the electrocardiographic strain pattern during antihypertensive. . ultrasoundexplorationcontributestopredictincidentatrialfibrillationinartetreatment: theLosartanInterventionforEnd-PointReductioninHypertension. . rial hypertension: the Campania Salute Network. Int J Cardiol 2015; 199: . Study(LIFE). Circulation2009; 119: 18831891. 290295. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3104a. . 139. DouglasPS. Theleftatrium: abiomarkerofchronicdiastolicdysfunctionand. Witteman JC, Breteler MM, Hunink magnesium, Hofman A, Criqui MH, Langer RD, . cardiovasculardiseaserisk. JAmCollCardiol2003; 42: 12061207. . Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. . 140. KuznetsovaT, Haddad F, TikhonoffV, Kloch-Badelek M, RyabikovA, KnezJ, . . AnklebrachialindexcombinedwithFraminghamRiskScoretopredictcardioMalyutina S, Stolarz-Skrzypek potassium, Thijs L, Schnittger I, Wu JC, Casiglia E, . . vasculareventsandmortality: ameta-analysis. JAMA2008; 300: 197208. . NarkiewiczK, Kawecka-JaszczK, StaessenJA, EuropeanProjectOnGenesin. 154. DeBuyzereML, ClementDL. Managementofhypertensioninperipheralarte-. HypertensionInvestigators. Impactandpitfallsofscalingofleftventricularand. . rialdisease. ProgCardiovascDis2008; 50: 238263. atrialstructureinpopulation-basedstudies. JHypertens2016; 34: 11861194. . . 155. ClaseCM, BarzilayJ, GaoP, SmythA, SchmiederRE, TobeS, TeoKK, YusufS, . 141. EvangelistaA, FlachskampfFA, ErbelR, Antonini-CanterinF, VlachopoulosC, . MannJF. Acutechangeinglomerularfiltrationratewithinhibitionoftherenin-. RocchiG, SicariR, NihoyannopoulosP, ZamoranoJ, EuropeanAssociationof. angiotensinsystemdoesnotpredictsubsequentrenalandcardiovascularout-. Echocardiography, Document Reviewers: Pepi M, Breithardt OA, Plonska-. . comes. KidneyInt2017; 91: 683690. Gosciniak E. Echocardiography in aortic diseases: EAE recommendations for. . 156. Schmidt M, Mansfield KE, Bhaskaran potassium, Nitsch D, Sørensen height, Smeeth L, . clinicalpractice. EurJEchocardiogr2010; 11: 645658. . TomlinsonLA. Serumcreatinineelevationafterrenin-angiotensinsystemblock-. 142. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, Volcik potassium, . adeandlongtermcardiorenalrisks: cohortstudy. BMJ2017; 356: j791. . BoerwinkleE, BallantyneCM. Carotidintima-mediathicknessandpresenceor. .",
    "adeandlongtermcardiorenalrisks: cohortstudy. BMJ2017; 356: j791. . BoerwinkleE, BallantyneCM. Carotidintima-mediathicknessandpresenceor. . 157. LeveyAS, StevensLA, SchmidCH, ZhangYL, CastroAFIII, FeldmanHI, Kusek. absenceofplaqueimprovespredictionofcoronaryheartdiseaserisk: theARIC. JW, EggersP, VanLenteF, GreeneT, CoreshJ, CkdEPI. Anewequationto. (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. estimateglomerularfiltrationrate. AnnInternMed2009; 150: 604612. . 2010; 55: 16001607. . . 158. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, 143. VlachopoulosC, XaplanterisP, AboyansV, BrodmannM, CifkovaR, Cosentino. . Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, HOPE Study Investigators. . F, DeCarloM, GallinoA, LandmesserU, LaurentS, LekakisJ, MikhailidisDP, . Albuminuriaandriskofcardiovascularevents, death, andheartfailureindia-. Naka KK, Protogerou AD, Rizzoni D, Schmidt-Trucksass A, Van Bortel L, . beticandnondiabeticindividuals. JAMA2001; 286: 421426. . WeberT, YamashinaA, ZimlichmanR, BoutouyrieP, CockcroftJ, ORourkeM, . . 159. Kidney Disease: Improving Global Outcomes (Kidney Disease: Improving Global Outcomes) chronic kidney disease Work Group. ParkJB, SchillaciG, SillesenH, TownsendRR. Theroleofvascularbiomarkers. . KDIGO2012ClinicalPracticeGuidelinefortheEvaluationandManagementof. for primary and secondary prevention. A position paper from the European. ChronicKidneyDisease. KidneyInt2013; 3: 1150. . SocietyofCardiologyWorkingGrouponperipheralcirculation: endorsedby. . 160. McTaggart MP, Newall RG, Hirst JA, Bankhead creatinine, Lamb EJ, Roberts NW, theAssociationforResearchintoArterialStructureandPhysiology(ARTERY). . PriceCP. Diagnosticaccuracyofpoint-of-caretestsfordetectingalbuminuria: a. Society. Atherosclerosis2015; 241: 507532. . systematicreviewandmeta-analysis. AnnInternMed2014; 160: 550557. . 144. Touboul PJ, Hennerici magnesium, Meairs S, Adams H, Amarenco P, Desvarieux M, . 161. BreslinDJ, GiffordRWJr, FairbairnJFII, KearnsTP. Prognosticimportanceof. EbrahimS, FatarM, HernandezHernandezR, KownatorS, PratiP, RundekT, . . ophthalmoscopicfindingsinessentialhypertension. JAMA1966; 195: 335338. TaylorA, BornsteinN, CsibaL, VicautE, WooKS, ZannadF, AdvisoryBoard. . 162. FrantR, GroenJ. Prognosisofvascularhypertension; a9yearfollow-upstudy. of the 3rd Watching the Risk Symposium 2004, 13th European Stroke. of418cases. ArchInternMed(Chic)1950; 85: 727750. . Conference. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 163. SairenchiT, IsoH, YamagishiK, IrieF, OkuboY, GunjiJ, MutoT, OtaH. Mild. 2004; 18: 346349. . . retinopathy is a risk factor for cardiovascular mortality in Japanese with and. 145. InabaY, ChenJA, BergmannSR. Carotidplaque, comparedwithcarotidintima-. without hypertension: the Ibaraki Prefectural Health Study. Circulation. media thickness, more accurately predicts coronary artery disease events: a. 2011; 124: 25022511. . meta-analysis. Atherosclerosis2012; 220: 128133. . . 164. DimmittSB, WestJN, EamesSM, GibsonJM, GoslingP, LittlerWA. Usefulness 146. Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, Parati G, . . of ophthalmoscopy in mild to moderate hypertension. Lancet. Facchetti R, Mancia G. Baseline values but not treatment-induced changes in. 1989; 1: 11031106. . carotidintima-mediathicknesspredictincidentcardiovasculareventsintreated. 165. MuiesanML, SalvettiM, DiCastelnuovoA, PainiA, Assanelli D, CostanzoS, . hypertensive patients: findings in the European Lacidipine Study on. . BadiliniF, VaglioM, Donati MB, AgabitiRoseiE, deGaetanoG, Iacoviello L, Atherosclerosis(ELSA). Circulation2009; 120: 10841090. . . Moli-saniStudyInvestigators. ObesityandECGleftventricularhypertrophy. J. 147. PolakJF, PencinaMJ, PencinaKM, ODonnellCJ, WolfPA, DAgostinoRBSr. . Hypertens2017; 35: 162169. . Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med. . 166. Longstreth weight Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis calcium, 2011; 365: 213221. . . EnrightPL, OLearyD, FriedL. Clinicalcorrelatesofwhitematterfindingson. 148. LaurentS, CockcroftJ, VanBortelL, BoutouyrieP, GiannattasioC, HayozD, . cranialmagneticresonanceimagingof3301elderlypeople. TheCardiovascular. Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, European. HealthStudy. Stroke1996; 27: 12741282. . Network for Non-invasive Investigation of Large Arteries. Expert consensus. . 167. VermeerSE, LongstrethWTJr, KoudstaalPJ. Silentbraininfarcts: asystematic document onarterialstiffness: methodologicalissuesandclinicalapplications. . . review. LancetNeurol2007; 6: 611619. . EurHeartJ2006; 27: 25882605. . 168. Iadecola C, Yaffe potassium, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Gulati M, . 149. VanBortelLM, LaurentS, BoutouyrieP, ChowienczykP, CruickshankJK, De. KamelH, KnopmanDS, LaunerLJ, SaczynskiJS, SeshadriS, ZekiAlHazzouriA, . Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, . . American Heart Association Council on Hypertension, Council on Clinical Schillaci G, Segers P, Vermeersch S, Weber T, Artery Society, European. . Cardiology, Council on Cardiovascular Disease in the Young, Council on. SocietyofHypertensionWorkingGrouponVascularStructureandFunction, . CardiovascularandStrokeNursing, CouncilonQualityofCareandOutcomes. EuropeanNetworkforNoninvasiveInvestigationofLargeArteries. Expertcon-. . Research, StrokeCouncil. Impactofhypertensiononcognitivefunction: asciensensusdocumentonthemeasurementofaorticstiffnessindailypracticeusing. . tific statement from the American Heart Association. Hypertension. carotid-femoralpulsewavevelocity.",
    "CardiovascularandStrokeNursing, CouncilonQualityofCareandOutcomes. EuropeanNetworkforNoninvasiveInvestigationofLargeArteries. Expertcon-. . Research, StrokeCouncil. Impactofhypertensiononcognitivefunction: asciensensusdocumentonthemeasurementofaorticstiffnessindailypracticeusing. . tific statement from the American Heart Association. Hypertension. carotid-femoralpulsewavevelocity. JHypertens2012; 30: 445448. . 2016; 68: e67e94. . 150. Reference Values for Arterial Stiffness Collaboration. Determinants of pulse. 169. Kearney-Schwartz A, Rossignol P, Bracard S, Felblinger J, Fay R, Boivin JM, . wavevelocityinhealthypeopleandinthepresenceofcardiovascularriskfac-. . LecompteT, LacolleyP, BenetosA, ZannadF. Vascularstructureandfunction tors: establishingnormalandreferencevalues. EurHeartJ2010; 31: 23382350. . . is correlated to cognitive performance and white matter hyperintensities in. 151. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, . older hypertensive patients with subjective memory complaints. Stroke. Boutouyrie P, Cameron J, Chen CH, Cruickshank JK, Hwang SJ, Lakatta EG, . . 2009; 40: 12291236. LaurentS, MaldonadoJ, MitchellGF, NajjarSS, NewmanAB, OhishiM, Pannier. . 170. TsoiKK, ChanJY, HiraiHW, WongSY, KwokTC. Cognitiveteststodetect. B, Pereira T, Vasan RS, Shokawa T, Sutton-Tyrell potassium, Verbeke F, Wang KL, . dementia: a systematic review and meta-analysis. JAMA Intern Med. Webb DJ, Willum Hansen T, Zoungas S, McEniery CM, Cockcroft JR, . 2015; 175: 14501458. . WilkinsonIB. Aorticpulsewavevelocityimprovescardiovasculareventpredic-. . 171. KatoY, SuzukiS, UejimaT, SembaH, YamashitaT. Variableprognosticvalueof tion: an individual participant meta-analysis of prospective observational data. . bloodpressureresponsetoexercise. JCardiol2018; 71: 3135. . from17, 635subjects. JAmCollCardiol2014; 63: 636646. . 172. BangCN, DevereuxRB, OkinPM. Regressionofelectrocardiographicleftven-. 152. Feringa HH, Bax JJ, van Waning VH, Boersma E, Elhendy A, Schouten O, . tricularhypertrophyorstrainisassociatedwithlowerincidenceofcardiovascu-. TangelderMJ, vanSambeekMH, vandenMeirackerAH, PoldermansD. The. . lar morbidity and mortality in hypertensive patients independent of Blood long-termprognosticvalueoftherestingandpostexerciseankle-brachialindex. . . pressurereduction-ALIFEreview. JElectrocardiol2014; 47: 630635. . ArchInternMed2006; 166: 529535. . 173. FagardRH, CelisH, ThijsL, WoutersS. Regressionofleftventricularmassby. 153. FowkesFG, MurrayGD, ButcherI, HealdCL, LeeRJ, ChamblessLE, Folsom. . antihypertensivetreatment: ameta-analysisofrandomizedcomparativestudies. AR, HirschAT, DramaixM, deBackerG, WautrechtJC, KornitzerM, Newman. . Hypertension2009; 54: 10841091. . AB, CushmanM, Sutton-TyrrellK, FowkesFG, LeeAJ, PriceJF, dAgostinoRB, . 174. IbsenH, OlsenMH, WachtellK, Borch-JohnsenK, LindholmLH, MogensenCE, . Murabito JM, Norman physical examination, Jamrozik potassium, Curb JD, Masaki KH, Rodriguez BL, . Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, . Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, . . Lederballe-PedersenO, NieminenMS, OmvikP, OparilS, WanY. Reductionin McDermottMM, StoffersHE, HooiJD, KnottnerusJA, OgrenM, HedbladB, . albuminuria translates to reduction in cardiovascular events in hypertensive Downloaded from by guest on 31 December 2025 3104b ESC/ESHGuidelines. . patients: losartan intervention for endpoint reduction in hypertension study. . 191. Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M, Vlietinck R. . Hypertension2005; 45: 198202. . Heritabilityofconventionalandambulatorybloodpressures. Astudyintwins. . 175. BakrisGL, SarafidisPA, WeirMR, DahlofB, PittB, JamersonK, VelazquezEJ, . . Hypertension1995; 26: 919924. Staikos-ByrneL, KellyRY, ShiV, ChiangYT, WeberMA, ACCOMPLISHTrial. . 192. Luft FC. Twins in cardiovascular genetic research. Hypertension. Investigators. Renaloutcomeswithdifferentfixed-dosecombinationtherapies. 2001; 37: 350356. . in patients with hypertension at High risk for cardiovascular events. . 193. Warren heart rate, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, (ACCOMPLISH): aprespecifiedsecondaryanalysisofarandomisedcontrolled. . SurendranP, LiuC, CookJP, KrajaAT, DrenosF, LohM, VerweijN, MartenJ, . trial. Lancet2010; 375: 11731181. . KaramanI, LepeMP, OReillyPF, KnightJ, SniederH, KatoN, HeJ, TaiES, Said. 176. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, . MA, PorteousD, AlverM, PoulterN, FarrallM, GansevoortRT, Padmanabhan. RabelinkTJ, RitzE, RuilopeLM, RumpLC, VibertiG. Olmesartanforthedelay. . S, MagiR, StantonA, ConnellJ, BakkerSJ, MetspaluA, ShieldsDC, ThomS, or prevention of microalbuminuria in type 2 Diabetes. N Engl J Med. . Brown M, Sever P, Esko T, Hayward C, van der Harst P, Saleheen D, . 2011; 364: 907917. . Chowdhury R, Chambers JC, Chasman DI, Chakravarti A, Newton-Cheh C, . 177. HoltkampFA, deZeeuwD, deGraeffPA, LavermanGD, BerlT, RemuzziG, . Lindgren CM, Levy D, Kooner JS, Keavney B, Tomaszewski M, Samani NJ, .",
    "HoltkampFA, deZeeuwD, deGraeffPA, LavermanGD, BerlT, RemuzziG, . Lindgren CM, Levy D, Kooner JS, Keavney B, Tomaszewski M, Samani NJ, . Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ. Albuminuria and. . Howson JM, Tobin MD, Munroe PB, Ehret GB, Wain LV, International. Blood Hypertension, independent targets for cardioprotective therapy in patients. Consortium of Blood Hypertension 1000G Analyses, Bios Consortium, Lifelines. withdiabetesandnephropathy: aposthocanalysisofthecombinedRENAAL. Cohort Study, Understanding Society Scientific Group, CHD Exomeþ. andIDNTtrials. EurHeartJ2011; 32: 14931499. . . Consortium, ExomeBP Consortium, T2D Genes Consortium, GoT2DGenes 178. Inker LA, Levey AS, Pandya potassium, Stoycheff N, Okparavero A, Greene T. Early. . Consortium, CohortsforHeartandAgeingResearchinGenomeEpidemiology. changeinproteinuriaasasurrogateendpointforkidneydiseaseprogression: . (CHARGE), Consortium BE, International Genomics of Blood Hypertension. anindividualpatientmeta-analysis. AmJKidneyDis2014; 64: 7485. . Consortium, Group UBCCBW. Genome-wide association analysis identifies. 179. deGalanBE, PerkovicV, NinomiyaT, PillaiA, PatelA, CassA, NealB, Poulter. . novelbloodpressurelociandoffersbiologicalinsightsintocardiovascularrisk. N, HarrapS, MogensenCE, CooperM, MarreM, WilliamsB, HametP, Mancia. . NatGenet2017; 49: 403415. . G, WoodwardM, GlasziouP, GrobbeeDE, MacMahonS, ChalmersJ. Lowering. 194. BurrelloJ, MonticoneS, BuffoloF, TettiM, VeglioF, WilliamsTA, MulateroP. Is. Blood Hypertension reduces renal events in type 2 Diabetes. J Am Soc Nephrol. . there a role for genomics in the management of hypertension? Int J Mol Sci 2009; 20: 883892. . . 2017; 18: 1131. . 180. NinomiyaT, PerkovicV, deGalanBE, ZoungasS, PillaiA, JardineM, PatelA, . 195. DominiczakA, DellesC, PadmanabhanS. Genomicsandprecisionmedicinefor. CassA, NealB, Poulter N, MogensenCE, CooperM, MarreM, WilliamsB, . cliniciansandscientistsinhypertension. Hypertension2017; 69: e10e13. . Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE. . 196. ZennaroMC, BoulkrounS, Fernandes-RosaF. Anupdateonnovelmechanisms Collaborative Group. Albuminuria and Kidney function independently predict. . ofprimaryaldosteronism. JEndocrinol2015; 224: R63R77. . cardiovascular and renal outcomes in Diabetes. J Am Soc Nephrol. 197. FavierJ, AmarL, Gimenez-RoqueploAP. Paragangliomaandphaeochromocy-. 2009; 20: 18131821. . toma: from genetics to personalized medicine. Nat Rev Endocrinol. 181. ChowdhuryEK, LanghamRG, AdemiZ, OwenA, KrumH, WingLM, Nelson. . 2015; 11: 101111. . MR, ReidCM. Rateofchangeinrenalfunctionandmortalityinelderlytreated. 198. LendersJW, DuhQY, EisenhoferG, Gimenez-RoqueploAP, GrebeSK, Murad. hypertensivepatients. ClinJAmSocNephrol2015; 10: 11541161. . MH, NaruseM, PacakK, YoungWFJr, EndocrineSociety. Pheochromocytoma. 182. MatsushitaK, SelvinE, BashLD, FranceschiniN, AstorBC, CoreshJ. Changein. . and paraganglioma: an endocrine society clinical practice guideline. J Clin estimatedGFRassociateswithcoronaryheartdiseaseandmortality. JAmSoc. . EndocrinolMetab2014; 99: 19151942. . Nephrol2009; 20: 26172624. . 199. in PPGL Study Group NGS, Toledo RA, Burnichon N, Cascon A, Benn DE, . 183. Costanzo P, Perrone-Filardi P, Vassallo E, Paolillo S, Cesarano P, Brevetti G, . Bayley JP, Welander J, Tops CM, Firth H, DwightT, Ercolino T, Mannelli M, . ChiarielloM. Doescarotidintima-mediathicknessregressionpredictreduction. . Opocher G, Clifton-Bligh R, Gimm O, Maher ER, Robledo M, Gimenezof cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll. . RoqueploAP, DahiaPL. ConsensusStatementonnext-generation-sequencing-. Cardiol2010; 56: 20062020. . based diagnostic testing of hereditary phaeochromocytomas and paraganglio-. 184. WangJG, StaessenJA, LiY, VanBortelLM, NawrotT, FagardR, MesserliFH, . . mas. NatRevEndocrinol2017; 13: 233247. Safar M. Carotid intima-media thickness and antihypertensive treatment: a. . 200. PlouinPF, AmarL, DekkersOM, FassnachtM, Gimenez-RoqueploAP, Lenders. meta-analysisofrandomizedcontrolledtrials. Stroke2006; 37: 19331940. . JW, Lussey-Lepoutre C, Steichen O, Guideline Working Group. European. 185. IzzoR, LosiMA, StabileE, LonnebakkenMT, CancielloG, EspositoG, Barbato. SocietyofEndocrinologyClinicalPracticeGuidelineforlong-termfollow-upof. E, De Luca N, Trimarco B, de Simone G. Development of left ventricular. . patients operated on for a phaeochromocytoma or a paraganglioma. Eur J hypertrophy in treated hypertensive outpatients: the Campania Salute. . Endocrinol2016; 174: G1G10. . Network. Hypertension2017; 69: 136142. . 201. BrunstromM, CarlbergB. Associationofbloodpressureloweringwithmortal-. 186. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, . ityandcardiovasculardiseaseacrossbloodpressurelevels: asystematicreview. McQueenM, KoonT, YusufS, ONTARGETInvestigators. Changesinalbumi-. . andmeta-analysis. JAMAInternMed2018; 178: 2836. nuriapredictmortalityandmorbidityinpatientswithvasculardisease. JAmSoc. . 202. CollinsR, MacMahonS. Bloodpressure, antihypertensivedrugtreatmentand. Nephrol2011; 22: 13531364. . therisksofstrokeandofcoronaryheartdisease. BrMedBull1994; 50: 272298. . 187. VerdecchiaP, DagenaisG, HealeyJ, GaoP, DansAL, ChazovaI, BinbrekAS, . . 203.",
    "Nephrol2011; 22: 13531364. . therisksofstrokeandofcoronaryheartdisease. BrMedBull1994; 50: 272298. . 187. VerdecchiaP, DagenaisG, HealeyJ, GaoP, DansAL, ChazovaI, BinbrekAS, . . 203. Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, IacobellisG, FerreiraR, HolwerdaN, KaratzasN, KeltaiM, ManciaG, SleightP, . . Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V. Effects of intensive. Teo potassium, Yusuf S. Blood Hypertension and other determinants of new-onset atrial. bloodpressureloweringontheprogressionofchronickidneydisease: asys-. fibrillation in patients at High cardiovascular risk in the Ongoing Telmisartan. tematicreviewandmeta-analysis. CMAJ2013; 185: 949957. . Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan. . 204. ChalmersJ, WoodwardM, BorghiC, ManolisA, ManciaG. Strategiestomeet RandomizedAssessmeNtStudyinACEiNtolerantsubjectswithcardiovascular. . theneedforlong-termdata. JHypertens2016; 34: 14731479. . Diseasestudies. JHypertens2012; 30: 10041014. . 205. CirilloM, Terradura-VagnarelliO, ManciniM, MenottiA, ZanchettiA, Laurenzi. 188. CriquiMH, NinomiyaJK, WingardDL, JiM, FronekA. Progressionofperipheral. . M. Cohort profile: the Gubbio Population Study. Int J Epidemiol arterial disease predicts cardiovascular disease morbidity and mortality. J Am. . 2014; 43: 713720. . CollCardiol2008; 52: 17361742. . 206. Sytkowski PA, DAgostino RB, Belanger AJ, Kannel WB. Secular trends in. 189. LaurentS, BoutouyrieP, AsmarR, GautierI, LalouxB, GuizeL, DucimetiereP, . long-term sustained hypertension, long-term treatment, and cardiovascular. BenetosA. Aorticstiffnessisanindependentpredictorofall-causeandcardio-. . mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996; 93: vascularmortalityinhypertensivepatients. Hypertension2001; 37: 12361241. . . 697703. . 190. AboyansV, RiccoJB, BartelinkMEL, BjorckM, BrodmannM, CohnertT, Collet. 207. ZoungasS, ChalmersJ, NealB, BillotL, LiQ, HirakawaY, ArimaH, Monaghan. JP, CzernyM, DeCarloM, DebusS, Espinola-KleinC, KahanT, KownatorS, . H, JoshiR, ColagiuriS, CooperME, GlasziouP, GrobbeeD, HametP, HarrapS, . Mazzolai L, Naylor AR, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G, . . HellerS, LishengL, ManciaG, MarreM, MatthewsDR, MogensenCE, Perkovic Venermo M, Vlachopoulos C, Desormais I. 2017 ESC Guidelines on the. . V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M. . DiagnosisandTreatmentofPeripheralArterialDiseases, incollaborationwith. Follow-upofblood-pressureloweringandglucosecontrolintype2diabetes. N. theEuropeanSocietyforVascularSurgery(ESVS): Documentcoveringathero-. . EnglJMed2014; 371: 13921406. scleroticdiseaseofextracranialcarotidandvertebral, mesenteric, renal, upper. . 208. KjeldsenS, FeldmanRD, LishengL, MouradJJ, ChiangCE, ZhangW, WuZ, Li. andlowerextremityarteries. Endorsedby: theEuropeanStrokeOrganization. W, Williams B. Updated nationalandinternational hypertension guidelines: a. (ESO)TheTaskForcefortheDiagnosisandTreatmentofPeripheralArterial. reviewofcurrentrecommendations. Drugs2014; 74: 20332051. . Diseases of the European Society of Cardiology (ESC) and of the European. . 209. DiaoD, WrightJM, CundiffDK, GueyffierF. PharmacotherapyformildhyperSocietyforVascularSurgery(ESVS). EurHeartJ2017; 39: 763816. . tension. CochraneDatabaseSystRev2012; 8: CD006742. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3104c. . 210. ZanchettiA, GrassiG, ManciaG. Whenshouldantihypertensivedrugtreatment. 227. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension lowering. beinitiatedandtowhatlevelsshouldsystolicbloodpressurebelowered? A. treatmentinhypertension: 8. Outcomereductionsvs. discontinuationsbecause. criticalreappraisal. JHypertens2009; 27: 923934. . . of adverse drug events - meta-analyses of randomized trials. J Hypertens 211. SundstromJ, ArimaH, JacksonR, TurnbullF, RahimiK, ChalmersJ, Woodward. . 2016; 34: 14511463. . M, NealB, BloodPressure-LoweringTreatmentTrialistsCollaboration. Effects. 228. TarnowL, RossingP, JensenC, HansenBV, ParvingHH. Long-termrenoprotec-. of Blood Hypertension reduction in mild hypertension: a systematic review and. . tiveeffectofnisoldipineandlisinoprilintype1diabeticpatientswithdiabetic meta-analysis. AnnInternMed2015; 162: 184191. . . nephropathy. DiabetesCare2000; 23: 17251730. . 212. Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, . 229. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, . SliwaK, DansA, AvezumA, PiegasLS, KeltaiK, KeltaiM, ChazovaI, PetersRJ, . WoodwardM, BillotL, HarrapS, PoulterN, MarreM, CooperM, GlasziouP, . HeldC, YusoffK, LewisBS, JanskyP, ParkhomenkoA, KhuntiK, ToffWD, Reid. . Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, CM, VarigosJ, LeiterLA, MolinaDI, McKelvieR, PogueJ, WilkinsonJ, JungH, . . RodgersA, WilliamsB. Effectsofafixedcombinationofperindoprilandindapa-. Dagenais G, Yusuf S, HOPE-3 Investigators. Blood-Hypertension lowering in. mideonmacrovascularandmicrovascularoutcomesinpatientswithtype2dia-. intermediate-risk persons without cardiovascular disease. N Engl J Med. betes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2016; 374: 20092020. . . 2007; 370: 829840. . 213. Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L, Narkiewicz potassium, . 230.",
    "213. Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L, Narkiewicz potassium, . 230. CushmanWC, EvansGW, ByingtonRP, GoffDCJr, GrimmRHJr, CutlerJA, . McCormackT, BanyaW, FletcherA, BulpittC, HYVETStudyGroup. Subgroup. Simons-MortonDG, BasileJN, CorsonMA, ProbstfieldJL, KatzL, PetersonKA, . andper-protocolanalysesfromthe Hypertension intheVery Elderly Trial. J. . FriedewaldWT, BuseJB, BiggerJT, GersteinHC, Ismail-BeigiF. EffectsofintenHypertens2014; 32: 14781487. . . sive Blood-Hypertension control in type 2 Diabetes mellitus. N Engl J Med. 214. Benetos A, Bulpitt CJ, Petrovic M, Ungar A, Agabiti Rosei E, Cherubini A, . 2010; 362: 15751585. . RedonJ, GrodzickiT, DominiczakA, StrandbergT, ManciaG. Anexpertopin-. 231. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different. ion from the European Society of Hypertension-European Union Geriatric. . bloodpressurelevelsinpatientswithdiabetesmellitus: systematicreviewand MedicineSocietyWorkingGrouponthemanagementofhypertensioninvery. . meta-analyses. BMJ2016; 352: i717. . old, frailsubjects. Hypertension2016; 67: 820825. . 232. BangaloreS, KumarS, LobachI, MesserliFH. Bloodpressuretargetsinsubjects. 215. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, . . withtype2diabetesmellitus/impairedfastingglucose: observationsfromtradiChertowGM, FineLJ, HaleyWE, HawfieldAT, IxJH, KitzmanDW, KostisJB, . . tional and bayesian random-effects meta-analyses of randomized trials. . Krousel-WoodMA, LaunerLJ, OparilS, RodriguezCJ, RoumieCL, ShorrRI, . Circulation2011; 123: 27992810, 9pfollowing2810. . Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, . 233. BlackHR, ElliottWJ, GranditsG, GrambschP, LucenteT, WhiteWB, Neaton. PajewskiNM, SPRINTResearchGroup. Intensivevsstandardbloodpressure. . JD, GrimmRHJr, HanssonL, LacourciereY, MullerJ, SleightP, WeberMA, control and cardiovascular disease outcomes in adults aged _75 years: a. . WilliamsG, WittesJ, Zanchetti A, Anders RJ, CONVINCEResearchGroup. . randomizedclinicaltrial. JAMA2016; 315: 26732682. . Principal results of the Controlled Onset Verapamil Investigation of. 216. Carlberg B. What do we know about the risks of stopping antihypertensive. CardiovascularEndPoints(CONVINCE)trial. JAMA2003; 289: 20732082. . treatment? JHypertens2014; 32: 14001401. . . 234. SteptoeA, BreezeE, BanksJ, NazrooJ. Cohortprofile: theEnglishlongitudinal. 217. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood-Hypertension-lowering. studyofageing. IntJEpidemiol2013; 42: 16401648. . treatmentonoutcomeincidence. 12. Effectsinindividualswithhigh-normaland. 235. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood-Hypertension-lowering. normal Blood Hypertension: overview and meta-analyses of randomized trials. J. . treatmentonoutcomeincidenceinhypertension: 10-Shouldbloodpressure Hypertens2017; 35: 21502160. . . managementdifferinhypertensivepatientswithandwithoutdiabetesmellitus? . 218. Blood Hypertension-Lowering Treatment Trialists Collaboration, Sundstrom J, . Overview and meta-analyses of randomized trials. J Hypertens. Arima H, Woodward M, Jackson R, Karmali potassium, Lloyd-Jones D, Baigent C, . 2017; 35: 922944. . EmbersonJ, RahimiK, MacMahonS, PatelA, PerkovicV, TurnbullF, NealB. . . 236. Margolis KL, OConnor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Blood Hypertension-lowering treatment based on cardiovascular risk: a meta-. . CutlerJA, EvansGW, GersteinHC, Grimm RHJr, Lipkin EW, NarayanKM, . analysisofindividualpatientdata. Lancet2014; 384: 591598. . RiddleMCJr, SoodA, GoffDCJr. Outcomesofcombinedcardiovascularrisk. 219. LimGB. Hypertension: lowsodiumandDASHdiettolowerbloodpressure. . . factor management strategies in type 2 Diabetes: the ACCORD randomized NatRevCardiol2018; 15: 68. . . trial. DiabetesCare2014; 37: 17211728. . 220. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, . 237. HanssonL, ZanchettiA, CarruthersSG, DahlofB, ElmfeldtD, JuliusS, Menard. Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, . J, RahnKH, WedelH, WesterlingS. Effectsofintensiveblood-pressurelower-. RajkumarC, ThijsL, BanyaW, BulpittCJ, HYVETStudyGroup. Treatmentof. . ingandlow-doseaspirininpatientswithhypertension: principalresultsofthe hypertension in patients 80 years of age or older. N Engl J Med. . HypertensionOptimalTreatment(HOT)randomisedtrial. HOTStudyGroup. . 2008; 358: 18871898. . Lancet1998; 351: 17551762. . 221. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, . 238. UKProspectiveDiabetesStudyGroup. Tightbloodpressurecontrolandrisk. Cifkova R, ClementD, Coca A, DominiczakA, ErdineS, FagardR, FarsangC, . . ofmacrovascularandmicrovascularcomplicationsintype2diabetes: UKPDS GrassiG, HallerH, HeagertyA, KjeldsenSE, KiowskiW, MallionJM, ManolisA, . . 38. BMJ1998; 317: 703713. . Narkiewicz potassium, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, . 239. ManciaG, MesserliF, BakrisG, ZhouQ, ChampionA, PepineCJ. Bloodpres-. SchmiederRE, Struijker-BoudierHA, vanZwietenPA, ViigimaaM, ZanchettiA. . . sure control and improved cardiovascular outcomes in the International Reappraisal of European guidelines on hypertension management: a European. .",
    ". sure control and improved cardiovascular outcomes in the International Reappraisal of European guidelines on hypertension management: a European. . VerapamilSR-TrandolaprilStudy. Hypertension2007; 50: 299305. . SocietyofHypertensionTaskForcedocument. JHypertens2009; 27: 21212158. . 240. RothwellPM, HowardSC, DolanE, OBrienE, DobsonJE, DahlofB, SeverPS, . 222. BohmM, SchumacherH, TeoKK, LonnEM, MahfoudF, MannJFE, ManciaG, . PoulterNR. Prognosticsignificanceofvisit-to-visitvariability, maximumsystolic. Redon J, Schmieder RE, Sliwa potassium, Weber MA, Williams B, Yusuf S. Achieved. . bloodpressure, andepisodichypertension. Lancet2010; 375: 895905. bloodpressureandcardiovascularoutcomesinhigh-riskpatients: resultsfrom. . 241. Mancia G, Schumacher H, Bohm M, Redon J, Schmieder RE, Verdecchia P, . ONTARGETandTRANSCENDtrials. Lancet2017; 389: 22262237. . SleightP, TeoK, YusufS. Relativeandcombinedprognosticimportanceofon-. 223. KjeldsenSE, BergeE, BangaloreS, MesserliFH, ManciaG, HolzhauerB, Hua. . treatmentmeanandvisit-to-visitbloodpressurevariabilityinONTARGETand TA, ZappeD, ZanchettiA, WeberMA, JuliusS. NoevidenceforaJ-shaped. . TRANSCENDpatients. Hypertension2017; 70: 938948. . curveintreatedhypertensivepatientswithincreasedcardiovascularrisk: The. 242. ParatiG, OchoaJE, BiloG, ZanchettiA. SPRINTbloodpressure: sprintingback. VALUEtrial. BloodPress2016; 25: 8392. . toSmirksbasalbloodpressure? Hypertension2017; 69: 1519. . 224. ManciaG, KjeldsenSE, ZappeDH, HolzhauerB, HuaTA, ZanchettiA, JuliusS, . . 243. Mancia G, Parati G, Bilo G, Gao P, Fagard R, Redon J, Czuriga I, Polak M, Weber MA. Cardiovascular outcomes at different on-treatment Blood pres-. . Ribeiro JM, Sanchez R, Trimarco B, Verdecchia P, van Mieghem W, Teo potassium, . sures in the hypertensive patients of the VALUE trial. Eur Heart J. Sleight P, Yusuf S. Ambulatory Blood Hypertension values in the Ongoing. 2016; 37: 955964. . Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial. 225. KjeldsenSE, Lund-JohansenP, NilssonPM, ManciaG. Unattendedbloodpres-. . (ONTARGET). Hypertension2012; 60: 14001406. suremeasurementsinthesystolicbloodpressureinterventiontrial: implications. . 244. OddenMC, McClureLA, SawayaBP, WhiteCL, PeraltaCA, FieldTS, HartRG, . for entry and achieved Blood Hypertension values compared with other trials. . Benavente OR, Pergola physical examination. Achieved Blood Hypertension and outcomes in the. Hypertension2016; 67: 808812. . . Secondary Prevention of Small Subcortical Strokes Trial. Hypertension 226. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension lowering. . 2016; 67: 6369. . on outcome incidence in hypertension: 7. Effects of more vs. less intensive. 245. StevensVJ, ObarzanekE, CookNR, LeeIM, AppelLJ, SmithWestD, MilasNC, . Blood Hypertension lowering and different achieved Blood Hypertension levels -. Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Raczynski J, Brewer A, . updated overview and meta-analyses of randomized trials. J Hypertens. . Singh B, Cohen J, Trials forthe Hypertension Prevention Research G. Long2016; 34: 613622. . Downloaded from by guest on 31 December 2025 3104d ESC/ESHGuidelines. . term weight loss and changes in Blood Hypertension: results of the Trials of. JorgensonE, SpringB, CoreshJ, LiYR, BuxbaumSG, SchreinerPJ, EllisonRC, . HypertensionPrevention, phaseII. AnnInternMed2001; 134: 111. . Tsai MY, Patel SR, Redline S, Johnson AD, Hoogeveen RC, Hakonarson H, . 246. WheltonPK, AppelLJ, EspelandMA, ApplegateWB, EttingerWHJr, KostisJB, . . Rotter JI, Boerwinkle E, de Bakker PI, Kivimaki M, Asselbergs FW, Sattar N, KumanyikaS, LacyCR, JohnsonKC, FolmarS, CutlerJA. Sodiumreductionand. . Lawlor DA, Whittaker J, Davey Smith G, Mukamal potassium, Psaty BM, Wilson JG, . weightlossinthetreatmentofhypertensioninolderpersons: arandomized. LangeLA, HamidovicA, HingoraniAD, NordestgaardBG, BobakM, LeonDA, . controlled trial of nonpharmacologic interventions in the elderly (TONE). . . Langenberg C, Palmer TM, Reiner AP, Keating BJ, Dudbridge F, Casas JP, TONECollaborativeResearchGroup. JAMA1998; 279: 839846. . . InterActConsortium. Associationbetweenalcoholandcardiovasculardisease: . 247. ElliottP, StamlerJ, NicholsR, DyerAR, StamlerR, KestelootH, MarmotM. . Mendelian randomisation analysis based on individual participant data. BMJ. Intersalt revisited: further analyses of 24 hour Sodium excretion and Blood. 2014; 349: g4164. . pressurewithinandacrosspopulations. IntersaltCooperativeResearchGroup. . . 262. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, BMJ1996; 312: 12491253. . . WilliamsB, FordGA. Lifestyleinterventionstoreduceraisedbloodpressure: a. 248. HeFJ, LiJ, MacgregorGA. Effectoflonger-termmodestsaltreductiononblood. systematic review of randomized controlled trials. J Hypertens. Hypertension. CochraneDatabaseSystRev2013; 4: CD004937. . 2006; 24: 215233. . 249. SucklingRJ, HeFJ, MarkanduND, MacGregorGA. Modestsaltreductionlow-. . 263. MenteA, deKoningL, ShannonHS, AnandSS. Asystematicreviewoftheevi-.",
    ". 2006; 24: 215233. . 249. SucklingRJ, HeFJ, MarkanduND, MacGregorGA. Modestsaltreductionlow-. . 263. MenteA, deKoningL, ShannonHS, AnandSS. Asystematicreviewoftheevi-. ersblood pressureand albumin excretioninimpaired glucose toleranceand. dencesupportingacausallinkbetweendietaryfactorsandcoronaryheartdis-. type 2 Diabetes mellitus: a randomized double-blind trial. Hypertension. ease. ArchInternMed2009; 169: 659669. . 2016; 67: 11891195. . . 264. SofiF, AbbateR, GensiniGF, CasiniA. Accruingevidenceonbenefitsofadher250. GraudalNA, Hubeck-GraudalT, JurgensG. Effectsoflow-sodiumdietvs. High-. . encetotheMediterraneandietonhealth: anupdatedsystematicreviewand. sodiumdietonbloodpressure, renin, aldosterone, catecholamines, cholesterol, . meta-analysis. AmJClinNutr2010; 92: 11891196. . andtriglyceride(CochraneReview). AmJHypertens2012; 25: 115. . 265. EstruchR, RosE, Salas-SalvadoJ, CovasMI, CorellaD, ArosF, Gomez-Gracia. 251. He FJ, MacGregor GA. How far should salt intake be reduced? Hypertension. . E, Ruiz-GutierrezV, FiolM, LapetraJ, Lamuela-RaventosRM, Serra-MajemL, 2003; 42: 10931099. . . Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA, . 252. Bibbins-Domingo potassium, Chertow GM, Coxson PG, Moran A, Lightwood JM, . PREDIMED Study Investigators. Primary prevention of cardiovascular disease. PletcherMJ, GoldmanL. Projectedeffectofdietarysaltreductionsonfuture. . withaMediterraneandiet. NEnglJMed2013; 368: 12791290. cardiovasculardisease. NEnglJMed2010; 362: 590599. . . 266. Domenech M, Roman P, Lapetra J, Garcia de la Corte FJ, Sala-Vila A, de la. 253. He FJ, Burnier M, Macgregor GA. Nutrition in cardiovascular disease: salt in. TorreR, CorellaD, Salas-SalvadoJ, Ruiz-GutierrezV, Lamuela-RaventosRM, . hypertensionandheartfailure. EurHeartJ2011; 32: 30733080. . Toledo E, Estruch R, Coca A, Ros E. Mediterranean diet reduces 24-hour. 254. HeFJ, MacGregorGA. Saltreductionlowerscardiovascularrisk: meta-analysis. . ambulatory Blood Hypertension, Blood glucose, and lipids: one-year randomized, ofoutcometrials. Lancet2011; 378: 380382. . . clinicaltrial. Hypertension2014; 64: 6976. . 255. TaylorRS, AshtonKE, MoxhamT, HooperL, EbrahimS. Reduceddietarysalt. 267. DingM, BhupathirajuSN, SatijaA, vanDamRM, HuFB. Long-termcoffeecon-. for the prevention of cardiovascular disease: a meta-analysis of randomized. sumptionandriskofcardiovasculardisease: asystematic reviewandadose-. controlledtrials(Cochranereview). AmJHypertens2011; 24: 843853. . . response meta-analysis of prospective cohort studies. Circulation. 256. MenteA, ODonnellM, RangarajanS, DagenaisG, LearS, McQueenM, DiazR, . 2014; 129: 643659. . AvezumA, Lopez-JaramilloP, LanasF, LiW, LuY, YiS, RenshengL, IqbalR, . 268. LiG, ZhangY, ThabaneL, MbuagbawL, LiuA, LevineMA, HolbrookA. Effect. MonyP, YusufR, YusoffK, SzubaA, OguzA, RosengrenA, BahonarA, Yusufali. . ofgreenteasupplementationonbloodpressureamongoverweightandobese A, SchutteAE, ChifambaJ, MannJF, AnandSS, TeoK, YusufS. Associationsof. . adults: asystematicreviewandmeta-analysis. JHypertens2015; 33: 243254. . urinary Sodium excretion with cardiovascular events in individuals with and. 269. GreylingA, RasRT, ZockPL, LorenzM, HopmanMT, ThijssenDH, DraijerR. . without hypertension: a pooled analysis of data from four studies. Lancet. The effect of black tea on Blood Hypertension: a systematic review with meta-. 2016; 388: 465475. . . analysisofrandomizedcontrolledtrials. PLoSOne2014; 9: e103247. 257. BiniaA, JaegerJ, HuY, SinghA, ZimmermannD. Dailypotassiumintakeand. . 270. HallJE, doCarmoJM, daSilvaAA, WangZ, HallME. Obesity-inducedhyper-. Sodium-to-potassiumratiointhereductionofbloodpressure: ameta-analysis. tension: interaction of neurohumoral and renal mechanisms. Circ Res. ofrandomizedcontrolledtrials. JHypertens2015; 33: 15091520. . . 2015; 116: 9911006. 258. AburtoNJ, ZiolkovskaA, HooperL, ElliottP, CappuccioFP, MeerpohlJJ. Effect. . 271. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight. of lower Sodium intake on health: systematic review and meta-analyses. BMJ. reductiononbloodpressure: ameta-analysisofrandomizedcontrolledtrials. . 2013; 346: f1326. . Hypertension2003; 42: 878884. . 259. ODonnellM, MenteA, RangarajanS, McQueenMJ, WangX, LiuL, YanH, Lee. . 272. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, SF, MonyP, DevanathA, RosengrenA, Lopez-JaramilloP, DiazR, AvezumA, . . ClarkeR, EmbersonJ, HalseyJ, QizilbashN, CollinsR, PetoR. Body-massindex. Lanas F, Yusoff potassium, Iqbal R, Ilow R, Mohammadifard N, Gulec S, YusufaliAH, . andcause-specificmortalityin900000adults: collaborativeanalysesof57pro-. KrugerL, YusufR, ChifambaJ, KabaliC, DagenaisG, LearSA, TeoK, YusufS, . spectivestudies. Lancet2009; 373: 10831096. . PURE Investigators. Urinary Sodium and Potassium excretion, mortality, and. . 273. FlegalKM, KitBK, OrpanaH, GraubardBI. Associationofall-causemortality cardiovascularevents. NEnglJMed2014; 371: 612623. . . withoverweightandobesityusingstandardbodymassindexcategories: asys-. 260. Cushman WC, Cutler JA, Hanna E, Bingham SF, Follmann D, Harford T, . tematicreviewandmeta-analysis. JAMA2013; 309: 7182. . Dubbert P, Allender PS, Dufour M, Collins JF, Walsh SM, Kirk GF, Burg M, . . 274.",
    "Dubbert P, Allender PS, Dufour M, Collins JF, Walsh SM, Kirk GF, Burg M, . . 274. Global body mass index Mortality Collaboration, Di Angelantonio E, Bhupathiraju social history N, FelicettaJV, HamiltonBP, KatzLA, PerryHMJr, WillenbringML, LakshmanR, . . WormserD, GaoP, KaptogeS, BerringtondeGonzalezA, CairnsBJ, HuxleyR, . Hamburger RJ. Prevention and Treatment of Hypertension Study (PATHS): . JacksonChL, JoshyG, LewingtonS, MansonJE, MurphyN, PatelAV, SametJM, . effects of an alcohol treatment program on Blood Hypertension. Arch Intern Med. WoodwardM, ZhengW, ZhouM, BansalN, BarricarteA, CarterB, CerhanJR, . 1998; 158: 11971207. . . SmithGD, FangX, FrancoOH, GreenJ, HalseyJ, HildebrandJS, JungKJ, Korda 261. HolmesMV, DaleCE, ZuccoloL, SilverwoodRJ, GuoY, YeZ, Prieto-Merino. . RJ, McLerran DF, Moore SC, OKeeffe LM, Paige E, Ramond A, Reeves GK, . D, DehghanA, TrompetS, WongA, CavadinoA, DroganD, PadmanabhanS, . RollandB, SacerdoteC, SattarN, SofianopoulouE, StevensJ, ThunM, Ueshima. LiS, YesupriyaA, LeusinkM, SundstromJ, HubacekJA, PikhartH, Swerdlow. H, YangL, YunYD, WilleitP, BanksE, BeralV, ChenZ, GapsturSM, Gunter. DI, PanayiotouAG, BorinskayaSA, FinanC, ShahS, KuchenbaeckerKB, ShahT, . . MJ, HartgeP, JeeSH, LamTH, PetoR, PotterJD, WillettWC, ThompsonSG, . Engmann J, Folkersen L, Eriksson P, Ricceri F, Melander O, Sacerdote C, . Danesh J, Hu FB. Body-mass index and all-cause mortality: individual-. GambleDM, RayaproluS, RossOA, McLachlanS, VikhirevaO, SluijsI, Scott. participant-data meta-analysis of 239 prospective studies in four continents. . RA, AdamkovaV, FlickerL, BockxmeerFM, PowerC, Marques-VidalP, Meade. . Lancet2016; 388: 776786. T, MarmotMG, FerroJM, Paulos-PinheiroS, HumphriesSE, TalmudPJ, Mateo. . 275. JebbSA, AhernAL, OlsonAD, AstonLM, HolzapfelC, StollJ, Amann-Gassner. LeachI, VerweijN, LinnebergA, SkaabyT, DoevendansPA, CramerMJ, van. U, SimpsonAE, FullerNR, PearsonS, LauNS, ManderAP, HaunerH, Caterson. derHarstP, KlungelOH, DowlingNF, DominiczakAF, KumariM, Nicolaides. ID. Primarycarereferraltoacommercialproviderforweightlosstreatment. AN, WeikertC, BoeingH, EbrahimS, GauntTR, PriceJF, LannfeltL, PeaseyA, . . versus standard care: a randomised controlled trial. Lancet KubinovaR, PajakA, MalyutinaS, VoevodaMI, TamosiunasA, Maitland-vander. . 2011; 378: 14851492. . Zee AH, Norman physical examination, Hankey GJ, Bergmann MM, Hofman A, Franco OH, . 276. JordanJ, YumukV, SchlaichM, NilssonPM, Zahorska-MarkiewiczB, GrassiG, . CooperJ, PalmenJ, SpieringW, deJongPA, KuhD, HardyR, UitterlindenAG, . . Schmieder RE, Engeli S, Finer N. Joint statement of the European IkramMA, FordI, HypponenE, AlmeidaOP, WarehamNJ, KhawKT, Hamsten. . Association for the Study of Obesity and the European Society of. A, HusemoenLL, TjonnelandA, TolstrupJS, RimmE, BeulensJW, Verschuren. Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. WM, Onland-MoretNC, HofkerMH, WannametheeSG, WhincupPH, Morris. 2012; 30: 10471055. . R, VicenteAM, WatkinsH, FarrallM, JukemaJW, MeschiaJ, CupplesLA, Sharp. . 277. CornelissenVA, SmartNA. Exercisetrainingforbloodpressure: asystematic SJ, FornageM, KooperbergC, LaCroixAZ, DaiJY, LanktreeMB, SiscovickDS, . reviewandmeta-analysis. JAmHeartAssoc2013; 2: e004473. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3104e. . 278. Leitzmann MF, Park Y, Blair A, Ballard-Barbash R, Mouw T, Hollenbeck AR, . Schatzkin A, Sesso hemodialysis, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-. SchatzkinA. Physicalactivityrecommendationsanddecreasedriskofmortality. . JacquotteA, WillettWC, ThunMJ. Body-massindexandmortalityamong1. 46. ArchInternMed2007; 167: 24532460. . . millionwhiteadults. NEnglJMed2010; 363: 22112219. 279. RossiA, DikarevaA, BaconSL, DaskalopoulouSS. Theimpactofphysicalactiv-. . 291. ParvingHH, BrennerBM, McMurrayJJ, deZeeuwD, HaffnerSM, SolomonSD, . ity on mortality in patients with Hypertension: a systematic review. J. ChaturvediN, PerssonF, DesaiAS, NicolaidesM, RichardA, XiangZ, BrunelP, . Hypertens2012; 30: 12771288. . . PfefferMA, ALTITUDEInvestigators. Cardiorenalendpointsinatrialofaliski280. MannSJ, JamesGD, WangRS, PickeringTG. Elevationofambulatorysystolic. . renfortype2diabetes. NEnglJMed2012; 367: 22042213. . Blood Hypertension in hypertensive smokers. A case-control study. JAMA. 292. ThomopoulosC, ParatiG, ZanchettiA. Effectsofbloodpressure-loweringon. 1991; 265: 22262228. . outcome incidence in hypertension: 5. Head-to-head comparisons of various. 281. Kotseva potassium, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, . . classes of antihypertensive drugs - overview and meta-analyses. J Hypertens GybergV, AmouyelP, BruthansJ, CastroCondeA, CifkovaR, DeckersJW, De. . 2015; 33: 13211341. . Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, . 293. CorraoG, ZambonA, ParodiA, PoluzziE, BaldiI, MerlinoL, CesanaG, Mancia.",
    "293. CorraoG, ZambonA, ParodiA, PoluzziE, BaldiI, MerlinoL, CesanaG, Mancia. Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milicic D, . G. Discontinuation of and changes in drug therapy for hypertension among. MooreD, NicolaidesE, OganovR, PajakA, PogosovaN, ReinerZ, StagmoM, . . newly-treated patients: a population-based study in Italy. J Hypertens. Stork S, Tokgozoglu L, Vulic D. EUROASPIRE IV: A European Society of. 2008; 26: 819824. . Cardiologysurveyonthelifestyle, riskfactorandtherapeuticmanagementof. 294. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood-Hypertension-lowering. coronary patients from 24 European countries. Eur J Prev Cardiol. . treatmentinhypertension: 9. Discontinuationsforadverseeventsattributedto 2016; 23: 636648. . . differentclassesofantihypertensivedrugs: meta-analysesofrandomizedtrials. J. 282. YarliogluesM, KayaMG, ArdicI, CalapkorurB, DogduO, AkpekM, Ozdogru. Hypertens2016; 34: 19211932. . M, KalayN, DoganA, OzdogruI, OguzhanA. Acuteeffectsofpassivesmoking. 295. VolpeM, ManciaG, TrimarcoB. AngiotensinIIreceptorblockersandmyocar-. on Blood Hypertension and Heart rate in healthy females. Blood Press Monit. . dialinfarction: deedsandmisdeeds. JHypertens2005; 23: 21132118. 2010; 15: 251256. . . 296. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. . 283. GroppelliA, GiorgiDM, OmboniS, ParatiG, ManciaG. Persistentbloodpres-. Comparisonbetweenangiotensin-convertingenzymeinhibitorsandangiotensin. sureincreaseinducedbyheavysmoking. JHypertens1992; 10: 495499. . . receptor blockers on the risk of myocardial infarction, stroke and death: a 284. Primatesta P, Falaschetti E, Gupta S, Marmot magnesium, Poulter NR. Association. . meta-analysis. JHypertens2008; 26: 12821289. . between smoking and Blood Hypertension: evidence from the health survey for. 297. KronishIM, WoodwardM, SergieZ, OgedegbeG, FalzonL, MannDM. Meta-. England. Hypertension2001; 37: 187193. . analysis: impact of drug class on adherence to antihypertensives. Circulation. 285. DollR, PetoR, WheatleyK, GrayR, SutherlandI. Mortalityinrelationtosmok-. . 2011; 123: 16111621. ing: 40yearsobservationsonmaleBritishdoctors. BMJ1994; 309: 901911. . . 298. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, . 286. LimSS, VosT, FlaxmanAD, DanaeiG, ShibuyaK, Adair-RohaniH, AmannM, . Leehey DJ, McCullough PA, OConnor T, Palevsky PM, Reilly RF, Seliger SL, . Anderson heart rate, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, . WarrenSR, WatnickS, PeduzziP, GuarinoP, VANEPHRON-DInvestigators. . BalakrishnanK, BalmesJ, Barker-ColloS, BaxterA, BellML, BloreJD, BlythF, . . Combinedangiotensininhibitionforthetreatmentofdiabeticnephropathy. N. BonnerC, BorgesG, BourneR, BoussinesqM, BrauerM, BrooksP, BruceNG, . EnglJMed2013; 369: 18921903. . BrunekreefB, Bryan-HancockC, BucelloC, BuchbinderR, BullF, BurnettRT, . 299. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, . ByersTE, CalabriaB, CarapetisJ, CarnahanE, ChafeZ, CharlsonF, ChenH, . . Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, . . both in patients at High risk for vascular events. N Engl J Med. Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries potassium, . 2008; 358: 15471559. . DheraniM, DingEL, DorseyER, DriscollT, EdmondK, AliSE, EngellRE, Erwin. 300. ThomopoulosC, ParatiG, ZanchettiA. Effectsofbloodpressureloweringon. PJ, FahimiS, FalderG, FarzadfarF, FerrariA, FinucaneMM, FlaxmanS, Fowkes. . outcomeincidenceinhypertension: 4. EffectsofvariousclassesofantihypertenFG, FreedmanG, FreemanMK, GakidouE, GhoshS, GiovannucciE, GmelG, . . sivedrugsoverviewandmeta-analyses. JHypertens2015; 33: 195211. . GrahamK, GraingerR, GrantB, GunnellD, GutierrezHR, HallW, HoekHW, . 301. RoushGC, ErnstME, KostisJB, TandonS, SicaDA. Head-to-headcomparisons. HoganA, HosgoodHDIII, HoyD, HuH, HubbellBJ, HutchingsSJ, IbeanusiSE, . . of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive JacklynGL, JasrasariaR, JonasJB, KanH, KanisJA, KassebaumN, KawakamiN, . . andmetaboliceffects. Hypertension2015; 65: 10411046. . KhangYH, KhatibzadehS, KhooJP, KokC, LadenF, LallooR, LanQ, Lathlean. 302. OldeEngberinkRH, FrenkelWJ, vandenBogaardB, BrewsterLM, VogtL, van. T, LeasherJL, LeighJ, LiY, LinJK, LipshultzSE, LondonS, LozanoR, LuY, Mak. denBornBJ. Effectsofthiazide-typeandthiazide-likediureticsoncardiovascular. J, MalekzadehR, MallingerL, MarcenesW, MarchL, MarksR, MartinR, McGale. . events and mortality: systematic review and meta-analysis. Hypertension P, McGrathJ, MehtaS, MensahGA, MerrimanTR, MichaR, MichaudC, Mishra. . 2015; 65: 10331040. . V, Mohd Hanafiah potassium, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, . 303. Zanchetti A, Mancia G. Strategies for antihypertensive treatment decisions: .",
    "303. Zanchetti A, Mancia G. Strategies for antihypertensive treatment decisions: . Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, . howtoassessbenefits? JHypertens1997; 15: 215216. . OrchardJ, OsborneR, OstroB, PageA, PandeyKD, ParryCD, PassmoreE, . . 304. ZillichAJ, GargJ, BasuS, BakrisGL, CarterBL. Thiazidediuretics, Potassium, PatraJ, PearceN, PelizzariPM, PetzoldM, PhillipsMR, PopeD, PopeCAIII, . . and the development of Diabetes: a quantitative review. Hypertension. PowlesJ, RaoM, RazaviH, RehfuessEA, RehmJT, RitzB, RivaraFP, RobertsT, . 2006; 48: 219224. . RobinsonC, Rodriguez-PortalesJA, RomieuI, RoomR, RosenfeldLC, RoyA, . . 305. BrownMJ, WilliamsB, MorantSV, WebbDJ, CaulfieldMJ, CruickshankJK, Ford Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, . . I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald. SeedatS, ShiP, ShieldK, ShivakotiR, SinghGM, SleetDA, SmithE, SmithKR, . TM. Effectofamiloride, oramilorideplushydrochlorothiazide, versushydro-. StapelbergNJ, SteenlandK, StocklH, StovnerLJ, StraifK, StraneyL, Thurston. chlorothiazide on glucose tolerance and Blood Hypertension (PATHWAY-3): a. GD, TranJH, VanDingenenR, vanDonkelaarA, VeermanJL, VijayakumarL, . . parallel-group, double-blindrandomisedphase4trial. LancetDiabetesEndocrinol WeintraubR, WeissmanMM, WhiteRA, WhitefordH, WiersmaST, Wilkinson. . 2016; 4: 136147. . JD, WilliamsHC, WilliamsW, WilsonN, WoolfAD, YipP, ZielinskiJM, Lopez. 306. Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, Danchin N, . AD, MurrayCJ, EzzatiM, AlMazroaMA, MemishZA. Acomparativeriskassess-. . DeanfieldJE, HemingwayH, FoxKAA, TimmisAD, GaleCP. Beta-blockersand mentofburdenofdiseaseandinjuryattributableto67riskfactorsandriskfac-. . mortalityafteracutemyocardialinfarctioninpatientswithoutheartfailureor. tor clusters in 21 regions, 1990-2010: a systematic analysis for the Global. ventriculardysfunction. JAmCollCardiol2017; 69: 27102720. . BurdenofDiseaseStudy2010. Lancet2012; 380: 22242260. . 307. BakrisGL, FonsecaV, KatholiRE, McGillJB, MesserliFH, PhillipsRA, RaskinP, . 287. SteadLF, BuitragoD, PreciadoN, SanchezG, Hartmann-BoyceJ, LancasterT. . . WrightJTJr, OakesR, LukasMA, AndersonKM, BellDS, GEMINIInvestigators. Physician advice for smoking cessation. Cochrane Database Syst Rev. . Metaboliceffectsofcarvedilolvsmetoprololinpatientswithtype2diabetes. 2013; 5: CD000165. . mellitus and hypertension: a randomized controlled trial. JAMA. 288. Cahill potassium, Stevens S, Perera R, Lancaster T. Pharmacological interventions for. 2004; 292: 22272236. . smokingcessation: anoverviewandnetworkmeta-analysis. CochraneDatabase. . 308. Ayers potassium, Byrne LM, DeMatteoA, Brown NJ. Differential effects of nebivolol SystRev2013; 5: CD009329. . . andmetoprololoninsulinsensitivityandplasminogenactivatorinhibitorinthe. 289. SteadLF, KoilpillaiP, FanshaweTR, LancasterT. Combinedpharmacotherapy. metabolicsyndrome. Hypertension2012; 59: 893898. . andbehaviouralinterventionsforsmokingcessation. CochraneDatabaseSystRev. . 309. ChapmanN, ChangCL, DahlofB, SeverPS, WedelH, PoulterNR. Effectof 2016; 3: CD008286. . . doxazosin gastrointestinal therapeutic system as third-line antihypertensive. 290. BerringtondeGonzalezA, HartgeP, CerhanJR, FlintAJ, HannanL, MacInnisRJ, . therapy on Blood Hypertension and lipids in the Anglo-Scandinavian Cardiac. Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, . OutcomesTrial. Circulation2008; 118: 4248. . EnglishDR, FolsomAR, FreedmanDM, GilesG, HakanssonN, HendersonKD, . . 310. WilliamsB, MacDonaldTM, MorantS, WebbDJ, SeverP, McInnesG, FordI, Hoffman-BoltonJ, HoppinJA, KoenigKL, LeeIM, LinetMS, ParkY, PocobelliG, . CruickshankJK, Caulfield MJ, SalsburyJ, Mackenzie I, PadmanabhanS, Brown Downloaded from by guest on 31 December 2025 3104f ESC/ESHGuidelines. . MJ, BritishHypertensionSocietysPATHWAYStudiesGroup. Spironolactone. 329. MatsuzakiM, OgiharaT, UmemotoS, RakugiH, MatsuokaH, ShimadaK, Abe. versusplacebo, bisoprolol, anddoxazosintodeterminetheoptimaltreatment. . potassium, SuzukiN, EtoT, HigakiJ, ItoS, KamiyaA, KikuchiK, SuzukiH, TeiC, Ohashi for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, . . Y, SarutaT, CombinationTherapyofHypertensiontoPreventCardiovascular. crossovertrial. Lancet2015; 386: 20592068. . EventsTrialGroup. Preventionofcardiovasculareventswithcalciumchannel. 311. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, . . blocker-basedcombinationtherapiesinpatientswithhypertension: arandomtreatment intensification, and control in Western Europe and the United. . izedcontrolledtrial. JHypertens2011; 29: 16491659. . States. ArchInternMed2007; 167: 141147. . 330. LithellH, HanssonL, SkoogI, ElmfeldtD, HofmanA, OlofssonB, Trenkwalder. 312. CorraoG, ParodiA, NicotraF, ZambonA, MerlinoL, CesanaG, ManciaG. . P, ZanchettiA, GroupSS. TheStudyonCognitionandPrognosisintheElderly. Bettercompliancetoantihypertensivemedicationsreducescardiovascularrisk. . . (SCOPE): principal results of a randomized double-blind intervention trial. J JHypertens2011; 29: 610618. . . Hypertens2003; 21: 875886. . 313. TiffeT, WagnerM, RuckerV, MorbachC, GelbrichG, StorkS, Heuschmann. 331. LiuL, ZhangY, LiuG, LiW, ZhangX, ZanchettiA, GroupFS. TheFelodipine. PU. Controlofcardiovascularriskfactorsanditsdeterminantsinthegeneral. Event Reduction (FEVER) Study: a randomized long-term placebo-controlled. populationfindings from the STAAB cohort study. BMC Cardiovasc Disord. . trialinChinesehypertensivepatients. JHypertens2005; 23: 21572172. . 2017; 17: 276. . 332.",
    "populationfindings from the STAAB cohort study. BMC Cardiovasc Disord. . trialinChinesehypertensivepatients. JHypertens2005; 23: 21572172. . 2017; 17: 276. . 332. StaessenJA, FagardR, ThijsL, CelisH, ArabidzeGG, BirkenhagerWH, Bulpitt. 314. MensahGA, BakrisG. Treatmentandcontrolofhighbloodpressureinadults. . CJ, deLeeuwPW, DolleryCT, FletcherAE, ForetteF, LeonettiG, NachevC, . CardiolClin2010; 28: 609622. . . OBrien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised 315. GuptaP, PatelP, StrauchB, LaiFY, AkbarovA, GulsinGS, BeechA, Maresova. . double-blind comparison of placebo and active treatment for older patients. V, TophamPS, StanleyA, ThurstonH, SmithPR, HorneR, WidimskyJ, Keavney. withisolatedsystolichypertension. TheSystolicHypertensioninEurope(Syst-. B, HeagertyA, SamaniNJ, WilliamsB, TomaszewskiM. Biochemicalscreening. Eur)TrialInvestigators. Lancet1997; 350: 757764. . for nonadherence is associated with Blood Hypertension reduction and improve-. . 333. WangJG, StaessenJA, GongL, LiuL. Chinesetrialonisolatedsystolichypermentinadherence. Hypertension2017; 70: 10421048. . . tension in the elderly. Systolic Hypertension in China (Syst-China). 316. ALLHATOfficersandCoordinatorsfortheALLHATCollaborativeResearch. CollaborativeGroup. ArchInternMed2000; 160: 211220. . Group. Major outcomes in High-risk hypertensive patients randomized to. . 334. HanssonL, LindholmLH, EkbomT, DahlofB, LankeJ, ScherstenB, WesterPO, angiotensin-convertingenzymeinhibitororcalciumchannelblockervsdiuretic: . . HednerT, deFaireU. Randomisedtrialofoldandnewantihypertensivedrugs. TheAntihypertensiveandLipid-LoweringTreatmenttoPreventHeartAttack. inelderlypatients: cardiovascularmortalityandmorbiditytheSwedishTrialin. Trial(ALLHAT). JAMA2002; 288: 29812997. . OldPatientswithHypertension-2study. Lancet1999; 354: 17511756. . 317. DahlofB, DevereuxRB, KjeldsenSE, JuliusS, BeeversG, deFaireU, Fyhrquist. . 335. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, F, IbsenH, KristianssonK, Lederballe-PedersenO, LindholmLH, NieminenMS, . . Luomanmaki potassium, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, . OmvikP, OparilS, WedelH, LIFEStudyGroup. Cardiovascularmorbidityand. Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with. mortalityintheLosartanInterventionForEndpointreductioninhypertension. conventional therapy on cardiovascular morbidity and mortality in hyperten-. study(LIFE): arandomisedtrialagainstatenolol. Lancet2002; 359: 9951003. . . sion: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 318. DahlofB, SeverPS, PoulterNR, WedelH, BeeversDG, CaulfieldM, CollinsR, . . 1999; 353: 611616. . Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, OBrien E, . 336. ZanchettiA, HennigM, BaurechtH, TangR, CuspidiC, CarugoS, ManciaG. . Ostergren, J, ASCOTInvestigators. Preventionofcardiovasculareventswithan. . Prevalence and incidence of the metabolic syndrome in the European antihypertensiveregimenofamlodipineaddingperindopril asrequiredversus. . LacidipineStudyonAtherosclerosis(ELSA)anditsrelationwithcarotidintima-. atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian. mediathickness. JHypertens2007; 25: 24632470. . CardiacOutcomesTrial-BloodPressureLoweringArm(ASCOT-BPLA): amul-. 337. Julius S, Kjeldsen SE, Weber M, Brunner heart rate, Ekman S, Hansson L, Hua T, . ticentrerandomisedcontrolledtrial. Lancet2005; 366: 895906. . . Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, 319. McKavanaghP, LuskL, BallPA, VerghisRM, AgusAM, TrinickTR, DulyE, Walls. . VALUEtrialgroup. Outcomesinhypertensivepatients athighcardiovascular. GM, StevensonM, JamesB, HamiltonA, HarbinsonMT, DonnellyPM. Acom-. risktreatedwithregimensbasedonvalsartanoramlodipine: theVALUErando-. parisonofcardiaccomputerizedtomographyandexercisestresselectrocardio-. misedtrial. Lancet2004; 363: 20222031. . gramtestfortheinvestigationofstablechestpain: theclinicalresultsofthe. . 338. PROGRESS Collaborative Group. Randomised trial of a perindopril-based. CAPP randomized prospective trial. Eur Heart J Cardiovasc Imaging. Blood-Hypertension-loweringregimenamong6, 105individualswithpreviousstroke. 2015; 16: 441448. . ortransientischaemicattack. Lancet2001; 358: 10331041. . 320. HednerT. ProgressreportontheNordicdiltiazemstudy(NORDIL): anout-. . 339. HanssonL, HednerT, Lund-JohansenP, KjeldsenSE, LindholmLH, Syvertsen comestudyinhypertensivepatients. BloodPress1999; 8: 296299. . . JO, LankeJ, deFaireU, DahlofB, KarlbergBE. Randomisedtrialofeffectsofcal-. 321. ElgendyIY, BavryAA, GongY, HandbergEM, Cooper-DeHoffRM, PepineCJ. . ciumantagonistscomparedwithdiureticsandbeta-blockersoncardiovascular. Long-term mortality in hypertensive patients with coronary artery disease: . morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL). results from the ultrasound cohort of the International Verapamil (SR)/Trandolapril. . study. Lancet2000; 356: 359365. Study. Hypertension2016; 68: 11101114. . . 340. PepineCJ, HandbergEM, Cooper-DeHoffRM, MarksRG, KoweyP, Messerli. 322. CoopeJ, WarrenderTS. Randomisedtrialoftreatmentofhypertensionineld-. family history, ManciaG, CangianoJL, Garcia-BarretoD, KeltaiM, ErdineS, BristolHA, . erlypatientsinprimarycare. BrMedJ(ClinResEd)1986; 293: 11451151. . . KolbHR, BakrisGL, CohenJD, ParmleyWW, InvestigatorsI. Acalciumantago323. SHEPCooperativeResearchGroup. Preventionofstrokebyantihypertensive. . nist vsanon-calcium antagonist hypertension treatment strategy forpatients. drug treatment in older persons with isolated systolic hypertension. Final. with coronary artery disease. The International Verapamil-Trandolapril Study. results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. (INVEST): arandomizedcontrolledtrial. JAMA2003; 290: 28052816. . 1991; 265: 32553264. . . 341. WaldDS, LawM, MorrisJK, BestwickJP, WaldNJ. Combinationtherapyversus 324. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. . .",
    "Combinationtherapyversus 324. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. . . monotherapyinreducingbloodpressure: meta-analysison11, 000participants. MorbidityandmortalityintheSwedishTrialinOldPatientswithHypertension. from42trials. AmJMed2009; 122: 290300. . (STOP-Hypertension). Lancet1991; 338: 12811285. . 342. MacDonaldTM, WilliamsB, WebbDJ, MorantS, CaulfieldM, CruickshankJK, . 325. Mancia G, Grassi G, Zanchetti A. New-onset Diabetes and antihypertensive. . FordI, SeverP, MackenzieIS, PadmanabhanS, McCannGP, SalsburyJ, McInnes. drugs. JHypertens2006; 24: 310. . G, Brown MJ, British Hypertension Society Programme of Prevention And. 326. Brown MJ, Palmer creatinine, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, . Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). . Ruilope LM. Morbidity and mortality in patients randomised to double-blind. . Combinationtherapyissuperiortosequentialmonotherapyfortheinitialtreattreatment with a long-acting calcium-channel blocker or diuretic in the. . mentofhypertension: adouble-blindrandomizedcontrolledtrial. JAmHeart. International Nifedipine GITS study: Intervention as a Goal in Hypertension. Assoc2017; 6: e006986. . Treatment(INSIGHT). Lancet2000; 356: 366372. . 343. YusufS, LonnE, PaisP, BoschJ, Lopez-JaramilloP, ZhuJ, XavierD, AvezumA, . 327. JamersonK, WeberMA, BakrisGL, DahlofB, PittB, ShiV, HesterA, GupteJ, . . LeiterLA, PiegasLS, ParkhomenkoA, KeltaiM, KeltaiK, SliwaK, ChazovaI, GatlinM, VelazquezEJ, ACCOMPLISHTrialInvestigators. Benazeprilplusamlo-. . PetersRJ, HeldC, YusoffK, LewisBS, JanskyP, KhuntiK, ToffWD, ReidCM, . dipine or hydrochlorothiazide for hypertension in High-risk patients. N Engl J. Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, . Med2008; 359: 24172428. . . Dagenais G, HOPE-3 Investigators. Blood-Hypertension and cholesterol 328. OgiharaT, SarutaT, RakugiH, SaitoI, ShimamotoK, MatsuokaH, TeramukaiS, . . lowering in persons without cardiovascular disease. N Engl J Med 2016; 374: . HigakiJ, ItoS, ShimadaK, COLMInvestigators. Combinationtherapyofhyper-. 20322043. . tensionintheelderly: asubgroupanalysisoftheCombinationofOLMesartan. 344. XuW, GoldbergSI, ShubinaM, TurchinA. Optimalsystolicbloodpressuretar-. and a calcium channel blocker or diuretic in Japanese elderly hypertensive. . get, timetointensification, andtimetofollow-upintreatmentofhypertension: patientstrial. HypertensRes2015; 38: 8996. . populationbasedretrospectivecohortstudy. BMJ2015; 350: h158. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3104g. . 345. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg. Wijns W, Zeller T, Schmieder RE. Proceedings from the European Clinical. KS. Initialmonotherapyandcombinationtherapyandhypertensioncontrolthe. ConsensusConferenceforRenalDenervation: considerationsonfutureclinical. firstyear. Hypertension2012; 59: 11241131. . . trialdesign. EurHeartJ2015; 36: 22192227. 346. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, Merlino L, . . 364. BohmM, MahfoudF, UkenaC, HoppeUC, NarkiewiczK, NegoitaM, Ruilope. ManciaG. Reduceddiscontinuationofantihypertensivetreatmentbytwo-drug. L, SchlaichMP, SchmiederRE, WhitbournR, WilliamsB, ZeymerU, ZirlikA, . combination as first step. Evidence from daily life practice. J Hypertens. . ManciaG, GSRInvestigators. FirstreportoftheGlobalSYMPLICITYRegistry 2010; 28: 15841590. . . ontheeffectofrenalarterydenervationinpatientswithuncontrolledhyper-. 347. Conn VS, Ruppar TM, Chase JA, Enriquez M, Cooper PS. Interventions to. tension. Hypertension2015; 65: 766774. . improvemedicationadherenceinhypertensivepatients: systematicreviewand. 365. KrumH, SchlaichMP, SobotkaPA, BohmM, MahfoudF, Rocha-SinghK, Katholi. meta-analysis. CurrHypertensRep2015; 17: 94. . . R, Esler MD. Percutaneous renal denervation in patients with treatment348. ManciaG, Rea F, CuspidiC, GrassiG, CorraoG. Blood pressurecontrol in. . resistant hypertension: final 3-year report of the Symplicity hypertension-1 study. . hypertension. Pros and cons of available treatment strategies. J Hypertens. Lancet2014; 383: 622629. . 2017; 35: 225233. . 366. TownsendRR, MahfoudF, KandzariDE, KarioK, PocockS, WeberMA, Ewen. 349. Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ III, Graff A, Shojaee A, . . S, TsioufisK, TousoulisD, SharpASP, WatkinsonAF, SchmiederRE, SchmidA, . WaverczakWF, QianC, JonesCJ, NeutelJM. Atitrate-to-goalstudyofswitch-. ChoiJW, EastC, WaltonA, HopperI, CohenDL, WilenskyR, LeeDP, MaA, . ingpatientsuncontrolledonantihypertensivemonotherapytofixed-dosecom-. DevireddyCM, LeaJP, LurzPC, FenglerK, DaviesJ, ChapmanN, CohenSA, . binations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J. . DeBruinV, FahyM, JonesDE, RothmanM, BohmM, SpyralHTN-OFFMedtrial ClinHypertens(Greenwich)2011; 13: 404412. . . investigators. Catheter-based renal denervation in patients with uncontrolled. 350. VolpeM, ChristianRumpL, AmmentorpB, LaeisP. Efficacyandsafetyoftriple. hypertension inthe absence of antihypertensive medications (SPYRAL hypertension-. antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide. OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. combination. ClinDrugInvestig2012; 32: 649664. . . 2017; 390: 21602170. 351. Gupta AK, Arshad S, Poulter NR.",
    "Lancet. combination. ClinDrugInvestig2012; 32: 649664. . . 2017; 390: 21602170. 351. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of. . 367. BhattDL, KandzariDE, ONeillWW, DAgostinoR, FlackJM, KatzenBT, Leon. fixed-dose combinations of antihypertensive agents: a meta-analysis. . MB, LiuM, MauriL, NegoitaM, CohenSA, OparilS, Rocha-SinghK, Townsend. Hypertension2010; 55: 399407. . . respiratory rate, Bakris GL, fortheSymplicity hypertension-3 Investigators. Acontrolledtrial of 352. JungO, GechterJL, WunderC, PaulkeA, BartelC, GeigerH, ToennesSW. . . renal denervation for resistant hypertension. N Engl J Med. Resistanthypertension? Assessmentofadherencebytoxicologicalurineanaly-. 2014; 370: 13931401. . sis. JHypertens2013; 31: 766774. . 368. Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, . 353. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, . . Lederballe O, Rickers H, Kampmann U, Poulsen PL, Hansen KW, Btker HE, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, . . Peters CD, Engholm M, Bertelsen JB, Lassen JF, Langfeldt S, Andersen G, . Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, . Pedersen EB, Kaltoft A. Renal denervation in treatment-resistant essential. Widimsky P. 2017 ESC Guidelines for the management of acute myocardial. hypertension. A randomized, SHAM-controlled, double-blinded 24-h Blood. infarctioninpatientspresentingwithST-segmentelevation: TheTaskForcefor. . Hypertension-basedtrial. JHypertens2016; 34: 16391647. . themanagementofacutemyocardialinfarctioninpatientspresentingwithST-. 369. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, . segment elevation of the European Society of Cardiology (ESC). Eur Heart J. Mounier-Vehier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, . 2018; 39: 119177. . . Trillaud H, Pereira H, Plouin PF, Chatellier G, DENERHTN Investigators. 354. GuptaP, PatelP, HorneR, BuchananH, WilliamsB, TomaszewskiM. Howto. . Optimum and stepped care standardised antihypertensive treatment with or. screen for non-adherence to antihypertensive therapy. Curr Hypertens Rep. without renal denervation for resistant hypertension (DENERHTN): a multi-. 2016; 18: 89. . centre, open-label, randomisedcontrolledtrial. Lancet2015; 385: 19571965. . 355. CocaA, Agabiti-RoseiE, CifkovaR, ManolisAJ, RedonJ, ManciaG. Thepolypill. . 370. RosaJ, WidimskyP, TousekP, PetrakO, CurilaK, WaldaufP, BednarF, Zelinka in cardiovascular prevention: evidence, limitations and perspective - position. . T, HolajR, StrauchB, SomloovaZ, TaborskyM, VaclavikJ, KocianovaE, Branny. paper of the European Society of Hypertension. J Hypertens. M, NyklI, JiravskyO, WidimskyJJr. Randomizedcomparisonofrenaldenerva-. 2017; 35: 15461553. . . tion versus intensified pharmacotherapy including spironolactone in true356. Castellano JM, Sanz G, Penalvo JL, Bansilal S, Fernandez-Ortiz A, Alvarez L, . . resistant hypertension: six-month results from the Prague-15 study. . Guzman L, Linares JC, Garcia F, DAnielloF, Arnaiz JA, Varea S, MartinezF, . Hypertension2015; 65: 407413. . LorenzattiA, ImazI, Sanchez-GomezLM, RoncaglioniMC, BavieraM, SmithSC. 371. MahfoudF, SchmiederRE, AziziM, PathakA, SievertH, TsioufisC, ZellerT, . Jr, TaubertK, PocockS, BrotonsC, FarkouhME, FusterV. Apolypillstrategyto. . BertogS, Blankestijn PJ, BohmM, Burnier M, ChatellierG, Durand Zaleski I, improve adherence: results from the FOCUS project. J Am Coll Cardiol. . EwenS, GrassiG, JonerM, KjeldsenSE, LoboMD, LotanC, LuscherTF, Parati. 2014; 64: 20712082. . G, Rossignol P, Ruilope L, Sharif F, van Leeuwen E, Volpe M, Windecker S, . 357. WilliamsB, MacDonaldTM, MorantSV, WebbDJ, SeverP, McInnesGT, FordI, . Witkowski A, Wijns W. Proceedings from the 2nd European Clinical. CruickshankJK, CaulfieldMJ, PadmanabhanS, MackenzieIS, SalsburyJ, Brown. . Consensus Conference for device-based therapies for hypertension: state of MJ, BritishHypertensionSocietyprogrammeofPreventionAndTreatmentof. . theartandconsiderationsforthefuture. EurHeartJ2017; 38: 32723281. . Hypertension With Algorithm based Therapy (PATHWAY) Study Group. . 372. Ewen S, UkenaC, LinzD, KindermannI, CremersB, LaufsU, WagenpfeilS, . Endocrine and haemodynamic changes in resistant hypertension, and Blood. . Schmieder RE, Bohm M, Mahfoud F. Reduced effect of percutaneous renal pressureresponsestospironolactoneoramiloride: thePATHWAY-2mecha-. . denervationonbloodpressureinpatientswithisolatedsystolichypertension. . nismssubstudies. LancetDiabetesEndocrinol2018; 6: 464475. . Hypertension2015; 65: 193199. . 358. BisognanoJD, BakrisG, NadimMK, SanchezL, KroonAA, SchaferJ, deLeeuw. 373. MahfoudF, BakrisG, BhattDL, EslerM, EwenS, FahyM, KandzariD, KarioK, .",
    "358. BisognanoJD, BakrisG, NadimMK, SanchezL, KroonAA, SchaferJ, deLeeuw. 373. MahfoudF, BakrisG, BhattDL, EslerM, EwenS, FahyM, KandzariD, KarioK, . PW, SicaDA. Baroreflexactivationtherapylowersbloodpressureinpatients. . Mancia G, Weber M, Bohm M. Reduced Blood Hypertension-lowering effect of with resistant hypertension: results from the double-blind, randomized, . . catheter-basedrenaldenervationinpatientswithisolatedsystolichypertension: . placebo-controlledrheospivotaltrial. JAmCollCardiol2011; 58: 765773. . datafromSYMPLICITYHTN-3andtheGlobalSYMPLICITYRegistry. EurHeart. 359. WachterR, HalbachM, BakrisGL, BisognanoJD, HallerH, BeigeJ, KroonAA, . . J2017; 38: 93100. NadimMK, LovettEG, SchaferJE, deLeeuwPW. Anexploratorypropensity. . 374. BurchellAE, LoboMD, SulkeN, SobotkaPA, PatonJF. Arteriovenousanasto-. scorematchedcomparisonofsecond-generationandfirst-generationbarore-. mosis: isthisthewaytocontrolhypertension? Hypertension2014; 64: 612. . flexactivationtherapysystems. JAmSocHypertens2017; 11: 8191. . 375. NgFL, SaxenaM, MahfoudF, PathakA, LoboMD. Device-basedtherapyfor. 360. Spiering W, WilliamsB, VanderHeyden J, vanKleefM, LoR, VersmissenJ, . . hypertension. CurrHypertensRep2016; 18: 61. MoelkerA, KroonA, ReuterH, AnselG, StoneGW, BatesM, CALM-FIM_EUR. . 376. FaulJ, SchoorsD, BrouwersS, ScottB, JerrentrupA, GalvinJ, LuitjensS, Dolan. Investigators. Endovascularbaroreflexamplificationforresistanthypertension: a. E. Creationofaniliacarteriovenousshuntlowersbloodpressureinchronic. safetyandproof-of-principleclinicalstudy. Lancet2017; 390: 26552661. . obstructive pulmonary disease patients with hypertension. J Vasc Surg. 361. DiBonaGF. Physiologyinperspective: thewisdomofthebody. Neuralcontrol. . 2014; 59: 10781083. ofthekidney. AmJPhysiolRegulIntegrCompPhysiol2005; 289: R633R641. . . 377. Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E, van der. 362. EslerM. Sympatheticnervoussystemmovestowardcenterstageincardiovas-. GietM, HoyerJ, FurnissSS, ForanJP, WitkowskiA, JanuszewiczA, SchoorsD, . cular medicine: from Thomas Willis to resistant hypertension. Hypertension. . TsioufisK, RensingBJ, ScottB, NgGA, OttC, SchmiederRE, ROXCONTROL 2014; 63: e25e32. . . hypertension Investigators. Central arteriovenous anastomosis for the treatment of. 363. MahfoudF, BohmM, AziziM, PathakA, DurandZaleskiI, EwenS, TsioufisK, . patientswithuncontrolledhypertension(theROXCONTROLHTNstudy): a. AnderssonB, BlankestijnPJ, BurnierM, ChatellierG, GafoorS, GrassiG, Joner. randomisedcontrolledtrial. Lancet2015; 385: 16341641. . M, KjeldsenSE, LuscherTF, LoboMD, LotanC, ParatiG, RedonJ, RuilopeL, . . 378. Ott C, Lobo MD, Sobotka PA, MahfoudF, Stanton A, Cockcroft J, Sulke N, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, . Dolan E, van der Giet M, Hoyer J, Furniss SS, Foran JP, Witkowski A, Downloaded from by guest on 31 December 2025 3104h ESC/ESHGuidelines. . JanuszewiczA, SchoorsD, TsioufisK, RensingBJ, SaxenaM, ScottB, NgGA, . hypertensive crisis in the emergency departments: a large multicenter Italian. Achenbach S, Schmieder RE. Effect of arteriovenous anastomosis on Blood. study. PLoSOne2014; 9: e93542. . Hypertension reduction in patients with isolated systolic hypertension compared. . 404. vandenBornBJ, LowenbergEC, vanderHoevenNV, deLaatB, MeijersJC, withcombinedhypertension. JAmHeartAssoc2016; 5: e004234. . . LeviM, vanMontfransGA. Endothelialdysfunction, plateletactivation, throm-. 379. McBrydeFD, AbdalaAP, HendyEB, PijackaW, MarvarP, MoraesDJ, Sobotka. bogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. PA, PatonJF. Thecarotidbodyasaputativetherapeutictargetforthetreat-. . 2011; 29: 922927. mentofneurogenichypertension. NatCommun2013; 4: 2395. . . 405. Grassi D, OFlaherty M, Pellizzari M, Bendersky M, Rodriguez P, Turri D, . 380. NarkiewiczK, RatcliffeLE, HartEC, BriantLJ, ChrostowskaM, WolfJ, Szyndler. ForcadaP, FerdinandKC, KotliarC. Hypertensiveurgenciesintheemergency. A, Hering D, Abdala AP, Manghat N, Burchell AE, Durant C, Lobo MD, . department: evaluatingbloodpressureresponsetorestandtoantihypertensive. Sobotka PA, Patel NK, Leiter JC, Engelman ZJ, Nightingale AK, Paton JF. . . drugswithdifferentprofiles. JClinHypertens(Greenwich)2008; 10: 662667. Unilateralcarotidbodyresectioninresistanthypertension: asafetyandfeasibil-. . 406. PerezMI, MusiniVM. Pharmacologicalinterventionsforhypertensiveemergen-. itytrial. JACCBasicTranslSci2016; 1: 313324. . cies: aCochranesystematicreview. JHumHypertens2008; 22: 596607. . 381. NiewinskiP, JanczakD, RucinskiA, TubekS, EngelmanZJ, PiesiakP, JazwiecP, . 407. LaneDA, LipGY, BeeversDG. Improvingsurvivalofmalignant hypertension. BanasiakW, FudimM, SobotkaPA, JavaheriS, HartEC, PatonJF, PonikowskiP. . . patientsover40years. AmJHypertens2009; 22: 11991204. . Carotid body resection for sympathetic modulation in systolic Heart failure: . 408. AmraouiF, VanDerHoevenNV, VanValkengoedIG, VogtL, VanDenBornBJ. . resultsfromfirst-in-manstudy. EurJHeartFail2017; 19: 391400. . Mortalityandcardiovascularriskinpatientswithahistoryofmalignanthyper-. 382. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, . . tension: acase-controlstudy. JClinHypertens(Greenwich)2014; 16: 122126. OConnorPJ, SelbyJV, HoPM. Incidenceandprognosisofresistanthyperten-. . 409. GonzalezR, MoralesE, SeguraJ, RuilopeLM, PragaM. Long-termrenalsurvival. sioninhypertensivepatients. Circulation2012; 125: 16351642. . inmalignanthypertension. NephrolDialTransplant2010; 25: 32663272. . 383. MyatA, RedwoodSR, QureshiAC, SpertusJA, WilliamsB. Resistanthyperten-. 410. Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G, Mancia G. White-coat. sion. BMJ2012; 345: e7473. . . hypertension, asdefinedbyambulatorybloodpressuremonitoring, andsubclin384.",
    "sion. BMJ2012; 345: e7473. . . hypertension, asdefinedbyambulatorybloodpressuremonitoring, andsubclin384. delaSierraA, BanegasJR, SeguraJ, GorostidiM, RuilopeLM. Ambulatoryblood. . icalcardiacorgandamage: ameta-analysis. JHypertens2015; 33: 2432. . Hypertension monitoring and development of cardiovascular events in High-risk. 411. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Grassi G, . patientsincludedintheSpanishABPMregistry: theCARDIORISCEventstudy. . . SegaR. Increasedlong-termriskofnew-onsetdiabetesmellitusinwhite-coat JHypertens2012; 30: 713719. . . andmaskedhypertension. JHypertens2009; 27: 16721678. . 385. Williams B. Resistant hypertension: an unmet treatment need. Lancet. 412. TientcheuD, AyersC, DasSR, McGuireDK, deLemosJA, KheraA, KaplanN, . 2009; 374: 13961398. . Victor R, Vongpatanasin W. Target organ complications and cardiovascular. 386. ManteroF, MattarelloMJ, AlbigerNM. Detectingandtreatingprimaryaldoster-. . eventsassociatedwithmaskedhypertensionandwhite-coathypertension: analonism: primaryaldosteronism. ExpClinEndocrinolDiabetes2007; 115: 171174. . . ysisfromtheDallasHeartStudy. JAmCollCardiol2015; 66: 21592169. . 387. FagardRH. Resistanthypertension. Heart2012; 98: 254261. . 413. FagardRH, StaessenJA, ThijsL, GasowskiJ, BulpittCJ, ClementD, deLeeuw. 388. LaurentS, SchlaichM, EslerM. Newdrugs, procedures, anddevicesforhyper-. PW, DobovisekJ, JaaskiviM, LeonettiG, OBrienE, PalatiniP, ParatiG, Rodicio. tension. Lancet2012; 380: 591600. . . JL, Vanhanen H, Webster J. Response to antihypertensive therapy in older. 389. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to pre-. patients with sustained and nonsustained systolic hypertension. Systolic. scribed antihypertensive drug treatments: longitudinal study of electronically. Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation. compileddosinghistories. BMJ2008; 336: 11141117. . . 2000; 102: 11391144. 390. BakrisGL, LindholmLH, BlackHR, KrumH, LinasS, LinsemanJV, ArterburnS, . . 414. ManciaG, FacchettiR, ParatiG, ZanchettiA. Effectoflong-termantihyperten-. SagerP, WeberM. Divergentresultsusingclinicandambulatorybloodpres-. sivetreatmentonwhite-coathypertension. Hypertension2014; 64: 13881398. . sures: report of a darusentan-resistant hypertension trial. Hypertension. 415. StaessenJA, CelisH, ThijsL, FagardR, AmeryAK. Efficacyofantihypertensive. 2010; 56: 824830. . . drugs given once a day: the calcium antagonists revisited. J Hypertens Suppl 391. OxlundCS, HenriksenJE, TarnowL, SchousboeK, GramJ, JacobsenIA. Low. . 1994; 12: S107S115. . dosespironolactonereducesbloodpressureinpatientswithresistanthyper-. 416. BulpittCJ, BeckettNS, PetersR, LeonettiG, GergovaV, FagardR, BurchLA, . tensionandtype2diabetesmellitus: adoubleblindrandomizedclinicaltrial. J. . BanyaW, FletcherAE. BloodpressurecontrolintheHypertensionintheVery Hypertens2013; 31: 20942102. . . ElderlyTrial(HYVET). JHumHypertens2012; 26: 157163. . 392. LiuL, XuB, JuY. Additionofspironolactoneinpatientswithresistanthyperten-. 417. FranklinSS, ThijsL, AsayamaK, LiY, HansenTW, BoggiaJ, JacobsL, ZhangZ, . sion: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. Kikuya M, Bjorklund-Bodegard potassium, Ohkubo T, YangWY, JeppesenJ, DolanE, . 2017; 39: 257263. . . KuznetsovaT, Stolarz-SkrzypekK, TikhonoffV, MalyutinaS, CasigliaE, Nikitin 393. ZhaoD, LiuH, DongP, ZhaoJ. Ameta-analysisofadd-onuseofspironolac-. . Y, LindL, SandoyaE, Kawecka-JaszczK, FilipovskyJ, ImaiY, WangJG, OBrien. toneinpatientswithresistanthypertension. IntJCardiol2017; 233: 113117. . E, Staessen JA, IDACO Investigators. The cardiovascular risk of white-coat. 394. Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients. hypertension. JAmCollCardiol2016; 68: 20332043. . with resistant hypertension: a meta-analysis of randomised controlled trials. . . 418. FranklinSS, ThijsL, HansenTW, LiY, BoggiaJ, KikuyaM, Bjorklund-Bodegard HeartLungCirc2016; 25: 10211030. . . potassium, OhkuboT, JeppesenJ, Torp-PedersenC, DolanE, KuznetsovaT, Stolarz-. 395. PimentaE, GaddamKK, OparilS, AbanI, HusainS, DellItaliaLJ, CalhounDA. . SkrzypekK, TikhonoffV, MalyutinaS, CasigliaE, NikitinY, LindL, SandoyaE, . Effectsofdietarysodiumreductiononbloodpressureinsubjectswithresistant. . Kawecka-JaszczK, ImaiY, WangJ, IbsenH, OBrienE, StaessenJA, International hypertension: resultsfromarandomizedtrial. Hypertension2009; 54: 475481. . . Database on Ambulatory Blood Hypertension in Relation to Cardiovascular. 396. Rimoldi SF, Scherrer U, Messerli family history. Secondary arterial hypertension: when, . OutcomesInvestigators. Significanceofwhite-coathypertensioninolderper-. who, andhowtoscreen? EurHeartJ2014; 35: 12451254. . sonswithisolatedsystolichypertension: ameta-analysisusingtheInternational. 397. Grossman A, Messerli family history, Grossman E. Drug induced hypertensionAn. . Database on Ambulatory Blood Hypertension Monitoring in Relation to unappreciatedcauseofsecondaryhypertension. EurJPharmacol2015; 763: 1522. . . CardiovascularOutcomespopulation. Hypertension2012; 59: 564571. . 398. van den Born BJ, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, . 419. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, Grassi G. . Mahfoud F, Amraoui F, Persu A, Kahan T, Rosei EA, de Simone G, Gosse P, . Long-termprognosticvalueofwhitecoathypertension: aninsightfromdiag-. WilliamsB. ESCCouncilonhypertensionpositiondocumentonthemanagement. . nostic use of both ambulatory and home Blood Hypertension measurements. . of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacotherapy 2018; .",
    ". of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacotherapy 2018; . Hypertension2013; 62: 168174. . doi: 10. 1093/ehjcvp/pvy032. . 420. ManciaG, FacchettiR, GrassiG, BombelliM. Adverseprognosticvalueofper-. 399. VaughanCJ, DelantyN. Hypertensiveemergencies. Lancet2000; 356: 411417. . . sistentofficebloodpressureelevationinwhitecoathypertension. Hypertension 400. ChesterEM, AgamanolisDP, BankerBQ, VictorM. Hypertensiveencephalop-. . 2015; 66: 437444. . athy: aclinicopathologicstudyof20cases. Neurology1978; 28: 928939. . 421. Gorostidi M, Banegas JR, de la Sierra A, Vinyoles E, Segura J, Ruilope LM. . 401. vandenBornBJ, KoopmansRP, GroeneveldJO, vanMontfransGA. Ethnicdis-. Ambulatorybloodpressuremonitoringindailyclinicalpractice-theSpanish. paritiesintheincidence, presentationandcomplicationsofmalignanthyperten-. . ABPMRegistryexperience. EurJClinInvest2016; 46: 9298. sion. JHypertens2006; 24: 22992304. . . 422. ManciaG, BombelliM, FacchettiR, MadottoF, Quarti-TrevanoF, PoloFrizH, . 402. CremerA, AmraouiF, LipGY, MoralesE, RubinS, SeguraJ, VandenBornBJ, . Grassi G, Sega R. Long-term risk of sustained hypertension in white-coat or. GosseP. Frommalignanthypertensiontohypertension-MOD: amoderndefini-. . maskedhypertension. Hypertension2009; 54: 226232. tionforanoldbutstilldangerousemergency. JHumHypertens2016; 30: 463466. . . 423. OgedegbeG, AgyemangC, RavenellJE. Maskedhypertension: evidenceofthe. 403. PinnaG, PascaleC, FornengoP, ArrasS, PirasC, PanzarasaP, CarmosinoG, . needtotreat. CurrHypertensRep2010; 12: 349355. . Franza O, Semeraro V, Lenti S, Pietrelli S, Panzone S, Bracco C, Fiorini R, . 424. SundstromJ, NeoviusM, TyneliusP, RasmussenF. Associationofbloodpres-. Rastelli G, Bergandi D, Zampaglione B, Musso R, Marengo C, Santoro G, . . sure in lateadolescence with subsequent mortality: cohort study of Swedish Zamboni S, Traversa B, Barattini M, Bruno G. Hospital admissions for. maleconscripts. BMJ2011; 342: d643. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3104i. . 425. ZanchettiA, ThomopoulosC, ParatiG. Randomizedcontrolledtrialsofblood. Study): is severe hypertension just an elevated Blood Hypertension? Hypertension. Hypertension lowering in hypertension: a critical reappraisal. Circ Res. 2016; 68: 11531159. . 2015; 116: 10581073. . . 447. RedmanCW. Fetaloutcomeintrialofantihypertensivetreatmentinpregnancy. 426. Williams B. Hypertension inyoung people and prematuredeath. BMJ. . Lancet1976; 2: 753756. . 2011; 342: d1104. . 448. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on. 427. JuliusS, NesbittSD, EganBM, WeberMA, MichelsonEL, KacirotiN, BlackHR, . . hypertensionduringpregnancy: theeffectsofspecifictreatmentonthegrowth Grimm RH Jr, Messerli family history, Oparil S, Schork MA, Trial of Preventing. . anddevelopmentofthechildren. Lancet1982; 1: 647649. . Hypertension Study Investigators. Feasibility of treating prehypertension with. 449. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, . anangiotensin-receptorblocker. NEnglJMed2006; 354: 16851697. . FoidartJM, GibbsJS, Gohlke-BaerwolfC, GorenekB, IungB, KirbyM, MaasAH, . 428. ORourkeMF, AdjiA. Guidelinesonguidelines: focusonisolatedsystolichyper-. . Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, tensioninyouth. JHypertens2013; 31: 649654. . . SchaufelbergerM, SeelandU, TorraccaL. ESCGuidelinesonthemanagement. 429. YanoY, StamlerJ, GarsideDB, DaviglusML, FranklinSS, CarnethonMR, LiuK, . of cardiovascular diseases during pregnancy: the Task Force on the. Greenland P, Lloyd-Jones diabetes mellitus. Isolated systolic hypertension in young and. Management of Cardiovascular Diseases during Pregnancy of the European. middle-agedadultsand31-yearriskforcardiovascularmortality: theChicago. . SocietyofCardiology(ESC). EurHeartJ2011; 32: 31473197. . Heart Association Detection Project in Industry study. J Am Coll Cardiol. 450. AbalosE, DuleyL, SteynDW. Antihypertensivedrugtherapyformildtomod-. 2015; 65: 327335. . erate hypertension during pregnancy. Cochrane Database Syst Rev. 430. Palatini P, Mormino P, Canali C, Santonastaso M, De Venuto G, Zanata G, . . 2014; 2: CD002252. Pessina before meals. Factors affecting ambulatory Blood Hypertension reproducibility. . . 451. MageeLA, ChamC, WatermanEJ, OhlssonA, vonDadelszenP. Hydralazine. Results of the HARVEST Trial. Hypertension and Ambulatory Recording. for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. VenetiaStudy. Hypertension1994; 23: 211216. . 2003; 327: 955960. . 431. BriasoulisA, AgarwalV, TousoulisD, StefanadisC. Effectsofantihypertensive. . 452. DuleyL, Henderson-SmartDJ, MeherS. Drugsfortreatmentofveryhighblood treatmentinpatientsover65yearsofage: ameta-analysisofrandomisedcon-. . pressureduringpregnancy. CochraneDatabaseSystRev2006; 3: CD001449. . trolledstudies. Heart2014; 100: 317323. . 453. KoopmansCM, BijlengaD, GroenH, VijgenSM, AarnoudseJG, BekedamDJ, . 432. Corrao G, Rea F, Monzio Compagnoni M, Merlino L, Mancia G. Protective. . vandenBergPP, deBoerK, BurggraaffJM, BloemenkampKW, DrogtropAP, effects of antihypertensive treatment in patients aged 85 years or older. J. . FranxA, deGrootCJ, HuisjesAJ, KweeA, vanLoonAJ, LubA, PapatsonisDN, . Hypertens2017; 35: 14321441. .",
    "J. . FranxA, deGrootCJ, HuisjesAJ, KweeA, vanLoonAJ, LubA, PapatsonisDN, . Hypertens2017; 35: 14321441. . vanderPostJA, RoumenFJ, ScheepersHC, WillekesC, MolBW, vanPampus. 433. Corrao G, Mazzola P, Monzio Compagnoni M, Rea F, Merlino L, Annoni G, . magnesium. Inductionoflabourversusexpectantmonitoringforgestationalhyperten-. ManciaG. Antihypertensivemedications, loopdiuretics, andriskofhipfracture. . sionormildpre-eclampsiaafter36weeksgestation(HYPITAT): amulticentre, intheelderly: apopulation-basedcohortstudyof81, 617Italianpatientsnewly. . open-labelrandomisedcontrolledtrial. Lancet2009; 374: 979988. . treatedbetween2005and2009. DrugsAging2015; 32: 927936. . 454. RayJG, VermeulenMJ, SchullMJ, RedelmeierDA. Cardiovascularhealthafter. 434. Kjeldsen SE, Stenehjem A, Os I, Van de Borne P, Burnier M, Narkiewicz potassium, . maternal placental syndromes (CHAMPS): population-based retrospective. RedonJ, AgabitiRoseiE, ManciaG. Treatmentofhighbloodpressureinelderly. . cohortstudy. Lancet2005; 366: 17971803. . andoctogenarians: EuropeanSocietyofHypertensionstatementonbloodpres-. 455. BlackMH, ZhouH, SacksDA, DublinS, LawrenceJM, HarrisonTN, Reynolds. suretargets. BloodPress2016; 25: 333336. . potassium. Hypertensivedisordersfirstidentifiedinpregnancyincreaseriskforincident. 435. ESCCommitteeforPracticeGuidelines. 2018ESCGuidelinesforthemanage-. . prehypertension and hypertension in the year after delivery. J Hypertens ment of cardiovascular diseases during pregnancy. Eur Heart J 2018; doi: . . 2016; 34: 728735. . 10. 1093/eurheartj/ehy340. . 456. Chasan-TaberL, WillettWC, MansonJE, SpiegelmanD, HunterDJ, CurhanG, . 436. AmericanCollegeofObstetriciansGynecologistsTaskForceonHypertension. ColditzGA, StampferMJ. Prospectivestudyoforalcontraceptivesandhyper-. inPregnancy. Hypertensioninpregnancy. ReportoftheAmericanCollegeof. . tensionamongwomenintheUnitedStates. Circulation1996; 94: 483489. Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. . . 457. DongW, ColhounHM, PoulterNR. Bloodpressureinwomenusingoralcon-. ObstetGynecol2013; 122: 11221131. . traceptives: results from the Health Survey for England 1994. J Hypertens. 437. LoweSA, BowyerL, LustK, McMahonLP, MortonMR, NorthRA, PaechMJ, . . 1997; 15: 10631068. SaidJM. TheSOMANZGuidelinesforthemanagementofhypertensivedisor-. . 458. GillumLA, MamidipudiSK, JohnstonSC. Ischemicstrokeriskwithoralcontra-. dersofpregnancy2014. AustNZJObstetGynaecol2015; 55: 1116. . ceptives: ameta-analysis. JAMA2000; 284: 7278. . 438. BartschE, MedcalfKE, ParkAL, RayJG. Clinicalriskfactorsforpre-eclampsia. 459. World Health Organization. Medical eligibility criteria for contraceptive use. . determined in early pregnancy: systematic review and meta-analysis of large. . Third edition, 2004. cohortstudies. BMJ2016; 353: i1753. . . 9241562668. pdf(dateaccessedJune28th2018). . 439. BloodPressureAssociation. BloodPressureUK. . 460. LubiancaJN, MoreiraLB, GusM, Fuchs FD. Stopping oralcontraceptives: an. org(20April2018). . effectivebloodpressure-loweringinterventioninwomenwithhypertension. J. 440. Penny JA, Halligan AW, Shennan AH, Lambert after meals, Jones DR, de Swiet M, . . HumHypertens2005; 19: 451455. TaylorDJ. Automated, ambulatory, orconventionalbloodpressuremeasure-. . 461. MoscaL, BenjaminEJ, BerraK, BezansonJL, DolorRJ, Lloyd-JonesDM, Newby. mentinpregnancy: whichisthebetterpredictorofseverehypertension? AmJ. LK, PinaIL, RogerVL, ShawLJ, ZhaoD, BeckieTM, BushnellC, DArmientoJ, . ObstetGynecol1998; 178: 521526. . . Kris-EthertonPM, FangJ, GaniatsTG, GomesAS, GraciaCR, HaanCK, Jackson 441. SchmellaMJ, CliftonRG, AlthouseAD, RobertsJM. Uricaciddeterminationin. . EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier sodium, Ofili E, . gestationalhypertension: isitaseffectiveadelineatorofriskasproteinuriain. OparilS, OuyangP, PinnVW, SherifK, SmithSCJr, SopkoG, Chandra-Strobos. High-riskwomen? ReprodSci2015; 22: 12121219. . N, UrbinaEM, VaccarinoV, WengerNK. Effectiveness-basedguidelinesforthe. 442. Chappell LC, Shennan AH. Assessment of proteinuria in pregnancy. BMJ. . preventionofcardiovasculardiseaseinwomen2011update: aguidelinefrom 2008; 336: 968969. . . theAmericanHeartAssociation. JAmCollCardiol2011; 57: 14041423. . 443. CnossenJS, MorrisRK, terRietG, MolBW, vanderPostJA, CoomarasamyA, . 462. IssaZ, SeelyEW, RahmeM, El-HajjFuleihanG. Effectsofhormonetherapyon. Zwinderman AH, RobsonSC, BindelsPJ, KleijnenJ, KhanKS. Useofuterine. bloodpressure. Menopause2015; 22: 456468. . artery Doppler ultrasonography to predict pre-eclampsia and intrauterine. . 463. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, . growth restriction: a systematic review and bivariable meta-analysis. CMAJ. PerruoloE, ParatiG. PanethnicdifferencesinbloodpressureinEurope: asys-. 2008; 178: 701711. . tematicreviewandmeta-analysis. PLoSOne2016; 11: e0147601. . 444. ZeislerH, LlurbaE, ChantraineF, VatishM, StaffAC, SennstromM, Olovsson. . 464. WheltonPK, EinhornPT, MuntnerP, AppelLJ, CushmanWC, DiezRouxAV, M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, . . FerdinandKC, RahmanM, TaylorHA, ArdJ, ArnettDK, CarterBL, DavisBR, . VerlohrenS. PredictivevalueofthesFlt-1: PlGFratioinwomenwithsuspected. FreedmanBI, CooperLA, CooperR, Desvigne-NickensP, Gavini N, GoAS, . preeclampsia. NEnglJMed2016; 374: 1322. . HymanDJ, KimmelPL, MargolisKL, MillerERIII, MillsKT, MensahGA, Navar. 445. RolnikDL, WrightD, PoonLC, OGormanN, SyngelakiA, dePacoMatallana. . AM, Ogedegbe G, Rakotz MK, Thomas G, Tobin JN, Wright JT, Yoon SS, C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, . . CutlerJA. Researchneedstoimprovehypertensiontreatmentandcontrolin. Plasencia W, Papaioannou G, Tenenbaum-Gavish potassium, Meiri H, Gizurarson S, . AfricanAmericans. Hypertension2016; 68: 10661072. . MaclaganK, NicolaidesKH.",
    "CutlerJA. Researchneedstoimprovehypertensiontreatmentandcontrolin. Plasencia W, Papaioannou G, Tenenbaum-Gavish potassium, Meiri H, Gizurarson S, . AfricanAmericans. Hypertension2016; 68: 10661072. . MaclaganK, NicolaidesKH. Aspirinversusplaceboinpregnanciesathighrisk. . 465. KaufmanJS, CooperRS, McGeeDL. Socioeconomicstatusandhealthinblacks forpretermpreeclampsia. NEnglJMed2017; 377: 613622. . . and whites: the problem of residual confounding and the resiliency of race. . 446. MageeLA, vonDadelszenP, SingerJ, LeeT, ReyE, RossS, AsztalosE, Murphy. Epidemiology1997; 8: 621628. . KE, MenziesJ, SanchezJ, GafniA, HelewaM, HuttonE, KorenG, LeeSK, Logan. 466. AgyemangC, vanOeffelenAA, NorredamM, Kappelle LJ, KlijnCJ, BotsML, . AG, GanzevoortW, WelchR, ThorntonJG, MoutquinJM, CHIPSStudyGroup. . . Stronks potassium, Vaartjes I. Socioeconomic inequalities in stroke incidence among TheCHIPSrandomizedcontrolledtrial(ControlofHypertensioninPregnancy. migrantgroups: analysisofnationwidedata. Stroke2014; 45: 23972403. Downloaded from by guest on 31 December 2025 3104j ESC/ESHGuidelines. . 467. Mehanna M, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman. chronic kidney disease: prevalence and association with target organ damage. Clin J Am Soc. AB, SchwartzGL, JohnsonJA, TurnerST, Cooper-DeHoffRM. Bloodpressure. Nephrol2016; 11: 642652. . responsetometoprololandchlorthalidoneinEuropeanandAfricanAmericans. . 484. RossignolP, MassyZA, AziziM, BakrisG, RitzE, CovicA, GoldsmithD, Heine withhypertension. JClinHypertens(Greenwich)2017; 19: 13011308. . . GH, JagerKJ, KanbayM, MallamaciF, OrtizA, VanholderR, WiecekA, Zoccali. 468. ErlingerTP, VollmerWM, SvetkeyLP, AppelLJ. Thepotentialimpactofnon-. C, LondonGM, StengelB, FouqueD, European Renal Association-EDTAEURECA-mWorkingGroup, . pharmacologic population-wide Blood Hypertension reduction on coronary Heart. . ReddeInvestigacionRenal(REDINREN)Network, CardiovascularandRenal disease events: pronounced benefits in African-Americans and hypertensives. . . ClinicalTrialists(F-CRININI-CRCT)Network. Thedoublechallengeofresist-. PrevMed2003; 37: 327333. . anthypertensionandchronickidneydisease. Lancet2015; 386: 15881598. . 469. WrightJTJr, DunnJK, CutlerJA, DavisBR, CushmanWC, FordCE, Haywood. 485. MalhotraR, NguyenHA, BenaventeO, MeteM, HowardBV, MantJ, Odden. LJ, Leenen family history, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, . . MC, Peralta calcium, Cheung AK, Nadkarni glomerulonephritis, Coleman RL, Holman respiratory rate, HabibGB, ALLHATCollaborativeResearchGroup. Outcomesinhypertensive. . ZanchettiA, PetersR, BeckettN, StaessenJA, IxJH. Associationbetweenmore. blackandnonblackpatientstreatedwithchlorthalidone, amlodipine, andlisino-. intensive vs less intensive Blood Hypertension lowering and risk of mortality in. pril. JAMA2005; 293: 15951608. . chronic Kidney disease stages 3 to 5: a systematic review and meta-analysis. . 470. WrightJTJr, Harris-HaywoodS, PresselS, BarzilayJ, BaimbridgeC, BareisCJ, . . JAMAInternMed2017; 177: 14981505. . BasileJN, BlackHR, DartR, GuptaAK, HamiltonBP, EinhornPT, Haywood. 486. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, . LJ, JafriSZ, LouisGT, WheltonPK, ScottCL, SimmonsDL, StanfordC, Davis. SnapinnS, CooperME, MitchWE, BrennerBM. Albuminuria, atherapeutictar-. BR. Clinical outcomes by race in hypertensive patients with and without. . getforcardiovascularprotectionintype2diabeticpatientswithnephropathy. the metabolic syndrome: Antihypertensive and Lipid-Lowering. . Circulation2004; 110: 921927. . TreatmenttoPreventHeartAttack Trial (ALLHAT). ArchInternMed2008; . 487. JafarTH, StarkPC, SchmidCH, LandaM, MaschioG, deJongPE, deZeeuwD, . 168: 207217. . ShahinfarS, TotoR, LeveyAS, AIPRDStudyGroup. Progressionofchronickid-. 471. AgyemangC, NyaabaG, BeuneE, MeeksK, Owusu-DaboE, AddoJ, AikinsAD, . . neydisease: theroleofbloodpressurecontrol, proteinuria, andangiotensinMockenhauptFP, BahendekaS, DanquahI, SchulzeMB, GalbeteC, SprangerJ, . . converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. Agyei-BaffourP, HennemanP, Klipstein-GrobuschK, AdeyemoA, vanStraalen. 2003; 139: 244252. . J, Commodore-MensahY, AppiahLT, SmeethL, StronksK. Variationsinhyper-. . 488. UpadhyayA, EarleyA, HaynesSM, UhligK. Systematicreview: bloodpressure tensionawareness, treatment, andcontrolamongGhanaianmigrantslivingin. . targetinchronickidneydiseaseandproteinuriaasaneffectmodifier. AnnIntern. Amsterdam, Berlin, London, andnonmigrantGhanaianslivinginruralandurban. Med2011; 154: 541548. . Ghana-theRODAMstudy. JHypertens2018; 36: 169177. . 489. Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh potassium, Jacobsen SJ. Impact of achieved. 472. WijkmanM, LanneT, EngvallJ, LindstromT, OstgrenCJ, NystromFH. Masked. . bloodpressuresonmortalityriskandend-stagerenaldiseaseamongalarge, nocturnalhypertensionanovelmarkerofriskintype2diabetes. Diabetologia. . diversehypertensionpopulation. JAmCollCardiol2014; 64: 588597. . 2009; 52: 12581264. . 490. Farsang CK, Kiss I, Tykarski A, Narkiewicz potassium. Treatment of hypertension in. 473. MannJF, SchmiederRE, McQueenM, DyalL, SchumacherH, PogueJ, WangX, . patientswithchronicobstructivepulmonarydisease(COPD). EuropeanSociety. MaggioniA, BudajA, ChaithiraphanS, DicksteinK, KeltaiM, MetsarinneK, Oto. . ofHypertensionScientificNewsletter2016; 17: 62. . A, ParkhomenkoA, PiegasLS, SvendsenTL, TeoKK, YusufS. Renaloutcomes. 491. BakerJG, WilcoxRG. beta-Blockers, heartdiseaseandCOPD: currentcontro-. with telmisartan, ramipril, or both, in people at High vascular risk (the. versiesanduncertainties. Thorax2017; 72: 271276. . ONTARGETstudy): amulticentre, randomised, double-blind, controlledtrial. . . 492. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of Lancet2008; 372: 547553. . .",
    ". . 492. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of Lancet2008; 372: 547553. . . long-acting beta-agonists on severe asthma exacerbations and asthma-related. 474. PerssonF, LewisJB, LewisEJ, RossingP, HollenbergNK, ParvingHH. Aliskiren. deaths. AnnInternMed2006; 144: 904912. . in combination with losartan reduces albuminuria independent of baseline. 493. Rutten family history, Zuithoff NP, Hak E, GrobbeeDE, Hoes AW. Beta-blockers may. bloodpressureinpatientswithtype2diabetesandnephropathy. ClinJAmSoc. . reducemortalityandriskofexacerbationsinpatientswithchronicobstructive Nephrol2011; 6: 10251031. . . pulmonarydisease. ArchInternMed2010; 170: 880887. . 475. ZinmanB, WannerC, LachinJM, FitchettD, BluhmkiE, HantelS, MattheusM, . 494. Coiro S, Girerd N, Rossignol P, Ferreira JP, Maggioni A, Pitt B, Tritto I, . Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG. . Ambrosio G, Dickstein potassium, Zannad F. Association of beta-blocker treatment OUTCOMEInvestigators. Empagliflozin, cardiovascularoutcomes, andmortal-. . withmortalityfollowingmyocardialinfarctioninpatientswithchronicobstruc-. ityintype2diabetes. NEnglJMed2015; 373: 21172128. . tivepulmonarydiseaseandheartfailureorleftventriculardysfunction: apro-. 476. NealB, PerkovicV, MahaffeyKW, deZeeuwD, FulcherG, EronduN, Shaw. pensity matched-cohort analysis from the High-Risk Myocardial Infarction. W, LawG, DesaiM, MatthewsDR. Canagliflozinandcardiovascularandrenal. . DatabaseInitiative. EurJHeartFail2017; 19: 271279. eventsintype2diabetes. NEnglJMed2017; 377: 644657. . . 495. CazzolaM, NoscheseP, DAmatoG, MateraMG. Thepharmacologictreatment. 477. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, . of uncomplicated arterial hypertension in patients with airway dysfunction. . YusoffK, RydenL, LiuGL, TeoK, SleightP, YusufS. Bloodpressuretargetsrec-. Chest2002; 121: 230241. . ommended by guidelinesandincidence of cardiovascular andrenaleventsin. . 496. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, the Ongoing Telmisartan Alone and in Combination With Ramipril Global. . MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi potassium, . EndpointTrial(ONTARGET). Circulation2011; 124: 17271736. . PerkovicV, RodgersA. Effectsofintensivebloodpressureloweringoncardio-. 478. WannerC, Inzucchi SE, LachinJM, FitchettD, von EynattenM, Mattheus M, . . vascular and renal outcomes: updated systematic review and meta-analysis. Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME. . Lancet2016; 387: 435443. . Investigators. Empagliflozinandprogressionofkidneydiseaseintype2diabetes. . 497. Bangalore S, Messerli family history, Wun C, Zuckerman AL, DeMicco D, Kostis JB, . NEnglJMed2016; 375: 323334. . LaRosaJC, TreatingtoNewTargetsSteeringCommitteeandInvestigators. J-. 479. Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, . . Curverevisited: ananalysisoftheTreatingtoNewTargets(TNT)Trial. JAm JohansenOE. Impactofempagliflozinonbloodpressureinpatientswithtype2. . CollCardiol2009; 53: A217. . diabetesmellitusandhypertensionbybackgroundantihypertensivemedication. . 498. BangaloreS, QinJ, SloanS, MurphySA, CannonCP, PROVEIT-TIMI22Trial. Hypertension2016; 68: 13551364. . . Investigators. Whatistheoptimalbloodpressureinpatientsafteracutecoro480. BuseJB. Liraglutideandcardiovascularoutcomesintype2diabetes. NEnglJ. . narysyndromes? : relationshipofbloodpressureandcardiovasculareventsin. Med2016; 375: 17981799. . the PRavastatin OR atorVastatin Evaluation and Infection Therapy-. 481. BethelMA, PatelRA, MerrillP, LokhnyginaY, BuseJB, MentzRJ, PagidipatiNJ, . Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Ohman P, Poulter NR, . . 2010; 122: 21422151. RamachandranA, ZinmanB, HernandezAF, HolmanRR. Cardiovascularout-. . 499. MesserliFH, ManciaG, ContiCR, HewkinAC, KupferS, ChampionA, Kolloch. comeswithglucagon-likepeptide-1receptoragonistsinpatientswithtype2. R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering Blood. Diabetes: ameta-analysis. LancetDiabetesEndocrinol2018; 6: 105113. . pressureinhypertensivepatientswithcoronaryarterydiseasebedangerous? . 482. ThomopoulosC, ParatiG, ZanchettiA. Effectsofbloodpressureloweringon. . AnnInternMed2006; 144: 884893. outcomeincidenceinhypertension: 2. Effectsatdifferentbaselineandachieved. . 500. SleightP, RedonJ, VerdecchiaP, ManciaG, GaoP, FagardR, SchumacherH, . Blood Hypertension levelsoverview and meta-analyses of randomized trials. J. Weber M, Bohm M, Williams B, Pogue J, Koon T, Yusuf S, ONTARGET. Hypertens2014; 32: 22962304. . . Investigators. Prognosticvalueofbloodpressureinpatientswithhighvascular 483. DrawzPE, AlperAB, AndersonAH, BrecklinCS, CharlestonJ, ChenJ, DeoR, . . riskintheOngoingTelmisartanAloneandincombinationwithRamiprilGlobal. FischerMJ, HeJ, HsuCY, HuanY, KeaneMG, KusekJW, MakosGK, MillerER. EndpointTrialstudy. JHypertens2009; 27: 13601369. . III, SolimanEZ, SteigerwaltSP, TaliercioJJ, TownsendRR, WeirMR, WrightJT. 501. Vidal-PetiotE, FordI, GreenlawN, FerrariR, FoxKM, TardifJC, TenderaM, . Jr, XieD, RahmanM, ChronicRenalInsufficiencyCohortStudyInvestigators. . . Tavazzi L, Bhatt DL, Steg PG, CLARIFY Investigators. Cardiovascular event Masked hypertension and elevated nighttime Blood Hypertension in. ratesandmortalityaccordingtoachievedsystolicanddiastolicbloodpressure Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3104k. . inpatientswithstablecoronaryarterydisease: aninternationalcohortstudy. . from the American Heart Association/American Stroke Association. Stroke. Lancet2016; 388: 21422152. .",
    ". inpatientswithstablecoronaryarterydisease: aninternationalcohortstudy. . from the American Heart Association/American Stroke Association. Stroke. Lancet2016; 388: 21422152. . 2013; 44: 870947. . 502. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, . . 519. Sandset EC, Rice PM, Boysen G, Jatuzis D, Korv J, Luders S, Murray GD, Verdecchia P, Weber M, Bohm M, Williams B, Yusoff potassium, Teo potassium, Yusuf S, . . Richter PS, Roine RO, Terent A, Thijs V, Berge E. The angiotensin-receptor. ONTARGETInvestigators. Safetyandefficacyoflowbloodpressuresamong. blocker candesartan for treatment of acute stroke (SCAST): a randomised, . patients with Diabetes: subgroup analyses from the ONTARGET (ONgoing. . placebo-controlled, double-blindtrial. Lancet2011; 377: 741750. TelmisartanAloneandincombinationwithRamiprilGlobalEndpointTrial). J. . 520. Sandset EC, Murray GD, Rice PM, Kjeldsen SE, Berge E; Scandinavian. AmCollCardiol2012; 59: 7483. . Candesartan Acute Stroke Trial (SCAST) Study Group. Relation between. 503. LawMR, MorrisJK, WaldNJ. Useofbloodpressureloweringdrugsinthepre-. changeinbloodpressureinacutestrokeandriskofearlyadverseeventsand. ventionofcardiovasculardisease: meta-analysisof147randomisedtrialsinthe. . pooroutcome. Stroke2012; 43: 21082114. context of expectations from prospective epidemiological studies. BMJ. . 521. ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing. 2009; 338: b1665. . antihypertensive treatment, for management of Hypertension in acute. 504. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension-lowering. stroke (ENOS): a partial-factorial randomised controlled trial. Lancet. treatment. 6. Preventionofheartfailureandnew-onsetheartfailuremeta-anal-. . 2015; 385: 617628. . ysesofrandomizedtrials. JHypertens2016; 34: 373384. . 522. RobinsonTG, PotterJF, FordGA, BulpittCJ, ChernovaJ, JaggerC, JamesMA, . 505. SolimanEZ, ByingtonRP, BiggerJT, EvansG, OkinPM, GoffDCJr, ChenH. . KnightJ, MarkusHS, MistriAK, PoulterNR. Effectsofantihypertensivetreat-. Effectofintensivebloodpressureloweringonleftventricularhypertrophyin. . mentafteracutestrokeintheContinueorStopPost-StrokeAntihypertensives patientswithdiabetesmellitus: actiontocontrolcardiovascularriskindiabetes. . Collaborative Study (COSSACS): a prospective, randomised, open, blinded-. bloodpressuretrial. Hypertension2015; 66: 11231129. . endpointtrial. LancetNeurol2010; 9: 767775. . 506. VerdecchiaP, StaessenJA, AngeliF, deSimoneG, AchilliA, GanauA, Mureddu. 523. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A. G, PedeS, MaggioniAP, LucciD, ReboldiG, Cardio-SisInvestigators. Usualver-. . preliminaryresult. ChinMedJ(Engl)1995; 108: 710717. sustightcontrolofsystolicbloodpressureinnon-diabeticpatientswithhyper-. . 524. White chloride, Szychowski JM, Pergola physical examination, Field TS, Talbert R, Lau H, Peri potassium, . tension(Cardio-Sis): anopen-labelrandomisedtrial. Lancet2009; 374: 525533. . Benavente OR, Secondary Prevention of Small Subcortical Strokes Study. 507. McMurrayJJ, PackerM, DesaiAS, GongJ, LefkowitzMP, RizkalaAR, RouleauJL, . . Investigators. Canbloodpressurebeloweredsafelyinolderadultswithlacunar Shi VC, Solomon SD, Swedberg potassium, Zile MR. Angiotensin-neprilysin inhibition. . stroke? TheSecondaryPreventionofSmallSubcorticalStrokesstudyexperi-. versusenalaprilinheartfailure. NEnglJMed2014; 371: 9931004. . ence. JAmGeriatrSoc2015; 63: 722729. . 508. Manning LS, Mistri AK, Potter J, Rothwell PM, Robinson TG. Short-term. 525. Kernan WN, Ovbiagele B, Black heart rate, Bravata diabetes mellitus, Chimowitz myocardial infarction, Ezekowitz. bloodpressurevariabilityinacutestroke: posthocanalysisofthecontrolling. . MD, FangMC, FisherM, FurieKL, HeckDV, JohnstonSC, KasnerSE, KittnerSJ, hypertensionandhypotensionimmediatelypoststrokeandcontinueorstop. . Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA, American. post-stroke antihypertensives collaborative study trials. Stroke 2015; 46: . Heart Association Stroke Council, Council on Cardiovascular and Stroke. 15181524. . Nursing, Council on Clinical Cardiology, Council on Peripheral Vascular. 509. Rodriguez-LunaD, PineiroS, RubieraM, RiboM, CoscojuelaP, PagolaJ, Flores. . Disease. Guidelines for the prevention of stroke in patients with stroke and. A, MuchadaM, IbarraB, MelerP, SanjuanE, Hernandez-GuillamonM, Alvarez-. transient ischemic attack: a guideline for healthcare professionals from the. SabinJ, MontanerJ, MolinaCA. Impactofbloodpressurechangesandcourse. American Heart Association/American Stroke Association. Stroke. on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. . 2014; 45: 21602236. 2013; 20: 12771283. . . 526. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, . 510. SakamotoY, KogaM, YamagamiH, OkudaS, OkadaY, KimuraK, ShiokawaY, . Macmahon S, Neal B, PROGRESS Collaborative Group. Lower target Blood. Nakagawara J, Furui E, Hasegawa Y, Kario potassium, Arihiro S, Sato S, Kobayashi J, . pressures are safe and effective for the prevention of recurrent stroke: the. TanakaE, NagatsukaK, MinematsuK, ToyodaK. Systolicbloodpressureafter. . PROGRESStrial. JHypertens2006; 24: 12011208. intravenous antihypertensive treatment and clinical outcomes in hyperacute. . 527. Collier DJ, Poulter NR, Dahlof B, Sever PS, Wedel H, Buch J, Caulfield MJ.",
    ". 527. Collier DJ, Poulter NR, Dahlof B, Sever PS, Wedel H, Buch J, Caulfield MJ. . intracerebralhemorrhage: thestrokeacutemanagementwithurgentrisk-factor. Impactofamlodipine-basedtherapyamongolderandyoungerpatientsinthe. assessment and improvement-intracerebral hemorrhage study. Stroke. . Anglo-Scandinavian Cardiac Outcomes Trial-Blood Hypertension Lowering Arm 2013; 44: 18461851. . . (ASCOT-BPLA). JHypertens2011; 29: 583591. . 511. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, . 528. National Institute for Health and Clinical Excellence. Hypertension (CG127): . Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, . clinical management of primary hypertension in adults. www. nice. org. uk/guid. HeritierS, LiQ, WoodwardM, SimesRJ, DavisSM, ChalmersJ, INTERACT2. . ance/CG127(April2018). Investigators. Rapidblood-pressureloweringinpatients withacuteintracere-. . 529. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, . bralhemorrhage. NEnglJMed2013; 368: 23552365. . GarberS, McCaffreyDF, DakeMD, LevinRA. Occurrenceofsecondaryische-. 512. QureshiAI, PaleschYY, BarsanWG, HanleyDF, HsuCY, MartinRL, MoyCS, . mic events among persons with atherosclerotic vascular disease. Stroke. SilbergleitR, SteinerT, SuarezJI, ToyodaK, WangY, YamamotoH, YoonBW. . . 2002; 33: 901906. Intensiveblood-pressureloweringinpatientswithacutecerebralhemorrhage. . . 530. EmdinCA, RothwellPM, Salimi-KhorshidiG, KiranA, ConradN, CallenderT, . NEnglJMed2016; 375: 10331043. . MehtaZ, PendleburyST, AndersonSG, MohseniH, WoodwardM, RahimiK. . 513. Tsivgoulis G, Katsanos AH, Butcher KS, Boviatsis E, Triantafyllou N, Rizos I, . . Blood Hypertension and risk of vascular dementia: evidence from a primary care AlexandrovAV. Intensivebloodpressurereductioninacuteintracerebralhem-. . registry and a cohort study of transient ischemic attack and stroke. Stroke. orrhage: ameta-analysis. Neurology2014; 83: 15231529. . 2016; 47: 14291435. . 514. AhmedN, WahlgrenN, BraininM, CastilloJ, FordGA, KasteM, LeesKR, Toni. 531. NinomiyaT, OharaT, HirakawaY, YoshidaD, DoiY, HataJ, KanbaS, IwakiT, . D. Relationship of Blood Hypertension, antihypertensive therapy, and outcome in. . KiyoharaY. Midlifeandlate-lifebloodpressureanddementiainJapaneseeldischemic stroke treated with intravenous thrombolysis: retrospective analysis. . erly: theHisayamastudy. Hypertension2011; 58: 2228. . from Safe Implementation of Thrombolysis in Stroke-International Stroke. 532. SierraC, DeLaSierraA, SalameroM, SobrinoJ, Gomez-AngelatsE, CocaA. . ThrombolysisRegister(SITS-ISTR). Stroke2009; 40: 24422449. . . Silent cerebral white matter lesions and cognitive function in middle-aged 515. Wu W, Huo X, Zhao X, Liao X, Wang C, Pan Y, Wang Y, Wang Y. . . essentialhypertensivepatients. AmJHypertens2004; 17: 529534. . Relationshipbetweenbloodpressureandoutcomesinacuteischemicstroke. 533. SnyderHM, CorriveauRA, CraftS, FaberJE, GreenbergSM, KnopmanD, Lamb. patients administered lytic medication in the TIMS-China Study. PLoS One. BT, Montine TJ, Nedergaard M, Schaffer CB, Schneider JA, Wellington C, . 2016; 11: e0144260. . . WilcockDM, ZipfelGJ, ZlokovicB, BainLJ, BosettiF, GalisZS, KoroshetzW, 516. LeeM, OvbiageleB, HongKS, WuYL, LeeJE, RaoNM, FengW, SaverJL. Effect. . Carrillo MC. Vascular contributions to cognitive impairment and dementia. of Blood Hypertension lowering in early ischemic stroke: meta-analysis. Stroke. includingAlzheimersdisease. AlzheimersDement2015; 11: 710717. . 2015; 46: 18831889. . 534. LeviMarpillatN, Macquin-MavierI, TropeanoAI, Bachoud-LeviAC, MaisonP. . 517. ZhaoR, LiuFD, WangS, PengJL, TaoXX, ZhengB, ZhangQT, YaoQ, Shen. . Antihypertensive classes, cognitive decline and incidence of dementia: a netXL, LiWT, ZhaoY, LiuYS, SuJJ, ShuL, ZhangM, LiuJR. Bloodpressurereduc-. . workmeta-analysis. JHypertens2013; 31: 10731082. . tionintheacutephaseofanischemicstrokedoesnotimproveshort-orlong-. 535. GodinO, TzourioC, MaillardP, MazoyerB, DufouilC. Antihypertensivetreat-. termdependencyor mortality: a meta-analysis of current literature. Medicine. . ment and change in Blood Hypertension are associated with the progression of (Baltimore)2015; 94: e896. . . whitematterlesionvolumes: theThree-City(3C)-DijonMagneticResonance. 518. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, . ImagingStudy. Circulation2011; 123: 266273. . KhatriP, McMullanPWJr, QureshiAI, RosenfieldK, ScottPA, SummersDR, . 536. LipGYH, CocaA, KahanT, BorianiG, ManolisAS, OlsenMH, OtoA, Potpara. WangDZ, WintermarkM, YonasH. Guidelinesfortheearlymanagementof. . TS, SteffelJ, MarinF, deOliveiraFigueiredoMJ, deSimoneG, TzouWS, Chiang patients with acute ischemic stroke: a guideline for healthcare professionals. CE, WilliamsB, Reviewers, DanGA, GorenekB, FauchierL, SavelievaI, Hatala Downloaded from by guest on 31 December 2025 3104l ESC/ESHGuidelines. . R, vanGelderI, Brguljan-HitijJ, ErdineS, LovicD, KimYH, Salinas-ArceJ, Field.",
    ". R, vanGelderI, Brguljan-HitijJ, ErdineS, LovicD, KimYH, Salinas-ArceJ, Field. Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron. M. Hypertension and cardiac arrhythmias: a consensus document from the. Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, . European Heart Rhythm Association (EHRA) and ESC Council on. . Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Hypertension, endorsedbytheHeartRhythmSociety(HRS), Asia-PacificHeart. . GuenounM, HohnloserSH, KolhP, LipGY, ManolisA, McMurrayJ, Ponikowski. Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion. P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, . CardiacayElectrofisiologia(SOLEACE). Europace2017; 19: 891911. . . TaylorCJ, VanGelderIC, VoorsAA, WindeckerS, ZamoranoJL, Zeppenfeld 537. ManolisA, DoumasM, PoulimenosL, KallistratosM, ManciaG. Theunappreci-. . potassium. 2016ESCGuidelinesforthemanagementofatrialfibrillationdevelopedin. atedimportanceofbloodpressureinrecentandolderatrialfibrillationtrials. J. collaborationwithEACTS. EurHeartJ2016; 37: 28932962. . Hypertens2013; 31: 21092117. . 557. ZanchettiA, CrepaldiG, BondMG, GallusG, VegliaF, ManciaG, VenturaA, . 538. LaukkanenJA, KhanH, KurlS, WilleitP, KarppiJ, RonkainenK, DiAngelantonio. . Baggio G, Sampieri L, Rubba P, Sperti G, Magni A, PHYLLIS Investigators. E. Left ventricular mass and the risk of sudden cardiac death: a population-. . Different effects of antihypertensive regimens based on fosinopril or hydro-. basedstudy. JAmHeartAssoc2014; 3: e001285. . chlorothiazidewithorwithoutlipidloweringbypravastatinonprogressionof. 539. LipGY. Atrialfibrillationinpatientswithhypertension: trajectoriesofriskfac-. asymptomaticcarotidatherosclerosis: principalresultsofPHYLLISarandom-. tors in yet another manifestation of hypertensive target organ damage. . . izeddouble-blindtrial. Stroke2004; 35: 28072812. . Hypertension2016; 68: 544545. . 558. Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Volzke H, Tuomainen total protein, . 540. ConenD, TedrowUB, KoplanBA, GlynnRJ, BuringJE, AlbertCM. Influenceof. Sander D, Plichart M, Catapano AL, Robertson CM, Kiechl S, Rundek T, . systolicanddiastolicbloodpressureontheriskofincidentatrialfibrillationin. . DesvarieuxM, LindL, SchmidC, DasMahapatraP, GaoL, ZiegelbauerK, Bots women. Circulation2009; 119: 21462152. . . ML, ThompsonSG, PROG-IMTStudyGroup. Carotidintima-mediathickness. 541. Grundvold I, Skretteberg patient, Liestol potassium, Erikssen G, Kjeldsen SE, Arnesen H, . progression to predict cardiovascular events in the general population (the. Erikssen J, Bodegard J. Upper normal Blood pressures predict incident atrial. PROG-IMTcollaborativeproject): ameta-analysisofindividualparticipantdata. . fibrillationinhealthymiddle-agedmen: a35-yearfollow-upstudy. Hypertension. . Lancet2012; 379: 20532062. 2012; 59: 198204. . . 559. LaurentS, BoutouyrieP, VascularMechanismCollaboration. Dose-dependent. 542. FreedmanB, PotparaTS, LipGY. Strokepreventioninatrialfibrillation. Lancet. arterial destiffening and inward remodeling after olmesartan in hypertensives. 2016; 388: 806817. . . withmetabolicsyndrome. Hypertension2014; 64: 709716. 543. SchmiederRE, KjeldsenSE, JuliusS, McInnesGT, ZanchettiA, HuaTA, VALUE. . 560. OngKT, DelermeS, PannierB, SafarME, BenetosA, LaurentS, BoutouyrieP. . TrialGroup. Reducedincidenceofnew-onsetatrialfibrillationwithangiotensin. Aorticstiffnessisreducedbeyondbloodpressureloweringbyshort-termand. IIreceptorblockade: theVALUEtrial. JHypertens2008; 26: 403411. . long-termantihypertensivetreatment: ameta-analysisofindividualdatain294. 544. WachtellK, LehtoM, GerdtsE, OlsenMH, HornestamB, DahlofB, IbsenH, . . patients. JHypertens2011; 29: 10341042. JuliusS, KjeldsenSE, LindholmLH, NieminenMS, DevereuxRB. AngiotensinII. . 561. ShahinY, KhanJA, ChetterI. Angiotensinconvertingenzymeinhibitorseffect. receptorblockadereducesnew-onsetatrialfibrillationandsubsequentstroke. onarterialstiffnessandwavereflections: ameta-analysisandmeta-regression. compared to atenolol: the Losartan Intervention For EndPointReduction in. ofrandomisedcontrolledtrials. Atherosclerosis2012; 221: 1833. . Hypertension(LIFE)study. JAmCollCardiol2005; 45: 712719. . . 562. Ait-OufellaH, CollinC, BozecE, LalouxB, OngKT, DufouilC, BoutouyrieP, . 545. CohnJN, TognoniG, ValsartanHeartFailureTrialInvestigators. Arandomized. LaurentS. Long-termreductioninaorticstiffness: a5. 3-yearfollow-upinrou-. trial of the angiotensin-receptor blocker valsartan in chronic Heart failure. N. tineclinicalpractice. JHypertens2010; 28: 23362341. . EnglJMed2001; 345: 16671675. . . 563. GuerinAP, BlacherJ, PannierB, MarchaisSJ, SafarME, LondonGM. Impactof 546. DucharmeA, SwedbergK, PfefferMA, Cohen-SolalA, GrangerCB, Maggioni. . aortic stiffness attenuation on survival of patients in end-stage renal failure. . AP, MichelsonEL, McMurrayJJ, Olsson L, Rouleau JL, Young JB, OlofssonB, . Circulation2001; 103: 987992. . PuuM, YusufS, CHARMInvestigators. Preventionofatrialfibrillationinpatients. 564. Singer DR, Kite A. Management of hypertension in peripheral arterial. withsymptomaticchronicheartfailurebycandesartanintheCandesartanin. . disease: does the choice of drugs matter? Eur J Vasc Endovasc Surg 2008; 35: Heartfailure: AssessmentofReductioninMortalityandmorbidity(CHARM). . 701708. . program. AmHeartJ2006; 152: 8692. . 565. ParavastuSC, MendoncaDA, daSilvaA. Betablockersforperipheralarterial. 547. VermesE, TardifJC, BourassaMG, RacineN, LevesqueS, WhiteM, GuerraPG, . . disease. EurJVascEndovascSurg2009; 38: 6670. DucharmeA. Enalaprildecreasestheincidenceofatrialfibrillationinpatients. . 566. RadackK, DeckC. Beta-adrenergicblockertherapydoesnotworsenintermit-. with left ventricular dysfunction: insight from the Studies Of Left Ventricular. tentclaudicationinsubjectswithperipheralarterialdisease. Ameta-analysisof. Dysfunction(SOLVD)trials.",
    "Enalaprildecreasestheincidenceofatrialfibrillationinpatients. . 566. RadackK, DeckC. Beta-adrenergicblockertherapydoesnotworsenintermit-. with left ventricular dysfunction: insight from the Studies Of Left Ventricular. tentclaudicationinsubjectswithperipheralarterialdisease. Ameta-analysisof. Dysfunction(SOLVD)trials. Circulation2003; 107: 29262931. . randomizedcontrolledtrials. ArchInternMed1991; 151: 17691776. . 548. GISSI-atrial fibrillation Investigators, Disertori M, Latini R, Barlera S, Franzosi magnesium, . . 567. NakamuraK, StefanescuSchmidtA. Treatmentofhypertensionincoarctation StaszewskyL, MaggioniAP, LucciD, DiPasqualeG, TognoniG. Valsartanfor. . oftheaorta. CurrTreatOptionsCardiovascMed2016; 18: 40. . preventionofrecurrentatrialfibrillation. NEnglJMed2009; 360: 16061617. . 568. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, . 549. GoetteA, SchonN, KirchhofP, BreithardtG, FetschT, HauslerKG, KleinHU, . EvangelistaA, FalkV, FrankH, GaemperliO, GrabenwogerM, HaverichA, Iung. Steinbeck G, Wegscheider potassium, Meinertz T. Angiotensin II-antagonist in. . B, Manolis AJ, Meijboom F, Nienaber calcium, Roffi M, Rousseau H, Sechtem U, paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. . SirnesPA, AllmenRS, VrintsCJ, ESCCommitteeforPracticeGuidelines. 2014. 2012; 5: 4351. . ESCGuidelinesonthediagnosisandtreatmentofaorticdiseases: Document. 550. TveitA, GrundvoldI, OlufsenM, SeljeflotI, AbdelnoorM, ArnesenH, SmithP. . . coveringacuteandchronicaorticdiseasesofthethoracicandabdominalaorta Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. . of the adult. The Task Force for the Diagnosis and Treatment of Aortic. 2007; 120: 8591. . Diseases of the European Society of Cardiology (ESC). Eur Heart J. 551. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Blood Heuzey JY, Lechat P. . 2014; 35: 28732926. . Preventionofatrialfibrillationonsetbybeta-blockertreatmentinheartfailure: . . 569. ShoresJ, BergerKR, MurphyEA, PyeritzRE. Progressionofaorticdilatationand ameta-analysis. EurHeartJ2007; 28: 457462. . . thebenefitoflong-termbeta-adrenergicblockadeinMarfanssyndrome. NEngl. 552. SwedbergK, ZannadF, McMurrayJJ, KrumH, vanVeldhuisenDJ, ShiH, Vincent. JMed1994; 330: 13351341. . J, PittB, EMPHASIS-HFStudyInvestigators. Eplerenoneandatrialfibrillationin. 570. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, . mildsystolicheartfailure: resultsfromtheEMPHASIS-heart failure(EplerenoneinMild. . TimmermansJ, ScholteAJ, vandenBergMP, SpijkerboerAM, MarqueringHA, . Patients Hospitalization And SurvIval Study inHeart Failure) study. J Am Coll. Zwinderman AH, Mulder BJ. Losartanreduces aortic dilatation rate inadults. Cardiol2012; 59: 15981603. . with Marfan syndrome: a randomized controlled trial. Eur Heart J. 553. SchaerBA, SchneiderC, JickSS, ConenD, OsswaldS, MeierCR. Riskforinci-. . 2013; 34: 34913500. dentatrialfibrillationinpatientswhoreceiveantihypertensivedrugs: anested. . 571. SchaeferBM, LewinMB, StoutKK, GillE, PrueittA, ByersPH, OttoCM. The. case-controlstudy. AnnInternMed2010; 152: 7884. . bicuspidaorticvalve: anintegratedphenotypicclassificationofleafletmorphol-. 554. HungY, ChaoTF, LiuCJ, TuanTC, LinYJ, ChangSL, LoLW, HuYF, LiaoJN, . ogyandaorticrootshape. Heart2008; 94: 16341638. . ChungFP, LinWY, LinWS, ChengSM, ChenTJ, LipGY, ChenSA. Isanoral. . 572. Davies respiratory rate, Kaple RK, Mandapati D, Gallo A, Botta diabetes mellitus Jr, Elefteriades JA, anticoagulantnecessaryforyoungatrialfibrillationpatientswithaCHA2DS2-. . CoadyMA. Naturalhistoryofascendingaorticaneurysmsinthesettingofan. VAScscoreof1(men)or2(women)? JAmHeartAssoc2016; 5: e003839. . unreplacedbicuspidaorticvalve. AnnThoracSurg2007; 83: 13381344. . 555. ChaoTF, LiuCJ, WangKL, LinYJ, ChangSL, LoLW, HuYF, TuanTC, ChenTJ, . . 573. Lindman BR, Otto CM. Time to treat hypertension in patients with aortic LipGY, ChenSA. Shouldatrialfibrillationpatientswith1additionalriskfactor. . stenosis. Circulation2013; 128: 12811283. . oftheCHA2DS2-VAScscore(beyondsex)receiveoralanticoagulation? JAm. 574. Viigimaa M, Doumas M, Vlachopoulos C, Anyfanti P, Wolf J, Narkiewicz potassium, . CollCardiol2015; 65: 635642. . Mancia G. Hypertension and sexual dysfunction: time to act. J Hypertens. 556. KirchhofP, BenussiS, KotechaD, AhlssonA, AtarD, CasadeiB, CastellaM, . . 2011; 29: 403407. Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, . 575. ShamloulR, GhanemH. Erectiledysfunction. Lancet2013; 381: 153165. Downloaded from by guest on 31 December 2025 ESC/ESHGuidelines 3104m. 576. DongJY, ZhangYH, QinLQ. Erectiledysfunctionandriskofcardiovasculardis-. . 595. ChapmanMJ, GinsbergHN, AmarencoP, AndreottiF, BorenJ, CatapanoAL, . ease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. Descamps OS, Fisher E, Kovanen patient, Kuivenhoven JA, Lesnik P, Masana L, . 2011; 58: 13781385. . Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-. 577. LaTorreA, GiupponiG, DuffyD, ConcaA, CatanzaritiD. Sexualdysfunction. . Hansen A, Watts GF, European Atherosclerosis Society Consensus Panel. related to drugs: a critical review. Part IV: cardiovascular drugs. . . Triglyceride-rich lipoproteins and High-density lipoprotein cholesterol in. Pharmacopsychiatry2015; 48: 16. . patientsathighriskofcardiovasculardisease: evidenceandguidanceforman-. 578. Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, .",
    "Pharmacopsychiatry2015; 48: 16. . patientsathighriskofcardiovasculardisease: evidenceandguidanceforman-. 578. Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, . agement. EurHeartJ2011; 32: 13451361. . Mancia G. Sildenafil citrate for erectile dysfunction in men receiving multiple. . 596. SeverPS, DahlofB, PoulterNR, WedelH, BeeversG, CaulfieldM, CollinsR, antihypertensive agents: a randomized controlled trial. Am J Hypertens. . Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, OBrien E, . 2004; 17: 11351142. . OstergrenJ, ASCOTInvestigators. Preventionofcoronaryandstrokeevents. 579. Foy CG, Newman JC, Berlowitz DR, Russell LP, Kimmel PL, Wadley VG, . . with atorvastatin in hypertensive patients who have average or lower-thanThomasHN, LernerAJ, RileyWT. Bloodpressure, sexualactivity, anddysfunc-. . average cholesterol concentrations, in the Anglo-Scandinavian Cardiac. tion in women with hypertension: baseline findings from the Systolic Blood. OutcomesTrialLipidLoweringArm(ASCOT-LLA): amulticentrerandomised. PressureInterventionTrial(SPRINT). JSexMed2016; 13: 13331346. . controlledtrial. Lancet2003; 361: 11491158. . 580. Jain M, Townsend respiratory rate. Chemotherapy agents and hypertension: a focus on. . 597. RidkerPM, DanielsonE, FonsecaFA, GenestJ, GottoAMJr, KasteleinJJ, Koenig angiogenesisblockade. CurrHypertensRep2007; 9: 320328. . . W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, . 581. Abi Aad S, Pierce M, Barmaimon G, Farhat FS, Benjo A, Mouhayar E. . WillersonJT, GlynnRJ, JUPITERStudyGroup. Rosuvastatintopreventvascular. Hypertension induced by chemotherapeutic and immunosuppresive agents: a. . events in men and women with elevated C-reactive Protein. N Engl J Med newchallenge. CritRevOncolHematol2015; 93: 2835. . . 2008; 359: 21952207. . 582. Maitland ML, Bakris GL, Black heart rate, Chen history, Durand JB, Elliott WJ, Ivy SP, . 598. YusufS, BoschJ, DagenaisG, ZhuJ, XavierD, LiuL, PaisP, Lopez-JaramilloP, . LeierCV, LindenfeldJ, LiuG, RemickSC, SteingartR, TangWH. Initialassess-. LeiterLA, DansA, AvezumA, PiegasLS, ParkhomenkoA, KeltaiK, KeltaiM, . ment, surveillance, andmanagementofbloodpressureinpatientsreceivingvas-. . SliwaK, PetersRJ, HeldC, ChazovaI, YusoffK, LewisBS, JanskyP, KhuntiK, cularendothelialgrowthfactorsignalingpathwayinhibitors. JNatlCancerInst. . ToffWD, ReidCM, VarigosJ, Sanchez-VallejoG, McKelvieR, PogueJ, JungH, . 2010; 102: 596604. . Gao P, Diaz R, Lonn E, HOPE-3 Investigators. Cholesterol lowering in. 583. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular. intermediate-risk persons without cardiovascular disease. N Engl J Med. complications of cancer therapy: best practices in diagnosis, prevention, and. . 2016; 374: 20212031. management: Part2. JAmCollCardiol2017; 70: 25522565. . . 599. Authors/TaskForceMembers: CatapanoAL, GrahamI, DeBackerG, Wiklund. 584. MilanA, PuglisiE, FerrariL, BrunoG, LosanoI, VeglioF. Arterialhypertension. O, ChapmanMJ, DrexelH, HoesAW, JenningsCS, LandmesserU, Pedersen. andcancer. IntJCancer2014; 134: 22692277. . . TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, 585. AronsonS, MythenMG. Perioperativemanagementofhigh-riskpatients: going. . VlachopoulosC, WoodDA, ZamoranoJL. 2016ESC/EASGuidelinesforthe. beyondavoidhypoxiaandhypotension. JAMA2017; 318: 13301332. . ManagementofDyslipidaemias. EurHeartJ2016; 37: 29993058. . 586. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, Ford I, . 600. BoekholdtSM, HovinghGK, MoraS, ArsenaultBJ, AmarencoP, PedersenTR, . Gonzalez-JuanateyJR, GorenekB, HeyndrickxGR, HoeftA, HuberK, IungB, . . LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech before meals, Colquhoun D, Kjeldsen KP, Longrois D, Luscher TF, Pierard L, Pocock S, Price S, Roffi M, . . HitmanGA, BetteridgeDJ, ClearfieldMB, DownsJR, ColhounHM, GottoAM. Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C. 2014 ESC/erythropoiesis-stimulating agent. Jr, RidkerPM, GrundySM, KasteleinJJ. Verylowlevelsofatherogeniclipopro-. Guidelinesonnon-cardiacsurgery: cardiovascularassessmentandmanagement: . teinsandtheriskforcardiovascularevents: ameta-analysisofstatintrials. JAm. The Joint Task Force on non-cardiac surgery: cardiovascular assessment and. . CollCardiol2014; 64: 485494. managementoftheEuropeanSocietyofCardiology(ESC)andtheEuropean. . 601. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de. SocietyofAnaesthesiology(erythropoiesis-stimulating agent). EurHeartJ2014; 35: 23832431. . Craen AJ, Knopp RH, Nakamura H, Ridker P, vanDomburgR, DeckersJW. . 587. FutierE, LefrantJY, GuinotPG, GodetT, LorneE, CuvillonP, BertranS, Leone. . Thebenefitsofstatinsinpeoplewithoutestablishedcardiovasculardiseasebut M, PasteneB, PiriouV, MolliexS, AlbaneseJ, JuliaJM, TavernierB, ImhoffE, . . withcardiovascularriskfactors: meta-analysisofrandomisedcontrolledtrials. . BazinJE, ConstantinJM, PereiraB, JaberS. Effectofindividualizedvsstandard. BMJ2009; 338: b2376. . Blood Hypertension management strategies on postoperative organ dysfunction. 602. CholesterolTreatmentTrialistsCollaboration, FulcherJ, OConnellR, Voysey. amonghigh-riskpatientsundergoingmajorsurgery: arandomizedclinicaltrial. . .",
    ". Blood Hypertension management strategies on postoperative organ dysfunction. 602. CholesterolTreatmentTrialistsCollaboration, FulcherJ, OConnellR, Voysey. amonghigh-riskpatientsundergoingmajorsurgery: arandomizedclinicaltrial. . . M, EmbersonJ, BlackwellL, MihaylovaB, SimesJ, CollinsR, KirbyA, Colhoun JAMA2017; 318: 13461357. . . H, BraunwaldE, LaRosaJ, PedersenTR, TonkinA, DavisB, SleightP, Franzosi. 588. BouriS, Shun-ShinMJ, ColeGD, MayetJ, FrancisDP. Meta-analysisofsecure. magnesium, BaigentC, KeechA. EfficacyandsafetyofLDL-loweringtherapyamong. randomisedcontrolledtrialsofbeta-blockadetopreventperioperativedeathin. . menandwomen: meta-analysisofindividualdatafrom174, 000participantsin non-cardiacsurgery. Heart2014; 100: 456464. . . 27randomisedtrials. Lancet2015; 385: 13971405. . 589. Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, . 603. Lip GY. Hypertension and the prothrombotic state. J Hum Hypertens. SchillingerM, WiesbauerF, SteinwenderC. Perioperativebeta-blockersforpre-. 2000; 14: 687690. . venting surgery-related mortality and morbidity. Cochrane Database Syst Rev. . 604. LipGY, FelmedenDC, DwivediG. Antiplateletagentsandanticoagulantsfor 2018; 3: CD004476. . . hypertension. CochraneDatabaseSystRev2011; 12: CD003186. . 590. Zou Z, Yuan hemoglobin, Yang B, Xu F, Chen XY, Liu GJ, Shi XY. Perioperative. 605. Friberg L, Rosenqvist M, Lip GY. Evaluationof risk stratification schemes for. angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor. ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the. blockers for preventing mortality and morbidity in adults. Cochrane Database. . SwedishAtrialFibrillationcohortstudy. EurHeartJ2012; 33: 15001510. SystRev2016; 1: CD009210. . . 606. LipGY, AndreottiF, FauchierL, HuberK, HylekE, KnightE, LaneD, LeviM, . 591. RoshanovPS, RochwergB, PatelA, SalehianO, DuceppeE, Belley-CoteEP, Guyatt. Marin F, PalaretiG, KirchhofP. Bleedingrisk assessment andmanagement in. GH, SesslerDI, LeManachY, BorgesFK, TandonV, WorsterA, ThompsonA, . . atrialfibrillationpatients. ExecutiveSummaryofaPositionDocumentfromthe Koshy M, Devereaux B, Spencer FA, Sanders RD, Sloan EN, Morley EE, Paul J, . . European Heart Rhythm Association EHRA, endorsed by the European. RaymerKE, PunthakeeZ, DevereauxPJ. Withholdingversuscontinuingangiotensin-. SocietyofCardiologyESCWorkingGrouponThrombosis. ThrombHaemost. convertingenzymeinhibitorsorangiotensinIIreceptorblockersbeforenoncardiac. 2011; 106: 9971011. . surgery: ananalysisoftheVasculareventsInnoncardiacSurgerypatIentscOhort. . 607. LipGY, LaneDA. Bleedingriskassessmentinatrialfibrillation: observationson evaluatioNProspectiveCohort. Anesthesiology2017; 126: 1627. . . the use and misuse of bleeding risk scores. J Thromb Haemost. 592. LondonMJ, HurK, SchwartzGG, HendersonWG. Associationofperioperative. 2016; 14: 17111714. . beta-blockadewithmortalityandcardiovascularmorbidityfollowingmajornon-. 608. MarsoSP, DanielsGH, Brown-FrandsenK, KristensenP, MannJF, NauckMA, . cardiacsurgery. JAMA2013; 309: 17041713. . . NissenSE, PocockS, PoulterNR, RavnLS, SteinbergWM, StocknerM, Zinman. 593. Andersson C, Merie C, Jorgensen M, Gislason GH, Torp-Pedersen C, . B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial. OvergaardC, KoberL, JensenPF, HlatkyMA. Associationofbeta-blockerther-. Investigators. LiraglutideandCardiovascularOutcomesinType2Diabetes. N. apy with risks of adverse cardiovascular events and deaths in patients with. . EnglJMed2016; 375: 311322. ischemic Heart disease undergoing noncardiac surgery: a Danish nationwide. . 609. MarsoSP, BainSC, ConsoliA, EliaschewitzFG, JodarE, LeiterLA, LingvayI, . cohortstudy. JAMAInternMed2014; 174: 336344. . RosenstockJ, SeufertJ, WarrenML, WooV, HansenO, HolstAG, Pettersson. 594. KwonS, ThompsonR, FlorenceM, MaierR, McIntyreL, RogersT, FarrohkiE, . J, Vilsboll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular out-. WhitefordM, FlumDR. Beta-blockercontinuationafternoncardiacsurgery: a. . comesinpatientswithtype2diabetes. NEnglJMed2016; 375: 18341844. report from the surgical care and outcomes assessment program. Arch Surg. . 610. Birtwhistle RV, Godwin MS, Delva MD, Casson RI, Lam M, MacDonald SE, . 2012; 147: 467473. SeguinR, RuhlandL. Randomisedequivalencetrialcomparingthreemonthand Downloaded from by guest on 31 December 2025 3104n ESC/ESHGuidelines. sixmonthfollowupofpatientswithhypertensionbyfamilypractitioners. BMJ. . 620. Krousel-Wood M, Joyce C, Holt E, Muntner P, Webber LS, Morisky DE, . 2004; 328: 204. . Frohlich ED, Re RN. Predictors of decline in medication adherence: results. 611. ClarkCE, SmithLF, TaylorRS, CampbellJL. Nurseledinterventionstoimprove. from the cohort study of medication adherence among older adults. . controlofbloodpressureinpeoplewithhypertension: systematicreviewand. . Hypertension2011; 58: 804810. meta-analysis. BMJ2010; 341: c3995. . . 621. MazzagliaG, AmbrosioniE, AlacquaM, FilippiA, SessaE, ImmordinoV, Borghi. 612. Bray EP, Holder R, Mant J, McManus RJ. Does self-monitoring reduce Blood. C, BrignoliO, CaputiAP, CricelliC, MantovaniLG. Adherencetoantihyperten-. Hypertension? Meta-analysis with meta-regression of randomized controlled trials. . sivemedicationsandcardiovascularmorbidityamongnewlydiagnosedhyper-. AnnMed2010; 42: 371386. . . tensivepatients. Circulation2009; 120: 15981605. 613. NiiranenTJ, HanninenMR, JohanssonJ, ReunanenA, JulaAM. Home-measured. . 622. BurnierM, WuerznerG, Struijker-BoudierH, UrquhartJ. Measuring, analyzing, . bloodpressureisastrongerpredictorofcardiovascularriskthanofficeblood. and managing drug adherence in resistant hypertension.",
    "Home-measured. . 622. BurnierM, WuerznerG, Struijker-BoudierH, UrquhartJ. Measuring, analyzing, . bloodpressureisastrongerpredictorofcardiovascularriskthanofficeblood. and managing drug adherence in resistant hypertension. Hypertension. Hypertension: theFinn-Homestudy. Hypertension2010; 55: 13461351. . . 2013; 62: 218225. 614. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, . . 623. NaderiSH, BestwickJP, WaldDS. Adherencetodrugsthatpreventcardiovascular. AppelLJ, WheltonPK. Longtermeffectsofdietarysodiumreductiononcardi-. disease: meta-analysison376, 162patients. AmJMed2012; 125: 882887. e1. . ovasculardiseaseoutcomes: observationalfollow-upofthetrialsofhyperten-. 624. TomaszewskiM, WhiteC, PatelP, MascaN, DamaniR, HepworthJ, SamaniNJ, . sionprevention(TOHP). BMJ2007; 334: 885888. . . GuptaP, MadiraW, StanleyA, WilliamsB. Highratesofnon-adherencetoanti615. Gupta AK, McGlone M, Greenway FL, Johnson WD. Prehypertension in. . hypertensivetreatmentrevealedbyhigh-performanceliquidchromatography-. disease-free adults: a marker for an adverse cardiometabolic risk profile. . tandem mass spectrometry (HP LC-MS/MS) Urine analysis. Heart. HypertensRes2010; 33: 905910. . 2014; 100: 855861. . 616. SacksFM, SvetkeyLP, VollmerWM, AppelLJ, BrayGA, HarshaD, Obarzanek. . 625. BerraE, AziziM, CapronA, HoieggenA, RabbiaF, KjeldsenSE, StaessenJA, E, Conlin PR, Miller ER III, Simons-Morton DG, Karanja N, Lin PH, DASH-. . WallemacqP, PersuA. Evaluationofadherenceshouldbecomeanintegralpart. SodiumCollaborativeResearchGroup. Effectsonbloodpressureofreduced. of assessment of patients with apparently treatment-resistant hypertension. . dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH). . Hypertension2016; 68: 297306. diet. DASH-Sodium Collaborative Research Group. N Engl J Med. . 626. BurnierM. Managingresistance: isadherenceatargetfortreatment? CurrOpin. 2001; 344: 310. . NephrolHypertens2014; 23: 439443. . 617. Thompson AM, Hu T, Eshelbrenner chloride, Reynolds potassium, He J, Bazzano LA. . 627. Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The effect of self-. Antihypertensivetreatmentandsecondarypreventionofcardiovasculardisease. . monitoringofbloodpressureonmedicationadherenceandlifestylefactors: a eventsamongpersonswithouthypertension: ameta-analysis. JAMA2011; 305: . . systematicreviewandmeta-analysis. AmJHypertens2015; 28: 12091221. . 913922. . 628. BurnierM, BredeY, LowyA. Impactofprolongedantihypertensivedurationof. 618. VieraAJ, BanguraF, MitchellCM, CernaA, SloaneP. Doclinicianstellpatients. actiononpredictedclinicaloutcomesinimperfectlyadherentpatients: compar-. theyhaveprehypertension? JAmBoardFamMed2011; 24: 117118. . . isonofaliskiren, irbesartanandramipril. IntJClinPract2011; 65: 127133. . 619. GaleNK, GreenfieldS, GillP, GutridgeK, MarshallT. Patientandgeneralpracti-. 629. Lowy A, Munk VC, Ong social history, Burnier M, Vrijens B, Tousset EP, Urquhart J. . tioner attitudes to taking medication to prevent cardiovascular disease after. Effects on Blood Hypertension and cardiovascular risk of variations in patients. receivingdetailedinformationonrisksandbenefitsoftreatment: aqualitative. . adherencetoprescribedantihypertensivedrugs: roleofdurationofdrugaction. study. BMCFamPract2011; 12: 59. . IntJClinPract2011; 65: 4153. Downloaded from by guest on 31 December 2025"
  ],
  "metadatas": [
    {
      "source": "ehy339.pdf",
      "chunk_id": 0,
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "classification",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 1,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,creatinine,calcium,hemoglobin,albumin-creatinine ratio",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 2,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 596,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,cardiovascular disease,guideline",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 3,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 591,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 4,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,calcium,classification",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 5,
      "content_type": "monitoring",
      "content_type_confidence": 4,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,end-stage renal disease,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 6,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,cardiovascular disease,stage 1,stage 2,stage 3",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 7,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 595,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,blood pressure control,adherence,monitoring",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 8,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "monitoring",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 9,
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "word_count": 598,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,exercise,adherence,screening",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 10,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 598,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "diet,cardiovascular disease,exercise,monitoring",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 11,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 593,
      "entity_count": 6,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,calcium,hemoglobin,antihypertensive,cardiovascular disease,blood pressure control",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 12,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 598,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,albuminuria,creatinine,serum creatinine,heart failure,retinopathy,albumin-creatinine ratio",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 13,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 594,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,creatinine,serum creatinine,antihypertensive,retinopathy,albumin-creatinine ratio",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 14,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "albuminuria,antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 15,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 595,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "kidney function,antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 16,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "statins,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 17,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 593,
      "entity_count": 1,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 18,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 598,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 19,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 600,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,sodium,sodium restriction,blood pressure control",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 20,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 599,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,diet,exercise,physical activity",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 21,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 592,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "albuminuria,potassium,ACE inhibitors,ARBs,diuretics,thiazides,antihypertensive,cardiovascular disease,smoking cessation,physical activity",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 22,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 593,
      "entity_count": 9,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "proteinuria,potassium,ACE inhibitors,ARBs,diuretics,loop diuretics,thiazides,insulin,antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 23,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 595,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,antihypertensive,blood pressure control,adherence",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 24,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 594,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,diuretics,antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 25,
      "content_type": "treatment",
      "content_type_confidence": 9,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "proteinuria,calcium,ARBs,diuretics,blood pressure control",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 26,
      "content_type": "treatment",
      "content_type_confidence": 10,
      "word_count": 593,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,magnesium,ACE inhibitors,ARBs,diuretics,loop diuretics,antihypertensive,cardiovascular disease,blood pressure control,adherence",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 27,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 571,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,calcium,magnesium,ARBs,heart failure",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 28,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 585,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,catheter",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 29,
      "content_type": "treatment",
      "content_type_confidence": 9,
      "word_count": 598,
      "entity_count": 3,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,sodium,erythropoietin",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 30,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 511,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,calcium,magnesium,screening",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 31,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 594,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,proteinuria,creatinine,erythropoietin,heart failure",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 32,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 597,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "ACE inhibitors,ARBs",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 33,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,antihypertensive,cardiovascular disease,monitoring,stage 1",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 34,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 595,
      "entity_count": 8,
      "has_ckd": false,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "glomerular filtration rate,proteinuria,creatinine,uric acid,serum creatinine,diuretics,loop diuretics,monitoring",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 35,
      "content_type": "recommendation",
      "content_type_confidence": 5,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,proteinuria,creatinine,magnesium,albumin-creatinine ratio",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 36,
      "content_type": "treatment",
      "content_type_confidence": 11,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,ACE inhibitors,ARBs,antihypertensive,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 37,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 589,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,albuminuria,calcium,antihypertensive,retinopathy",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 38,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 600,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,end-stage renal disease,albuminuria,sodium,calcium,sodium restriction,ACE inhibitors,ARBs,diuretics",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 39,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 596,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,proteinuria,calcium,diuretics,heart failure",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 40,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 597,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,ARBs,heart failure",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 41,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,antihypertensive,heart failure",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 42,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 592,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,ACE inhibitors,ARBs,antihypertensive,heart failure,blood pressure control",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 43,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,ARBs,antihypertensive,smoking cessation,adherence",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 44,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 599,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,antihypertensive,statins,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 45,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,cardiovascular disease,blood pressure control",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 46,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 550,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "antihypertensive,blood pressure control,adherence",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 47,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 600,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,diet,antihypertensive,cardiovascular disease,exercise,screening,classification",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 48,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 587,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,sodium,calcium,sodium restriction,ACE inhibitors,statins,cardiovascular disease,retinopathy,blood pressure control,adherence",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 49,
      "content_type": "treatment",
      "content_type_confidence": 7,
      "word_count": 595,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 50,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 596,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 51,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 599,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 52,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 592,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 53,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 596,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "magnesium,monitoring",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 54,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 590,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,hemoglobin,monitoring",
      "year": "2018",
      "organization": "Unknown",
      "section": "40. CuspidiC"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 55,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 598,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,potassium,dialysis,screening",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 56,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 595,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,antihypertensive,exercise,monitoring",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 57,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 595,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 58,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,magnesium,antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 59,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 597,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,creatinine,potassium,calcium,magnesium,cardiovascular disease,retinopathy",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 60,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 592,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "albuminuria,potassium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 61,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 590,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "kidney function,albuminuria,potassium,antihypertensive,guideline",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 62,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 598,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nephropathy,potassium,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 63,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,antihypertensive,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown",
      "section": "213. Beckett N"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 64,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 65,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 586,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,nutrition,diet,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 66,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 597,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "potassium,antihypertensive,hemodialysis",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 67,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 588,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,magnesium,antihypertensive,adherence",
      "year": "2018",
      "organization": "Unknown",
      "section": "293. CorraoG"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 68,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,antihypertensive,smoking cessation",
      "year": "2018",
      "organization": "Unknown",
      "section": "303. Zanchetti A"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 69,
      "content_type": "evidence",
      "content_type_confidence": 8,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 70,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 597,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "creatinine,calcium,antihypertensive,catheter,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 71,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "antihypertensive,adherence",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 72,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 600,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "catheter,heart failure",
      "year": "2018",
      "organization": "Unknown",
      "section": "358. BisognanoJD"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 73,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 598,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,antihypertensive,adherence,monitoring",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 74,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 598,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 75,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 600,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "proteinuria,sodium,potassium,magnesium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 76,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 597,
      "entity_count": 6,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,albuminuria,proteinuria,potassium,calcium,antihypertensive",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 77,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 599,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "albuminuria,potassium",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 78,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 600,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,chloride,antihypertensive,guideline",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 79,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 587,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "antihypertensive,guideline",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 80,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 597,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "renal failure,potassium,antihypertensive,heart failure",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 81,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 600,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,magnesium,heart failure",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 82,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 593,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "antihypertensive,cardiovascular disease",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 83,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 600,
      "entity_count": 4,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "magnesium,hemoglobin,adherence,monitoring",
      "year": "2018",
      "organization": "Unknown"
    },
    {
      "source": "ehy339.pdf",
      "chunk_id": 84,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 339,
      "entity_count": 6,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium,chloride,diet,cardiovascular disease,adherence",
      "year": "2018",
      "organization": "Unknown"
    }
  ],
  "ids": [
    "ehy339_0",
    "ehy339_1",
    "ehy339_2",
    "ehy339_3",
    "ehy339_4",
    "ehy339_5",
    "ehy339_6",
    "ehy339_7",
    "ehy339_8",
    "ehy339_9",
    "ehy339_10",
    "ehy339_11",
    "ehy339_12",
    "ehy339_13",
    "ehy339_14",
    "ehy339_15",
    "ehy339_16",
    "ehy339_17",
    "ehy339_18",
    "ehy339_19",
    "ehy339_20",
    "ehy339_21",
    "ehy339_22",
    "ehy339_23",
    "ehy339_24",
    "ehy339_25",
    "ehy339_26",
    "ehy339_27",
    "ehy339_28",
    "ehy339_29",
    "ehy339_30",
    "ehy339_31",
    "ehy339_32",
    "ehy339_33",
    "ehy339_34",
    "ehy339_35",
    "ehy339_36",
    "ehy339_37",
    "ehy339_38",
    "ehy339_39",
    "ehy339_40",
    "ehy339_41",
    "ehy339_42",
    "ehy339_43",
    "ehy339_44",
    "ehy339_45",
    "ehy339_46",
    "ehy339_47",
    "ehy339_48",
    "ehy339_49",
    "ehy339_50",
    "ehy339_51",
    "ehy339_52",
    "ehy339_53",
    "ehy339_54",
    "ehy339_55",
    "ehy339_56",
    "ehy339_57",
    "ehy339_58",
    "ehy339_59",
    "ehy339_60",
    "ehy339_61",
    "ehy339_62",
    "ehy339_63",
    "ehy339_64",
    "ehy339_65",
    "ehy339_66",
    "ehy339_67",
    "ehy339_68",
    "ehy339_69",
    "ehy339_70",
    "ehy339_71",
    "ehy339_72",
    "ehy339_73",
    "ehy339_74",
    "ehy339_75",
    "ehy339_76",
    "ehy339_77",
    "ehy339_78",
    "ehy339_79",
    "ehy339_80",
    "ehy339_81",
    "ehy339_82",
    "ehy339_83",
    "ehy339_84"
  ]
}